0000875320-17-000060.txt : 20171030 0000875320-17-000060.hdr.sgml : 20171030 20171030171507 ACCESSION NUMBER: 0000875320-17-000060 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 85 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171030 DATE AS OF CHANGE: 20171030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 171163257 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 10-Q 1 a2017q310-q.htm 10-Q Document

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2017
or
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM              TO             
Commission file number 000-19319
____________________________________________
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
Massachusetts
04-3039129
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
50 Northern Avenue, Boston, Massachusetts
02210
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (617) 341-6100
____________________________________________

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x
Accelerated filer o
Non-accelerated filer o 
Smaller reporting company o
 
 
 
 
Emerging growth company o
                                       (Do not check if a smaller reporting company)
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Stock, par value $0.01 per share
252,902,848
Class
Outstanding at October 20, 2017
 



VERTEX PHARMACEUTICALS INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2017

TABLE OF CONTENTS
 
 
Page
 
 
 
Condensed Consolidated Statements of Operations - Three and Nine Months Ended September 30, 2017 and 2016
 
Condensed Consolidated Statements of Comprehensive Income (Loss) - Three and Nine Months Ended September 30, 2017 and 2016
 
Condensed Consolidated Balance Sheets - September 30, 2017 and December 31, 2016
 
Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest - Nine Months Ended September 30, 2017 and 2016
 
Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2017 and 2016
 
 
 
“We,” “us,” “Vertex” and the “Company” as used in this Quarterly Report on Form 10-Q refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“Vertex,” “KALYDECO®” and “ORKAMBI®” are registered trademarks of Vertex. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners.



Part I. Financial Information
Item 1.    Financial Statements

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share amounts)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Revenues:
 
 
 
 
 
 
 
Product revenues, net
$
549,642

 
$
409,689

 
$
1,544,252

 
$
1,229,750

Royalty revenues
2,231

 
3,835

 
6,643

 
12,713

Collaborative revenues
26,292

 
259

 
286,123

 
1,008

Total revenues
578,165

 
413,783

 
1,837,018

 
1,243,471

Costs and expenses:
 
 
 
 
 
 
 
Cost of product revenues
72,186

 
53,222

 
188,963

 
147,165

Royalty expenses
688

 
855

 
2,104

 
2,813

Research and development expenses
454,947

 
272,370

 
1,017,961

 
799,238

Sales, general and administrative expenses
120,710

 
106,055

 
361,285

 
322,921

Restructuring expenses, net
337

 
8

 
13,859

 
1,038

Intangible asset impairment charge
255,340

 
—

 
255,340

 
—

Total costs and expenses
904,208

 
432,510

 
1,839,512

 
1,273,175

Loss from operations
(326,043
)
 
(18,727
)
 
(2,494
)
 
(29,704
)
Interest expense, net
(13,574
)
 
(20,140
)
 
(45,003
)
 
(60,993
)
Other (expenses) income, net
(77,553
)
 
(167
)
 
(80,634
)
 
3,025

Loss before (benefit from) provision for income taxes
(417,170
)
 
(39,034
)
 
(128,131
)
 
(87,672
)
(Benefit from) provision for income taxes
(125,903
)
 
503

 
(117,581
)
 
24,118

Net loss
(291,267
)
 
(39,537
)
 
(10,550
)
 
(111,790
)
Loss (income) attributable to noncontrolling interest
188,315

 
696

 
173,350

 
(33,207
)
Net (loss) income attributable to Vertex
$
(102,952
)
 
$
(38,841
)
 
$
162,800

 
$
(144,997
)
 
 
 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
 
 
Net (loss) income:
 
 
 
 
 
 
 
Basic
$
(0.41
)
 
$
(0.16
)
 
$
0.66

 
$
(0.59
)
Diluted
$
(0.41
)
 
$
(0.16
)
 
$
0.64

 
$
(0.59
)
Shares used in per share calculations:
 
 
 
 
 
 
 
Basic
250,268

 
244,920

 
247,963

 
244,529

Diluted
250,268

 
244,920

 
252,095

 
244,529

The accompanying notes are an integral part of these condensed consolidated financial statements.


2

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Comprehensive Income (Loss)
(unaudited)
(in thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Net loss
$
(291,267
)
 
$
(39,537
)
 
$
(10,550
)
 
$
(111,790
)
Changes in other comprehensive loss:
 
 
 
 
 
 
 
Unrealized holding gains (losses) on marketable securities, net of tax of zero, respectively
5,961

 
(96
)
 
(7,786
)
 
104

Unrealized (losses) gains on foreign currency forward contracts, net of tax of $0.9 million, $0.2 million, $2.9 million and $(0.4) million, respectively
(5,453
)
 
2,149

 
(27,379
)
 
1,936

Foreign currency translation adjustment
(3,884
)
 
(2,508
)
 
(11,137
)
 
(7,709
)
Total changes in other comprehensive loss
(3,376
)
 
(455
)
 
(46,302
)
 
(5,669
)
Comprehensive loss
(294,643
)
 
(39,992
)
 
(56,852
)
 
(117,459
)
Comprehensive loss (income) attributable to noncontrolling interest
188,315

 
696

 
173,350

 
(33,207
)
Comprehensive (loss) income attributable to Vertex
$
(106,328
)
 
$
(39,296
)
 
$
116,498

 
$
(150,666
)
The accompanying notes are an integral part of these condensed consolidated financial statements.


3

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share amounts)
 
September 30,
 
December 31,
 
2017
 
2016
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
1,384,966

 
$
1,183,945

Marketable securities, available for sale
427,282

 
250,612

Restricted cash and cash equivalents (VIE)
1,803

 
47,762

Accounts receivable, net
263,493

 
201,083

Inventories
98,192

 
77,604

Prepaid expenses and other current assets
152,238

 
70,534

Total current assets
2,327,974

 
1,831,540

Property and equipment, net
759,978

 
698,362

Intangible assets
29,000

 
284,340

Goodwill
50,384

 
50,384

Cost method investments
20,447

 
20,276

Other assets
10,542

 
11,885

Total assets
$
3,198,325

 
$
2,896,787

Liabilities and Shareholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
77,138

 
$
61,451

Accrued expenses
378,554

 
315,249

Deferred revenues, current portion
13,003

 
6,005

Accrued restructuring expenses, current portion
4,205

 
6,047

Capital lease obligations, current portion
19,881

 
19,426

Customer deposits
190,272

 
73,416

Credit facility
—

 
300,000

Other liabilities, current portion
27,686

 
10,943

Total current liabilities
710,739

 
792,537

Deferred revenues, excluding current portion
2,917

 
6,632

Accrued restructuring expenses, excluding current portion
146

 
1,907

Capital lease obligations, excluding current portion
20,259

 
34,976

Deferred tax liability
10,682

 
134,063

Construction financing lease obligation, excluding current portion
547,051

 
486,359

Advance from collaborator
77,258

 
73,423

Other liabilities, excluding current portion
26,029

 
28,699

Total liabilities
1,395,081

 
1,558,596

Commitments and contingencies


 


Shareholders’ equity:
 
 
 
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding
—

 
—

Common stock, $0.01 par value; 500,000,000 shares authorized; 252,683,346 and 248,300,517 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively
2,500

 
2,450

Additional paid-in capital
7,034,113

 
6,506,795

Accumulated other comprehensive (loss) income
(25,129
)
 
21,173

Accumulated deficit
(5,220,407
)
 
(5,373,836
)
Total Vertex shareholders’ equity
1,791,077

 
1,156,582

Noncontrolling interest
12,167

 
181,609

Total shareholders’ equity
1,803,244

 
1,338,191

Total liabilities and shareholders’ equity
$
3,198,325

 
$
2,896,787

The accompanying notes are an integral part of these condensed consolidated financial statements.


4

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Shareholders’ Equity and Noncontrolling Interest
(unaudited)
(in thousands)
 
Common Stock
 
Additional
Paid-in Capital
 
Accumulated
Other
Comprehensive (Loss) Income
 
Accumulated Deficit
 
Total Vertex
Shareholders’ Equity
 
Noncontrolling
Interest
 
Total
Shareholders’ Equity
 
Shares
 
Amount
 
 
 
 
 
 
Balance at December 31, 2015
246,307

 
$
2,427

 
$
6,197,500

 
$
1,824

 
$
(5,261,784
)
 
$
939,967

 
$
153,661

 
$
1,093,628

Other comprehensive loss, net of tax
—

 
—

 
—

 
(5,669
)
 
—

 
(5,669
)
 
—

 
(5,669
)
Net (loss) income
—

 
—

 
—

 
—

 
(144,997
)
 
(144,997
)
 
33,207

 
(111,790
)
Issuance of common stock under benefit plans
1,722

 
19

 
50,875

 
—

 
—

 
50,894

 
—

 
50,894

Stock-based compensation expense
—

 
—

 
181,351

 
—

 
—

 
181,351

 
(73
)
 
181,278

Balance at September 30, 2016
248,029

 
$
2,446

 
$
6,429,726

 
$
(3,845
)
 
$
(5,406,781
)
 
$
1,021,546

 
$
186,795

 
$
1,208,341

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2016
248,301

 
$
2,450

 
$
6,506,795

 
$
21,173

 
$
(5,373,836
)
 
$
1,156,582

 
$
181,609

 
$
1,338,191

Cumulative effect adjustment for adoption of new accounting guidance
—

 
—

 
9,371

 
 
 
(9,371
)
 
—

 
—

 
—

Other comprehensive loss, net of tax
—

 
—

 
—

 
(46,302
)
 
—

 
(46,302
)
 
—

 
(46,302
)
Net income (loss)
—

 
—

 
—

 
—

 
162,800

 
162,800

 
(173,350
)
 
(10,550
)
Issuance of common stock under benefit plans
4,382

 
50

 
298,956

 
—

 
—

 
299,006

 
33

 
299,039

Stock-based compensation expense
—

 
—

 
218,991

 
—

 
—

 
218,991

 
—

 
218,991

VIE noncontrolling interest upon deconsolidation
—

 
—

 
—

 
—

 
—

 
—

 
3,910

 
3,910

Other
—

 
—

 
—

 
—

 
—

 
—

 
(35
)
 
(35
)
Balance at September 30, 2017
252,683

 
$
2,500

 
$
7,034,113

 
$
(25,129
)
 
$
(5,220,407
)
 
$
1,791,077

 
$
12,167

 
$
1,803,244

The accompanying notes are an integral part of these condensed consolidated financial statements.


5

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
 
Nine Months Ended September 30,
 
2017
 
2016
Cash flows from operating activities:
 
 
 
Net loss
$
(10,550
)
 
$
(111,790
)
Adjustments to reconcile net loss to net cash provided by operating activities:
 
 
 
Stock-based compensation expense
215,334

 
178,623

Depreciation and amortization expense
44,965

 
45,947

Write-downs of inventories to net realizable value
11,138

 
—

Deferred income taxes
(113,969
)
 
23,544

Impairment of property and equipment
1,946

 
—

Intangible asset impairment charge
255,340

 
—

Acquired in-process research & development
160,000

 
—

Deconsolidation of VIE
76,644

 
—

Other non-cash items, net
(4,787
)
 
(904
)
Changes in operating assets and liabilities:
 
 
 
Accounts receivable, net
(54,455
)
 
(9,760
)
Inventories
(28,570
)
 
(11,536
)
Prepaid expenses and other assets
(90,006
)
 
(8,979
)
Accounts payable
6,925

 
(21,532
)
Accrued expenses and other liabilities
148,102

 
26,121

Accrued restructuring expense
(3,863
)
 
(8,151
)
Deferred revenues
3,237

 
(10,204
)
Net cash provided by operating activities
617,431

 
91,379

Cash flows from investing activities:
 
 
 
Purchases of marketable securities
(431,653
)
 
(616,625
)
Maturities of marketable securities
247,149

 
535,379

Expenditures for property and equipment
(56,817
)
 
(41,775
)
Purchase of in-process research & development
(160,000
)
 
—

(Decrease) increase in restricted cash and cash equivalents (VIE)
(15,643
)
 
20,490

Investment in equity securities
—

 
(23,075
)
Decrease (increase) in other assets
380

 
(93
)
Net cash used in investing activities
(416,584
)
 
(125,699
)
Cash flows from financing activities:
 
 
 
Issuances of common stock under benefit plans
298,205

 
51,165

Payments on revolving credit facility
(300,000
)
 
—

Advance from collaborator
10,000

 
—

Payments on capital lease obligations
(14,188
)
 
(13,330
)
Proceeds from capital lease financing
—

 
2,030

Payments on construction financing lease obligation
(412
)
 
(356
)
Proceeds related to construction financing lease obligation
4,700


—

Repayments of advanced funding
(3,132
)
 
—

Net cash (used in) provided by financing activities
(4,827
)
 
39,509

Effect of changes in exchange rates on cash
5,001

 
(265
)
Net increase in cash and cash equivalents
201,021

 
4,924

Cash and cash equivalents—beginning of period
1,183,945

 
714,768

Cash and cash equivalents—end of period
$
1,384,966

 
$
719,692

 
 
 
 
Supplemental disclosure of cash flow information:
 
 
 
Cash paid for interest
$
51,990

 
$
64,662

Cash paid for income taxes
$
4,154

 
$
1,617

Capitalization of costs related to construction financing lease obligation
$
33,827

 
$
824

Issuances of common stock from employee benefit plans receivable
$
868

 
$
19


The accompanying notes are an integral part of these condensed consolidated financial statements.

6
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)


A. Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals. As of September 30, 2017, the Company deconsolidated Parion Sciences, Inc. (“Parion”), a VIE the Company has consolidated since 2015. The Company's consolidated balance sheet as of September 30, 2017 excludes Parion. Please refer to Note C, “Collaborative Arrangements and Acquisitions” for further information regarding the deconsolidation of Parion.

Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2017 and 2016.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2016, which are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 that was filed with the Securities and Exchange Commission (the “SEC”) on February 23, 2017 (the “2016 Annual Report on Form 10-K”).
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation and deconsolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
The Company’s significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in the 2016 Annual Report on Form 10-K.
Recent Accounting Pronouncements
In 2014, the Financial Accounting Standards Board (“FASB”) issued new guidance applicable to revenue recognition that will be effective January 1, 2018. Early adoption was permitted for the year-ending December 31, 2017. The new guidance applies a more principles based approach to recognizing revenue. Under the new guidance, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new guidance must be adopted using either a modified retrospective approach or a full retrospective approach for all periods presented. Under the modified retrospective method, the cumulative effect of applying the standard would be recognized at the date of initial application within retained earnings. Under the full retrospective approach, the standard would be applied to each prior reporting period presented. Upon adoption, the Company will use the modified retrospective method. The Company continues to evaluate the new guidance and the effect the adoption will have on the condensed consolidated financial


7
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

statements.  The Company’s project team is finalizing its review of existing customer contracts and current accounting policies to identify and assess the potential differences that would result from applying the requirements of the new standard. Based on the Company’s assessment performed to date, the new revenue recognition guidance could impact the Company’s accounting for product shipments to certain countries through early access programs, including the French early access programs, whereby the associated product has received regulatory approval but the price is not fixed or determinable based on the status of ongoing pricing discussions, and could impact the Company’s accounting for certain reimbursement agreements that the Company plans to negotiate in the fourth quarter of 2017. As the Company completes its assessment, it is implementing appropriate changes to its controls to support revenue recognition and additional revenue-related disclosures under the new standard.
In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The amended guidance became effective for the Company during the first quarter of 2017. The amended guidance eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in additional paid-in capital. This created approximately $410.8 million of deferred tax asset (“DTA”) relating to federal and state net operating losses (“NOLs”) that are fully reserved by an equal increase in valuation allowance. The Company recorded DTAs of approximately $404.7 million relating to Federal NOLs and approximately $6.1 million relating to State NOLs, both of which are offset by a full valuation allowance. Upon adoption, the Company also elected to change its accounting policy to account for forfeitures of options and awards as they occur. The change was applied on a modified retrospective basis with a cumulative effect adjustment to the Company’s accumulated deficit of $9.4 million, which increased the accumulated deficit as of January 1, 2017. This change also resulted in an increase to the DTA of $3.4 million, which is offset by a full valuation allowance. As a result, there was no cumulative-effect adjustment to accumulated deficit. The provisions related to the recognition of excess tax benefits in the income statement and classification in the statement of cash flows were adopted prospectively, and as such, the prior periods were not retrospectively adjusted.
In 2016, the FASB issued amended guidance related to the recording of financial assets and financial liabilities. Under the amended guidance, equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) are to be measured at fair value with changes in fair value recognized in net income. However, an entity has the option to either measure equity investments without readily determinable fair values at fair value or at cost adjusted for changes in observable prices minus impairment. Changes in measurement under either alternative will be recognized in net income. The amended guidance is effective for the year ending December 31, 2018. Early adoption is permitted. The Company expects the implementation of this standard to have an impact on its consolidated financial statements and related disclosures, as the Company held publicly traded equity investments as of September 30, 2017 as well as equity investments accounted for under the cost method. A cumulative-effect adjustment to the balance sheet will be recorded as of the beginning of the fiscal year of adoption. The implementation of this amended guidance is expected to increase volatility in net income as the volatility currently recorded in other comprehensive income related to changes in the fair market value of available-for-sale equity investments will be reflected in net income after adoption.

In 2016, the FASB issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This guidance requires entities to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.

In 2016, the FASB issued amended guidance related to intra-entity transfers other than inventory. This guidance removes the current exception in GAAP prohibiting entities from recognizing current and deferred income tax expenses or benefits related to transfer of assets, other than inventory, within the consolidated entity. The current exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. The amended guidance is effective for the year ending December 31, 2018. Early adoption is permitted. The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.



8
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

In 2017, the FASB issued amended guidance related to business combinations. The amended guidance clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new accounting guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company early adopted this new guidance as of January 1, 2017 and will apply this new guidance to future acquisitions.

In 2017, the FASB issued amended guidance related to measurements of goodwill. The amended guidance eliminates a step from the goodwill impairment test. Under the amended guidance, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The amended guidance is effective for the year-ending December 31, 2020. Early adoption is permitted. The Company does not expect a significant effect on its condensed consolidated financial statements upon adoption of this new guidance.

In 2017, the FASB issued amended guidance related to the scope of stock option modification accounting, to reduce diversity in practice and provide clarity regarding existing guidance. The new accounting guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company does not expect the adoption of this guidance to have a material effect on its condensed consolidated financial statements and related disclosures.

In 2017, the FASB issued amended guidance applicable to hedge accounting. The new accounting guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those periods. Early adoption is permitted. The amended guidance helps simplify certain aspects of hedge accounting and enables entities to more accurately present their risk management activities in their financial statements.  The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.

For a discussion of other recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2016 Annual Report on Form 10-K.

B.
Product Revenues, Net
The Company sells its products principally to a limited number of specialty pharmacy providers in North America as well as government-owned and supported customers in international markets (collectively, its “Customers”). The Company’s Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery to the Customer as long as (i) there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii) collectibility is reasonably assured and (iii) the price is fixed or determinable.
In order to conclude that the price is fixed or determinable, the Company must be able to (i) calculate its gross product revenues from sales to Customers and (ii) reasonably estimate its net product revenues upon delivery to its Customers’ locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a) trade allowances, such as invoice discounts for prompt payment and Customer fees, (b) estimated government and private payor rebates, chargebacks and discounts, (c) estimated reserves for expected product returns and (d) estimated costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers.
The Company makes significant estimates and judgments that materially affect the Company’s recognition of net product revenues. In certain instances, the Company may be unable to reasonably conclude that the price is fixed or determinable at the time of delivery, in which case it defers the recognition of revenues. Once the Company is able to determine that the price is fixed or determinable, it recognizes the net product revenues associated with the units in which revenue recognition was deferred.
Revenue recognition related to the Company’s French early access programs could be impacted by the new revenue recognition guidance that is effective January 1, 2018 and described in Note A, “Basis of Presentation and Accounting


9
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Policies”. The Company’s ORKAMBI net product revenues to date do not include any revenues from product sales in France because the price is not fixed or determinable. The Company began distributing ORKAMBI through early access programs in France during the fourth quarter of 2015. As of September 30, 2017, the Company’s condensed consolidated balance sheet includes $190.3 million collected in France related to shipments of ORKAMBI under the early access programs that is classified as Customer deposits. The Company expects that the difference between the amounts collected based on the invoiced price and the final price for ORKAMBI in France will be returned to the French government.
If the Company concludes as of December 31, 2017 that the price of the ORKAMBI supplied under the early access programs is fixed or determinable based on, among other factors, the status of negotiations in France, it would record net product revenues for all sales since the inception of the early access programs for ORKAMBI based on the fixed or determinable price in the fourth quarter of 2017.
If the Company concludes that the price is not fixed or determinable as of December 31, 2017, these amounts would be subject to the new guidance applicable to revenue recognition effective January 1, 2018 using the modified retrospective adoption approach.  Pursuant to the new guidance, the Company would record a cumulative effect adjustment to the Company’s accumulated deficit in the first quarter of 2018. The amount of the adjustment to accumulated deficit would be determined based upon (i) the status of pricing discussions in France upon adoption and (ii) the Company’s estimate of the amount of consideration the Company expects to retain related to the French ORKAMBI sales that occurred on or prior to December 31, 2017 that would not be subject to a significant reversal in amounts recognized. For French ORKAMBI sales after December 31, 2017 under the early access programs, the Company would recognize product revenues based on the Company’s estimate of consideration the Company expects to retain for which it is probable that a significant reversal in amounts recognized will not occur. In future periods, if the Company’s estimates regarding the amounts it will receive for ORKAMBI supplied pursuant to these programs change, the effect of the change in estimates would be reflected in net product revenues in the period in which the change in estimate occurred.
The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2017:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2016
$
2,568

 
$
81,927

 
$
3,492

 
$
1,214

 
$
89,201

Provision related to current period sales
18,776

 
118,592

 
3,603

 
12,238

 
153,209

Adjustments related to prior period sales
(188
)
 
(4,327
)
 
(13
)
 
(355
)
 
(4,883
)
Credits/payments made
(18,409
)
 
(97,393
)
 
(1,809
)
 
(10,021
)
 
(127,632
)
Balance at September 30, 2017
$
2,747

 
$
98,799

 
$
5,273

 
$
3,076

 
$
109,895



10
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

C.
Collaborative Arrangements and Acquisitions
Cystic Fibrosis Foundation Therapeutics Incorporated
The Company has a research, development and commercialization agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (“CFFT”) that was originally entered into in May 2004, and was most recently amended in October 2016 (the “2016 Amendment”). Pursuant to the agreement, as amended, the Company has agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016 and tiered royalties ranging from single digits to sub-teens on any approved drugs first synthesized and/or tested during a research term on or before February 28, 2014, including (i) KALYDECO (ivacaftor) and ORKAMBI (lumacaftor in combination with ivacaftor), which are the Company’s current products and (ii) tezacaftor in combination with ivacaftor. For combination products, such as ORKAMBI, sales will be allocated equally to each of the active pharmaceutical ingredients in the combination product.
In the first quarter of 2016, CFFT earned a commercial milestone payment of $13.9 million from the Company upon achievement of certain sales levels of lumacaftor. There are no additional commercial milestone payments payable by the Company to CFFT pursuant to the agreement. Pursuant to the 2016 Amendment, the CFFT provided the Company an upfront program award of $75.0 million and agreed to provide development funding to the Company of up to $6.0 million annually. The program award plus any future development funding represent a form of financing pursuant to Accounting Standards Codification (ASC) 730, Research and Development, and thus the amounts are recorded as a liability on the condensed consolidated balance sheet, primarily reflected in Advance from collaborator. The liability is reduced over the estimated royalty term of the agreement. Reductions in the liability are reflected as an offset to cost of product revenues and as interest expense.
The Company has royalty obligations to CFFT for ivacaftor, lumacaftor and tezacaftor until the expiration of patents covering those compounds. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent extensions. The Company has patents in the United States and European Union covering the composition-of-matter of lumacaftor that expire in 2030 and 2026, respectively, subject to potential extension. The Company has patents in the United States and European Union covering the composition-of-matter of tezacaftor that expire in 2027 and 2028, respectively, subject to potential extension.
CRISPR Therapeutics AG
In 2015, the Company entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. The Company has the exclusive right to license up to six CRISPR-Cas9-based targets, including targets for the potential treatment of sickle cell disease. In connection with the CRISPR Agreement, the Company made an upfront payment to CRISPR of $75.0 million and a $30.0 million investment in CRISPR pursuant to a convertible loan agreement that converted into preferred stock in January 2016. The Company expensed $75.0 million to research and development, and the $30.0 million investment was recorded at cost and was classified as a long-term asset on the Company’s condensed consolidated balance sheets. In the second quarter of 2016, the Company made an additional preferred stock investment in CRISPR of approximately $3.1 million. In connection with CRISPR’s initial public offering in October 2016, the Company purchased $10.0 million of common shares at the public offering price and the Company’s preferred stock investments in CRISPR converted into common shares. As of September 30, 2017, the Company recorded the fair value of its investment in CRISPR common shares of $56.9 million in marketable securities and a $13.7 million unrealized gain related to these common shares in accumulated other comprehensive income (loss) on the condensed consolidated balance sheet.
The Company will fund all of the discovery activities conducted pursuant to the CRISPR Agreement. For potential hemoglobinapathy treatments, including treatments for sickle cell disease, the Company and CRISPR will share equally all development costs and worldwide revenues. For other targets that the Company elects to license, the Company would lead all development and global commercialization activities. For each of up to six targets that the Company elects to license, other than hemoglobinapathy targets, CRISPR has the potential to receive up to $420.0 million in development, regulatory and commercial milestones and royalties on net product sales.


11
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The Company may terminate the CRISPR Agreement upon 90 days’ notice to CRISPR prior to any product receiving marketing approval or upon 270 days’ notice after a product has received marketing approval. The CRISPR Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the CRISPR Agreement will continue in effect until the expiration of the Company’s payment obligations under the CRISPR Agreement.
Merck KGaA

On January 10, 2017, the Company entered into a strategic collaboration and license agreement (the “Merck KGaA Agreement”) with Merck KGaA, Darmstadt, Germany (“Merck KGaA”). Pursuant to the Merck KGaA Agreement, the Company granted Merck KGaA an exclusive worldwide license to research, develop and commercialize four oncology research and development programs. Under the Merck KGaA Agreement, the Company granted Merck KGaA exclusive, worldwide rights to two clinical-stage programs targeting DNA damage repair: its ataxia telangiectasia and Rad3-related protein inhibitor program, including VX-970 and VX-803, and its DNA-dependent protein kinase inhibitor program, including VX-984. In addition, the Company granted Merck KGaA exclusive, worldwide rights to two pre-clinical programs.

The Merck KGaA Agreement provided for an upfront payment from Merck KGaA to the Company of $230.0 million. During the first quarter of 2017, the Company received $193.6 million of the upfront payment and the remaining $36.4 million was remitted to the German tax authorities. Pursuant to a tax treaty between the United States and Germany, the Company filed a refund application for the tax withholding and expects to receive the refund in the fourth quarter of 2017. The income tax receivable is included in Prepaid expenses and other current assets at September 30, 2017. In addition to the upfront payment, the Company will receive tiered royalties on potential sales of licensed products, calculated as a percentage of net sales, that range from (i) mid-single digits to mid-twenties for clinical-stage programs and (ii) mid-single digits to high single digits for the pre-clinical research programs. Merck KGaA has assumed full responsibility for development and commercialization costs for all programs.

The Company evaluated the deliverables, primarily consisting of a license to the four programs and the obligation to complete certain fully-reimbursable research and development and transition activities as directed by Merck KGaA, pursuant to the Merck KGaA Agreement, under the multiple element arrangement accounting guidance. The Company concluded that the license has stand-alone value from the research and development and transition activities based on the resources and know-how possessed by Merck KGaA, and thus concluded that there are two units of accounting in the arrangement. The Company determined the relative selling price of the units of accounting based on the Company’s best estimate of selling price. The Company utilized key assumptions to determine the best estimate of selling price for the license, which included future potential net sales of licensed products, development timelines, reimbursement rates for personnel costs, discount rates, and estimated third-party development costs. The Company utilized a discounted cash flow model to determine its best estimate of selling price for the license and determined the best estimate of selling price for the research and development and transition activities based on what it would sell the services for separately. Based on this analysis, the Company recognized approximately $231.7 million in collaborative revenues related to the upfront payment upon delivery of the license and to the research and development and transition activities provided during the first quarter of 2017. During the three and nine months ended September 30, 2017, the Company recorded the reimbursement for the research and development and transition activities of $5.2 million and $12.8 million, respectively, as revenue in the Company’s consolidated statements of operations primarily due to the fact that the Company is the primary obligor in the arrangement. The Company is providing research and development and transition activities and will recognize the revenues and associated expenses as the services are provided.

Merck KGaA may terminate the Merck KGaA Agreement or any individual program by providing 90 days’ notice, or, in the case of termination of a program with a product that has received marketing approval, 180 days’ notice. The Merck KGaA Agreement also may be terminated by either party for a material breach by the other party, subject to notice and cure provisions. Unless earlier terminated, the Merck KGaA Agreement will continue in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.



12
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Variable Interest Entities
The Company has entered into several agreements pursuant to which it has licensed rights to certain drug candidates from third-party collaborators, resulting in the consolidation of the third parties’ financial statements into the Company’s condensed consolidated financial statements as VIEs. In order to account for the fair value of the contingent payments, which consist of milestone, royalty and option payments, related to these collaborations under GAAP, the Company uses present-value models based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the timing of achieving the milestones, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent payments. The following collaborations are reflected in the Company’s financial statements as consolidated VIEs for portions or all of the periods presented:

Parion Sciences, Inc.

In June 2015, the Company entered into a strategic collaboration and license agreement (the “Parion Agreement”) with Parion.  Pursuant to the agreement, the Company is collaborating with Parion to develop investigational epithelial sodium channel (“ENaC”) inhibitors, including VX-371 (formerly P-1037) and VX-551 (formerly P-1055), for the potential treatment of CF and all other pulmonary diseases.  The Company is leading development activities for VX-371 and VX-551 and is responsible for all costs, subject to certain exceptions, related to development and commercialization of the compounds.

Pursuant to the Parion Agreement, the Company has worldwide development and commercial rights to Parion’s lead investigational ENaC inhibitors, VX-371 and VX-551, for the potential treatment of CF and all other pulmonary diseases and has the option to select additional compounds discovered in Parion’s research program.  Parion received an $80.0 million up-front payment and has the potential to receive up to an additional (i) $490.0 million in development and regulatory milestone payments for development of ENaC inhibitors in CF, including $360.0 million related to global filing and approval milestones, (ii) $370.0 million in development and regulatory milestones for VX-371 and VX-551 in non-CF pulmonary indications and (iii) $230.0 million in development and regulatory milestones should the Company elect to develop an additional ENaC inhibitor from Parion’s research program. The Company has agreed to pay Parion tiered royalties that range from the low double digits to mid-teens as a percentage of potential sales of licensed products.

The Company may terminate the Parion Agreement upon 90 days’ notice to Parion prior to any licensed product receiving marketing approval or upon 180 days’ notice after a licensed product has received marketing approval. If the Company experiences a change of control prior to the initiation of the first Phase 3 clinical trial for a licensed product, Parion may terminate the Parion Agreement upon 30 days’ notice, subject to the Company’s right to receive specified royalties on any subsequent commercialization of licensed products. The Parion Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Parion Agreement will continue in effect until the expiration of the Company’s royalty obligations, which expire on a country-by-country basis on the later of (i) the date the last-to-expire patent covering a licensed product expires or (ii) ten years after the first commercial sale in the country.

The Company determined that it had a variable interest in Parion via the Parion Agreement, and that the variable interest represented a variable interest in Parion as a whole because the fair value of the ENaC inhibitors represented more than half of the total fair value of Parion’s assets. The Company also concluded that it was the primary beneficiary as it had the power to direct the activities that most significantly affect the economic performance of Parion and it had the obligation to absorb losses and right to receive benefits that potentially could be significant to Parion.  Accordingly, the Company consolidated Parion's financial statements from June 4, 2015 through September 30, 2017. The Company deconsolidated Parion effective September 30, 2017. Notwithstanding the applicable accounting treatment, the Company's interests in Parion have been and continue to be limited to those accorded to the Company in the Parion Agreement.



13
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

As of June 4, 2015, the Company consolidated Parion’s financial statements, which included $255.3 million of intangible assets on the Company’s condensed consolidated balance sheet for Parion’s in-process research and development assets. These in-process research and development assets relate to Parion’s pulmonary ENaC platform, including the intellectual property related to VX-371 and VX-551, that are licensed by Parion to the Company. The Company also recorded the fair value of the net assets attributable to noncontrolling interest of $164.3 million, deferred tax liability of $91.0 million resulting primarily from a basis difference in the intangible assets and certain other net liabilities held by Parion of $10.5 million.  The difference between the fair values of the consideration and noncontrolling interest and the fair value of Parion’s net assets was recorded as goodwill. When determining the valuation of goodwill, the fair value of consideration for the license was zero since there was no consideration transferred outside the condensed consolidated financial statements. While there was a transfer of $80.0 million for the upfront payment to Parion, the cash remained within the Company’s condensed consolidated balance sheet since Parion was part of the consolidated entity. The cash received, net of any cash spent by Parion, was classified as restricted cash and cash equivalents (VIE) within the condensed consolidated balance sheet as it was attributed to the noncontrolling interest holders of Parion.

In the second quarter of 2017, Parion signed a license agreement with an affiliate of Shire plc related to the development of a drug candidate for the potential treatment of dry eye disease. The Company evaluated the license agreement entered into by Parion as a reconsideration event to determine whether it should continue to consolidate Parion as a variable interest entity into its condensed consolidated financial statements. The Company determined that there was no substantive change in the design of Parion subsequent to Parion’s agreement with Shire. Additionally, the Company concluded that it was appropriate to continue to consolidate the financial results of Parion because it continued to have (i) the power to direct the activities that most significantly affect the economic performance of Parion and (ii) the obligation to absorb losses and right to receive benefits that potentially could be significant to Parion. Based on the consolidation of Parion’s financial statements, during the three and nine months ended September 30, 2017, the Company has recognized (i) $20.0 million and $40.0 million, respectively, of collaborative revenues and (ii) a tax provision of $7.4 million and $14.8 million, respectively, both of which were attributable to noncontrolling interest related to payments that Parion received from Shire in the three and nine months ended September 30, 2017. The Company has no interest in Parion’s license agreement with Shire, including the economic benefits and/or obligations derived therefrom.
As of September 30, 2017, the Company determined that the fair value of Parion’s pulmonary ENaC platform had declined significantly based on data received in September 2017 from a Phase 2 clinical trial of VX-371 that did not meet its primary efficacy endpoint. The Company recorded an impairment charge of $255.3 million, which represented the entire value of the intangible asset in the third quarter of 2017. After evaluating the results of the clinical trial, the Company determined that it was no longer the primary beneficiary of Parion as it no longer had the power to direct the significant activities of Parion. The most important factor in this determination was the decrease in the fair value of Parion’s pulmonary ENaC platform relative to Parion’s other activities. Accordingly, the Company deconsolidated Parion as of September 30, 2017. The impairment charge of $255.3 million, decrease in the fair value of the contingent payments payable by the Company to Parion of $69.6 million and benefit from income taxes of $126.2 million resulting from these charges were recorded in the third quarter of 2017 attributable to noncontrolling interest. The benefit from income taxes consisted of benefits of $97.7 million and $28.5 million attributable to the impairment charge and decrease in the fair value of contingent payments, respectively. The net effect of these charges and impact of the deconsolidation was a loss of $7.1 million recorded in other income (expense), net attributable to Vertex in the consolidated statement of operations for the three and nine months ended September 30, 2017. The loss of $7.1 million was approximately the difference between (i) the aggregate of $85.0 million in upfront and milestone payments that the Company has made to Parion to date pursuant to the Parion Agreement and (ii) losses the Company recorded in 2015, 2016, and the first half of 2017 based on increases in the fair value of contingent payments payable by the Company to Parion.
Please refer to Note J, "Intangible Assets and Goodwill," for further information regarding the impairment of Parion’s pulmonary ENaC platform.
In connection with the deconsolidation of Parion, the Company evaluated whether the results of Parion should be presented as discontinued operations for the three and nine month period ending September 30, 2017. The Company concluded that the deconsolidation of Parion based on data from the Phase 2 clinical trial of VX-371 is not a development that significantly impacts the Company’s overall operations and financial results or plans to treat patients with CF. Research


14
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

and development expenses incurred related to this program accounted for a minor portion of the Company’s overall annual research and development expenses and the Company remains focused on developing medicines to treat CF. Therefore, the Company has not presented the results related to Parion as discontinued operations in its condensed consolidated statements of operations for the three and nine month ending September 30, 2017.
BioAxone Biosciences, Inc.
In October 2014, the Company entered into a license and collaboration agreement (the “BioAxone Agreement”) with BioAxone Biosciences, Inc. (“BioAxone”), which resulted in the consolidation of BioAxone as a VIE beginning on October 1, 2014. The Company paid BioAxone initial payments of $10.0 million in the fourth quarter of 2014.
BioAxone has the potential to receive up to $90.0 million in milestones and fees, including development, regulatory and milestone payments and a license continuation fee. In addition, BioAxone would receive royalties and commercial milestones on future net product sales of VX-210, if any. The Company recorded an in-process research and development intangible asset of $29.0 million for VX-210 and a corresponding deferred tax liability of $11.3 million attributable to BioAxone. The Company holds an option to purchase BioAxone at a predetermined price. The option expires on the earliest of (a) the day the FDA accepts the Biologics License Application submission for VX-210, (b) the day the Company elects to continue the license instead of exercising the option to purchase BioAxone and (c) March 15, 2018, subject to the Company’s option to extend this date by one year.
Aggregate VIE Financial Information
An aggregate summary of net income attributable to noncontrolling interest related to the Company’s VIEs for the three and nine months ended September 30, 2017 and 2016 is as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Loss attributable to noncontrolling interest before (benefit from) provision for income taxes and changes in fair value of contingent payments
$
238,946

 
$
2,406

 
$
222,448

 
$
6,080

(Benefit from) provision for income taxes
(120,181
)
 
(510
)
 
(111,658
)
 
20,063

Decrease (increase) in fair value of contingent payments
69,550

 
(1,200
)
 
62,560

 
(59,350
)
Net loss (income) attributable to noncontrolling interest
$
188,315

 
$
696

 
$
173,350

 
$
(33,207
)

The decreases in the noncontrolling interest holders’ claim to net assets with respect to the fair value of the contingent payments in the three and nine months ended September 30, 2017 were primarily due to the decrease in the fair value of Parion’s pulmonary ENaC platform described above. The increases in the fair value of the contingent payments in the three and nine months ended September 30, 2016 were primarily due to a separate Phase 2 clinical trial of VX-371 achieving its primary safety endpoint in the second quarter of 2016. During the three and nine months ended September 30, 2017 and 2016, the (increases) decreases in the fair value of the contingent payments related to the Company’s VIEs were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Parion
$
69,550

 
$
(1,100
)
 
$
63,460

 
$
(58,500
)
BioAxone
—

 
(100
)
 
(900
)
 
(850
)

The fair value of the contingent payments related to the Parion Agreement and the BioAxone Agreement as of the dates set forth in the table:



15
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

 
September 30, 2017
 
December 31, 2016
 
(in thousands)
Parion
$
—

 
$
238,800

BioAxone
18,900

 
18,000


The table below summarizes items related to the Company’s VIEs included in the Company’s condensed consolidated balance sheets as of the dates set forth in the table. Amounts as of September 30, 2017 related to BioAxone while amounts as of December 31, 2016 related to Parion and BioAxone.
 
September 30, 2017
 
December 31, 2016
 
(in thousands)
Restricted cash and cash equivalents (VIE)
$
1,803

 
$
47,762

Prepaid expenses and other current assets
42

 
6,812

Intangible assets
29,000

 
284,340

Other assets
280

 
399

Accounts payable
455

 
415

Accrued expenses
1,021

 
1,330

Other liabilities, current portion
119

 
2,137

Deferred tax liability
8,338

 
131,446

Other liabilities, excluding current portion
—

 
300

Noncontrolling interest
12,167

 
181,609


The Company has recorded the VIEs’ cash and cash equivalents as restricted cash and cash equivalents (VIE) because (i) the Company does not have any interest in or control over the VIEs’ cash and cash equivalents and (ii) the Company’s agreements with each VIE do not provide for the VIEs’ cash and cash equivalents to be used for the development of the assets that the Company licensed from the applicable VIE. Assets recorded as a result of consolidating the Company’s VIEs’ financial condition into the Company’s balance sheets do not represent additional assets that could be used to satisfy claims against the Company’s general assets.
Other Collaborations
The Company has entered into various agreements pursuant to which it collaborates with third parties, including inlicensing and outlicensing arrangements. Although the Company does not consider any of these arrangements to be material, the most notable of these arrangements are described below.

Moderna Therapeutics, Inc.
In July 2016, the Company entered into a strategic collaboration and licensing agreement (the “Moderna Agreement”) with Moderna Therapeutics, Inc. (“Moderna”) pursuant to which the parties are seeking to identify and develop messenger Ribonucleic Acid (“mRNA”) Therapeutics for the treatment of CF. In connection with the Moderna Agreement, in the third quarter of 2016, the Company made an upfront payment to Moderna of $20.0 million and a $20.0 million cost-method investment in Moderna pursuant to a convertible promissory note that converted into preferred stock in August 2016. Moderna has the potential to receive future development and regulatory milestones of up to $275.0 million, including $220.0 million in approval and reimbursement milestones, as well as tiered royalty payments on future sales.
Under the terms of the Moderna Agreement, Moderna will lead discovery efforts and the Company will lead all preclinical, development and commercialization activities associated with the advancement of mRNA Therapeutics that result from this collaboration and will fund all expenses related to the collaboration.
The Company may terminate the Moderna Agreement by providing advance notice to Moderna, with the required length of notice dependent on whether any product developed under the Moderna Agreement has received marketing approval. The Moderna Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure


16
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

provisions. Unless earlier terminated, the Moderna Agreement will continue in effect until the expiration of the Company’s payment obligations under the Moderna Agreement.

The Company evaluates the carrying value of its $20.0 million cost-method investment in Moderna, which is not a publicly traded company, for impairment on a quarterly basis and has not recorded any adjustments to the carrying value of its investment to date.
Janssen Pharmaceuticals, Inc.
In June 2014, the Company entered into an agreement (the “Janssen Agreement”) with Janssen Pharmaceuticals, Inc. (“Janssen Inc.”), which was amended in October 2014 to clarify certain roles and responsibilities of the parties.

Pursuant to the Janssen Agreement, Janssen Inc. has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including JNJ-3872 (formerly VX-787). The Company received non-refundable payments of $35.0 million from Janssen Inc. in 2014, which were recorded as collaborative revenue. The Company has the potential to receive development, regulatory and commercial milestone payments as well as royalties on future product sales, if any. Janssen Inc. may terminate the Janssen Agreement, subject to certain exceptions, upon six months’ notice.
Janssen Inc. is responsible for costs related to the development and commercialization of the compounds. During the three and nine months ended September 30, 2017 the Company recorded reimbursement for these development activities of zero and $1.8 million, respectively. During the three and nine months ended September 30, 2016 the Company recorded reimbursement for these development activities of $2.8 million and $10.6 million, respectively. The reimbursements are recorded as a reduction to development expense in the Company’s condensed consolidated statements of operations primarily due to the fact that Janssen Inc. directs the activities and selects the suppliers associated with these activities.
Asset Acquisition
Concert Pharmaceuticals
In July 2017, the Company completed the acquisition of certain CF assets including VX-561 (formerly CTP-656) from Concert Pharmaceuticals Inc. (“Concert”) pursuant to an asset purchase agreement that was entered into in March 2017 (the “Concert Agreement”). VX-561 is an investigational CFTR potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of CF. As part of the Concert Agreement, Vertex paid Concert $160.0 million in cash for all worldwide development and commercialization rights to VX-561. If VX-561 is approved as part of a combination regimen to treat CF, Concert could receive up to an additional $90.0 million in milestones based on regulatory approval in the U.S. and reimbursement in the UK, Germany or France. The Company determined that substantially all of the fair value of the Concert Agreement was attributable to a single in-process research and development asset, VX-561, which did not constitute a business. The Company cannot conclude that there is any alternative future use for the acquired in-process research and development asset. Thus, the Company recorded the $160.0 million upfront payment as a research and development expense in the three and nine months ended September 30, 2017. The total purchase price for the transaction was $165.1 million including $5.1 million of transaction costs that were recorded as sales, general and administrative expenses. If the Company achieves one or more of the $90.0 million of regulatory approval and reimbursement milestones, the Company will record the value of the milestone as an intangible asset and will begin amortizing the asset in cost of product revenues in the period that the relevant milestone is achieved.
D.
Earnings Per Share
Basic net income (loss) per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net income (loss) per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.


17
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The following table sets forth the computation of basic and diluted net income (loss) per share for the periods ended:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands, except per share amounts)
Basic net income (loss) attributable to Vertex per common share calculation:
 
 
 
 
 
 
 
Net income (loss) attributable to Vertex common shareholders
$
(102,952
)
 
$
(38,841
)
 
$
162,800

 
$
(144,997
)
Less: Undistributed earnings allocated to participating securities
—

 
—

 
(203
)
 
—

Net income (loss) attributable to Vertex common shareholders—basic
$
(102,952
)
 
$
(38,841
)
 
$
162,597

 
$
(144,997
)
 
 
 
 
 
 
 
 
Basic weighted-average common shares outstanding
250,268

 
244,920

 
247,963

 
244,529

Basic net income (loss) attributable to Vertex per common share
$
(0.41
)
 
$
(0.16
)
 
$
0.66

 
$
(0.59
)
 
 
 
 
 
 
 
 
Diluted net income (loss) attributable to Vertex per common share calculation:
 
 
 
 
 
 
 
Net income (loss) attributable to Vertex common shareholders
$
(102,952
)
 
$
(38,841
)
 
$
162,800

 
$
(144,997
)
Less: Undistributed earnings allocated to participating securities
—

 
—

 
(200
)
 
—

Net income (loss) attributable to Vertex common shareholders—diluted
$
(102,952
)
 
$
(38,841
)
 
$
162,600

 
$
(144,997
)
 
 
 
 
 
 
 
 
Weighted-average shares used to compute basic net income (loss) per common share
250,268

 
244,920

 
247,963

 
244,529

Effect of potentially dilutive securities:
 
 
 
 
 
 
 
Stock options
—

 
—

 
2,700

 
—

Restricted stock and restricted stock units
—

 
—

 
1,204

 
—

Other
—

 
—

 
228

 
—

Weighted-average shares used to compute diluted net income (loss) per common share
250,268

 
244,920

 
252,095

 
244,529

Diluted net income (loss) attributable to Vertex per common share
$
(0.41
)
 
$
(0.16
)
 
$
0.64

 
$
(0.59
)
The Company did not include the securities in the following table in the computation of the dilutive net income (loss) per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Stock options
10,278

 
12,947

 
3,904

 
12,947

Unvested restricted stock and restricted stock units
4,241

 
3,624

 
281

 
3,624

E.
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market


18
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of September 30, 2017, the Company’s investments were primarily in money market funds, government-sponsored enterprise securities, corporate equity securities, corporate debt securities and commercial paper. Additionally, the Company utilizes foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on its condensed consolidated statement of operations.
As of September 30, 2017, all of the Company’s financial assets and liabilities that were subject to fair value measurements were valued using observable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, government-sponsored enterprise securities and corporate equity securities. The Company’s financial assets and liabilities valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consisted of investments in highly-rated investment-grade corporations and foreign currency forward contracts with highly reputable and creditworthy counterparties.
.


19
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The following table sets forth the Company’s financial assets (excluding VIE cash and cash equivalents, which are recorded as Restricted cash and cash equivalents (VIE)) and liabilities subject to fair value measurements:
 
Fair Value Measurements as of September 30, 2017
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
466,702

 
$
466,702

 
$
—

 
$
—

Government-sponsored enterprise securities
14,979

 
14,979

 
—

 
—

Corporate debt securities
4,488

 
—

 
4,488

 
—

Commercial paper
14,608

 
—

 
14,608

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
56,944

 
56,944

 
—

 
—

Corporate debt securities
295,171

 
—

 
295,171

 
—

Commercial paper
75,167

 
—

 
75,167

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
42

 
—

 
42

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
8

 
—

 
8

 
—

Total financial assets
$
928,109


$
538,625

 
$
389,484

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(13,897
)
 
$
—

 
$
(13,897
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(977
)
 
—

 
(977
)
 
—

Total financial liabilities
$
(14,874
)
 
$
—

 
$
(14,874
)
 
$
—

 
Fair Value Measurements as of December 31, 2016
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
280,560

 
$
280,560

 
$
—

 
$
—

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
15,508

 
15,508

 
—

 
—

Corporate equity securities
64,560

 
64,560

 
—

 
—

Commercial paper
59,404

 
—

 
59,404

 
—

Corporate debt securities
111,140

 
—

 
111,140

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
14,407

 
—

 
14,407

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
1,186

 
$
—

 
1,186

 
$
—

Total financial assets
$
546,765

 
$
360,628

 
$
186,137

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(144
)
 
$
—

 
$
(144
)
 
$
—

Total financial liabilities
$
(144
)
 
$
—

 
$
(144
)
 
$
—



20
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The Company’s VIE invested in cash equivalents consisting of money market funds of $1.5 million as of September 30, 2017, which are valued based on Level 1 inputs. These cash equivalents are not included in the table above. The Company’s noncontrolling interest related to the Company’s VIE includes the fair value of the contingent payments, which consist of milestone, royalty and option payments, which are valued based on Level 3 inputs. Please refer to Note C, “Collaborative Arrangements and Acquisitions,” for further information.
F.
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of September 30, 2017
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
1,350,891

 
$
—

 
$
—

 
$
1,350,891

Government-sponsored enterprise securities
14,979

 
—

 
—

 
14,979

Commercial paper
14,610

 
—

 
(2
)
 
14,608

Corporate debt securities
4,488

 
—

 
—

 
4,488

Total cash and cash equivalents
$
1,384,968

 
$
—

 
$
(2
)
 
$
1,384,966

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
43,213

 
13,731

 
—

 
56,944

Commercial paper (matures within 1 year)
75,186

 
1

 
(20
)
 
75,167

Corporate debt securities (matures within 1 year)
235,679

 
8

 
(106
)
 
235,581

Corporate debt securities (matures after 1 year)
59,651

 
—

 
(61
)
 
59,590

Total marketable securities
$
413,729

 
$
13,740

 
$
(187
)
 
$
427,282

Total cash, cash equivalents and marketable securities
$
1,798,697

 
$
13,740

 
$
(189
)
 
$
1,812,248

 
 
 
 
 
 
 
 
As of December 31, 2016
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
1,183,945

 
$
—

 
$
—

 
$
1,183,945

Total cash and cash equivalents
$
1,183,945

 
$
—

 
$
—

 
$
1,183,945

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (matures within 1 year)
$
15,506

 
$
2

 
$
—

 
$
15,508

Corporate equity securities
43,213

 
21,347

 
—

 
64,560

Commercial paper (matures within 1 year)
59,331

 
73

 
—

 
59,404

Corporate debt securities (matures within 1 year)
111,225

 
—

 
(85
)
 
111,140

Total marketable securities
$
229,275

 
$
21,422

 
$
(85
)
 
$
250,612

Total cash, cash equivalents and marketable securities
$
1,413,220

 
$
21,422

 
$
(85
)
 
$
1,434,557

The Company has a limited number of marketable securities in insignificant loss positions as of September 30, 2017, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs of the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in the three and nine months ended September 30, 2017 and 2016.


21
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

G.
Accumulated Other Comprehensive Income (Loss)
A summary of the Company’s changes in accumulated other comprehensive income (loss) by component is shown below:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains (Losses) on Marketable Securities, Net of Tax
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts, Net of Tax
 
Total
 
(in thousands)
Balance at December 31, 2016
$
(7,862
)
 
$
17,521

 
$
11,514

 
$
21,173

Other comprehensive loss before reclassifications
(11,137
)
 
(7,786
)
 
(25,981
)
 
(44,904
)
Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
(1,398
)
 
(1,398
)
Net current period other comprehensive (loss) income
$
(11,137
)
 
$
(7,786
)
 
$
(27,379
)
 
$
(46,302
)
Balance at September 30, 2017
$
(18,999
)
 
$
9,735

 
$
(15,865
)
 
$
(25,129
)
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains on Marketable Securities
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts, Net of Tax
 
Total
 
(in thousands)
Balance at December 31, 2015
$
(2,080
)
 
$
126

 
$
3,778

 
$
1,824

Other comprehensive (loss) income before reclassifications
(7,709
)
 
104

 
6,715

 
(890
)
Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
(4,779
)
 
(4,779
)
Net current period other comprehensive (loss) income
$
(7,709
)
 
$
104

 
$
1,936

 
$
(5,669
)
Balance at September 30, 2016
$
(9,789
)
 
$
230

 
$
5,714

 
$
(3,845
)
H.
Hedging
The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from one to eighteen months.
The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company’s risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company determines that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of September 30, 2017, all hedges were determined to be highly effective and the Company had not recorded any ineffectiveness related to the hedging program.
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:


22
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

 
As of September 30, 2017
 
As of December 31, 2016
Foreign Currency
(in thousands)
Euro
$
234,477

 
$
164,368

British pound sterling
77,387

 
65,237

Australian dollar
31,283

 
23,776

Total foreign currency forward contracts
$
343,147

 
$
253,381

The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company’s condensed consolidated balance sheets:
As of September 30, 2017
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
42

 
Other liabilities, current portion
 
$
(13,897
)
Other assets
 
8

 
Other liabilities, excluding current portion
 
(977
)
Total assets
 
$
50

 
Total liabilities
 
$
(14,874
)
As of December 31, 2016
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
14,407

 
Other liabilities, current portion
 
$
(144
)
Other assets
 
1,186

 
Other liabilities, excluding current portion
 
—

Total assets
 
$
15,593

 
Total liabilities
 
$
(144
)
As of September 30, 2017, the Company expects amounts recorded in prepaid and other currents assets and other liabilities, current portion to be reclassed to earnings within twelve months.
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s condensed consolidated balance sheets:
 
As of September 30, 2017
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
50

 
$
—

 
$
50

 
$
(50
)
 
$
—

Total liabilities
$
(14,874
)
 
$
—

 
$
(14,874
)
 
$
50

 
$
(14,824
)
 
As of December 31, 2016
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
15,593

 
$
—

 
$
15,593

 
$
(144
)
 
$
15,449

Total liabilities
$
(144
)
 
$
—

 
$
(144
)
 
$
144

 
$
—



23
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The Company also enters into foreign exchange forward contracts with contractual maturities of less than one month designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities including intercompany balances. The Company recognized losses of $4.1 million and $13.0 million, recorded in other income (expense), net, for the three and nine months ended September 30, 2017, respectively, related to foreign exchange contracts, which are not designated as hedging instruments under GAAP. The Company recognized a loss of  $1.2 million and a gain of $0.5 million, for the three and nine months ended September 30, 2016, respectively, related to foreign exchange contracts not designated as hedging instruments.

As of September 30, 2017, the notional amount of foreign exchange contracts where hedge accounting under GAAP is not applied was $113.8 million. The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts not designated for hedge accounting included on the Company’s condensed consolidated balance sheets:
 
As of September 30, 2017
 
As of December 31, 2016
 
(in thousands)
Prepaid expenses and other current assets
$
1,709

 
$
660


I. Inventories
Inventories consisted of the following:
 
As of September 30, 2017
 
As of December 31, 2016
 
(in thousands)
Raw materials
$
12,678

 
$
6,348

Work-in-process
67,826

 
56,672

Finished goods
17,688

 
14,584

Total
$
98,192

 
$
77,604

Based on its evaluation of, among other factors, information regarding tezacaftor's safety and efficacy, the Company has capitalized $9.6 million of inventory costs for tezacaftor manufactured in preparation for its potential product launch as of September 30, 2017. In periods prior, the Company expensed costs associated with tezacaftor’s raw materials and work-in-process as a development expense. The Company submitted a New Drug Application to the United States Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for tezacaftor in combination with ivacaftor. The Company plans to continue to monitor the status of the tezacaftor regulatory process and the other factors used to determine whether or not to capitalize the tezacaftor inventory and, if there are significant negative developments regarding tezacaftor, the Company could be required to impair previously capitalized costs.
J. Intangible Assets and Goodwill
Intangible Assets
As of September 30, 2017 and December 31, 2016, in-process research and development intangible assets of $29.0 million and $284.3 million, respectively, were recorded on the Company’s condensed consolidated balance sheet. In 2015, the Company recorded an in-process research development intangible asset of $255.3 million related to Parion’s pulmonary ENaC platform, including the intellectual property related to VX-371 and VX-551, that are licensed by Parion to the Company. In 2014, the Company recorded an in-process research development intangible asset of $29.0 million related to VX-210 that is licensed by BioAxone to the Company.
In connection with its preparation of its financial statements for the three and nine months ended September 30, 2017, the Company determined that there were indicators that the value of the pulmonary ENaC platform intangible asset had become impaired. The Company determined that the fair value of the intangible asset had decreased significantly based on data received in September 2017 from a Phase 2 clinical trial of VX-371 that did not meet its primary efficacy endpoint. Based on this data, the Company evaluated the fair value of Parion’s pulmonary ENaC platform using the discounted cash


24
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

flow approach from the perspective of a market participant and determined that the fair value of the intangible asset was zero as of September 30, 2017. The discounted cash flow model pertaining to the impairment of the pulmonary ENaC platform includes (i) assumptions regarding the probability of obtaining marketing approval for the drug candidate, (ii) estimates regarding the timing of and the expected costs to develop and commercialize the drug candidate, (iii) estimates of future cash flows from potential product sales with respect to the drug candidate and (iv) appropriate discount and tax rates. The Company recorded a $255.3 million impairment charge and a benefit from income taxes of $97.7 million in the three and nine months ended September 30, 2017 attributable to noncontrolling interest.
Goodwill
As of September 30, 2017 and December 31, 2016, goodwill of $50.4 million was recorded on the Company’s condensed consolidated balance sheet.
K. Long-term Obligations
Fan Pier Leases
In 2011, the Company entered into two lease agreements, pursuant to which the Company leases approximately 1.1 million square feet of office and laboratory space in two buildings (the “Fan Pier Buildings”) at Fan Pier in Boston, Massachusetts (the “Fan Pier Leases”). The Company commenced lease payments in December 2013, and will make lease payments pursuant to the Fan Pier Leases through December 2028. The Company has an option to extend the term of the Fan Pier Leases for an additional ten years.
Because the Company was involved in the construction project, the Company was deemed for accounting purposes to be the owner of the Fan Pier Buildings during the construction period and recorded project construction costs incurred by the landlord. Upon completion of the Fan Pier Buildings, the Company evaluated the Fan Pier Leases and determined that the Fan Pier Leases did not meet the criteria for “sale-leaseback” treatment. Accordingly, the Company began depreciating the asset and incurring interest expense related to the financing obligation in 2013. The Company bifurcates its lease payments pursuant to the Fan Pier Leases into (i) a portion that is allocated to the Buildings and (ii) a portion that is allocated to the land on which the Fan Pier Buildings were constructed. The portion of the lease obligations allocated to the land is treated as an operating lease that commenced in 2011.
Property and equipment, net, included $479.0 million and $489.0 million as of September 30, 2017 and December 31, 2016, respectively, related to construction costs for the Fan Pier Buildings. The carrying value of the Company’s lease agreement liability for the Fan Pier Buildings was $472.2 million and $472.6 million as of September 30, 2017 and December 31, 2016, respectively.
San Diego Lease
On December 2, 2015, the Company entered into a lease agreement for 3215 Merryfield Row, San Diego, California with ARE-SD Region No. 23, LLC (the “San Diego Building”). Pursuant to this agreement, the Company agreed to lease approximately 170,000 square feet of office and laboratory space in a building to be built in San Diego, California. The lease will commence upon completion of the building, scheduled for the first half of 2018, and will extend for 16 years from the commencement date. Pursuant to the lease agreement, during the initial 16-year term, the Company will pay an average of approximately $10.2 million per year in aggregate rent, exclusive of operating expenses. The Company has the option to extend the lease term for up to two additional five-year terms.

Because the Company is involved in the construction project, the Company is deemed for accounting purposes to be the owner of the San Diego Building during the construction period and recorded project construction costs incurred by the landlord. The Company bifurcates its lease payments pursuant to the San Diego Lease into (i) a portion that is allocated to the San Diego Building and (ii) a portion that is allocated to the land on which the San Diego Building was constructed. Although the Company will not begin making lease payments pursuant to the San Diego Lease until the commencement date, the portion of the lease obligation allocated to the land is treated for accounting purposes as an operating lease that commenced in the fourth quarter of 2016. Upon completion of the San Diego Building, the Company will evaluate the San


25
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Diego Lease and determine if the San Diego Lease meets the criteria for “sale-leaseback” treatment. If the San Diego Lease meets the “sale-leaseback” criteria, the Company will remove the asset and the related liability from its consolidated balance sheet and treat the San Diego Lease as either an operating or a capital lease based on the Company’s assessment of the accounting guidance. The Company expects that upon completion of construction of the San Diego Building the San Diego Lease will not meet the “sale-leaseback” criteria. If the San Diego Lease does not meet “sale-leaseback” criteria, the Company will treat the San Diego Lease as a financing obligation and will depreciate the asset over its estimated useful life.

Property and equipment, net, included $73.9 million and $15.0 million as of September 30, 2017 and December 31, 2016, respectively, related to construction costs for the San Diego Building. The carrying value of the Company’s lease agreement liability for the San Diego Building was $71.8 million and $12.6 million as of September 30, 2017 and December 31, 2016, respectively.

Revolving Credit Facility
In October 2016, the Company entered into a Credit Agreement (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein. The Credit Agreement provides for a $500.0 million revolving facility, $300.0 million of which was drawn at closing (the “Loans”) and was repaid in February 2017. The Credit Agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the borrowing capacity under the Credit Agreement be increased by an additional $300.0 million. The Credit Agreement matures on October 13, 2021.
The proceeds of the borrowing under the Credit Agreement were used primarily to repay the Company’s then outstanding indebtedness under the Macquarie Loan (as defined below). The Loans will bear interest, at the Company’s option, at either a base rate or a Eurodollar rate, in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.75% to 1.50% and the applicable margins on Eurodollar loans range from 1.75% to 2.50%, in each case based on the Company’s consolidated leverage ratio (the ratio of the Company’s total consolidated debt to the Company’s trailing twelve-month EBITDA).
The Loans are guaranteed by certain of the Company’s domestic subsidiaries and secured by substantially all of the Company’s assets and the assets of the Company’s domestic subsidiaries (excluding intellectual property, owned and leased real property and certain other excluded property) and by the equity interests of the Company’s subsidiaries, subject to certain exceptions. Under the terms of the Credit Agreement, the Company must maintain, subject to certain limited exceptions, a consolidated leverage ratio of 3.00 to 1.00 and consolidated EBITDA of at least $200.0 million, in each case to be measured on a quarterly basis.
The Credit Agreement contains customary representations and warranties and usual and customary affirmative and negative covenants. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Term Loan
In July 2014, the Company entered into a credit agreement with the lenders party thereto, and Macquarie US Trading LLC (“Macquarie”), as administrative agent. The credit agreement provided for a $300.0 million senior secured term loan (the “Macquarie Loan”). On October 13, 2016, the Company terminated and repaid all outstanding obligations under the Macquarie Loan.
The Macquarie Loan initially bore interest at a rate of 7.2% per annum, which was reduced to 6.2% per annum based on the FDA’s approval of ORKAMBI. The Term Loan bore interest at a rate of LIBOR plus 5.0% per annum during the third year of the term.
The Company incurred $5.3 million in fees paid to Macquarie that were recorded as a discount on the Macquarie Loan and were recorded as interest expense using the effective interest method over the term of the loan in the Company’s condensed consolidated statements of operations.
L. Stock-based Compensation Expense


26
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

During the three and nine months ended September 30, 2017 and 2016, the Company recognized the following stock-based compensation expense:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
 
 
Stock options
$
25,969

 
$
28,773

 
$
80,865

 
$
86,859

Restricted stock and restricted stock units
46,737

 
30,966

 
131,388

 
88,107

ESPP share issuances
2,428

 
2,425

 
6,738

 
6,385

Less stock-based compensation expense capitalized to inventories
(1,364
)
 
(955
)
 
(3,657
)
 
(2,728
)
Total stock-based compensation included in costs and expenses
$
73,770

 
$
61,209

 
$
215,334

 
$
178,623

 
 
 
 
 
 
 


Stock-based compensation expense by line item:
 
 
 
 
 
 
 
Research and development expenses
$
46,186

 
$
39,980

 
$
134,855

 
$
115,068

Sales, general and administrative expenses
27,584

 
21,229

 
80,479

 
63,555

Total stock-based compensation included in costs and expenses
$
73,770

 
$
61,209

 
$
215,334

 
$
178,623

The following table sets forth the Company’s unrecognized stock-based compensation expense by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of September 30, 2017
 
Unrecognized Expense
 
Weighted-average
Recognition Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
175,298

 
2.60
Restricted stock and restricted stock units
$
289,008

 
2.64
ESPP share issuances
$
2,636

 
0.46


27
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The following table summarizes information about stock options outstanding and exercisable at September 30, 2017:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$18.93–$20.00
 
128

 
0.35
 
$
18.93

 
128

 
$
18.93

$20.01–$40.00
 
834

 
2.21
 
$
34.51

 
834

 
$
34.51

$40.01–$60.00
 
877

 
4.83
 
$
49.17

 
877

 
$
49.17

$60.01–$80.00
 
821

 
6.46
 
$
75.62

 
649

 
$
75.44

$80.01–$100.00
 
4,587

 
8.33
 
$
89.37

 
1,397

 
$
89.47

$100.01–$120.00
 
1,137

 
7.36
 
$
109.34

 
586

 
$
109.24

$120.01–$140.00
 
1,260

 
7.88
 
$
130.24

 
688

 
$
129.86

$140.01–$160.00
 
—

 
0.00
 
$
—

 
—

 
$
—

$160.01–$163.74
 
634

 
9.80
 
$
162.94

 
3

 
$
162.94

Total
 
10,278

 
7.22
 
$
91.28

 
5,162

 
$
77.92

M. Other Arrangements
Sale of HIV Protease Inhibitor Royalty Stream
In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of $160.0 million. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline plc. As of September 30, 2017, the Company had $8.0 million in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.
N. Income Taxes
The Company is subject to United States federal, state, and foreign income taxes. For the three and nine months ended September 30, 2017, the Company recorded a benefit from income taxes of $125.9 million and $117.6 million, respectively, which included a benefit of $120.2 million and $111.7 million, respectively, related to the Company’s VIEs’ income tax provision. The VIEs’ benefit from income taxes during the the three and nine months ended September 30, 2017 related primarily to the impairment of Parion’s pulmonary ENaC platform and decrease in the fair value of the contingent payments payable by the Company to Parion. The Company has no liability for taxes payable by the Company’s VIEs and the income tax provision and related liability have been allocated to noncontrolling interest. For the three and nine months ended September 30, 2016, the Company recorded a provision for income taxes of $0.5 million and $24.1 million, respectively, which included a benefit of $0.5 million and a provision of $20.1 million, respectively, related to the Company’s VIEs’ income tax provision.
As of September 30, 2017 and December 31, 2016, the Company did not have unrecognized tax benefits. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. As of September 30, 2017, no interest and penalties have been accrued. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of September 30, 2017 and December 31, 2016.
The Company continues to maintain a valuation allowance on the majority of its net operating losses and other deferred tax assets because it has a history of cumulative losses.  Accordingly, the Company has not reported any tax benefit relating


28
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

to the remaining net operating loss carryforwards (NOLs) and income tax credit carryforwards that will be utilized in future periods in these jurisdictions.  The Company’s U.S. federal net operating loss carryforwards totaled approximately $4.1 billion as of December 31, 2016. On a quarterly basis, the Company reassesses the valuation allowance on its deferred income tax assets weighing positive and negative evidence to assess the recoverability of the deferred tax assets. Based on the Company’s recent financial performance and its future projections, it could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods.  However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The Company’s total deferred tax asset balance subject to the valuation allowance was approximately $1.7 billion at December 31, 2016.
As described in Note A, “Basis of Presentation and Accounting Policies”, the Company adopted amended guidance, during the nine month period ended September 30, 2017. The amended guidance eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in additional paid-in capital and requires excess tax benefits and tax deficiencies to be recorded in the condensed consolidated statement of operations when the awards vest or are settled. Amendments related to accounting for excess tax benefits have been adopted prospectively, resulting in a tax benefit of $31.4 million and $62.2 million for the three and nine months ended September 30, 2017, respectively. In connection with the adoption of this new standard, the Company recorded a cumulative-effect adjustment of $410.8 million as of January 1, 2017 to accumulated deficit and deferred tax assets, with an equal offsetting adjustment to the Company’s valuation allowance. In addition, the Company has recorded $9.4 million related to the impact from adoption of the provisions related to forfeiture rates to accumulated deficit. This change also increased the Company’s deferred tax assets by $3.4 million that is offset by an increase to the valuation allowance in the same amount.

The Company files United States federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction for years before 2011, except where the Company has net operating losses or tax credit carryforwards that originate before 2011. The Company currently is under examination by the Canada Revenue Agency for the years ending December 31, 2011 through December 31, 2013. No adjustments have been reported.
At September 30, 2017, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to United States federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries.
O. Restructuring Liabilities
Research and Development Restructuring
In February 2017, the Company decided to consolidate its research activities into its Boston, Milton Park and San Diego locations and closed its research site in Canada affecting approximately 70 positions. The Company has incurred aggregate restructuring charges of approximately $12.3 million in the nine months ended September 30, 2017. As of September 30, 2017, the restructuring liability primarily relates to laboratory and office space for the research site in Canada that terminates in October 2018. The Company does not anticipate any significant additional charges related to this restructuring event in the future.


29
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The restructuring charge and other activities recorded during the the three and nine months ended September 30, 2017 and the related liability balance as of September 30, 2017 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2017
 
(in thousands)
Liability, beginning of the period
$
3,507

 
$
—

Restructuring (credits) expense
(125
)
 
12,315

Cash payments
(750
)
 
(7,869
)
Asset impairments and other non-cash items
—

 
(1,814
)
Liability, end of the period
$
2,632

 
$
2,632

2003 Kendall Restructuring
In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a 15-year lease that terminates in April 2018. The Company has not used more than 50% of this space since it adopted the plan to restructure its operations in 2003. This unused laboratory and office space currently is subleased to third parties.
The activities related to the restructuring liability for the three and nine months ended September 30, 2017 and 2016 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Liability, beginning of the period
$
1,990

 
$
6,388

 
$
4,328

 
$
7,944

Restructuring expense
227

 
30

 
1,054

 
222

Cash payments
(4,003
)
 
(5,340
)
 
(12,962
)
 
(13,104
)
Cash received from subleases
2,732

 
2,866

 
8,526

 
8,882

Liability, end of the period
$
946

 
$
3,944

 
$
946

 
$
3,944

Fan Pier Move Restructuring
In connection with the relocation of its Massachusetts operations to Fan Pier in Boston, Massachusetts, which commenced in 2013, the Company is incurring restructuring charges related to its remaining lease obligations at its facilities in Cambridge, Massachusetts. The majority of these restructuring charges were recorded in the third quarter of 2014 upon decommissioning three facilities in Cambridge. During 2015, the Company terminated two of these lease agreements resulting in a credit to restructuring expense equal to the difference between the Company’s estimated future cash flows related to its lease obligations for these facilities and the termination payment paid to the Company’s landlord on the effective date of the termination. The third major facility included in this restructuring activity is 120,000 square feet of the Kendall Square Facility that the Company continued to use for its operations following its 2003 Kendall Restructuring. The rentable square footage in this portion of the Kendall Square Facility was subleased to a third party in February 2015. The Company will continue to incur charges through April 2018 related to the difference between the Company’s estimated future cash flows related to this portion of the Kendall Square Facility, which include an estimate for sublease income to be received from the Company’s sublessee and its actual cash flows. The Company discounted the estimated cash flows related to this restructuring activity at a discount rate of 9%.
The activities related to the restructuring liability for the three and nine months ended September 30, 2017 and 2016 were as follows:


30
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Liability, beginning of the period
$
1,521

 
$
4,863

 
$
3,626

 
$
5,964

Restructuring expense
235

 
90

 
490

 
472

Cash payments
(3,262
)
 
(4,199
)
 
(10,578
)
 
(10,451
)
Cash received from subleases
2,279

 
2,539

 
7,235

 
7,308

Liability, end of the period
$
773

 
$
3,293

 
$
773

 
$
3,293

Other Restructuring Activities
The Company has engaged in several other restructuring activities that are unrelated to its Research and Development Restructuring, 2003 Kendall Restructuring and Fan Pier Move Restructuring. The most significant activity commenced in October 2013 when the Company adopted a restructuring plan that included (i) a workforce reduction primarily related to the commercial support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection neared approval and (ii) the write-off of certain assets. This action resulted from the Company’s decision to focus its investment on future opportunities in CF and other research and development programs.
The remaining restructuring activities were completed in 2016. As such, there was no outstanding liability as of September 30, 2017. The activities related to the Company’s other restructuring liabilities for the three and nine months ended September 30, 2016 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2016
 
(in thousands)
Liability, beginning of the period
$
1,233

 
$
1,450

Restructuring expense
(112
)
 
344

Cash payments
(1,121
)
 
(1,794
)
Liability, end of the period
$
—

 
$
—

P. Commitments and Contingencies
Guaranties and Indemnifications
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of September 30, 2017 or December 31, 2016.


31

Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
We are in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. We use precision medicine approaches with the goal of creating transformative medicines for patients in specialty markets. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and development programs in other indications. Our two marketed products are ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor) and we are currently seeking approval for tezacaftor in combination with ivacaftor, which is a two-drug combination regimen for patients with CF. We currently are evaluating multiple triple combination regimens that include next-generation CFTR corrector compounds in patients with CF in Phase 2 clinical trials and plan to initiate pivotal development of one or two triple-combination regimens in the first half of 2018.
Cystic Fibrosis
ORKAMBI and KALYDECO are collectively approved to treat approximately 40% of the 75,000 CF patients in North America, Europe and Australia. ORKAMBI is approved as a treatment for approximately 25,000 patients who have two copies of the F508del mutation, or F508del homozygous, in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene. KALYDECO is approved for the treatment of approximately 6,000 CF patients who have the G551D mutation or other specified mutations in their CFTR gene. Our goal is to develop treatment regimens that will provide benefits to as many patients with CF as possible and will enhance the benefits that currently are being provided to patients taking our medicines.
If tezacaftor in combination with ivacaftor is approved, we expect that it would provide an additional treatment option primarily to CF patients who are currently eligible for either ORKAMBI or KALYDECO. If we are able to successfully develop a triple combination regimen that includes a next-generation CFTR corrector compound, including VX-440, VX-152, VX-659 or VX-445, we believe such regimen could potentially provide benefit to all CF patients who have at least one F508del mutation in their CFTR gene (approximately 90% of all CF patients). This would include (i) the first treatment option that treats the underlying cause of CF for patients who have one copy of the F508del mutation in their CFTR gene and a second mutation in their CFTR gene that results in minimal CFTR function, or F508del/Min patients, and (ii) an additional treatment option to CF patients who are eligible for either ORKAMBI, KALYDECO or, if approved, tezacaftor in combination with ivacaftor.
ORKAMBI
In October 2017, we obtained results from a 2-part open-label Phase 3 clinical trial of ORKAMBI in 60 patients with CF two to five years of age who have two copies of the F508del mutation in their CFTR gene. The clinical trial met its primary endpoint of safety, showing ORKAMBI was generally well tolerated and that there were no new safety concerns compared to prior clinical trials of ORKAMBI in patients six through eleven years of age. Secondary endpoints showed decreases in the sweat chloride and improvements in nutritional status as measured by change in weight (weight-for-age z score) and body mass index (BMI-for-age z score). Based on these results, we expect to submit a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, and a Marketing Authorization Application, or MAA, line extension to the European Medicines Agency, or EMA, in the first quarter of 2018.
KALYDECO
We are evaluating KALYDECO in a Phase 3 clinical trial in patients with CF two years of age and younger with one of 10 gating and R117H mutations. The clinical trial will evaluate the safety of KALYDECO in this age group. We have completed enrollment in patients aged 12 to 24 months.
Tezacaftor in combination with ivacaftor
In the first quarter of 2017, we obtained positive results from two Phase 3 clinical trials of tezacaftor, a corrector compound, in combination with ivacaftor. The clinical trials demonstrated that the tezacaftor/ivacaftor combination provided statistically significant improvements in lung function (percent predicted forced expiratory volume in one second, or ppFEV1) in patients with CF 12 years of age and older who have certain mutations in their CFTR gene. The 24-week EVOLVE clinical trial evaluated tezacaftor in combination with ivacaftor in F508del homozygous patients with CF. This clinical trial met its primary endpoint with a mean absolute improvement in ppFEV1 through 24 weeks of 4.0 percentage points from baseline compared to placebo (p < 0.0001). The second clinical trial, EXPAND, was an 8-week crossover clinical trial that evaluated the combination treatment in patients with CF who have one mutation that results in residual CFTR function and one F508del mutation. This clinical trial met the primary endpoints of absolute change in ppFEV1 from baseline to the average of the Week


32

4 and Week 8 measurements, with the tezacaftor/ivacaftor combination treatment demonstrating a mean absolute improvement of 6.8 percentage points compared to placebo (p < 0.0001) and the ivacaftor monotherapy group demonstrating a mean absolute improvement of 4.7 percentage points compared to placebo (p < 0.0001). Across both clinical trials, the tezacaftor/ivacaftor combination treatment was generally well tolerated.
Based on these results, we submitted a NDA to the FDA and an MAA to the EMA for tezacaftor in combination with ivacaftor in patients with CF 12 years of age and older who are F508del homozygous or who have one copy of the F508del mutation in their CFTR gene and a second mutation in their CFTR gene that results in residual CFTR function. The FDA has granted us priority review of the NDA and the target date for the FDA to complete its review of the NDA under the Prescription Drug User Fee Act, or PDUFA, is February 28, 2018. We expect the EMA to complete its review in the second half of 2018.
In October 2017, we announced top-line results from a Phase 3, randomized, double-blind, parallel group, clinical trial evaluating the combination of tezacaftor and ivacaftor in patients with CF 12 years of age and older who were already receiving ivacaftor monotherapy with one copy of the F508del mutation and one copy of a gating mutation. The clinical trial enrolled 151 patients with CF. The clinical trial did not meet its primary endpoint of absolute change in ppFEV1 from baseline through 8 weeks. For those receiving the combination of tezacaftor and ivacaftor, ppFEV1 improved by 0.5 percentage points compared to 0.2 percentage points in those receiving placebo in addition to ivacaftor (p=0.5846). Safety data from the clinical trial showed that the combination of tezacaftor and ivacaftor was generally well tolerated and were consistent with prior Phase 3 clinical trials of the tezacaftor/ivacaftor combination. Secondary endpoints were changes in sweat chloride and change in CFQ-R. Sweat chloride decreased by 5.8 mmol/L in those who received tezacaftor in combination with ivacaftor as compared to those who received placebo in addition to ivacaftor (p=0.0216). There was no change in CFQ-R in the combination group compared to the ivacaftor monotherapy group. Based on these results, we do not plan to seek regulatory approval for tezacaftor in combination with ivacaftor for these patients, the vast majority of whom are eligible for KALYDECO monotherapy.
Next-generation CFTR corrector compounds
In July 2017, we obtained positive results from Phase 1 and Phase 2 clinical trials of three different triple combination regimens in patients with CF who have one copy of the F508del mutation in their CFTR gene and a second mutation that results in minimal CFTR function. Initial data from the Phase 2 clinical trials showed mean absolute improvements in ppFEV1 of 9.7 and 12.0 percentage points for VX-152 (200mg q12h) and VX-440 (600mg q12h), respectively, in triple combination with tezacaftor and ivacaftor. Initial data from the Phase 1 clinical trial showed mean absolute improvement in ppFEV1 of 9.6 percentage points for VX-659 in triple combination with tezacaftor and ivacaftor. We amended our ongoing Phase 2 clinical trials of VX-445 and VX-659 to include additional cohorts of patients to evaluate these next-generation CFTR corrector compounds as part of a potential once-daily combination with tezacaftor and VX-561 (formerly CTP-656), the latter of which we acquired from Concert Pharmaceuticals, Inc., or Concert, in the third quarter of 2017. We expect to report additional data on our next-generation corrector program in early 2018. Pending data from these clinical trials and discussions with regulatory agencies, we plan to initiate pivotal development of one or two triple combination regimens in the first half of 2018.
ENaC Inhibition
VX-371 is an investigational epithelial sodium channel, or ENaC, inhibitor, that we exclusively licensed from Parion Sciences, Inc., or Parion, in 2015. In October 2017, we announced the results of a Phase 2 28-day clinical trial evaluating VX-371 + hypertonic saline versus hypertonic saline alone in 142 patients with CF 12 years of age and older who are homozygous for the F508del mutation and were already receiving ORKAMBI and continued to receive ORKAMBI throughout the clinical trial. The clinical trial did not meet its primary efficacy endpoint. In patients being treated with ORKAMBI, the addition of hypertonic saline resulted in a decrease of 0.1 percentage points ppFEV1 at day 28. In patients being treated with ORKAMBI, the addition of VX-371 + hypertonic saline resulted in an increase of 0.1 percentage points ppFEV1 at day 28. Safety data from the clinical trial showed that the addition of VX-371, with or without hypertonic saline, was generally well tolerated in patients already receiving ORKAMBI, and the safety profile was consistent with that observed in prior clinical trials of VX-371 monotherapy. Based on the results of this clinical trial, we recognized an impairment charge related to Parion’s pulmonary ENaC platform in third quarter of 2017 and deconsolidated Parion as a VIE, effective September 30, 2017.
A Phase 2 clinical trial of VX-371 monotherapy in patients with primary ciliary dyskinesia (PCD) is ongoing.


33

Research and Development    
We are engaged in a number of other research and mid- and early-stage development programs, including VX-150 for pain and VX-210 for acute spinal cord injury. We have also entered into third-party collaborations, pursuant to which we are engaged in the discovery and development of nucleic acid-based therapies for a variety of diseases, including CF. We plan to continue investing in our research programs and fostering scientific innovation in order to identify and develop transformative medicines. Our current research programs include programs targeting cystic fibrosis, adrenoleukodystrophy, alpha-1 antritrypsin deficiency, sickle cell disease and polycystic kidney disease. We believe that pursuing research in diverse areas allows us to balance the risks inherent in drug development and may provide drug candidates that will form our pipeline in future years.
Discovery and development of a new pharmaceutical product is a difficult and lengthy process that requires significant financial resources along with extensive technical and regulatory expertise and can take 10 to 15 years or more. Potential drug candidates are subjected to rigorous evaluations, driven in part by stringent regulatory considerations, designed to generate information concerning efficacy, side-effects, proper dosage levels and a variety of other physical and chemical characteristics that are important in determining whether a drug candidate should be approved for marketing as a pharmaceutical product. Most chemical compounds that are investigated as potential drug candidates never progress into development, and most drug candidates that do advance into development never receive marketing approval. Because our investments in drug candidates are subject to considerable risks, we closely monitor the results of our discovery, research, clinical trials and nonclinical studies and frequently evaluate our drug development programs in light of new data and scientific, business and commercial insights, with the objective of balancing risk and potential. This process can result in abrupt changes in focus and priorities as new information becomes available and as we gain additional understanding of our ongoing programs and potential new programs, as well as those of our competitors.
If we believe that data from a completed registration program support approval of a drug candidate, we submit an NDA to the FDA requesting approval to market the drug candidate in the United States and seek analogous approvals from comparable regulatory authorities in foreign jurisdictions. To obtain approval, we must, among other things, demonstrate with evidence gathered in nonclinical studies and well-controlled clinical trials that the drug candidate is safe and effective for the disease it is intended to treat and that the manufacturing facilities, processes and controls for the manufacture of the drug candidate are adequate. The FDA and foreign regulatory authorities have substantial discretion in deciding whether or not a drug candidate should be granted approval based on the benefits and risks of the drug candidate in the treatment of a particular disease, and could delay, limit or deny regulatory approval. If regulatory delays are significant or regulatory approval is limited or denied altogether, our financial results and the commercial prospects for the drug candidate involved will be harmed.
Collaboration Arrangements
We have entered into collaborations with biotechnology and pharmaceutical companies in order to acquire rights or to license drug candidates or technologies that enhance our pipeline and/or our research capabilities. Over the last several years, we entered into collaboration agreements with:
•
CRISPR Therapeutics AG, or CRISPR, pursuant to which we are collaborating on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology;
•
Parion, pursuant to which we are developing ENaC inhibitors for the treatment of pulmonary diseases;
•
Moderna Therapeutics, Inc., or Moderna, pursuant to which we are seeking to identify and develop mRNA therapeutics for the treatment of CF; and
•
BioAxone Biosciences, Inc., or BioAxone, pursuant to which we are evaluating VX-210 as a potential treatment for patients who have spinal cord injuries.
Generally, when we in-license a technology or drug candidate, we make upfront payments to the collaborator, assume the costs of the program and agree to make contingent payments, which could consist of milestone, royalty and option payments. Depending on many factors, including the structure of the collaboration, the significance of the drug candidate that we license to the collaborator’s operations and the other activities in which our collaborators are engaged, the accounting for these transactions can vary significantly. For example, the upfront payments and expenses incurred in connection with our CRISPR and Moderna collaborations are being expensed as research expenses because (i) the collaboration represents a small portion of the overall business of these collaborators and (ii) the licenses associated with these collaborations do not represent a business pursuant to the consolidation accounting guidance. CRISPR’s and Moderna’s activities unrelated to our collaborations have no effect on our consolidated financial statements. Parion and BioAxone have historically been accounted for as variable interest entities, or VIEs, that were included in our consolidated financial statements due to (i) the significance


34

of the respective licensed programs to Parion and BioAxone as a whole, (ii) our power to control the significant activities under each collaboration and (iii) our obligation to absorb losses and right to receive benefits that potentially could be significant. As of September 30, 2017, we determined that the above conditions were no longer satisfied with respect to Parion following a determination that the fair value of the ENaC inhibitors licensed from Parion had declined significantly based on the results of a Phase 2 clinical trial of VX-371 that did not meet its primary efficacy endpoint. As a result, we no longer account for Parion as a VIE and have deconsolidated Parion from our consolidated financial statements as of September 30, 2017. BioAxone continues to be accounted for as a VIE and remains included in our consolidated financial statements as of September 30, 2017.
Collaborators we account for as a VIE may engage in activities unrelated to our collaboration. The revenues and expenses unrelated to the programs we in-license from our VIEs have historically been immaterial to our consolidated financial statements. With respect to each of Parion, prior to its deconsolidation as of September 30, 2017, and BioAxone, the activities unrelated to our collaboration have represented approximately 2% of our total revenues and total expenses on an annual basis. As a result of the deconsolidation of Parion, we expect these amounts to decrease in future periods. For any consolidated VIEs, we evaluate the fair value of the contingent payments payable by us on a quarterly basis. Changes in the fair value of these contingent future payments affect net income attributable to Vertex on a dollar-for-dollar basis, with increases in the fair value of contingent payments payable by us to a VIE resulting in a decrease in net income attributable to Vertex (or an increase in net loss attributable to Vertex) and decreases in the fair value of contingent payments payable by us to a VIE resulting in an increase in net income attributable to Vertex (or decrease in net loss attributable to Vertex).
We also out-licensed internally developed programs to collaborators who are leading the development of these programs. These outlicense arrangements include our collaboration agreements with:
•
Merck KGaA, which is advancing four oncology research and development programs; and
•
Janssen Pharmaceuticals, Inc., which is developing JNJ-3872 (formerly VX-787) for the treatment of influenza.
Pursuant to these out-licensing arrangements, our collaborators are responsible for the research, development and commercialization costs associated with these programs and we are entitled to receive contingent milestone and/or royalty payments. As a result, we do not expect to incur significant expenses in connection with these programs and have the potential for future collaborative and/or royalty revenues resulting from these programs.

Regulatory Compliance
Our marketing of pharmaceutical products is subject to extensive and complex laws and regulations. We have a corporate compliance program designed to actively identify, prevent and mitigate risk through the implementation of compliance policies and systems, and through the promotion of a culture of compliance. Among other laws, regulations and standards, we are subject to various U.S. federal and state laws, and comparable foreign laws pertaining to health care fraud and abuse, including anti-kickback and false claims statutes, and laws prohibiting the promotion of drugs for unapproved or off-label uses. Anti-kickback laws make it illegal for a prescription drug manufacturer to solicit, offer, receive or pay any remuneration to induce the referral of business, including the purchase or prescription of a particular drug. False claims laws prohibit anyone from presenting for payment to third-party payors, including Medicare and Medicaid, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. We expect to continue to devote substantial resources to maintain, administer and expand these compliance programs globally.
Reimbursement
Sales of our products depend, to a large degree, on the extent to which our products are covered by third-party payors, such as government health programs, commercial insurance and managed health care organizations. We dedicate substantial management and other resources in order to obtain and maintain appropriate levels of reimbursement for our products from third-party payors, including governmental organizations in the United States and ex-U.S. markets. In the United States, we continue to engage in discussions with numerous commercial insurers and managed health care organizations, along with government health programs that are typically managed by authorities in the individual states. In Europe and other ex-U.S. markets, we are working to obtain government reimbursement for ORKAMBI on a country-by-country basis, because in many foreign countries patients are unable to access prescription pharmaceutical products that are not reimbursed by their governments.  To date, we have reached a pricing and reimbursement agreement for ORKAMBI with several European countries, including Germany, Ireland and Italy, and remain in negotiations with several others. Consistent with our experience with KALYDECO when it was first approved, we expect reimbursement discussions in ex-U.S. markets may take a significant period of time.


35

Recent Transaction
Concert Pharmaceuticals
In July 2017, we acquired certain CF assets, including VX-561, from Concert, pursuant to an agreement that we entered into in March 2017. VX-561 is an investigational CFTR potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of CF. Pursuant to the agreement, in the third quarter of 2017, we paid Concert $160.0 million in cash for all worldwide development and commercialization rights to VX-561. If VX-561 is approved as part of a combination regimen to treat CF, Concert could receive up to an additional $90.0 million in milestones based on regulatory approval in the U.S. and reimbursement in the UK, Germany or France. In the third quarter of 2017, we recorded the $160.0 million payment as a research and development expense.


36

RESULTS OF OPERATIONS
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2017
 
2016
 
$
 
%
 
2017
 
2016
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Revenues
$
578,165

 
$
413,783

 
$
164,382

 
40
%
 
$
1,837,018

 
$
1,243,471

 
$
593,547

 
48
%
Operating costs and expenses
904,208

 
432,510

 
471,698

 
109
%
 
1,839,512

 
1,273,175

 
566,337

 
44
%
Other items, net
223,091

 
(20,114
)
 
243,205

 
n/a

 
165,294

 
(115,293
)
 
280,587

 
n/a

Net (loss) income attributable to Vertex
$
(102,952
)
 
$
(38,841
)
 
$
(64,111
)
 
n/a

 
$
162,800

 
$
(144,997
)
 
$
307,797

 
n/a

Net Income (Loss) Attributable to Vertex
Net loss attributable to Vertex was $(103.0) million in the third quarter of 2017 as compared to a net loss attributable to Vertex of $(38.8) million in the third quarter of 2016. Our revenues increased in the third quarter of 2017 as compared to the third quarter of 2016 primarily due to increased ORKAMBI and KALYDECO net product revenues. Our operating costs and expenses in the third quarter of 2017 included a $255.3 million impairment charge related to Parion’s pulmonary ENaC platform and a $160.0 million payment to Concert in connection with the acquisition of VX-561, for which there were no comparable expenses in the third quarter of 2016. The increase in operating costs and expenses in the third quarter of 2017 as compared to the third quarter of 2016 also included increases in cost of product revenues, research and development expenses and sales, general and administrative expenses. Other items, net, in the third quarter of 2017 primarily reflects an income tax benefit and certain other benefits associated with the impairment of Parion’s pulmonary ENaC platform, for which there were no comparable benefits in the third quarter of 2016.
Net income attributable to Vertex was $162.8 million in the nine months ended September 30, 2017 as compared to a net loss attributable to Vertex of $(145.0) million in the nine months ended September 30, 2016. Our revenues increased significantly in the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016 due to increased ORKAMBI and KALYDECO net product revenues and $230.0 million in one-time collaborative revenues related to the strategic collaboration and license agreement we established with Merck KGaA in the first quarter of 2017. Our operating costs and expenses in the nine months ended September 30, 2017 included a $255.3 million impairment charge related to Parion’s pulmonary ENaC platform and a $160.0 million payment to Concert in connection with the acquisition of VX-561, for which there were no comparable expenses in the nine months ended September 30, 2016. The increase in operating costs and expenses in the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016 also included increases in cost of product revenues, research and development expenses, sales, general and administrative expenses and restructuring expenses. Other items, net, in the nine months ended September 30, 2017 primarily reflects an income tax benefit and certain other benefits associated with the impairment of Parion’s pulmonary ENaC platform, for which there were no comparable benefits in the nine months ended September 30, 2016.
Diluted Net Income (Loss) Per Share Attributable to Vertex Common Shareholders
Diluted net loss per share attributable to Vertex common shareholders was $(0.41) in the third quarter of 2017 as compared to a diluted net loss per share attributable to Vertex common shareholders of $(0.16) in the third quarter of 2016. Diluted net income per share attributable to Vertex common shareholders was $0.64 in the nine months ended September 30, 2017 as compared to a diluted net loss per share attributable to Vertex common shareholders of $(0.59) in the nine months ended September 30, 2016.


37

Revenues
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2017
 
2016
 
$
 
%
 
2017
 
2016
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Product revenues, net
$
549,642

 
$
409,689

 
$
139,953

 
34
 %
 
$
1,544,252

 
$
1,229,750

 
$
314,502

 
26
 %
Royalty revenues
2,231

 
3,835

 
(1,604
)
 
(42
)%
 
6,643

 
12,713

 
(6,070
)
 
(48
)%
Collaborative revenues
26,292

 
259

 
26,033

 
n/a

 
286,123

 
1,008

 
285,115

 
n/a

Total revenues
$
578,165

 
$
413,783

 
$
164,382

 
40
 %
 
$
1,837,018

 
$
1,243,471

 
$
593,547

 
48
 %
Product Revenues, Net
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2017
 
2016
 
$
 
%
 
2017
 
2016
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
ORKAMBI
$
336,183

 
$
234,046

 
$
102,137

 
44
%
 
$
955,451

 
$
702,670

 
$
252,781

 
36
%
KALYDECO
213,461

 
175,608

 
37,853

 
22
%
 
$
588,809

 
$
526,352

 
$
62,457

 
12
%
INCIVEK
(2
)
 
35

 
(37
)
 
n/a

 
(8
)
 
728

 
(736
)
 
n/a

Total product revenues, net
$
549,642

 
$
409,689

 
$
139,953

 
34
%
 
$
1,544,252

 
$
1,229,750

 
$
314,502

 
26
%
In the third quarter and the nine months ended September 30, 2017, we recognized approximately $43.1 million and $110.9 million, respectively, in ex-U.S. ORKAMBI net product revenues, as compared to $22.8 million and $47.5 million in the third quarter and the nine months ended September 30, 2016, respectively. We believe that the level of our ORKAMBI revenues for the remainder of 2017 will be dependent upon whether, when and on what terms we are able to obtain reimbursement in additional ex-U.S. markets, the number and rate at which additional patients begin treatment with ORKAMBI, the proportion of initiated patients who remain on treatment and the compliance rates for patients who remain on treatment.
Under the current revenue recognition guidance applicable for the year ending December 31, 2017, we do not recognize any net product revenues on sales of products unless the price is fixed or determinable. Pursuant to new revenue recognition guidance that will become effective January 1, 2018 and is described in Note A, “Basis of Presentation and Accounting Policies” to our condensed consolidated financial statements, we will be required to make estimates of the amount of consideration that will be retained by us that will not be subject to a significant reversal in amounts recognized as net product revenues. Our condensed consolidated balance sheet includes $190.3 million collected as of September 30, 2017 in France related to ORKAMBI supplied under early access programs at the invoiced price, which has not resulted in any net product revenues because the final price is not fixed or determinable under the current guidance.
If we conclude as of December 31, 2017, that the price of the ORKAMBI supplied under the French early access programs is fixed or determinable, we would record net product revenues for all sales since the inception of these programs based on the fixed or determinable price in the fourth quarter of 2017. If the price is not fixed and determinable as of December 31, 2017, these amounts will be subject to the new guidance. In this case, amounts for prior periods will be recognized in the first quarter of 2018 as a cumulative effect adjustment to our accumulated deficit based on an estimate of the amount of consideration that we would retain that would not be subject to a significant reversal in amounts recognized.
KALYDECO net product revenues increased in the third quarter of 2017 as compared to the third quarter of 2016 primarily due to additional patients being treated with KALYDECO as a result of label expansions. The increase in KALYDECO net product revenues in the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016 included approximately $9 million in one-time revenue credits in the first quarter of 2017 related to the finalization of reimbursement agreements in certain European countries. In the third quarter and the nine months ended September 30, 2017, we recognized approximately $80.3 million and $242.5 million, respectively, in ex-U.S. KALYDECO net product revenues, as compared to $75.1 million and $227.6 million in the third quarter and the nine months ended September 30, 2016, respectively.
We have withdrawn INCIVEK, which we previously marketed as a treatment for hepatitis C virus infection, from the market in the United States.


38

Royalty Revenues
Our royalty revenues were $2.2 million and $6.6 million in the third quarter and the nine months ended September 30, 2017, respectively, as compared to $3.8 million and $12.7 million in the third quarter and the nine months ended September 30, 2016, respectively. Our royalty revenues primarily consist of revenues related to a cash payment we received in 2008 when we sold our rights to certain HIV royalties.
Collaborative Revenues
Our collaborative revenues were $26.3 million and $286.1 million in the third quarter and the nine months ended September 30, 2017, respectively, as compared to $0.3 million and $1.0 million in the third quarter and the nine months ended September 30, 2016, respectively. The increase in our collaborative revenues during the third quarter of 2017 as compared to the third quarter of 2016 was primarily related to amounts received from Merck for transition activities we received pursuant to our collaboration with Merck KGaA and a $20.0 million milestone payment received by Parion in the third quarter of 2017 pursuant to a license agreement it entered into with a third party. We are not a party to such license agreement and have no economic interest in either the license or the milestone payment. Parion was deconsolidated as a VIE as of September 30, 2017 and future payments received by Parion pursuant to this license agreement will no longer be recognized by us as collaborative revenue. The increase in our collaborative revenues during the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016 was primarily due to revenue recognized related to the one-time upfront payment Merck KGaA paid in the first quarter of 2017 and $40 million in upfront and milestone payments received by Parion in 2017 pursuant to its license agreement with a third party. Our collaborative revenues have historically fluctuated significantly from one period to another and may continue to fluctuate in the future.
Operating Costs and Expenses
`
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2017
 
2016
 
$
 
%
 
2017
 
2016
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Cost of product revenues
$
72,186

 
$
53,222

 
$
18,964

 
36
 %
 
$
188,963

 
$
147,165

 
$
41,798

 
28
 %
Royalty expenses
688

 
855

 
(167
)
 
(20
)%
 
2,104

 
2,813

 
(709
)
 
(25
)%
Research and development expenses
454,947

 
272,370

 
182,577

 
67
 %
 
1,017,961

 
799,238

 
218,723

 
27
 %
Sales, general and administrative expenses
120,710

 
106,055

 
14,655

 
14
 %
 
361,285

 
322,921

 
38,364

 
12
 %
Restructuring expenses, net
337

 
8

 
329

 
n/a

 
13,859

 
1,038

 
12,821

 
n/a

Intangible asset impairment charge
255,340

 
—

 
255,340

 
n/a

 
255,340

 
—

 
255,340

 
n/a

Total costs and expenses
$
904,208

 
$
432,510

 
$
471,698

 
109
 %
 
$
1,839,512

 
$
1,273,175

 
$
566,337

 
44
 %
Cost of Product Revenues
Our cost of product revenues includes the cost of producing inventories that corresponded to product revenues for the reporting period, plus the third-party royalties payable on our net sales of our products. Pursuant to our agreement with Cystic Fibrosis Foundation Therapeutics Incorporated, or CFFT, our tiered third-party royalties on sales of KALYDECO and ORKAMBI, calculated as a percentage of net sales, range from the single digits to the sub-teens. As a result of the tiered royalty rate, our cost of product revenues as a percentage of CF product revenues is lower at the beginning of each calendar year.
In the third quarter of 2017, our cost of product revenues increased as compared to the third quarter of 2016 primarily due to the increased CF net product revenues. In the fourth quarter of 2017, we expect our cost of product revenues as a percentage of total CF product revenues to be similar to the cost of product revenues as a percentage of total CF product revenues in the third quarter of 2017.
In the nine months ended September 30, 2016, our cost of product revenues included a $13.9 million commercial milestone that was earned by CFFT related to sales of ORKAMBI. There are no further commercial milestones payable to CFFT.


39

Royalty Expenses
Royalty expenses primarily consist of expenses related to a subroyalty payable to a third party on net sales of an HIV protease inhibitor sold by GlaxoSmithKline. Royalty expenses do not include royalties we pay to CFFT on sales of KALYDECO and ORKAMBI, which instead are included in cost of product revenues.
Research and Development Expenses
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2017
 
2016
 
$
 
%
 
2017
 
2016
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Research expenses
$
76,131

 
$
99,162

 
$
(23,031
)
 
(23
)%
 
$
226,409

 
$
242,058

 
$
(15,649
)
 
(6
)%
Development expenses
378,816

 
173,208

 
205,608

 
119
 %
 
791,552

 
557,180

 
234,372

 
42
 %
Total research and development expenses
$
454,947

 
$
272,370

 
$
182,577

 
67
 %
 
$
1,017,961

 
$
799,238

 
$
218,723

 
27
 %
Our research and development expenses include internal and external costs incurred for research and development of our drugs and drug candidates. We do not assign our internal costs, such as salary and benefits, stock-based compensation expense, laboratory supplies and other direct expenses and infrastructure costs, to individual drugs or drug candidates, because the employees within our research and development groups typically are deployed across multiple research and development programs. These internal costs are significantly greater than our external costs, such as the costs of services provided to us by clinical research organizations and other outsourced research, which we allocate by individual program. All research and development costs for our drugs and drug candidates are expensed as incurred.
Since January 1, 2014, we have incurred $3.9 billion in research and development expenses associated with drug discovery and development. The successful development of our drug candidates is highly uncertain and subject to a number of risks. In addition, the duration of clinical trials may vary substantially according to the type, complexity and novelty of the drug candidate and the disease indication being targeted. The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of therapeutic pharmaceutical products, typically requiring lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to discontinuation or redirection of development activities. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The duration and cost of discovery, nonclinical studies and clinical trials may vary significantly over the life of a project and are difficult to predict. Therefore, accurate and meaningful estimates of the ultimate costs to bring our drug candidates to market are not available.
In 2016 and the nine months ended September 30, 2017, costs related to our CF programs represented the largest portion of our development costs. Any estimates regarding development and regulatory timelines for our drug candidates are highly subjective and subject to change. We recently submitted an NDA and an MAA for tezacaftor in combination with ivacaftor. The target date for the FDA to complete its review of the NDA under PDUFA is February 28, 2018 and we expect the EMA to complete its review of our in MAA in the second half of 2018. We cannot make a meaningful estimate when, if ever, our other clinical development programs will generate revenues and cash flows.


40

Research Expenses
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2017
 
2016
 
$
 
%
 
2017
 
2016
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Research Expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Salary and benefits
$
20,445

 
$
21,525

 
$
(1,080
)
 
(5
)%
 
$
61,486

 
$
61,503

 
$
(17
)
 
—
 %
Stock-based compensation expense
15,641

 
14,023

 
1,618

 
12
 %
 
44,366

 
38,088

 
6,278

 
16
 %
Laboratory supplies and other direct expenses
10,791

 
11,726

 
(935
)
 
(8
)%
 
33,980

 
33,410

 
570

 
2
 %
Outsourced services
10,230

 
10,054

 
176

 
2
 %
 
29,644

 
20,749

 
8,895

 
43
 %
Collaboration and asset acquisition payments
425

 
22,000

 
(21,575
)
 
(98
)%
 
425

 
33,000

 
(32,575
)
 
(99
)%
Infrastructure costs
18,599

 
19,834

 
(1,235
)
 
(6
)%
 
56,508

 
55,308

 
1,200

 
2
 %
Total research expenses
$
76,131

 
$
99,162

 
$
(23,031
)
 
(23
)%
 
$
226,409

 
$
242,058

 
$
(15,649
)
 
(6
)%
We maintain a substantial investment in research activities. Our research expenses decreased by 23% in the third quarter of 2017 as compared to the third quarter of 2016 and decreased by 6% in the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016. Collaboration and asset acquisition payments in the third quarter of 2016 included a $20.0 million payment to Moderna for which there was no comparable expense in the third quarter of 2017. Collaboration and asset acquisition payments in the nine months ended September 30, 2016 included both the Moderna payment and $13.0 million in expenses related to the acquisition of early-stage research assets for which there were no comparable expenses in the nine months ended September 30, 2017. We expect to continue to invest in our research programs with a focus on identifying drug candidates with the goal of creating transformative medicines.
Development Expenses
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2017
 
2016
 
$
 
%
 
2017
 
2016
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Development Expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Salary and benefits
$
54,125

 
$
44,788

 
$
9,337

 
21
%
 
$
156,759

 
$
134,201

 
$
22,558

 
17
 %
Stock-based compensation expense
30,545

 
25,957

 
4,588

 
18
%
 
90,489

 
76,980

 
13,509

 
18
 %
Laboratory supplies and other direct expenses
10,828

 
10,784

 
44

 
—
%
 
34,171

 
32,039

 
2,132

 
7
 %
Outsourced services
89,637

 
60,838

 
28,799

 
47
%
 
251,677

 
216,881

 
34,796

 
16
 %
Collaboration and asset acquisition payments
160,000

 
—

 
160,000

 
n/a

 
160,250

 
—

 
160,250

 
n/a

Drug supply costs
3,151

 
2,655

 
496

 
19
%
 
6,143

 
9,512

 
(3,369
)
 
(35
)%
Infrastructure costs
30,530

 
28,186

 
2,344

 
8
%
 
92,063

 
87,567

 
4,496

 
5
 %
Total development expenses
$
378,816

 
$
173,208

 
$
205,608

 
119
%
 
$
791,552

 
$
557,180

 
$
234,372

 
42
 %
Our development expenses increased by 119% in the third quarter of 2017 as compared to the third quarter of 2016 and increased by 42% in the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016, primarily due the $160.0 million payment to Concert in connection with the acquisition of VX-561 in the third quarter of 2017 and to increased outsourced services expenses related to ongoing clinical trials, including trials involving our next-generation CFTR corrector compounds that we are evaluating as part of triple combination treatment regimens. In the fourth quarter of 2017, we expect our outsourced services expenses to increase as compared to the third quarter of 2017 due to expenses related to the advancement of our triple-combination regimens.


41

Sales, General and Administrative Expenses
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2017
 
2016
 
$
 
%
 
2017
 
2016
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Sales, general and administrative expenses
$
120,710

 
$
106,055

 
$
14,655

 
14
%
 
$
361,285

 
$
322,921

 
$
38,364

 
12
%
Sales, general and administrative expenses increased by 14% in the third quarter of 2017 as compared to the third quarter of 2016 and increased by 12% in the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016, primarily due to increased global support for KALYDECO and ORKAMBI.
Restructuring Expenses, Net
We recorded restructuring expenses of $0.3 million and $13.9 million in the third quarter and the nine months ended September 30, 2017, respectively, as compared to restructuring expenses of $8.0 thousand and $1.0 million in the third quarter and the nine months ended September 30, 2016, respectively. The increases in our restructuring expenses in the nine months ended September 30, 2017 primarily relate to our decision to consolidate our research activities into our Boston, Milton Park and San Diego locations and to close our research site in Canada.
Intangible Asset Impairment Charge
In the third quarter of 2017, we recorded a $255.3 million impairment charge related to Parion’s pulmonary ENaC platform that we licensed from Parion in 2015 and a benefit from income taxes of $97.7 million related to this impairment charge attributable to Parion. There were no corresponding intangible asset impairment charges in the third quarter and the nine months ended September 30, 2016.
Other Items
Interest Expense, Net
Interest expense, net was $13.6 million and $45.0 million in the third quarter and the nine months ended September 30, 2017, respectively, as compared to $20.1 million and $61.0 million in the third quarter and the nine months ended September 30, 2016, respectively. The decrease in interest expense, net in the third quarter and the nine months ended September 30, 2017 as compared to the third quarter and the nine months ended September 30, 2016 was primarily due to the repayment of the $300.0 million outstanding under our revolving credit facility in February 2017. In the fourth quarter of 2017, we expect to incur approximately $15 million of interest expense associated with the leases for our corporate headquarters and our interest expense related to our revolving credit facility will be dependent on whether, and to what extent, we reborrow amounts under the existing facility.
Other (Expenses) Income, Net
Other (expense) income, net was an expense of $77.6 million and $80.6 million in the third quarter and the nine months ended September 30, 2017 as compared to expense of $0.2 million in the third quarter of 2016 and income of $3.0 million in the nine months ended September 30, 2016. Other (expense) income, net in the third quarter and the nine months ended September 30, 2017 was primarily related to the deconsolidation of Parion. Other (expense) income, net in the third quarter and the nine months ended September 30, 2016 was primarily due to foreign exchange gains and losses.
Income Taxes
We recorded a benefit from income taxes of $125.9 million and $117.6 million in the third quarter and the nine months ended September 30, 2017 as compared to a provision for income taxes of $0.5 million and $24.1 million in the third quarter and the nine months ended September 30, 2016. The benefit from income taxes in the third quarter and the nine months ended September 30, 2017 was primarily related to a benefit of $126.2 million attributable to noncontrolling interest as a result of our impairment of Parion’s pulmonary ENaC platform and decrease in the fair value of the contingent payments payable by us to Parion.  The provision for income taxes in the third quarter and the nine months ended September 30, 2016 was primarily due to income tax on our VIEs.
We continue to maintain a valuation allowance on the majority of our net operating losses and other deferred tax assets because we have a history of cumulative losses.  Accordingly, we have not reported any tax benefit relating to the remaining net operating loss carryforwards (NOLs) and income tax credit carryforwards that will be utilized in future periods in these


42

jurisdictions.  Our U.S. federal net operating loss carryforwards totaled approximately $4.1 billion as of December 31, 2016. On a quarterly basis, we reassess the valuation allowance on our deferred income tax assets weighing positive and negative evidence to assess the recoverability of the deferred tax assets. Based on our recent financial performance and our future projections, we could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods.  However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. Our total deferred tax asset balance subject to the valuation allowance was approximately $1.7 billion at December 31, 2016.
Noncontrolling Interest (VIEs)
The net (income) loss attributable to noncontrolling interest (VIEs) recorded on our condensed consolidated statements of operations reflects Parion and BioAxone’s net (income) loss for the reporting period, adjusted for any changes in the noncontrolling interest holders’ claim to net assets, including contingent milestone, royalty and option payments. A summary of net income attributable to noncontrolling interest related to our VIEs for the three and nine months ended September 30, 2017 and 2016 is as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
 
 
 
 
Loss attributable to noncontrolling interest before (benefit from) provision for income taxes and changes in fair value of contingent payments
$
238,946

 
$
2,406

 
$
222,448

 
$
6,080

(Benefit from) provision for income taxes
(120,181
)
 
(510
)
 
(111,658
)
 
20,063

Decrease (increase) in fair value of contingent payments
69,550

 
(1,200
)
 
62,560

 
(59,350
)
Net loss (income) attributable to noncontrolling interest
$
188,315

 
$
696

 
$
173,350

 
$
(33,207
)

The net loss attributable to noncontrolling interest in the third quarter and nine months ended September 30, 2017 was primarily related to the $255.3 million impairment charge related to Parion’s pulmonary ENaC platform, a decrease in fair value of the contingent payments payable by us to Parion of $69.6 million and benefit from income taxes of $126.2 million related to these charges.
As of September 30, 2017, we have deconsolidated Parion.
LIQUIDITY AND CAPITAL RESOURCES
As of September 30, 2017, we had cash, cash equivalents and marketable securities of $1.81 billion, which represented an increase of $378 million from $1.43 billion as of December 31, 2016. In the nine months ended of September 30, 2017, our cash, cash equivalents and marketable securities balance increased due to cash receipts from product sales, cash received from issuances of common stock under our employee benefit plans and cash received from our collaboration with Merck KGaA in the first quarter of 2017, partially offset by the $300.0 million repayment of our revolving credit facility in the first quarter of 2017 and the $160.0 million payment to Concert in connection with the acquisition of VX-561 in the third quarter of 2017. We expect that our future cash flows will be substantially dependent on CF product sales.
Sources of Liquidity
We intend to rely on our existing cash, cash equivalents and marketable securities together with cash flows from product sales as our primary source of liquidity. We are receiving cash flows from sales of ORKAMBI and KALYDECO from the United States and ex-U.S. markets. Future net product revenues for ORKAMBI from ex-U.S. markets will be dependent on, among other things, the timing of and ability to complete reimbursement discussions in European countries.
In February 2017, we repaid the $300.0 million we had borrowed under our $500.0 million revolving credit facility. We may repay and reborrow amounts under the revolving credit agreement without penalty. Subject to certain conditions, we may request that the borrowing capacity under this credit agreement be increased by an additional $300.0 million.
In the nine months ended September 30, 2017, we received significant proceeds from the issuance of common stock under our employee benefit plans, but the amount and timing of future proceeds from employee benefits plans is uncertain. Other possible sources of liquidity include strategic collaborative agreements that include research and/or development funding, commercial debt, public and private offerings of our equity and debt securities, development milestones and


43

royalties on sales of products, software and equipment leases, strategic sales of assets or businesses and financial transactions. Negative covenants in our credit agreement may prohibit or limit our ability to access these sources of liquidity.
Future Capital Requirements
We incur substantial operating expenses to conduct research and development activities and to operate our organization. Under the terms of our credit agreement entered into in October 2016, we are required to repay any outstanding principal amounts in 2021. We also have substantial facility and capital lease obligations, including leases for two buildings in Boston, Massachusetts that continue through 2028 and capital expenditures for our building under construction in San Diego, California. As of September 30, 2017, we have collected approximately $190.3 million from ORKAMBI early access programs in France for which the price is not fixed or determinable. We expect we will be required to repay a portion of the collected amounts to the French government based on the difference between the invoiced price of ORKAMBI and the final price for ORKAMBI in France.

In addition, we have entered into certain collaboration agreements with third parties that include the funding of certain research, development and commercialization efforts with the potential for future milestone and royalty payments by us upon the achievement of pre-established developmental and regulatory target and we may enter into additional business development transactions that require additional capital.

We expect that cash flows from ORKAMBI and KALYDECO, together with our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors, including the amounts of future revenues generated by ORKAMBI and KALYDECO and the potential introduction of one or more of our other drug candidates to the market, the level of our business development activities and the number, breadth, cost and prospects of our research and development programs.

Financing Strategy
We have a $500.0 million revolving credit facility that we entered into in October 2016. We may repay and reborrow amounts under the revolving credit agreement without penalty. In addition, subject to certain conditions, we may request that the borrowing capacity under this credit agreement be increased by an additional $300.0 million. We may raise additional capital through public offerings or private placements of our securities or securing new collaborative agreements or other methods of financing. We will continue to manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.
CONTRACTUAL COMMITMENTS AND OBLIGATIONS
Our commitments and obligations were reported in our Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission, or SEC, on February 23, 2017. There have been no material changes from the contractual commitments and obligations previously disclosed in that Annual Report on Form 10-K, except that:
•
In February 2017, we repaid the outstanding $300 million balance of our revolving credit facility.
•
In July 2017, we acquired certain CF assets including VX-561 from Concert pursuant to an asset purchase agreement. At closing, we paid Concert $160 million in cash for all worldwide development and commercialization rights to VX-561 and may be required to pay up to an additional $90 million in milestones based on regulatory approval in the U.S. and reimbursement in the UK, Germany or France.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations is based upon our condensed consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate. During the nine months ended September 30, 2017, there were no material changes to our critical accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the SEC on February 23, 2017.
RECENT ACCOUNTING PRONOUNCEMENTS
For a discussion of recent accounting pronouncements, please refer to Note A, “Basis of Presentation and Accounting Policies—Recent Accounting Pronouncements.”
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
As part of our investment portfolio, we own financial instruments that are sensitive to market risks. The investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. None of these market risk-sensitive instruments are held for trading purposes.
Interest Rate Risk
We invest our cash in a variety of financial instruments, principally securities issued by the U.S. government and its agencies, investment-grade corporate bonds and commercial paper, and money market funds. These investments are denominated in U.S. dollars. All of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. Substantially all of our investment portfolio consists of marketable securities with active secondary or resale markets to help ensure portfolio liquidity, and we have implemented guidelines limiting the term-to-maturity of our investment instruments. Due to the conservative nature of these instruments, we do not believe that we have a material exposure to interest rate risk. If interest rates were to increase or decrease by 1%, the fair value of our investment portfolio would increase or decrease by an immaterial amount.
Foreign Exchange Market Risk
As a result of our foreign operations, we face exposure to movements in foreign currency exchange rates, primarily the Euro, British Pound, Australian Dollar and Canadian Dollar, against the U.S. dollar. The current exposures arise primarily from cash, accounts receivable, intercompany receivables, payables and inventories. Both positive and negative affects to our net revenues from international product sales from movements in foreign currency exchange rates are partially mitigated by the natural, opposite affect that foreign currency exchange rates have on our international operating costs and expenses.
We have a foreign currency management program with the objective of reducing the effect of exchange rate fluctuations on our operating results and forecasted revenues and expenses denominated in foreign currencies. We currently have cash flow hedges for the Euro, British Pound and Australian Dollar related to forecasted product revenues that qualify for hedge accounting treatment under U.S. GAAP. We do not seek hedge accounting treatment for our forward contracts related to monetary assets and liabilities that impact our operating results. As of September 30, 2017, we held foreign exchange forward contracts with notional amounts totaling $456.9 million. As of September 30, 2017, our outstanding foreign exchange forward contracts had a net fair value of $(13.1) million.
Based on our foreign currency exchange rate exposures at September 30, 2017, a hypothetical 10% adverse fluctuation in exchange rates would decrease the fair value of our foreign exchange forward contracts that are designated as cash flow hedges by approximately $34.3 million at September 30, 2017. The resulting loss on these forward contracts would be offset by the gain on the underlying transactions and therefore would have minimal impact on future anticipated earnings and cash flows. Similarly, adverse fluctuations in exchange rates that would decrease the fair value of our foreign exchange forward contracts that are not designated as hedge instruments would be offset by a positive impact of the underlying monetary assets and liabilities.
Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our chief executive officer and chief financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, as of September 30, 2017 our disclosure controls and procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Controls Over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) occurred during the three months ended September 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II. Other Information
Item 1.     Legal Proceedings
There have been no material changes from the legal proceedings previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission, or SEC, on February 23, 2017.
Item 1A. Risk Factors
Information regarding risk factors appears in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the SEC on February 23, 2017. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K, except that the first four risk factors set forth below shall replace the first three risk factors set forth in the Annual Report on Form 10-K and the fifth risk factor set forth below shall be added as a new risk factor.

All of our product revenues and the vast majority of our total revenues are derived from sales of medicines for the treatment of cystic fibrosis. If we are unable to continue to increase revenues from sales of our cystic fibrosis medicines or if we do not meet the expectations of investors or public equity market analysts, our business would be materially harmed and the market price of our common stock would likely decline.

Substantially all of our product revenues and the vast majority of our total revenues are derived from the sale of CF medicines. As a result, our future success is dependent on our ability to continue to increase revenues from sales of our CF medicines. In the near term, this will require us to maintain KALYDECO net product revenues and increase ORKAMBI net product revenues. In the medium term, this will require us to obtain approval for, and successfully commercialize, tezacaftor in combination with ivacaftor. In the longer term, this will require us to successfully develop, obtain approval for and commercialize at least one triple-combination therapy that will allow us to treat patients who have one copy of the F508del mutation in their CFTR gene and a second mutation in their CFTR gene that results in minimal CFTR function and to improve the treatment options available to patients with CF who are eligible for our current medicines. If we are unable to increase our CF product revenues or if we experience adverse developments with respect to development or commercialization of our CF medicines, our results of operations will be adversely affected and our business will be materially harmed.

We are investing significant resources in the development of our next-generation CFTR corrector compounds in triple combinations and if we are unable to show the safety and efficacy of these compounds, experience delays in doing so or are unable to successfully commercialize at least one of these medicines, our business would be materially harmed.

We are investing significant resources in the development of our next-generation CFTR corrector compounds, including VX-152, VX-440, VX-659 and VX-445, which we are evaluating as part of triple combination treatment regimens for the treatment of patients with CF. We believe that a significant portion of the long-term value attributed to our company by investors is based on the commercial potential of these triple-combination therapies. In July 2017, we obtained initial positive results from Phase 2 clinical trials of VX-152 and VX-440 and a Phase 1 clinical trial of VX-659. In each case, these clinical trials enrolled a limited number of patients with CF and we expect to receive additional information regarding these compounds in early 2018. Based on these results, we expect to initiate pivotal programs to evaluate one or two of these triple combination regimens in the first half of 2018.
In order to ultimately obtain approval for a triple-combination regimen, we will need to demonstrate that the compounds are safe and effective in a significantly larger number of patients than were involved in the clinical trials conducted to date. Initial results from ongoing clinical trials may differ materially from final results from such clinical trials. The results from preclinical and early clinical studies do not always accurately predict results in later, large-scale clinical trials. If the data from our ongoing or planned clinical trials or non-clinical studies of triple combination regimens including our next-generation CFTR compounds are not favorable, the FDA and comparable foreign regulatory authorities may not approve these treatment regimens and/or we may be forced to delay or terminate the development of these treatment regimens, which would have an adverse effect on our business. Even successfully completed large-scale clinical trials may not result in marketable medicines. If a triple combination that includes a next-generation CFTR corrector compounds fails to achieve its primary endpoint in clinical trials, if safety issues arise or if the results from our clinical trials are otherwise inadequate to support regulatory approval of our triple combination therapies, commercialization of that combination regimen could be delayed or halted.


44

Even if we gain marketing approval for one or more combination therapies containing a next-generation CFTR corrector compound in a timely manner, we cannot be sure that such combination therapy will be commercially successful. In addition, since we expect that a significant portion of the patients for whom a triple combination treatment regimen would be indicated would also be eligible for our then existing medicines, a portion of the revenues from our triple combination regimens will likely displace revenues from our then marketed products reducing the overall effect of the commercialization of our triple combination regimens on our total revenues.
If the anticipated or actual timing of marketing approvals for these compounds, or the market acceptance of these compounds, if approved, including treatment reimbursement levels agreed to by third-party payors, do not meet the expectations of investors or public market analysts, the market price of our common stock would likely decline.

Our business currently depends heavily on ORKABMI and KALYDECO net product revenues and we expect to continue to depend on these revenues at least until we obtain approval for tezacaftor in combination with ivacaftor.

Our two marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF who have specific mutations in their CFTR gene. ORKAMBI and KALYDECO net product revenues represented approximately 52% and 32% of our total revenues in the nine months ended September 30, 2017, respectively, and we expect ORKAMBI and KALYDECO net product revenues to represent substantially all of our total revenues for the remainder of 2017.
A majority of our net product revenues are from sales of ORKAMBI and most of our ORKAMBI net product revenues have come from the United States. We have recognized limited ex-U.S. net product revenues due to the ongoing reimbursement discussions in many ex-U.S. countries and have experienced challenges in the commercialization of ORKAMBI both in the United States and in ex-U.S. markets. Our ORKAMBI U.S. revenues have been affected by uptake, discontinuations and compliance rates. Our ORKAMBI ex-U.S. revenues have been affected by the same factors as our U.S. ORKAMBI revenues and challenges with respect to obtaining reimbursement for ORKAMBI in ex-U.S. markets. Factors that affect our ORKAMBI net product revenues include:
•
the rate at which patients initiate treatment of ORKAMBI, the proportion of initiated patients who remain on treatment and the compliance rate for patients who remain on treatment;
•
the safety and efficacy profile of ORKAMBI;
•
our ability to obtain reimbursement for ORKAMBI and any changes in reimbursement policies of payors and other third parties; and
•
legal, administrative, regulatory or legislative developments, including pricing limitations.
Since the regulations that govern pricing, coverage and reimbursement for drugs vary widely from country to country, there is no assurance that coverage and reimbursement will be available outside of the United States and, even if it is available, the timing or the level of reimbursement may not be satisfactory. Adverse pricing limitations or a delay in obtaining coverage and reimbursement would decrease our future net product revenues and harm our business.
If we continue to experience challenges with the commercialization of ORKAMBI or are unable to sustain KALYDECO net product revenues or if either medicine were to become subject to problems such as safety or efficacy issues, the introduction or greater acceptance of competing products, changes in reimbursement policies of payors and other third parties, or adverse legal, administrative, regulatory or legislative developments, our ability commercialization of our products would be impaired and our stock price would likely decline.

Our business depends on the success of tezacaftor in combination with ivacaftor, which has not been approved by the FDA or the European Commission. If we are unable to obtain marketing approval or experience material delays in obtaining marketing approval for, or reimbursement arrangements relating to, tezacaftor in combination with ivacaftor, our business could be materially harmed.

In the first quarter of 2017, we obtained positive results from two Phase 3 clinical trials of tezacaftor in combination with ivacaftor that showed statistically significant improvements in lung function in patients with CF 12 years of age and older who have certain mutations in their CFTR gene. Based on these results, we submitted an NDA in the United States and an MAA in Europe for this potential combination regimen. The target date for the FDA to complete its review of the NDA under the Prescription Drug User Fee Act is February 28, 2018. We expect the EMA to complete its review in the second half


45

of 2018. Obtaining approval of an NDA or an MAA is a lengthy, expensive and uncertain process, and we may not be successful. Obtaining approval depends on many factors including:
•
whether or not the FDA and European regulatory authorities determine that the evidence gathered in well-controlled clinical trials, other clinical trials and nonclinical studies demonstrates that the combination regimen is safe; and
•
whether or not the FDA and European regulatory authorities are satisfied that the manufacturing facilities, processes and controls for the combination are adequate, that the labeling is satisfactory and that plans for post-marketing studies, safety monitoring and risk evaluation and mitigation are sufficient.
Obtaining marketing approval for the combination of tezacaftor and ivacaftor in one country or region does not ensure that we will be able to obtain marketing approval in any other country or region.
Even if a tezacaftor in combination with ivacaftor is approved, the FDA or the European Commission, as the case may be, may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. If we experience material delays in obtaining marketing approval for the combination of tezacaftor and ivacaftor in either the United States or Europe, our future net product revenues and cash flows will be adversely effected. If we do not obtain approval to market the combination of tezacaftor and ivacaftor in the United States or Europe, our business will be materially harmed. Additionally, even if the combination of tezacaftor and ivacaftor receives marketing approval, coverage and reimbursement may not be available and, even if it is available, the level of reimbursement may not be satisfactory.

We may not realize the anticipated benefits of our acquisition of VX-561 from Concert Pharmaceuticals, Inc.

In July 2017, we acquired certain CF assets from Concert Pharmaceuticals, Inc., or Concert, including VX-561, an investigational CFTR potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of CF. We amended our ongoing Phase 2 clinical trials of VX-445 and VX-659 to include additional cohorts of patients to evaluate these next-generation CFTR corrector compounds in combination with tezacaftor and VX-561. Acquisitions are inherently risky and we may not realize the anticipated benefits of such transaction, which involves numerous risks including:
•
that we fail to successfully develop and/or integrate VX-561 into our pipeline in order to achieve our strategic objectives;
•
that we receive inadequate or unfavorable data from clinical trials evaluating the VX-561 in combination with other CFTR modulators; and
•
the potential failure of the due diligence processes to identify significant problems, liabilities or other shortcomings or challenges of VX-561 or any of the other assets acquired from Concert, including but not limited to, problems, liabilities or other shortcomings or challenges with respect to intellectual property, product quality, safety, and other known and unknown liabilities.
    
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part I-Item 2, contain or incorporate a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding:
•
our expectations regarding the amount of, timing of and trends with respect to our revenues, costs and expenses and other gains and losses, including those related to net product revenues from KALYDECO and ORKAMBI;
•
our expectations regarding clinical trials, development timelines, timing of our receipt of data from our ongoing and planned clinical trials and regulatory authority filings and submissions for our products and drug candidates, including the NDA and MAA submission for tezacaftor in combination with ivacaftor and the ongoing and planned clinical trials to evaluate our next-generation CFTR correctors;
•
our ability to successfully market KALYDECO and ORKAMBI or any of our other drug candidates for which we obtain regulatory approval;


46

•
the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings;
•
our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our drug candidates for further investigation, clinical trials or potential use as a treatment;
•
our plan to continue investing in our research and development programs and our strategy to develop our drug candidates, alone or with third party-collaborators;
•
the establishment, development and maintenance of collaborative relationships;
•
potential business development activities;
•
our post-closing integration of the assets acquired from Concert;
•
potential fluctuations in foreign currency exchange rates;
•
our ability to use our research programs to identify and develop new drug candidates to address serious diseases and significant unmet medical needs; and
•
our liquidity and our expectations regarding the possibility of raising additional capital.
Any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many factors mentioned in this Quarterly Report on Form 10-Q will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially from expected results. We also provide a cautionary discussion of risks and uncertainties under “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the SEC on February 23, 2017. These are factors and uncertainties that we think could cause our actual results to differ materially from expected results. Other factors and uncertainties besides those listed there could also adversely affect us.
Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “intends,” “expects” and similar expressions are intended to identify forward-looking statements. There are a number of factors and uncertainties that could cause actual events or results to differ materially from those indicated by such forward-looking statements, many of which are beyond our control. In addition, the forward-looking statements contained herein represent our estimate only as of the date of this filing and should not be relied upon as representing our estimate as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.
Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Repurchases of Equity Securities
The table set forth below shows all repurchases of securities by us during the three months ended September 30, 2017:
Period
 
Total Number
of Shares Purchased
Average Price
Paid per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
Maximum Number of
Shares that May Yet
be Purchased Under
the Plans or Programs
July 1, 2017 to July 31, 2017
2,040
$0.01
—
—
August 1, 2017 to August 31, 2017
15,811
$0.01
—
—
September 1, 2017 to September 30, 2017
2,589
$0.01
—
—
Total
20,440
$0.01
—
—
The repurchases were made under the terms of our Amended and Restated 2006 Stock and Option Plan and our Amended and Restated 2013 Stock and Option Plan. Under these plans, we award shares of restricted stock to our employees that typically are subject to a lapsing right of repurchase by us. We may exercise this right of repurchase if a restricted stock recipient’s service to us is terminated. If we exercise this right, we are required to repay the purchase price paid by or on behalf of the recipient for the repurchased restricted shares, which typically is the par value per share of $0.01. Repurchased shares are returned and are available for future awards under the terms of our Amended and Restated 2013 Stock and Option Plan.
Item 6.    Exhibits
Exhibit Number
Exhibit Description
10.1

10.2
31.1
31.2
32.1
101.INS
XBRL Instance
101.SCH
XBRL Taxonomy Extension Schema
101.CAL
XBRL Taxonomy Extension Calculation
101.LAB
XBRL Taxonomy Extension Labels
101.PRE
XBRL Taxonomy Extension Presentation
101.DEF
XBRL Taxonomy Extension Definition
* Management contract, compensatory plan or agreement.






47

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Vertex Pharmaceuticals Incorporated
 
 
 
October 30, 2017
By:
/s/ Thomas Graney
 
 
Thomas Graney
 
 
Senior Vice President and Chief Financial Officer
(principal financial officer and
duly authorized officer)



48
 EX-10.1 2 a2017q310-q_exhibit101.htm EXHIBIT 10.1 Exhibit


EMPLOYMENT AGREEMENT
This Employment Agreement (this “Agreement”) is made and entered into as of this 6th day of September, 2017, by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (together with its successors and assigns, the “Company”), and Tom Graney (the “Executive”).
W IT N E S S E T H
WHEREAS, the Company is employing the Executive as the Company’s Senior Vice President, Chief Financial Officer; and
WHEREAS, the Executive has been designated as an Executive Officer of the Company;
NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein and for other good and valuable consideration, the receipt of which mutually is acknowledged, the Company and the Executive (each individually a “Party”, and together the “Parties”) agree as follows:
1. DEFINITIONS.
“Base Salary” shall mean the Executive’s base salary in accordance with Section 4 below.
“Board” shall mean the Board of Directors of the Company.
“Cause” shall mean (i) the Executive is convicted of a crime involving moral turpitude, (ii) the Executive commits a material breach of any provision of this Agreement not involving the performance or nonperformance of duties, or (iii) the Executive, in carrying out the Executive’s duties, acts or fails to act in a manner that is determined, in the sole discretion of the Board, after written notice of any such act or failure to act and a reasonable opportunity to cure the deficiency has been provided to the Executive, to be (A) willful gross neglect or (B) willful gross misconduct resulting, in either case, in material harm to the Company unless such act, or failure to act, was believed by the Executive, in good faith, to be in the best interests of the Company.
“Change of Control” shall have the meaning set forth in the Change of Control Agreement.
“Change of Control Agreement” shall mean the Change of Control letter agreement between the Company and the Executive of even date herewith.
“Code” shall mean the Internal Revenue Code of 1986, as amended.
“Common Stock” shall mean the common stock of the Company.
“Disability” or “Disabled” shall mean a disability as determined under the Company’s long-term disability plan or program in effect at the time the disability first occurs, or if no such


293773v1


plan or program exists at the time of disability, then a “disability” as defined under Section 22(e)(3) of the Code.
“Effective Date” shall mean September 13, 2017.
“Good Reason” shall mean that, without the Executive’s consent, one or more of the following events occurs:
(i)
the Executive’s duties are materially diminished to an extent that results in the Executive no longer being an “officer,” as such term is defined in Rule 16a-1(f) promulgated under the Securities Exchange Act of 1934; or
(ii)
the Executive’s Base Salary is decreased unless such reduction is part of an across-the-board proportionate reduction in the salaries of the Company’s senior management team; or
(iii)
the office to which the Executive is assigned is relocated to a place 35 or more miles away and such relocation is not at the Executive’s request or with the Executive’s prior agreement (and other than, for Executives assigned to the Company’s principal executive offices, in connection with a change in location of the Company’s principal executive offices);
provided that Good Reason shall not exist unless and until within 30 days after the event giving rise to Good Reason under either (i) or (ii) above has occurred, the Executive delivers a written termination notice to the Company stating that an event giving rise to Good Reason has occurred and identifying with reasonable detail the event that the Executive asserts constitutes Good Reason under either (i) or (ii) above and the Company fails or refuses to cure or eliminate the event giving rise to Good Reason on or within 30 days after receiving such notice and, with respect to the event giving rise to Good Reason under (iii) above, the Executive delivers a written termination notice to the Company within 30 days after the event giving rise to Good Reason occurs. To avoid doubt, the termination of the Executive’s employment would become effective at the close of business on the thirtieth day after the Company receives the Executive’s termination notice, unless, in the case of an event giving rise to Good Reason under either (i) or (ii) above, the Company cures or eliminates the event giving rise to Good Reason prior to such time.
“Severance Payment” shall mean an amount equal to the sum of the Base Salary in effect on the date of termination of Executive’s employment, plus the amount of the Target Bonus for the Executive for the year in which the Executive’s employment is terminated; provided, however, that if the Executive terminates the Executive’s employment for Good Reason based on a reduction in Base Salary, then the Base Salary to be used in calculating the Severance Payment shall be the Base Salary in effect immediately prior to such reduction in Base Salary.

2


“Target Bonus” shall mean the target cash bonus for which the Executive is eligible on an annual basis, at a level consistent with the Executive’s title and responsibilities, under the Company’s bonus program then in effect and applicable to the Company’s senior executives generally.
2. TERM OF EMPLOYMENT.
The Company hereby employs the Executive, and the Executive hereby accepts such employment, continuing until termination in accordance with the terms of this Agreement. The period during which the Executive is employed hereunder is referred to in this Agreement as the “term of employment.”
3. POSITION.
On the Effective Date, the Executive is employed as the Company’s Senior Vice President, Chief Financial Officer, reporting to the Company’s Executive Vice President, Chief Operating Officer.
4. BASE SALARY.
The Executive’s annualized Base Salary as of the date of this Agreement is $550,000, payable in accordance with the regular payroll practices of the Company. The Base Salary shall be reviewed no less frequently than annually, and any changes thereto (which shall thereafter be deemed the Executive’s Base Salary) shall be solely within the discretion of the Board.
5. TARGET BONUS PROGRAM.
During the term of employment, the Executive shall be eligible to participate in the Company’s annual cash incentive compensation program applicable to the Company’s senior executives, as any such programs are established and modified from time to time by the Board in its sole discretion, and in accordance with the terms of such program, with a Target Bonus as determined by the Board.
6. INCENTIVE COMPENSATION PROGRAMS/SIGN-ON AWARDS.
(a) During the term of employment, the Executive shall be eligible to participate in the Company’s incentive compensation programs applicable to the Company’s senior executives, as such programs may be established and modified from time to time by the Board in its sole discretion.
(b) Sign-On Cash Bonus: The Executive shall receive a sign-on cash bonus in the amount of $150,000 payable (with appropriate deductions as required by law) to the Executive at the first regular pay date applicable to the Executive after the Effective Date. If the Executive terminates this Agreement without Good Reason, and other than as a result of death or Disability, during the period commencing on the Effective Date and ending on the first anniversary of the

3


Effective Date, the Executive shall repay the sign-on cash bonus to the Company within 60 days of such termination.
(c) Sign-On Restricted Stock Unit Grant: Subject to approval from the Board, the Executive will receive, in accordance with the terms of a Restricted Stock Unit agreement executed and delivered to the Company by the Executive on the Effective Date (the “Grant Date”), restricted stock units with respect to shares of Common Stock with a fair market value (average of high and low stock price) on Executive’s date of hire equal to $1,500,000 pursuant to Vertex Pharmaceuticals Incorporated’s Stock and Option Plan. This grant, including but not limited to the vesting schedule and the forfeiture provision contained therein, shall be subject to the other terms and conditions specified in a separate Restricted Stock Unit agreement attached hereto as Exhibit A.
7. EMPLOYEE BENEFIT PROGRAMS.
During the term of employment, the Executive shall be entitled to participate in all employee welfare and pension benefit plans, programs and/or arrangements offered by the Company to its senior executives, as such plans, programs and arrangements may be amended from time to time, to the same extent and on the same terms applicable to other senior executives. Nothing in this section shall preclude the Company from amending or terminating any of its employee benefit plans, programs or arrangements.
8. VACATION.
During the term of employment, the Executive shall be entitled to paid vacation days each calendar year in accordance with the Company’s vacation policy then in effect.
9. TERMINATION OF EMPLOYMENT.
(a) Termination in Connection with a Change of Control. To the extent the Executive is entitled, in connection with the Executive’s termination of employment, to severance or other benefits under the Change of Control Agreement, the Executive shall not be entitled to corresponding benefits under this Section 9.
(b) Termination by the Company for Cause; or Termination by the Executive without Good Reason. If the Company terminates the Executive’s employment for Cause, or if the Executive voluntarily terminates the Executive’s employment, other than for Good Reason, death or Disability, the term of employment shall end as of the date specified below, and the Executive shall be entitled to the following:
(i)
Base Salary earned by Executive but not paid through the date of termination of Executive’s employment under this Section 9(b); and
(ii)
any amounts earned, accrued or owing to the Executive but not yet paid under Sections 5, 6, or 7 above.

4


Termination by Company for Cause shall be effective as of the date noticed by the Company. Voluntary termination by Executive other than for Good Reason, death or Disability shall be effective upon 90 days’ prior written notice to the Company and shall not be deemed a breach of this Agreement.
(c) Termination by the Company Without Cause; or Termination by the Executive for Good Reason. If the Executive's employment is terminated by the Company without Cause (other than due to death or Disability), or is terminated by the Executive for Good Reason (in accordance with the notice and cure provisions set forth in the definition of “Good Reason” above), the Executive shall be entitled to the following (provided that, with respect to (iii) and (v) such amounts shall be subject to and in exchange for a general release of all claims against the Company, its subsidiaries, and their officers, directors, agents and representatives, which is executed by Executive and becomes enforceable and non-revocable within 60 days of the date of termination):
(i)
Base Salary earned by Executive but not paid through the date of termination of Executive’s employment under this Section 9(c);
(ii)
all incentive compensation awards earned by Executive but not paid prior to the date of termination of Executive’s employment under this Section 9(c);
(iii)
a lump sum cash payment to the Executive in an amount equal to the Severance Payment, payable within ten days after the execution of a general release and expiration, without revocation, of any applicable revocation periods under the general release provided that if the 60-day period during which the release is required to become effective and irrevocable begins in one calendar year and ends in another calendar year, the Severance Payment shall not be made before the first day of the second calendar year;
(iv)
any amounts earned, accrued or owing to the Executive but not yet paid under Sections 5, 6 or 7 above;
(v)
if COBRA coverage is elected by the Executive, the Company shall pay the cost of insurance continuation premiums on the Executive’s behalf (whether or not covered by COBRA) to continue standard medical, dental and life insurance coverage for the Executive (or the cash equivalent of same in the event the Executive is ineligible for continued coverage), on a monthly basis, until the earlier of:
(A)
the date 12 months after the date the Executive’s employment is terminated; or
(B)
the date, or dates, on which the Executive receives equivalent coverage and benefits under the plans, programs and/or arrangements of a subsequent

5


employer (such coverage and benefits to be determined on a coverage-by-coverage or benefit-by-benefit basis).
If Executive is a “specified employee” under Section 409A(a)(2)(B)(i) of the Code, any payment of “nonqualified deferred compensation” (as defined under Section 409A of the Code and related guidance and as determined by the Company) attributable to a “separation from service” (as defined under Section 409A of the Code, after giving effect to the presumptions contained therein, and related guidance) shall not commence until the first full business day that is six months and one day after the applicable separation from service (or, if earlier, the Executive’s Death) (“Deferred Payment Date”). Any payments that would otherwise have been made between the separation from service and the Deferred Payment Date, but for this paragraph, shall be made in a lump sum on the Deferred Payment Date. Payments that, in any case, are scheduled to be made after the Deferred Payment Date shall continue according to the applicable payment schedule. For purposes of this Agreement, all references to “termination of employment” and correlative phrases shall be construed to require a “separation from service” (as defined above”), to the extent required to company with Section 409A of the Code.
10. ASSIGNABILITY; BINDING NATURE.
This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors, heirs (in the case of the Executive) and assigns. No rights or obligations of the Company under this Agreement may be assigned or transferred by the Company except that such rights or obligations may be assigned or transferred pursuant to a merger or consolidation in which the Company is not the continuing entity, or the sale or liquidation of all or substantially all of the assets of the Company; provided, however, that the assignee or transferee is the successor to all or substantially all of the assets of the Company and such assignee or transferee assumes the liabilities, obligations and duties of the Company, as contained in this Agreement, either contractually or as a matter of law.
11. REPRESENTATIONS.
The Company represents and warrants that it is fully authorized and empowered to enter into this Agreement, and that the performance of its obligations under this Agreement will not violate any agreement between it and any other person, firm or organization. The Executive represents and warrants that no agreement exists between her and any other person, firm or organization that would be violated by the performance of the Executive’s obligations under this Agreement.
12. INDEMNIFICATION; INSURANCE.
The Executive shall at all times be indemnified and eligible for advancement of expenses on the same basis as is provided for the Company’s other executive officers and in accordance with the provisions of the Company’s charter and by-laws then in effect. The Executive shall

6


also be covered under all of the Company’s policies of liability insurance maintained for the benefit of its directors and officers on the same basis as is provided for its other executive officers.
13. ENTIRE AGREEMENT; TERMINATION.
This Agreement, the agreements referenced herein and the Employee Non-Disclosure, Non-Competition & Inventions Agreement between the Executive and the Company contain the entire understanding and agreement between the Parties concerning the subject matter hereof and supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the Parties with respect thereto. Subject to the terms of this Agreement, the Company shall be entitled to terminate the Executive’s employment at any time, and the Executive may terminate the Executive’s employment by the Company, at any time subject to the provisions of Section 9(b) of this Agreement, in each case by written notice provided in accordance with Section 20 of this Agreement.
14. AMENDMENT OR WAIVER.
No provision in this Agreement may be amended unless such amendment is agreed to in writing and signed by the Executive and an authorized officer of the Company provided that the Company may, without the Executive’s consent, unilaterally adopt amendments that may be required so that this Agreement continues to comply with applicable law or regulations, including without limitation Section 409A of the Code. No waiver by either Party of any breach by the other Party of any condition or provision contained in this Agreement to be performed by such other Party shall be deemed a waiver of a similar or dissimilar condition or provision at the same or any prior or subsequent time. Any waiver must be in writing and signed by the Executive or an authorized officer of the Company, as the case may be.
15. SEVERABILITY.
If any provision or portion of this Agreement shall be determined to be invalid or unenforceable for any reason, in whole or in part, the remaining provisions of this Agreement shall be unaffected thereby and shall remain in full force and effect to the fullest extent permitted by law.
16. SURVIVORSHIP.
The respective rights and obligations of the Parties hereunder shall survive any termination of the Executive’s employment to the extent necessary to the intended preservation of such rights and obligations.
17. BENEFICIARIES/REFERENCES.
The Executive shall be entitled, to the extent permitted under any applicable law, to select and change a beneficiary or beneficiaries to receive any compensation or benefit payable

7


hereunder following the Executive’s death by giving the Company written notice thereof. In the event of the Executive’s death or a judicial determination of the Executive’s incompetence, reference in this Agreement to the Executive shall be deemed, where appropriate, to refer to the Executive’s beneficiary, estate or other legal representative.
18. GOVERNING LAW/JURISDICTION.
This Agreement shall be governed by and construed and interpreted in accordance with the laws of The Commonwealth of Massachusetts without reference to principles of conflict of laws.
19. RESOLUTION OF DISPUTES.
Any disputes arising under or in connection with this Agreement may, at the election of the Executive or the Company, be resolved by binding arbitration, to be held in Massachusetts in accordance with the Rules and Procedures of the American Arbitration Association. If arbitration is elected, the Executive and the Company shall mutually select the arbitrator. If the Executive and the Company cannot agree on the selection of an arbitrator, each Party shall select an arbitrator and the two arbitrators shall select a third arbitrator, and the three arbitrators shall form an arbitration panel that shall resolve the dispute by majority vote. Judgment upon the award rendered by the arbitrator or arbitrators may be entered in any court having jurisdiction thereof. Costs of the arbitrator or arbitrators and other similar costs in connection with an arbitration shall be shared equally by the Parties; all other costs, such as attorneys’ fees incurred by each Party, shall be borne by the Party incurring such costs.
20. NOTICES.
All notices that are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, addressed as follows:

If to the Company:    Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210
Attn: Chief Executive Officer
        
If to the Executive:    at the Executive’s home address listed in the Company records.

8



Any such notice shall be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile on a business day; (b) on the business day after dispatch if sent by nationally-recognized overnight courier; and/or (c) on the fifth business day following the date of mailing if sent by mail.
21. HEADINGS.
The headings of the sections contained in this Agreement are for convenience only and shall not be deemed to control or affect the meaning or construction of any provision of this Agreement.
22. COUNTERPARTS.
This Agreement may be executed in two or more counterparts.
23. SECTION 409A OF THE CODE.
It is the intention of the Company and the Executive that this Agreement and the payments provided for herein are either exempt from or meet the requirements of Section 409A of the Code. The Company and the Executive agree to cooperate in good faith in preparing and executing such amendments to this Agreement, if any, as the Company or Executive may reasonably request solely for the purpose of assuring that this Agreement and the payments provided hereunder remain exempt from or meet the requirements of Section 409A, as applicable. Nothing in this Section 23 shall require the Company to increase the Executive’s compensation or make the Executive whole for any such changes. Each payment in a series of payments provided to the Executive pursuant to this Agreement will be deemed a separate payment for purposes of Section 409A. In no event, however, shall the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A of the Code.
Each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments. The Executive’s right to payment or reimbursement for any expenses hereunder shall be subject to the following additional rules: (i) the amount of expenses eligible for payment or reimbursement during any calendar year shall not affect the expenses eligible for payment or reimbursement in any other calendar year, (ii) payment or reimbursement shall be made not later than December 31 of the calendar year following the calendar year in which the expense or payment was incurred, and (iii) the right to payment or reimbursement is not subject to liquidation or exchange for any other benefit.
24. TAX WITHHOLDING; NO GUARANTEE OF ANY TAX CONSEQUENCES.

9


All payments hereunder shall be subject to all applicable withholding for any federal, state or local income taxes including any excise taxes under the Code. Notwithstanding any other provision of this Agreement to the contrary or other representation, the Company does not in any way guarantee the tax consequences of any payment or compensation under this Agreement including, without limitation, under Section 409A of the Code.
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.
Vertex Pharmaceuticals Incorporated
    
By:
/s/ Ian Smith
 
Executive Vice President, Chief Operating and Financial Officer

Executive
/s/ Tom Graney
Tom Graney


10
 EX-10.2 3 a2017q310-q_exhibit102.htm EXHIBIT 10.2 Exhibit

Tom Graney
September 6, 2017
Page 1


September 6, 2017
Tom Graney
88 Pembroke Street
Boston, MA 02118

RE:    Change of Control Agreement
Dear Tom:
You are a key member of the senior management team of Vertex Pharmaceuticals Incorporated (the “Company”). As a result, the Company would like to provide you with the following “change of control” benefits to help ensure that if the Company becomes involved in a “change of control” transaction, there will be no distraction from your attention to the needs of the Company.

I.
Definitions. For the purposes of this Amended and Restated Change of Control Agreement (this “Agreement”), capitalized terms shall have the following meanings:
1.
“Cause” shall mean:
(a)
your conviction of a crime involving moral turpitude;
(b)
your willful refusal or failure to follow a lawful directive or instruction of the Company’s Board of Directors or the individual(s) to whom you report, provided that you receive prior written notice of the directive(s) or instruction(s) that you failed to follow, and provided further that the Company, in good faith, gives you 30 days to correct such failure and further provided that if you correct the failure(s), any termination of your employment on account of such failure shall not be treated for purposes of this Agreement as a termination of employment for “Cause”;
(c)
in carrying out your duties you commit (i) willful gross negligence, or (ii) willful gross misconduct, resulting in either case in material harm to the Company, unless such act, or failure to act, was believed by you, in good faith, to be in the best interests of the Company; or
(d)
your violation of the Company’s policies made known to you regarding confidentiality, securities trading or inside information.
2.
“Change of Control” shall mean that:
(a)
any “person” or “group” as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934 (the “Act”), becomes a beneficial owner, as such term is used in Rule 13d-3 promulgated under the Act, of securities of the Company representing more than 50% of the combined voting power of the outstanding securities of the Company having the right to vote in the election of directors; or

288812v1

Tom Graney
September 6, 2017
Page 2

(b)
all or substantially all the business or assets of the Company are sold or disposed of, or the Company or a subsidiary of the Company combines with another company pursuant to a merger, consolidation, or other similar transaction, other than (i) a transaction solely for the purpose of reincorporating the Company or one of its subsidiaries in a different jurisdiction or recapitalizing or reclassifying the Company’s stock; or (ii) a merger or consolidation in which the shareholders of the Company immediately prior to such merger or consolidation continue to own at least a majority of the outstanding voting securities of the Company or the surviving entity immediately after the merger or consolidation.
3.
“Code” shall mean the Internal Revenue Code of 1986, as amended.
4.
“Disability” shall mean a disability as determined under the Company's long-term disability plan or program in effect at the time the disability first occurs, or if no such plan or program exists at the time of disability, then a “disability” as defined Section 22(e)(3) of the Code.
5.
“Good Reason” shall mean one of the following events has occurred without your consent:

(a)
You suffer a material reduction in the authorities, duties or job title and responsibilities associated with your position as Senior Vice President, Chief Financial Officer for the Company as of the date hereof;
(b)
your annual base salary is decreased;
(c)
the office to which you are assigned is relocated to a place 35 or more miles away; or
(d)
following a Change of Control, the Company’s successor fails to assume the Company’s rights and obligations under this Agreement;
provided that Good Reason shall not exist unless and until within 30 days after the event giving rise to Good Reason under (a), (b), (c) or (d) above has occurred, you deliver a written termination notice to the Company stating that an event giving rise to Good Reason has occurred and identifying with reasonable detail the event that you assert constitutes Good Reason under (a), (b), (c) or (d) above and the Company fails or refuses to cure or eliminate the event giving rise to Good Reason on or within 30 days after receiving your notice. To avoid doubt, the termination of your employment would become effective at the close of business on the thirtieth day after the Company receives your termination notice, unless the Company cures or eliminates the event giving rise to Good Reason prior to such time.

6.
“Termination Date” shall mean the last day of your employment with the Company.


Tom Graney
September 6, 2017
Page 3

II.
Severance Benefits upon Change of Control. If:
(A)
your employment is terminated by the Company (except for termination for Cause or due to a Disability) and the Termination Date is within 90 days prior to a Change of Control or within 12 months after a Change of Control; or
(B)
you, of your own initiative, (i) terminate your employment for Good Reason (in accordance with the notice and cure provisions set forth in Section I.5 above) and (ii) the event giving rise to Good Reason occurs within 90 days prior to a Change of Control or within 12 months after a Change of Control;
then, you shall receive the following benefits:

1.
Severance Payment. In exchange for your execution within 60 days of the Termination Date of a general release, in a form satisfactory to the Company, of all claims against the Company, its subsidiaries, and its and their officers, directors and representatives, that becomes enforceable and irrevocable within such 60-day period, the Company shall make a cash payment (the “Severance Payment”) to you in an amount equal to:
(a)
(i) your annual base salary (provided, however, that if you terminate your employment for Good Reason based on a reduction in your annual base salary, then the annual base salary to be used in calculating the Severance Payment shall be your annual base salary in effect immediately prior to such reduction in annual base salary) plus your target bonus under any bonus program applicable to you for the year in which the Termination Date occurs; plus
(b)
a prorata portion of your target bonus for the portion of the year in which the Termination Date occurs under any bonus program applicable to you; plus
(c)
all cash incentive compensation awards earned by you but not paid prior to the Termination Date; provided that, if a fiscal year has been completed and the incentive award for such fiscal year has not been determined, the incentive compensation for such completed fiscal year shall equal the target bonus for such fiscal year.
Except with respect to any portion of the Severance Payment that is delayed as set forth in this paragraph, the Severance Payment shall be made in cash within ten days after the execution by you of the general release referred to above and expiration without revocation of any applicable revocation periods under such general release (or, if the Change of Control resulting in your becoming entitled to such benefits occurs after such execution and expiration, within ten days after the Change of Control), provided that, if the 60-day period during which the general release is required to become effective and irrevocable begins in one calendar year and ends in another calendar year, the Severance Payment shall not be


Tom Graney
September 6, 2017
Page 4

made before the first day of the second calendar year. The Severance Payment shall be divided into two portions, consisting of a portion that does not constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code and a portion, if any, that does constitute nonqualified deferred compensation. If you are a “specified employee” as defined in Section 409A(a)(2)(B)(i) of the Code, the commencement of the delivery of any such payments that constitute nonqualified deferred compensation payable upon a “separation from service” under Section 409A(a)(2)(A)(i) of the Code will be delayed until the first business day that is more than six months after your Termination Date. The determination of whether, and the extent to which, any of the payments to be made to you hereunder are nonqualified deferred compensation shall be made after the application of all applicable exclusions, including those set forth under Treasury Reg. § 1.409A-1(b)(9). Any payments that are intended to qualify for the exclusion for separation pay due to involuntary separation from service set forth in Reg. §1.409A-1(b)(9)(iii) must be paid no later than the last day of the second taxable year following the taxable year in which the Termination Date occurs. To the extent that the termination of your employment does not constitute a separation of service under Section 409A(a)(2)(A)(i) of the Code (as the result of further services that are reasonably anticipated to be provided by you to the Company at the time your employment is terminated), the payment of any non-qualified deferred compensation will be further delayed until the first business day that is more than six months after the date of a subsequent event constituting a separation of service under Section 409A(a)(2)(A)(i) of the Code.
2.
Accelerated Vesting.

(a)
On the Termination Date, stock options for the purchase of the Company’s securities held by you as of the Termination Date and not then exercisable shall immediately become exercisable in full. The options to which this accelerated vesting applies shall remain exercisable until the earlier of (a) the end of the 90-day period immediately following the later of (i) the Termination Date or (ii) the date of the Change of Control and (b) the date the stock option(s) would otherwise expire; and

(b)
On the Termination Date, the Company’s lapsing repurchase right with respect to shares of restricted stock held by you shall lapse in full (subject to your making satisfactory arrangements with the Company providing for the payment to the Company of all required withholding taxes).

Notwithstanding anything to the contrary in this Agreement, the terms of any option agreement or restricted stock agreement shall govern the acceleration, if any, of vesting or lapsing of the Company’s repurchase rights and period of exercisability of such awards, as applicable, except to the extent that the terms of this Agreement are more favorable to you.

3.
Continued Insurance Coverage. If COBRA coverage is elected by you, the Company shall pay the cost of insurance continuation premiums on your behalf (whether or not covered by


Tom Graney
September 6, 2017
Page 5

COBRA) to continue standard medical, dental and life insurance coverage for you (or the cash equivalent of same if you are ineligible for continued coverage) until the earlier of (i) the date 12 months after the Termination Date or (ii) the date you begin receiving substantially equivalent coverage and benefits through a subsequent employer.

4.
No Mitigation. You shall not be required to mitigate the amount of the Severance Payment or any other benefit provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Agreement be reduced (except as provided in Article II Section 3(ii)) by any compensation earned by you as the result of other employment, by retirement benefits, or be offset against any amount claimed to be owed by you to the Company or otherwise (except for any required withholding taxes); provided, that if the Company makes any other severance payments to you under any other program or agreement, such amounts shall be offset against the payments the Company is obligated to make pursuant to this Agreement.
III.
Miscellaneous.
1.
Employee’s Obligations. Upon the termination of employment, you shall promptly deliver to the Company all property of the Company and all material documents, statistics, account records, programs and other similar tangible items which may by in your possession or under your control and which relate in a material way to the business or affairs of the Company or its subsidiaries, and no copies of any such documents or any part thereof shall be retained by you.
2.
Entire Agreement. This Agreement and the “Employee Non-Disclosure, Non-Competition & Inventions Agreement” previously executed by you covers the entire understanding of the parties as to the subject matter hereof, superseding all prior understandings and agreements related hereto, including the previous Change of Control Agreement between you and the Company. No modification or amendment of the terms and conditions of this Agreement shall be effective unless in writing and signed by the parties or their respective duly authorized agents, provided, however, that the Company may, without your consent, unilaterally adopt amendments that may be required so that this Agreement continues to comply with applicable law or regulation, including without limitation Section 409A of the Code, provided such amendments do not adversely affect the benefits to be provided to you under Section II of this Agreement.
3.
Governing Law. This Agreement shall be governed by the laws of The Commonwealth of Massachusetts, as applied to contracts entered into and performed entirely in Massachusetts by Massachusetts residents.

4.
Successors and Assigns. This Agreement may be assigned by the Company upon a sale, transfer or reorganization of the Company. Upon a Change of Control, the Company shall


Tom Graney
September 6, 2017
Page 6

require the successor to assume the Company’s rights and obligations under this Agreement. The Company’s failure to do so shall constitute a material breach of this Agreement. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their successors, permitted assigns, legal representatives and heirs.



Tom Graney
September 6, 2017
Page 7

Kindly indicate your acceptance of the foregoing by signing and dating this Agreement as noted below, and returning one fully executed original to my attention.

Very truly yours,

Vertex Pharmaceuticals Incorporated


By: /s/ Jeffrey M. Leiden            
Jeffrey M. Leiden, M.D., Ph.D.
Chairman, President &
Chief Executive Officer

ACCEPTED AND AGREED:


/s/ Tom Graney    
Tom Graney




 EX-31.1 4 a2017q310-q_exhibit311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION
I, Jeffrey M. Leiden, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
October 30, 2017
/s/ Jeffrey M. Leiden
 
 
 
 
 
Jeffrey M. Leiden
 
 
Chief Executive Officer and President




 EX-31.2 5 a2017q310-q_exhibit312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION
I, Thomas Graney, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
October 30, 2017
/s/ Thomas Graney
 
 
 
 
 
Thomas Graney
 
 
Senior Vice President and Chief Financial Officer



 EX-32.1 6 a2017q310-q_exhibit321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that the Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:
October 30, 2017
 
 
 
/s/ Jeffrey M. Leiden
 
 
 
 
 
Jeffrey M. Leiden
 
 
Chief Executive Officer and President
 
 
 
Date:
October 30, 2017
 
 
 
/s/ Thomas Graney
 
 
 
 
 
Thomas Graney
 
 
Senior Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
 





 EX-101.INS 7 vrtx-20170930.xml XBRL INSTANCE DOCUMENT 0000875320 2017-01-01 2017-09-30 0000875320 2017-10-20 0000875320 2017-07-01 2017-09-30 0000875320 2016-07-01 2016-09-30 0000875320 2016-01-01 2016-09-30 0000875320 2016-12-31 0000875320 2017-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0000875320 us-gaap:RetainedEarningsMember 2016-12-31 0000875320 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0000875320 us-gaap:CommonStockMember 2015-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0000875320 2015-12-31 0000875320 2016-09-30 0000875320 us-gaap:ParentMember 2016-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0000875320 us-gaap:CommonStockMember 2017-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000875320 us-gaap:CommonStockMember 2016-12-31 0000875320 us-gaap:CommonStockMember 2016-09-30 0000875320 us-gaap:RetainedEarningsMember 2017-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2016-09-30 0000875320 us-gaap:ParentMember 2016-12-31 0000875320 us-gaap:ParentMember 2016-01-01 2016-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-09-30 0000875320 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2016-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2017-09-30 0000875320 us-gaap:ParentMember 2017-01-01 2017-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000875320 us-gaap:RetainedEarningsMember 2015-12-31 0000875320 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0000875320 us-gaap:ParentMember 2017-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000875320 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0000875320 us-gaap:RetainedEarningsMember 2016-09-30 0000875320 us-gaap:ParentMember 2015-12-31 0000875320 vrtx:AccountingStandardsUpdate201609ForfeitureRateComponentMember us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2015-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0000875320 vrtx:AccountingStandardsUpdate201609ForfeitureRateComponentMember us-gaap:RetainedEarningsMember 2016-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0000875320 vrtx:AccountingStandardsUpdate201609ExcessTaxBenefitMember us-gaap:StateAndLocalJurisdictionMember 2017-03-31 0000875320 vrtx:AccountingStandardsUpdate201609ExcessTaxBenefitMember 2017-03-31 0000875320 vrtx:AccountingStandardsUpdate201609ExcessTaxBenefitMember 2016-12-31 0000875320 us-gaap:AccountingStandardsUpdate201609Member us-gaap:RetainedEarningsMember 2016-12-31 0000875320 vrtx:AccountingStandardsUpdate201609ExcessTaxBenefitMember us-gaap:DomesticCountryMember 2017-03-31 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedMember 2017-09-30 0000875320 us-gaap:AllowanceForSalesReturnsMember 2017-01-01 2017-09-30 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2017-01-01 2017-09-30 0000875320 vrtx:CopayMitigationRebatesMember 2017-01-01 2017-09-30 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2016-12-31 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2016-12-31 0000875320 vrtx:CopayMitigationRebatesMember 2017-09-30 0000875320 us-gaap:AllowanceForSalesReturnsMember 2017-09-30 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2017-01-01 2017-09-30 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2017-09-30 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2017-09-30 0000875320 vrtx:CopayMitigationRebatesMember 2016-12-31 0000875320 us-gaap:AllowanceForSalesReturnsMember 2016-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2016-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesInc.Member 2017-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesInc.Member 2016-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2016-01-01 2016-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2016-07-01 2016-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2017-01-01 2017-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2017-07-01 2017-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-01-01 2017-09-30 0000875320 vrtx:ParionSciencesInc.Member 2017-07-01 2017-09-30 0000875320 vrtx:MerckKGaAMember 2017-01-10 2017-01-10 0000875320 vrtx:ModernaTherapeuticsInc.Member 2016-07-01 2016-07-31 0000875320 vrtx:ParionSciencesInc.Member 2015-06-01 2015-06-30 0000875320 vrtx:JanssenPharmaceuticalsInc.Member 2016-07-01 2016-09-30 0000875320 vrtx:ParionSciencesInc.Member 2015-06-04 2017-09-30 0000875320 vrtx:MerckKGaAMember 2017-01-01 2017-03-31 0000875320 vrtx:ConcertPharmaceuticalsMember 2017-07-01 2017-07-30 0000875320 vrtx:ParionSciencesInc.Member vrtx:EnacInhibitorsinCfMember 2015-06-01 2015-06-30 0000875320 vrtx:BioAxoneBiosciencesInc.Member 2014-10-01 2014-10-31 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedMember 2016-01-01 2016-03-31 0000875320 us-gaap:CommonStockMember vrtx:CRISPRTherapeuticsAGMember 2016-10-01 2016-10-31 0000875320 vrtx:JanssenPharmaceuticalsInc.Member 2016-01-01 2016-09-30 0000875320 vrtx:MerckKGaAMember 2017-01-01 2017-09-30 0000875320 vrtx:BioAxoneBiosciencesInc.Member 2014-10-01 2014-12-31 0000875320 vrtx:ConcertPharmaceuticalsMember 2017-07-01 2017-07-31 0000875320 vrtx:ParionSciencesInc.Member 2015-06-04 0000875320 us-gaap:CommonStockMember vrtx:CRISPRTherapeuticsAGMember 2017-09-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedMember 2017-01-01 2017-09-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedMember 2016-10-01 2016-10-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2015-01-01 2015-12-31 0000875320 vrtx:BioAxoneBiosciencesInc.Member 2014-10-31 0000875320 vrtx:MerckKGaAMember 2017-07-01 2017-09-30 0000875320 vrtx:JanssenPharmaceuticalsInc.Member 2017-01-01 2017-09-30 0000875320 us-gaap:PreferredStockMember vrtx:CRISPRTherapeuticsAGMember 2016-04-01 2016-06-30 0000875320 vrtx:CRISPRTherapeuticsAGMember 2015-12-31 0000875320 vrtx:JanssenPharmaceuticalsInc.Member 2014-01-01 2014-12-31 0000875320 vrtx:ParionSciencesInc.Member vrtx:EnacInhibitorsinNonCfMember 2015-06-01 2015-06-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-07-01 2017-09-30 0000875320 vrtx:GermanTaxAuthorityMember vrtx:MerckKGaAMember 2017-01-01 2017-03-31 0000875320 vrtx:JanssenPharmaceuticalsInc.Member 2017-07-01 2017-09-30 0000875320 vrtx:JanssenPharmaceuticalsInc.Member 2014-06-01 2014-06-30 0000875320 vrtx:ParionSciencesInc.Member vrtx:AdditionalEnacInhibitorsMember 2015-06-01 2015-06-30 0000875320 vrtx:ConcertPharmaceuticalsMember 2017-07-31 0000875320 vrtx:ParionSciencesInc.Member 2015-06-04 2015-06-04 0000875320 vrtx:ConcertPharmaceuticalsMember 2017-07-01 2017-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesInc.Member 2016-01-01 2016-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesInc.Member 2016-07-01 2016-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2016-07-01 2016-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesInc.Member 2017-01-01 2017-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesInc.Member 2017-07-01 2017-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2016-01-01 2016-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2016-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2017-09-30 0000875320 vrtx:ConcertPharmaceuticalsMember 2017-01-01 2017-09-30 0000875320 us-gaap:RestrictedStockMember 2017-07-01 2017-09-30 0000875320 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0000875320 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0000875320 us-gaap:RestrictedStockMember 2016-07-01 2016-09-30 0000875320 vrtx:RestrictedStockandRestrictedStockUnitsMember 2016-01-01 2016-09-30 0000875320 vrtx:RestrictedStockandRestrictedStockUnitsMember 2016-07-01 2016-09-30 0000875320 vrtx:RestrictedStockandRestrictedStockUnitsMember 2017-07-01 2017-09-30 0000875320 vrtx:RestrictedStockandRestrictedStockUnitsMember 2017-01-01 2017-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2017-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2016-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2016-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2016-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2017-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2017-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-09-30 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2017-09-30 0000875320 vrtx:CashAndMoneyMarketFundsMember 2016-12-31 0000875320 vrtx:CorporateDebtSecuritiesDueAfterOneYearMember 2017-09-30 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2017-09-30 0000875320 us-gaap:CashAndCashEquivalentsMember 2016-12-31 0000875320 us-gaap:EquitySecuritiesMember 2016-12-31 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000875320 vrtx:U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember 2016-12-31 0000875320 us-gaap:CorporateDebtSecuritiesMember 2017-09-30 0000875320 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2016-12-31 0000875320 vrtx:CashAndMoneyMarketFundsMember 2017-09-30 0000875320 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2017-09-30 0000875320 us-gaap:CashAndCashEquivalentsMember 2017-09-30 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2016-12-31 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2017-09-30 0000875320 us-gaap:EquitySecuritiesMember 2017-09-30 0000875320 us-gaap:CommercialPaperMember 2017-09-30 0000875320 vrtx:ResearchandDevelopmentRestructuringMember 2017-01-01 2017-09-30 0000875320 vrtx:KendallRestructuringMember 2017-01-01 2017-09-30 0000875320 us-gaap:OtherRestructuringMember 2017-01-01 2017-09-30 0000875320 vrtx:FanPierMoveMember 2017-01-01 2017-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-09-30 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-01-01 2017-09-30 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-09-30 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2017-09-30 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-09-30 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-01-01 2016-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2016-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-07-01 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-07-01 2016-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2017-01-01 2017-09-30 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-09-30 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-09-30 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-09-30 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-09-30 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-12-31 0000875320 us-gaap:OtherAssetsMember 2017-09-30 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember 2017-09-30 0000875320 us-gaap:OtherCurrentLiabilitiesMember 2017-09-30 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2017-09-30 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2017-09-30 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2016-12-31 0000875320 us-gaap:ForeignExchangeForwardMember 2016-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2016-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember 2016-12-31 0000875320 us-gaap:OtherAssetsMember 2016-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember 2016-12-31 0000875320 vrtx:TezacaftorMember 2017-09-30 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-07-01 2017-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesInc.Member 2014-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2015-12-31 0000875320 us-gaap:OtherIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesInc.Member 2017-01-01 2017-09-30 0000875320 us-gaap:BuildingMember vrtx:SanDiegoLeaseMember 2016-12-31 0000875320 vrtx:FanPierLeasesMember 2011-01-01 2011-12-31 0000875320 us-gaap:LineOfCreditMember 2016-10-31 0000875320 us-gaap:SeniorLoansMember us-gaap:LondonInterbankOfferedRateLIBORMember 2014-07-01 2014-07-31 0000875320 vrtx:SanDiegoLeaseMember 2015-12-02 2015-12-02 0000875320 us-gaap:SeniorLoansMember 2015-12-31 0000875320 us-gaap:ConstructionInProgressMember vrtx:SanDiegoLeaseMember 2017-09-30 0000875320 us-gaap:ConstructionInProgressMember vrtx:SanDiegoLeaseMember 2016-12-31 0000875320 us-gaap:LineOfCreditMember us-gaap:MinimumMember us-gaap:BaseRateMember 2016-10-31 0000875320 us-gaap:ConstructionInProgressMember vrtx:FanPierLeasesMember 2016-12-31 0000875320 2016-10-31 0000875320 vrtx:SanDiegoLeaseMember 2015-12-02 0000875320 us-gaap:SeniorLoansMember 2014-07-31 0000875320 us-gaap:BuildingMember vrtx:SanDiegoLeaseMember 2017-09-30 0000875320 us-gaap:ConstructionInProgressMember vrtx:FanPierLeasesMember 2017-09-30 0000875320 us-gaap:BuildingMember vrtx:FanPierLeasesMember 2016-12-31 0000875320 vrtx:FanPierLeasesMember 2011-12-31 0000875320 us-gaap:LineOfCreditMember 2016-10-01 2016-10-31 0000875320 us-gaap:BuildingMember vrtx:FanPierLeasesMember 2017-09-30 0000875320 us-gaap:LineOfCreditMember us-gaap:MaximumMember us-gaap:BaseRateMember 2016-10-31 0000875320 2016-10-01 2016-10-31 0000875320 us-gaap:LineOfCreditMember us-gaap:MaximumMember us-gaap:EurodollarMember 2016-10-31 0000875320 us-gaap:LineOfCreditMember us-gaap:MinimumMember us-gaap:EurodollarMember 2016-10-31 0000875320 2017-02-01 2017-02-28 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars140.0Member 2017-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars140.0Member 2017-01-01 2017-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars140.01toDollars160.0Member 2017-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars160.01toDollars163.74Member 2017-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars18.93toDollars20.00Member 2017-09-30 0000875320 vrtx:ExercisePriceRangefromDollars20.01toDollars40.00Member 2017-09-30 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2017-01-01 2017-09-30 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2017-01-01 2017-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars160.01toDollars163.74Member 2017-01-01 2017-09-30 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2017-09-30 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2017-09-30 0000875320 vrtx:ExercisePriceRangefromDollars20.01toDollars40.00Member 2017-01-01 2017-09-30 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2017-09-30 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2017-09-30 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2017-01-01 2017-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars18.93toDollars20.00Member 2017-01-01 2017-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars140.01toDollars160.0Member 2017-01-01 2017-09-30 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2017-01-01 2017-09-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2017-07-01 2017-09-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2016-07-01 2016-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2016-07-01 2016-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2016-01-01 2016-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2016-01-01 2016-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2017-01-01 2017-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2017-07-01 2017-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2017-01-01 2017-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2016-07-01 2016-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2017-01-01 2017-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2017-07-01 2017-09-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2016-01-01 2016-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2017-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2017-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2017-09-30 0000875320 2008-01-01 2008-12-31 0000875320 us-gaap:InternalRevenueServiceIRSMember 2016-12-31 0000875320 2016-01-01 2016-12-31 0000875320 us-gaap:OtherRestructuringMember 2016-07-01 2016-09-30 0000875320 us-gaap:OtherRestructuringMember 2016-09-30 0000875320 us-gaap:OtherRestructuringMember 2016-01-01 2016-09-30 0000875320 us-gaap:OtherRestructuringMember 2015-12-31 0000875320 us-gaap:OtherRestructuringMember 2016-06-30 0000875320 us-gaap:OtherRestructuringMember 2017-09-30 0000875320 vrtx:FanPierMoveMember 2015-12-31 0000875320 vrtx:ResearchandDevelopmentRestructuringMember 2017-02-01 2017-02-28 0000875320 vrtx:FanPierMoveMember 2014-07-01 2014-09-30 0000875320 vrtx:FanPierMoveMember 2015-01-01 2015-12-31 0000875320 vrtx:KendallRestructuringMember 2003-01-01 2003-12-31 0000875320 vrtx:ResearchandDevelopmentRestructuringMember 2017-07-01 2017-09-30 0000875320 vrtx:ResearchandDevelopmentRestructuringMember 2017-06-30 0000875320 vrtx:ResearchandDevelopmentRestructuringMember 2017-09-30 0000875320 vrtx:ResearchandDevelopmentRestructuringMember 2016-12-31 0000875320 vrtx:KendallRestructuringMember 2016-07-01 2016-09-30 0000875320 vrtx:KendallRestructuringMember 2016-01-01 2016-09-30 0000875320 vrtx:KendallRestructuringMember 2016-12-31 0000875320 vrtx:KendallRestructuringMember 2017-09-30 0000875320 vrtx:KendallRestructuringMember 2017-07-01 2017-09-30 0000875320 vrtx:KendallRestructuringMember 2016-06-30 0000875320 vrtx:KendallRestructuringMember 2015-12-31 0000875320 vrtx:KendallRestructuringMember 2017-06-30 0000875320 vrtx:KendallRestructuringMember 2016-09-30 0000875320 vrtx:FanPierMoveMember 2016-09-30 0000875320 vrtx:FanPierMoveMember 2016-07-01 2016-09-30 0000875320 vrtx:FanPierMoveMember 2016-12-31 0000875320 vrtx:FanPierMoveMember 2016-06-30 0000875320 vrtx:FanPierMoveMember 2017-07-01 2017-09-30 0000875320 vrtx:FanPierMoveMember 2017-06-30 0000875320 vrtx:FanPierMoveMember 2017-09-30 0000875320 vrtx:FanPierMoveMember 2016-01-01 2016-09-30 xbrli:shares vrtx:pre-clinical_stage_program vrtx:milestone iso4217:USD xbrli:shares vrtx:segment iso4217:USD vrtx:clinical-stage_program vrtx:development_program vrtx:target vrtx:term_extension vrtx:lease utreg:sqft xbrli:pure vrtx:position vrtx:building vrtx:facility false --12-31 Q3 2017 2017-09-30 10-Q 0000875320 252902848 Large Accelerated Filer VERTEX PHARMACEUTICALS INC / MA 23776000 164368000 65237000 253381000 31283000 234477000 77387000 343147000 113800000 61451000 415000 77138000 455000 201083000 263493000 315249000 1330000 378554000 1021000 21173000 -25129000 6506795000 7034113000 181278000 181351000 -73000 181351000 218991000 218991000 0 218991000 61209000 39980000 21229000 178623000 115068000 63555000 73770000 46186000 27584000 215334000 134855000 80479000 0 12947000 3624000 12947000 3624000 10278000 4241000 3904000 281000 1100000 120000 170000 0 1946000 2896787000 3198325000 1831540000 2327974000 360628000 186137000 0 546765000 538625000 389484000 0 928109000 250612000 427282000 0 0 0 0 164300000 1200000 100000 1100000 59350000 850000 58500000 -69550000 0 -69550000 -69600000 -62560000 900000 -63460000 18000000 238800000 18900000 0 91000000 5100000 19426000 19881000 34976000 20259000 714768000 719692000 1183945000 1384966000 280560000 0 0 280560000 0 0 466702000 14979000 14608000 4488000 0 0 0 0 0 0 14608000 4488000 466702000 14979000 4924000 201021000 0.01 0.01 500000000 500000000 248300517 252683346 248300517 252683346 2450000 2500000 -39296000 -150666000 -106328000 116498000 -696000 33207000 -188315000 -173350000 -39992000 -117459000 -294643000 -56852000 20276000 20447000 53222000 147165000 72186000 188963000 432510000 1273175000 904208000 1839512000 0 9371000 9400000 -9400000 -9371000 73416000 190272000 190300000 0.05 300000000 0.062 0.072 0.015 0.025 0.0075 0.0175 5300000 -7100000 -7100000 3400000 6005000 13003000 6632000 2917000 1700000000 134063000 131446000 10682000 8338000 0 45947000 44965000 0 0 15449000 0 144000 50000 15593000 50000 660000 15593000 15593000 1709000 50000 144000 144000 14874000 -1200000 500000 -4100000 -13000000 144000 14874000 0 144000 0 144000 0 13897000 0 13897000 0 977000 0 977000 0 0 0 14824000 144000 50000 P18M P1M P1M 855000 2813000 688000 2104000 -0.16 -0.59 -0.41 0.66 -0.16 -0.59 -0.41 0.64 -265000 5001000 955000 2728000 1364000 3657000 175298000 289008000 2636000 P2Y7M6D P2Y7M21D P5M16D 0 144000 0 144000 0 14874000 0 14874000 1186000 14407000 8000 42000 0 1186000 0 1186000 0 14407000 0 14407000 0 8000 0 8000 0 42000 0 42000 144000 0 13897000 977000 0 -76644000 50400000 50384000 50400000 50384000 0 0 255340000 255300000 255300000 255340000 255300000 0 0 0 0 -2406000 -6080000 -238946000 -222448000 -39034000 -87672000 -417170000 -128131000 500000 503000 -510000 -500000 24100000 24118000 20100000 20063000 -125903000 -125900000 -97700000 -120200000 -120181000 7400000 -126200000 -117581000 -117600000 -97700000 -111700000 -111658000 14800000 1617000 4154000 -21532000 6925000 9760000 54455000 26121000 148102000 -10204000 3237000 11536000 28570000 23544000 -113969000 8979000 90006000 -20490000 15643000 0 0 0 0 0 0 0 2700000 1204000 -20140000 -60993000 -13574000 -45003000 64662000 51990000 14584000 17688000 77604000 98192000 6348000 12678000 56672000 67826000 0 11138000 1558596000 1395081000 2896787000 3198325000 792537000 710739000 500000000.0 300000000 0 0 0 64560000 15508000 59404000 111140000 0 0 0 0 0 0 59404000 111140000 64560000 15508000 0 0 56944000 75167000 295171000 0 0 0 0 75167000 295171000 56944000 181609000 181609000 12167000 12167000 39509000 -4827000 -125699000 -416584000 91379000 617431000 -38841000 -144997000 -102952000 162800000 -696000 -696000 33207000 33207000 -188315000 -188315000 -173350000 -173350000 -38841000 -144997000 -102952000 162597000 -38841000 -144997000 -102952000 162600000 824000 33827000 1 -18727000 -29704000 -326043000 -2494000 410800000 4100000000 410800000 404700000 6100000 11885000 399000 10542000 280000 6715000 104000 -890000 -7709000 -25981000 -7786000 -44904000 -11137000 -2508000 -7709000 -3884000 -11137000 -455000 -5669000 1936000 104000 -5669000 -7709000 -5669000 -3376000 -46302000 -27379000 -7786000 -46302000 -11137000 -46302000 2149000 1936000 -5453000 -27379000 -200000 400000 -900000 -2900000 -96000 104000 5961000 -7786000 0 0 0 0 29000000 255300000 284300000 284340000 284340000 29000000 29000000 29000000 255300000 9600000 10943000 2137000 27686000 119000 28699000 300000 26029000 0 904000 4787000 -167000 3025000 -77553000 -80634000 93000 -380000 1121000 4199000 5340000 1794000 10451000 13104000 3262000 4003000 750000 10578000 12962000 7869000 616625000 431653000 0 160000000 23075000 0 41775000 56817000 0.01 0.01 1000000 1000000 0 0 0 0 0 0 70534000 6812000 152238000 42000 193600000 0 4700000 51165000 298205000 300000000 2030000 0 535379000 247149000 -39537000 -111790000 33207000 -144997000 -144997000 -291267000 -10550000 -173350000 162800000 162800000 698362000 489000000 15000000 759978000 479000000 73900000 4779000 0 4779000 0 1398000 0 1398000 0 2800000 10600000 0 1800000 356000 412000 300000000 0 300000000 13330000 14188000 272370000 799238000 454947000 1017961000 0 160000000 47762000 47762000 1803000 1803000 70 8000 -112000 90000 30000 1038000 344000 472000 222000 337000 235000 227000 -125000 13859000 490000 1054000 12315000 12300000 1450000 5964000 7944000 1233000 4863000 6388000 0 3293000 3944000 3626000 4328000 0 1521000 1990000 3507000 0 773000 946000 2632000 6047000 4205000 1907000 146000 -8151000 -3863000 -5373836000 -5220407000 413783000 1243471000 578165000 1837018000 3835000 12713000 2231000 6643000 409689000 1229750000 549642000 1544252000 106055000 322921000 120710000 361285000 178623000 215334000 120.01 140.01 160.01 18.93 100.01 20.01 40.01 60.01 80.01 5162000 688000 0 3000 128000 586000 834000 877000 649000 1397000 10278000 1260000 0 634000 128000 1137000 834000 877000 821000 4587000 140.00 160.00 163.74 20.00 120 40 60 80 100 28773000 30966000 2425000 86859000 88107000 6385000 25969000 46737000 2428000 80865000 131388000 6738000 77.92 129.86 0.00 162.94 18.93 109.24 34.51 49.17 75.44 89.47 91.28 130.24 0.00 162.94 18.93 109.34 34.51 49.17 75.62 89.37 P7Y2M19D P7Y10M17D P0D P9Y9M18D P4M6D P7Y4M10D P2Y2M16D P4Y9M29D P6Y5M16D P8Y3M29D 246307000 248029000 248301000 252683000 1722000 4382000 50894000 50875000 19000 0 50894000 299039000 298956000 50000 33000 299006000 1156582000 1791077000 1093628000 3778000 126000 1824000 -2080000 6197500000 2427000 153661000 939967000 -5261784000 1208341000 5714000 230000 -3845000 -9789000 6429726000 2446000 186795000 1021546000 -5406781000 1338191000 11514000 17521000 21173000 -7862000 6506795000 2450000 181609000 1156582000 -5373836000 1803244000 -15865000 9735000 -25129000 -18999000 7034113000 2500000 12167000 1791077000 -5220407000 35000 35000 0 0 0 0 -200000 0 0 0 203000 0 0 0 0 0 -4883000 -13000 -188000 -355000 -4327000 89201000 3492000 2568000 1214000 81927000 109895000 5273000 2747000 3076000 98799000 244920000 244529000 250268000 252095000 244920000 244529000 250268000 247963000 6000000.0 0 2 10200000 165100000 1434557000 250612000 1183945000 59404000 64560000 1183945000 111140000 15508000 1812248000 56900000 427282000 1384966000 14608000 75167000 4488000 56944000 14979000 1350891000 59590000 235581000 1413220000 229275000 1183945000 59331000 43213000 1183945000 111225000 15506000 1798697000 413729000 1384968000 14610000 75186000 4488000 43213000 14979000 1350891000 59651000 235679000 21422000 21422000 0 73000 21347000 0 0 2000 13740000 13700000 13740000 0 0 1000 0 13731000 0 0 0 8000 85000 85000 0 0 0 0 85000 0 189000 187000 2000 2000 20000 0 0 0 0 61000 106000 90000000 220000000 P30D 230000000 490000000 370000000 275000000 420000000 160000000 20000000 10000000 30000000 3100000 P90D P90D 360000000 75000000.0 75000000 160000000 160000000 4 2 2 6 P180D P270D P10Y P6M P90D P180D 80000000 80000000 20000000 230000000.0 85000000 10000000 35000000 75000000 P1Y 259000 1008000 26292000 20000000 5200000 286123000 40000000 12800000 231700000 36400000 472600000 12600000 472200000 71800000 486359000 547051000 0 0 3.00 200000000.0 8000000 73423000 77258000 31400000 62200000 19000 868000 -28500000 -97700000 0 0 0 228000 0 2 2 0.09 P15Y P5Y P16Y 300000000.0 90000000.0 13900000 3910000 3910000 2 1 P10Y 10500000 0 10000000 160000000.0 0 3132000 0 1814000 2539000 2866000 7308000 8882000 2279000 2732000 7235000 8526000 0.5 3 153209000 3603000 18776000 12238000 118592000 127632000 1809000 18409000 10021000 97393000 1500000 11300000 29000000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (&#8220;Vertex&#8221; or the &#8220;Company&#8221;) in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, pharmaceuticals. As of September 30, 2017, the Company deconsolidated Parion Sciences, Inc. (&#8220;Parion&#8221;), a VIE the Company has consolidated since 2015. The Company's consolidated balance sheet as of September 30, 2017 excludes Parion. Please refer to Note C, &#8220;Collaborative Arrangements and Acquisitions&#8221; for further information regarding the deconsolidation of Parion. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, which are contained in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> that was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on </font><font style="font-family:inherit;font-size:10pt;">February&#160;23, 2017</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;</font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K&#8221;). </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s cash, cash equivalents and marketable securities is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,350,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,350,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,979</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,979</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,384,968</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,384,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate equity securities </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (matures within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (matures within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">235,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">235,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (matures after 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,651</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">413,729</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(187</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">427,282</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,798,697</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,812,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,183,945</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,183,945</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,183,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,183,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (matures within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,506</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,213</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,347</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (matures within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (matures within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(85</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">229,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(85</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">250,612</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,413,220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(85</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,434,557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a limited number of marketable securities in insignificant loss positions as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs of the investment at maturity. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborative Arrangements and Acquisitions</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cystic Fibrosis Foundation Therapeutics Incorporated</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a research, development and commercialization agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (&#8220;CFFT&#8221;) that was originally entered into in May 2004, and was most recently amended in October 2016 (the &#8220;2016 Amendment&#8221;). Pursuant to the agreement, as amended, the Company has agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016 and tiered royalties ranging from single digits to sub-teens on any approved drugs first synthesized and/or tested during a research term on or before February 28, 2014, including (i) KALYDECO (ivacaftor) and ORKAMBI (lumacaftor in combination with ivacaftor), which are the Company&#8217;s current products and (ii) tezacaftor in combination with ivacaftor. For combination products, such as ORKAMBI, sales will be allocated equally to each of the active pharmaceutical ingredients in the combination product.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2016, CFFT earned a commercial milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$13.9 million</font><font style="font-family:inherit;font-size:10pt;"> from the Company upon achievement of certain sales levels of lumacaftor. There are </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> additional commercial milestone payments payable by the Company to CFFT pursuant to the agreement. Pursuant to the 2016 Amendment, the CFFT provided the Company an upfront program award of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> and agreed to provide development funding to the Company of up to </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> annually. The program award plus any future development funding represent a form of financing pursuant to Accounting Standards Codification (ASC) 730, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development</font><font style="font-family:inherit;font-size:10pt;">, and thus the amounts are recorded as a liability on the condensed consolidated balance sheet, primarily reflected in Advance from collaborator. The liability is reduced over the estimated royalty term of the agreement. Reductions in the liability are reflected as an offset to cost of product revenues and as interest expense.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has royalty obligations to CFFT for ivacaftor, lumacaftor and tezacaftor until the expiration of patents covering those compounds. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent extensions. The Company has patents in the United States and European Union covering the composition-of-matter of lumacaftor that expire in 2030 and 2026, respectively, subject to potential extension. The Company has patents in the United States and European Union covering the composition-of-matter of tezacaftor that expire in 2027 and 2028, respectively, subject to potential extension.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">CRISPR Therapeutics AG</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2015, the Company entered into a strategic collaboration, option and license agreement (the &#8220;CRISPR Agreement&#8221;) with CRISPR Therapeutics AG and its affiliates (&#8220;CRISPR&#8221;) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. The Company has the exclusive right to license up to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> CRISPR-Cas9-based targets, including targets for the potential treatment of sickle cell disease. In connection with the CRISPR Agreement, the Company made an upfront payment to CRISPR of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> and a </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> investment in CRISPR pursuant to a convertible loan agreement that converted into preferred stock in January 2016. The Company expensed </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> to research and development, and the </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> investment was recorded at cost and was classified as a long-term asset on the Company&#8217;s condensed consolidated balance sheets. In the second quarter of 2016, the Company made an additional preferred stock investment in CRISPR of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">. In connection with CRISPR&#8217;s initial public offering in October 2016, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> of common shares at the public offering price and the Company&#8217;s preferred stock investments in CRISPR converted into common shares. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded the fair value of its investment in CRISPR common shares of </font><font style="font-family:inherit;font-size:10pt;">$56.9 million</font><font style="font-family:inherit;font-size:10pt;"> in marketable securities and a </font><font style="font-family:inherit;font-size:10pt;">$13.7 million</font><font style="font-family:inherit;font-size:10pt;"> unrealized gain related to these common shares in accumulated other comprehensive income (loss) on the condensed consolidated balance sheet. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company will fund all of the discovery activities conducted pursuant to the CRISPR Agreement. For potential hemoglobinapathy treatments, including treatments for sickle cell disease, the Company and CRISPR will share equally all development costs and worldwide revenues. For other targets that the Company elects to license, the Company would lead all development and global commercialization activities. For each of up to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> targets that the Company elects to license, other than hemoglobinapathy targets, CRISPR has the potential to receive up to </font><font style="font-family:inherit;font-size:10pt;">$420.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development, regulatory and commercial milestones and royalties on net product sales.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may terminate the CRISPR Agreement upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice to CRISPR prior to any product receiving marketing approval or upon </font><font style="font-family:inherit;font-size:10pt;">270</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice after a product has received marketing approval. The CRISPR Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the CRISPR Agreement will continue in effect until the expiration of the Company&#8217;s payment obligations under the CRISPR Agreement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Merck KGaA</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 10, 2017, the Company entered into a strategic collaboration and license agreement (the &#8220;Merck KGaA Agreement&#8221;) with Merck KGaA, Darmstadt, Germany (&#8220;Merck KGaA&#8221;). Pursuant to the Merck KGaA Agreement, the Company granted Merck KGaA an exclusive worldwide license to research, develop and commercialize </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> oncology research and development programs. Under the Merck KGaA Agreement, the Company granted Merck KGaA exclusive, worldwide rights to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> clinical-stage programs targeting DNA damage repair: its ataxia telangiectasia and Rad3-related protein inhibitor program, including VX-970 and VX-803, and its DNA-dependent protein kinase inhibitor program, including VX-984. In addition, the Company granted Merck KGaA exclusive, worldwide rights to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> pre-clinical programs.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Merck KGaA Agreement provided for an upfront payment from Merck KGaA to the Company of </font><font style="font-family:inherit;font-size:10pt;">$230.0 million</font><font style="font-family:inherit;font-size:10pt;">. During the first quarter of 2017, the Company received </font><font style="font-family:inherit;font-size:10pt;">$193.6 million</font><font style="font-family:inherit;font-size:10pt;"> of the upfront payment and the remaining </font><font style="font-family:inherit;font-size:10pt;">$36.4 million</font><font style="font-family:inherit;font-size:10pt;"> was remitted to the German tax authorities. Pursuant to a tax treaty between the United States and Germany, the Company filed a refund application for the tax withholding and expects to receive the refund in the fourth quarter of 2017. The income tax receivable is included in Prepaid expenses and other current assets at September 30, 2017. In addition to the upfront payment, the Company will receive tiered royalties on potential sales of licensed products, calculated as a percentage of net sales, that range from (i) mid-single digits to mid-twenties for clinical-stage programs and (ii) mid-single digits to high single digits for the pre-clinical research programs. Merck KGaA has assumed full responsibility for development and commercialization costs for all programs. </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the deliverables, primarily consisting of a license to the </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> programs and the obligation to complete certain fully-reimbursable research and development and transition activities as directed by Merck KGaA, pursuant to the Merck KGaA Agreement, under the multiple element arrangement accounting guidance. The Company concluded that the license has stand-alone value from the research and development and transition activities based on the resources and know-how possessed by Merck KGaA, and thus concluded that there are two units of accounting in the arrangement. The Company determined the relative selling price of the units of accounting based on the Company&#8217;s best estimate of selling price. The Company utilized key assumptions to determine the best estimate of selling price for the license, which included future potential net sales of licensed products, development timelines, reimbursement rates for personnel costs, discount rates, and estimated third-party development costs. The Company utilized a discounted cash flow model to determine its best estimate of selling price for the license and determined the best estimate of selling price for the research and development and transition activities based on what it would sell the services for separately. Based on this analysis, the Company recognized approximately </font><font style="font-family:inherit;font-size:10pt;">$231.7 million</font><font style="font-family:inherit;font-size:10pt;"> in collaborative revenues related to the upfront payment upon delivery of the license and to the research and development and transition activities provided during the first quarter of 2017. During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded the reimbursement for the research and development and transition activities of </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$12.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, as revenue in the Company&#8217;s consolidated statements of operations primarily due to the fact that the Company is the primary obligor in the arrangement. The Company is providing research and development and transition activities and will recognize the revenues and associated expenses as the services are provided.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merck KGaA may terminate the Merck KGaA Agreement or any individual program by providing </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice, or, in the case of termination of a program with a product that has received marketing approval, </font><font style="font-family:inherit;font-size:10pt;">180</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice. The Merck KGaA Agreement also may be terminated by either party for a material breach by the other party, subject to notice and cure provisions. Unless earlier terminated, the Merck KGaA Agreement will continue in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Interest Entities</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered into several agreements pursuant to which it has licensed rights to certain drug candidates from third-party collaborators, resulting in the consolidation of the third parties&#8217; financial statements into the Company&#8217;s condensed consolidated financial statements as VIEs. In order to account for </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent payments, which consist of milestone, royalty and option payments</font><font style="font-family:inherit;font-size:10pt;">, related to these collaborations under GAAP, the Company uses present-value models based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the timing of achieving the milestones, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent payments. The following collaborations are reflected in the Company&#8217;s financial statements as consolidated VIEs for portions or all of the periods presented:</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Parion Sciences,&#160;Inc.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2015, the Company entered into a strategic collaboration and license agreement (the &#8220;Parion Agreement&#8221;) with Parion.&#160; Pursuant to the agreement, the Company is collaborating with Parion to develop investigational epithelial sodium channel (&#8220;ENaC&#8221;) inhibitors, including VX-371 (formerly P-1037) and VX-551 (formerly P-1055), for the potential treatment of CF and all other pulmonary diseases.&#160; The Company is leading development activities for VX-371 and VX-551 and is responsible for all costs, subject to certain exceptions, related to development and commercialization of the compounds.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Parion Agreement, the Company has worldwide development and commercial rights to Parion&#8217;s lead investigational ENaC inhibitors, VX-371 and VX-551, for the potential treatment of CF and all other pulmonary diseases and has the option to select additional compounds discovered in Parion&#8217;s research program.&#160; Parion received an </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;"> up-front payment and has the potential to receive up to an additional (i) </font><font style="font-family:inherit;font-size:10pt;">$490.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestone payments for development of ENaC inhibitors in CF, including </font><font style="font-family:inherit;font-size:10pt;">$360.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to global filing and approval milestones, (ii) </font><font style="font-family:inherit;font-size:10pt;">$370.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestones for VX-371 and VX-551 in non-CF pulmonary indications and (iii)&#160;</font><font style="font-family:inherit;font-size:10pt;">$230.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestones should the Company elect to develop an additional ENaC inhibitor from Parion&#8217;s research program. The Company has agreed to pay Parion tiered royalties that range from the low double digits to mid-teens as a percentage of potential sales of licensed products.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may terminate the Parion Agreement upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice to Parion prior to any licensed product receiving marketing approval or upon </font><font style="font-family:inherit;font-size:10pt;">180</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice after a licensed product has received marketing approval. If the Company experiences a change of control prior to the initiation of the first Phase 3 clinical trial for a licensed product, Parion may terminate the Parion Agreement upon </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice, subject to the Company&#8217;s right to receive specified royalties on any subsequent commercialization of licensed products. The Parion Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Parion Agreement will continue in effect until the expiration of the Company&#8217;s royalty obligations, which expire on a country-by-country basis on the later of (i)&#160;the date the last-to-expire patent covering a licensed product expires or (ii)&#160;</font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years after the first commercial sale in the country.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that it had a variable interest in Parion via the Parion Agreement, and that the variable interest represented a variable interest in Parion as a whole because the fair value of the ENaC inhibitors represented more than half of the total fair value of Parion&#8217;s assets. The Company also concluded that it was the primary beneficiary as it had the power to direct the activities that most significantly affect the economic performance of Parion and it had the obligation to absorb losses and right to receive benefits that potentially could be significant to Parion. &#160;Accordingly, the Company consolidated Parion's financial statements from June&#160;4, 2015 through September 30, 2017. The Company deconsolidated Parion effective September 30, 2017. Notwithstanding the applicable accounting treatment, the Company's interests in Parion have been and continue to be limited to those accorded to the Company in the Parion Agreement. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June 4, 2015, the Company consolidated Parion&#8217;s financial statements, which included </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;"> of intangible assets on the Company&#8217;s condensed consolidated balance sheet for Parion&#8217;s in-process research and development assets. These in-process research and development assets relate to Parion&#8217;s pulmonary ENaC platform, including the intellectual property related to VX-371 and VX-551, that are licensed by Parion to the Company. The Company also recorded the fair value of the net assets attributable to noncontrolling interest of </font><font style="font-family:inherit;font-size:10pt;">$164.3 million</font><font style="font-family:inherit;font-size:10pt;">, deferred tax liability of </font><font style="font-family:inherit;font-size:10pt;">$91.0 million</font><font style="font-family:inherit;font-size:10pt;"> resulting primarily from a basis difference in the intangible assets and certain other net liabilities held by Parion of </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;">.&#160; The difference between the fair values of the consideration and noncontrolling interest and the fair value of Parion&#8217;s net assets was recorded as goodwill. When determining the valuation of goodwill, the fair value of consideration for the license was zero since there was no consideration transferred outside the condensed consolidated financial statements. While there was a transfer of </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;"> for the upfront payment to Parion, the cash remained within the Company&#8217;s condensed consolidated balance sheet since Parion was part of the consolidated entity. The cash received, net of any cash spent by Parion, was classified as restricted cash and cash equivalents (VIE) within the condensed consolidated balance sheet as it was attributed to the noncontrolling interest holders of Parion.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the second quarter of 2017, Parion signed a license agreement with an affiliate of Shire plc related to the development of a drug candidate for the potential treatment of dry eye disease. The Company evaluated the license agreement entered into by Parion as a reconsideration event to determine whether it should continue to consolidate Parion as a variable interest entity into its condensed consolidated financial statements. The Company determined that there was no substantive change in the design of Parion subsequent to Parion&#8217;s agreement with Shire. Additionally, the Company concluded that it was appropriate to continue to consolidate the financial results of Parion because it continued to have (i) the power to direct the activities that most significantly affect the economic performance of Parion and (ii) the obligation to absorb losses and right to receive benefits that potentially could be significant to Parion. Based on the consolidation of Parion&#8217;s financial statements, during </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has recognized (i) </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of collaborative revenues and (ii) a tax provision of </font><font style="font-family:inherit;font-size:10pt;">$7.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$14.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, both of which were attributable to noncontrolling interest related to payments that Parion received from Shire in </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The Company has no interest in Parion&#8217;s license agreement with Shire, including the economic benefits and/or obligations derived therefrom.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of September 30, 2017, the Company determined that the fair value of Parion&#8217;s pulmonary ENaC platform had declined significantly based on data received in September 2017 from a Phase 2 clinical trial of VX-371 that did not meet its primary efficacy endpoint. The Company recorded an impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;">, which represented the entire value of the intangible asset in the third quarter of 2017. After evaluating the results of the clinical trial, the Company determined that it was no longer the primary beneficiary of Parion as it no longer had the power to direct the significant activities of Parion. The most important factor in this determination was the decrease in the fair value of Parion&#8217;s pulmonary ENaC platform relative to Parion&#8217;s other activities. Accordingly, the Company deconsolidated Parion as of September 30, 2017. The impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;">, decrease in the fair value of the contingent payments payable by the Company to Parion of </font><font style="font-family:inherit;font-size:10pt;">$69.6 million</font><font style="font-family:inherit;font-size:10pt;"> and benefit from income taxes of </font><font style="font-family:inherit;font-size:10pt;">$126.2 million</font><font style="font-family:inherit;font-size:10pt;"> resulting from these charges were recorded in the third quarter of 2017 attributable to noncontrolling interest. The benefit from income taxes consisted of benefits of </font><font style="font-family:inherit;font-size:10pt;">$97.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$28.5 million</font><font style="font-family:inherit;font-size:10pt;"> attributable to the impairment charge and decrease in the fair value of contingent payments, respectively. The net effect of these charges and impact of the deconsolidation was a loss of </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> recorded in other income (expense), net attributable to Vertex in the consolidated statement of operations for the three and nine months ended September 30, 2017. The loss of </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> was approximately the difference between (i) the aggregate of </font><font style="font-family:inherit;font-size:10pt;">$85.0 million</font><font style="font-family:inherit;font-size:10pt;"> in upfront and milestone payments that the Company has made to Parion to date pursuant to the Parion Agreement and (ii) losses the Company recorded in 2015, 2016, and the first half of 2017 based on increases in the fair value of contingent payments payable by the Company to Parion. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please refer to Note J, "Intangible Assets and Goodwill," for further information regarding the impairment of Parion&#8217;s pulmonary ENaC platform.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the deconsolidation of Parion, the Company evaluated whether the results of Parion should be presented as discontinued operations for the three and nine month period ending September 30, 2017. The Company concluded that the deconsolidation of Parion based on data from the Phase 2 clinical trial of VX-371 is not a development that significantly impacts the Company&#8217;s overall operations and financial results or plans to treat patients with CF. Research and development expenses incurred related to this program accounted for a minor portion of the Company&#8217;s overall annual research and development expenses and the Company remains focused on developing medicines to treat CF. Therefore, the Company has not presented the results related to Parion as discontinued operations in its condensed consolidated statements of operations for the three and nine month ending September 30, 2017. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BioAxone Biosciences, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, the Company entered into a license and collaboration agreement (the &#8220;BioAxone Agreement&#8221;) with BioAxone Biosciences, Inc. (&#8220;BioAxone&#8221;), which resulted in the consolidation of BioAxone as a VIE beginning on October 1, 2014. The Company paid BioAxone initial payments of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the fourth quarter of 2014. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BioAxone has the potential to receive up to </font><font style="font-family:inherit;font-size:10pt;">$90.0 million</font><font style="font-family:inherit;font-size:10pt;"> in milestones and fees, including development, regulatory and milestone payments and a license continuation fee. In addition, BioAxone would receive royalties and commercial milestones on future net product sales of VX-210, if any. The Company recorded an in-process research and development intangible asset of </font><font style="font-family:inherit;font-size:10pt;">$29.0 million</font><font style="font-family:inherit;font-size:10pt;"> for VX-210 and a corresponding deferred tax liability of </font><font style="font-family:inherit;font-size:10pt;">$11.3 million</font><font style="font-family:inherit;font-size:10pt;"> attributable to BioAxone. The Company holds an option to purchase BioAxone at a predetermined price. The option expires on the earliest of (a) the day the FDA accepts the Biologics License Application submission for VX-210, (b) the day the Company elects to continue the license instead of exercising the option to purchase BioAxone and (c) March 15, 2018, subject to the Company&#8217;s option to extend this date by </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> year. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Aggregate VIE Financial Information</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An aggregate summary of net income attributable to noncontrolling interest related to the Company&#8217;s VIEs for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss attributable to noncontrolling interest before (benefit from) provision for income taxes and changes in fair value of contingent payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">238,946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">222,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Benefit from) provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(120,181</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(510</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(111,658</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,063</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Decrease (increase) in fair value of contingent payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">62,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(59,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss (income) attributable to noncontrolling interest</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">188,315</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">696</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">173,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(33,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The decreases in the noncontrolling interest holders&#8217; claim to net assets with respect to the fair value of the contingent payments in </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> were primarily due to the decrease in the fair value of Parion&#8217;s pulmonary ENaC platform described above. The increases in the fair value of the contingent payments in </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were primarily due to a separate Phase 2 clinical trial of VX-371 achieving its primary safety endpoint in the second quarter of 2016. During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the (increases) decreases in the fair value of the contingent payments related to the Company&#8217;s VIEs were as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Parion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(58,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">BioAxone</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(900</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(850</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the contingent payments related to the Parion Agreement and the BioAxone Agreement as of the dates set forth in the table: </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Parion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">238,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">BioAxone</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below summarizes items related to the Company&#8217;s VIEs included in the Company&#8217;s condensed consolidated balance sheets as of the dates set forth in the table. Amounts as of September 30, 2017 related to BioAxone while amounts as of December 31, 2016 related to Parion and BioAxone.</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted cash and cash equivalents (VIE)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">47,762</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,812</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">280</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">399</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued expenses </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,021</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,338</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,446</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">181,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has recorded the VIEs&#8217; cash and cash equivalents as restricted cash and cash equivalents (VIE) because (i)&#160;the Company does not have any interest in or control over the VIEs&#8217; cash and cash equivalents and (ii)&#160;the Company&#8217;s agreements with each VIE do not provide for the VIEs&#8217; cash and cash equivalents to be used for the development of the assets that the Company licensed from the applicable VIE. Assets recorded as a result of consolidating the Company&#8217;s VIEs&#8217; financial condition into the Company&#8217;s balance sheets do not represent additional assets that could be used to satisfy claims against the Company&#8217;s general assets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Collaborations</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered into various agreements pursuant to which it collaborates with third parties, including inlicensing and outlicensing arrangements. Although the Company does not consider any of these arrangements to be material, the most notable of these arrangements are described below. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Moderna Therapeutics, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, the Company entered into a strategic collaboration and licensing agreement (the &#8220;Moderna Agreement&#8221;) with Moderna Therapeutics, Inc. (&#8220;Moderna&#8221;) pursuant to which the parties are seeking to identify and develop messenger Ribonucleic Acid (&#8220;mRNA&#8221;) Therapeutics for the treatment of CF. In connection with the Moderna Agreement, in the third quarter of 2016, the Company made an upfront payment to Moderna of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> and a </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> cost-method investment in Moderna pursuant to a convertible promissory note that converted into preferred stock in August 2016. Moderna has the potential to receive&#160;future development and regulatory milestones of up to&#160;</font><font style="font-family:inherit;font-size:10pt;">$275.0 million</font><font style="font-family:inherit;font-size:10pt;">, including </font><font style="font-family:inherit;font-size:10pt;">$220.0 million</font><font style="font-family:inherit;font-size:10pt;">&#160;in approval and reimbursement milestones, as well as tiered royalty payments on future sales.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Moderna Agreement, Moderna&#160;will lead discovery efforts and the Company will lead all preclinical, development and commercialization activities associated with the advancement of mRNA Therapeutics that result from this collaboration and will fund all expenses related to the collaboration.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may terminate the Moderna Agreement by providing advance notice to Moderna, with the required length of notice dependent on whether any product developed under the Moderna Agreement has received marketing approval. The Moderna Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Moderna Agreement will continue in effect until the expiration of the Company&#8217;s payment obligations under the Moderna Agreement. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the carrying value of its </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> cost-method investment in Moderna, which is not a publicly traded company, for impairment on a quarterly basis and has not recorded any adjustments to the carrying value of its investment to date. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Janssen Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, the Company entered into an agreement (the &#8220;Janssen Agreement&#8221;) with Janssen Pharmaceuticals, Inc. (&#8220;Janssen Inc.&#8221;), which was amended in October 2014 to clarify certain roles and responsibilities of the parties. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Janssen Agreement, Janssen Inc. has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including JNJ-3872 (formerly VX-787). The Company received non-refundable payments of </font><font style="font-family:inherit;font-size:10pt;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Janssen Inc. in 2014, which were recorded as collaborative revenue. The Company has the potential to receive development, regulatory and commercial milestone payments as well as royalties on future product sales, if any. Janssen Inc. may terminate the Janssen Agreement, subject to certain exceptions, upon </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months&#8217; notice. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen Inc. is responsible for costs related to the development and commercialization of the compounds. During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> the Company recorded reimbursement for these development activities of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> the Company recorded reimbursement for these development activities of </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$10.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The reimbursements are recorded as a reduction to development expense in the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;"> primarily due to the fact that Janssen Inc. directs the activities and selects the suppliers associated with these activities. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Asset Acquisition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Concert Pharmaceuticals</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the Company completed the acquisition of certain CF assets including VX-561 (formerly CTP-656) from Concert Pharmaceuticals Inc. (&#8220;Concert&#8221;) pursuant to an asset purchase agreement that was entered into in March 2017 (the &#8220;Concert Agreement&#8221;). VX-561 is an investigational CFTR potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of CF. As part of the Concert Agreement, Vertex paid Concert&#160;</font><font style="font-family:inherit;font-size:10pt;">$160.0 million</font><font style="font-family:inherit;font-size:10pt;">&#160;in cash for all worldwide development and commercialization rights to VX-561. If VX-561 is approved as part of a combination regimen to treat CF, Concert could receive up to an additional </font><font style="font-family:inherit;font-size:10pt;">$90.0 million</font><font style="font-family:inherit;font-size:10pt;">&#160;in milestones based on regulatory approval in the&#160;U.S.&#160;and reimbursement in the&#160;UK,&#160;Germany or France. The Company determined that substantially all of the fair value of the Concert Agreement was attributable to a single in-process research and development asset, VX-561, which did not constitute a business. The Company cannot conclude that there is any alternative future use for the acquired in-process research and development asset. Thus, the Company recorded the </font><font style="font-family:inherit;font-size:10pt;">$160.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment as a research and development expense in the three and nine months ended September 30, 2017. The total purchase price for the transaction was </font><font style="font-family:inherit;font-size:10pt;">$165.1 million</font><font style="font-family:inherit;font-size:10pt;"> including </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;"> of transaction costs that were recorded as sales, general and administrative expenses. If the Company achieves </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> or more of the </font><font style="font-family:inherit;font-size:10pt;">$90.0 million</font><font style="font-family:inherit;font-size:10pt;"> of regulatory approval and reimbursement milestones, the Company will record the value of the milestone as an intangible asset and will begin amortizing the asset in cost of product revenues in the period that the relevant milestone is achieved.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Guaranties and Indemnifications</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As permitted under Massachusetts law, the Company&#8217;s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors&#8217; and officers&#8217; liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company&#8217;s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator&#8217;s institution relating to personal injury or property damage, violations of law or certain breaches of the Company&#8217;s contractual obligations arising out of the research or clinical testing of the Company&#8217;s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company&#8217;s contractual obligations. The indemnification provisions appearing in the Company&#8217;s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> material contingent liabilities accrued as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s changes in accumulated other comprehensive income (loss) by component is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains (Losses) on Marketable Securities, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Foreign Currency Forward Contracts, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive loss before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,137</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,786</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25,981</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(44,904</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,398</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,398</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,137</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,786</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(27,379</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(46,302</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,735</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,865</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Foreign Currency Forward Contracts, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,709</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,715</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(890</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,779</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,779</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,709</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,936</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,669</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,789</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">230</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,714</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term Obligations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fan Pier Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2011, the Company entered into </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> lease agreements, pursuant to which the Company leases approximately </font><font style="font-family:inherit;font-size:10pt;">1.1 million</font><font style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> buildings (the &#8220;Fan Pier Buildings&#8221;) at Fan Pier in Boston, Massachusetts (the &#8220;Fan Pier Leases&#8221;). The Company commenced lease payments in December 2013, and will make lease payments pursuant to the Fan Pier Leases through December 2028. The Company has an option to extend the term of the Fan Pier Leases for an additional </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the Company was involved in the construction project, the Company was deemed for accounting purposes to be the owner of the Fan Pier Buildings during the construction period and recorded project construction costs incurred by the landlord. Upon completion of the Fan Pier Buildings, the Company evaluated the Fan Pier Leases and determined that the Fan Pier Leases did not meet the criteria for &#8220;sale-leaseback&#8221; treatment. Accordingly, the Company began depreciating the asset and incurring interest expense related to the financing obligation in 2013. The Company bifurcates its lease payments pursuant to the Fan Pier Leases into (i)&#160;a portion that is allocated to the Buildings and (ii)&#160;a portion that is allocated to the land on which the Fan Pier Buildings were constructed. The portion of the lease obligations allocated to the land is treated as an operating lease that commenced in 2011.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net, included </font><font style="font-family:inherit;font-size:10pt;">$479.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$489.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to construction costs for the Fan Pier Buildings. The carrying value of the Company&#8217;s lease agreement liability for the Fan Pier Buildings was </font><font style="font-family:inherit;font-size:10pt;">$472.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$472.6 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">San Diego Lease</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 2, 2015, the Company entered into a lease agreement for 3215 Merryfield Row, San Diego, California with ARE-SD Region No. 23, LLC (the &#8220;San Diego Building&#8221;). Pursuant to this agreement, the Company agreed to lease approximately </font><font style="font-family:inherit;font-size:10pt;">170,000</font><font style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in a building to be built in San Diego, California. The lease will commence upon completion of the building, scheduled for the first half of 2018, and will extend for </font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;"> years from the commencement date. Pursuant to the lease agreement, during the initial </font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;">-year term, the Company will pay an average of approximately </font><font style="font-family:inherit;font-size:10pt;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;"> per year in aggregate rent, exclusive of operating expenses. The Company has the option to extend the lease term for up to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> additional </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year terms.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the Company is involved in the construction project, the Company is deemed for accounting purposes to be the owner of the San Diego Building during the construction period and recorded project construction costs incurred by the landlord. The Company bifurcates its lease payments pursuant to the San Diego Lease into (i) a portion that is allocated to the San Diego Building and (ii) a portion that is allocated to the land on which the San Diego Building was constructed. Although the Company will not begin making lease payments pursuant to the San Diego Lease until the commencement date, the portion of the lease obligation allocated to the land is treated for accounting purposes as an operating lease that commenced in the fourth quarter of 2016. Upon completion of the San Diego Building, the Company will evaluate the San Diego Lease and determine if the San Diego Lease meets the criteria for &#8220;sale-leaseback&#8221; treatment. If the San Diego Lease meets the &#8220;sale-leaseback&#8221; criteria, the Company will remove the asset and the related liability from its consolidated balance sheet and treat the San Diego Lease as either an operating or a capital lease based on the Company&#8217;s assessment of the accounting guidance. The Company expects that upon completion of construction of the San Diego Building the San Diego Lease will not meet the &#8220;sale-leaseback&#8221; criteria. If the San Diego Lease does not meet &#8220;sale-leaseback&#8221; criteria, the Company will treat the San Diego Lease as a financing obligation and will depreciate the asset over its estimated useful life. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net, included </font><font style="font-family:inherit;font-size:10pt;">$73.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to construction costs for the San Diego Building. The carrying value of the Company&#8217;s lease agreement liability for the San Diego Building was </font><font style="font-family:inherit;font-size:10pt;">$71.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$12.6 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revolving Credit Facility</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the Company entered into a Credit Agreement (the &#8220;Credit Agreement&#8221;) with Bank of America, N.A., as administrative agent and the lenders referred to therein. The Credit Agreement provides for a </font><font style="font-family:inherit;font-size:10pt;">$500.0 million</font><font style="font-family:inherit;font-size:10pt;"> revolving facility, </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;"> of which was drawn at closing (the &#8220;Loans&#8221;) and was repaid in February 2017. The Credit Agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the borrowing capacity under the Credit Agreement be increased by an additional </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Credit Agreement matures on October 13, 2021.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The proceeds of the borrowing under the Credit Agreement were used primarily to repay the Company&#8217;s then outstanding indebtedness under the Macquarie Loan (as defined below). The Loans will bear interest, at the Company&#8217;s option, at either a base rate or a Eurodollar rate, in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from </font><font style="font-family:inherit;font-size:10pt;">0.75%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1.50%</font><font style="font-family:inherit;font-size:10pt;"> and the applicable margins on Eurodollar loans range from </font><font style="font-family:inherit;font-size:10pt;">1.75%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2.50%</font><font style="font-family:inherit;font-size:10pt;">, in each case based on the Company&#8217;s consolidated leverage ratio (the ratio of the Company&#8217;s total consolidated debt to the Company&#8217;s trailing twelve-month EBITDA).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loans are guaranteed by certain of the Company&#8217;s domestic subsidiaries and secured by substantially all of the Company&#8217;s assets and the assets of the Company&#8217;s domestic subsidiaries (excluding intellectual property, owned and leased real property and certain other excluded property) and by the equity interests of the Company&#8217;s subsidiaries, subject to certain exceptions. Under the terms of the Credit Agreement, the Company must maintain, subject to certain limited exceptions, a consolidated leverage ratio of </font><font style="font-family:inherit;font-size:10pt;">3.00</font><font style="font-family:inherit;font-size:10pt;"> to 1.00 and consolidated EBITDA of at least </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;">, in each case to be measured on a quarterly basis.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Credit Agreement contains customary representations and warranties and usual and customary affirmative and negative covenants. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Term Loan</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014, the Company entered into a credit agreement with the lenders party thereto, and Macquarie US Trading LLC (&#8220;Macquarie&#8221;), as administrative agent. The credit agreement provided for a </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;"> senior secured term loan (the &#8220;Macquarie Loan&#8221;). On October 13, 2016, the Company terminated and repaid all outstanding obligations under the Macquarie Loan. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Macquarie Loan initially bore interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">7.2%</font><font style="font-family:inherit;font-size:10pt;"> per annum, which was reduced to </font><font style="font-family:inherit;font-size:10pt;">6.2%</font><font style="font-family:inherit;font-size:10pt;"> per annum based on the FDA&#8217;s approval of ORKAMBI. The Term Loan bore interest at a rate of LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum during the third year of the term. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurred </font><font style="font-family:inherit;font-size:10pt;">$5.3 million</font><font style="font-family:inherit;font-size:10pt;"> in fees paid to Macquarie that were recorded as a discount on the Macquarie Loan and were recorded as interest expense using the effective interest method over the term of the loan in the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hedging</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company&#8217;s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">eighteen</font><font style="font-family:inherit;font-size:10pt;"> months. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company&#8217;s risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge&#8217;s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company determines that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, all hedges were determined to be highly effective and the Company had not recorded any ineffectiveness related to the hedging program.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the notional amount of the Company&#8217;s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign Currency</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">234,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77,387</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">65,237</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,283</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">343,147</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">253,381</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value of the Company&#8217;s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company&#8217;s condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2017</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,897</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(977</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,874</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,593</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of September 30, 2017, the Company expects amounts recorded in prepaid and other currents assets and other liabilities, current portion to be reclassed to earnings within twelve months.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company&#8217;s condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,874</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,874</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,824</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">144</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also enters into foreign exchange forward contracts with contractual maturities of less than </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> month designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities including intercompany balances. The Company recognized losses of&#160;</font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$13.0 million</font><font style="font-family:inherit;font-size:10pt;">, recorded in other income (expense), net, for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to foreign exchange contracts, which are not designated as hedging instruments under GAAP. The Company recognized a loss of&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#160;and a gain of&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">,&#160;for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to foreign exchange contracts not designated as hedging instruments. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of&#160;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the notional amount of foreign exchange contracts where hedge accounting under GAAP is not applied was&#160;</font><font style="font-family:inherit;font-size:10pt;">$113.8 million</font><font style="font-family:inherit;font-size:10pt;">. The following table summarizes the fair value of the Company&#8217;s outstanding foreign currency forward contracts not designated for hedge accounting included on the Company&#8217;s condensed consolidated balance sheets:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based Compensation Expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized the following stock-based compensation expense:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,969</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,773</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,865</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">86,859</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">46,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,428</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,738</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,385</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less stock-based compensation expense capitalized to inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">73,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,209</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">215,334</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">178,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by line item:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">46,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">134,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sales, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,555</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">73,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,209</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">215,334</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">178,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s unrecognized stock-based compensation expense by type of award and the weighted-average period over which that expense is expected to be recognized:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrecognized Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Recognition Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">175,298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.60</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">289,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.64</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.46</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Remaining <br clear="none"/>Contractual Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$18.93&#8211;$20.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$20.01&#8211;$40.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">834</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">834</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$40.01&#8211;$60.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$60.01&#8211;$80.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.46</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.62</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$80.01&#8211;$100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,587</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">89.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">89.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$100.01&#8211;$120.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,137</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.36</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">586</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$120.01&#8211;$140.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">130.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$140.01&#8211;$160.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$160.01&#8211;$163.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">162.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">162.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">91.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77.92</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Earnings Per Share</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income (loss) per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net income (loss) per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income (loss) per share for the periods ended:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except per share amounts)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">Basic net income (loss) attributable to Vertex per common share calculation:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net income (loss) attributable to Vertex common shareholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(102,952</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38,841</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">162,800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144,997</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Undistributed earnings allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net income (loss) attributable to Vertex common shareholders&#8212;basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(102,952</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38,841</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">162,597</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144,997</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic weighted-average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">250,268</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">244,920</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">247,963</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">244,529</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic net income (loss) attributable to Vertex per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">Diluted net income (loss) attributable to Vertex per common share calculation:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net income (loss) attributable to Vertex common shareholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(102,952</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38,841</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">162,800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144,997</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Undistributed earnings allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net income (loss) attributable to Vertex common shareholders&#8212;diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(102,952</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38,841</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">162,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144,997</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted-average shares used to compute basic net income (loss) per common share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">250,268</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">244,920</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">247,963</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">244,529</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Effect of potentially dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">228</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted-average shares used to compute diluted net income (loss) per common share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">250,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">244,920</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">252,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">244,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Diluted net income (loss) attributable to Vertex per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not include the securities in the following table in the computation of the dilutive net income (loss) per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unvested restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,241</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,624</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">281</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,624</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Company&#8217;s financial assets and liabilities reflects the Company&#8217;s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company&#8217;s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4920634920635%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:88%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unobservable inputs based on the Company&#8217;s assessment of the assumptions that market participants would use in pricing the asset or liability.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company&#8217;s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s investments were primarily in money market funds, government-sponsored enterprise securities, corporate equity securities, corporate debt securities and commercial paper. Additionally, the Company utilizes foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on its condensed consolidated statement of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, all of the Company&#8217;s financial assets and liabilities that were subject to fair value measurements were valued using observable inputs. The Company&#8217;s financial assets valued based on Level&#160;1 inputs consisted of money market funds, government-sponsored enterprise securities and corporate equity securities. The Company&#8217;s financial assets and liabilities valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consisted of investments in highly-rated investment-grade corporations and foreign currency forward contracts with highly reputable and creditworthy counterparties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s financial assets (excluding VIE cash and cash equivalents, which are recorded as Restricted cash and cash equivalents (VIE)) and liabilities subject to fair value measurements:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements as of September 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (asset position):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">466,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">466,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,979</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,979</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,608</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,608</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,944</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,944</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">295,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">295,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">928,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">538,625</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">389,484</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (liability position):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(977</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(977</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,874</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,874</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements as of December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (asset position):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">280,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">280,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,186</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,186</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">546,765</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">360,628</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186,137</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (liability position):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s VIE invested in cash equivalents consisting of money market funds of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, which are valued based on Level 1 inputs. These cash equivalents are not included in the table above. The Company&#8217;s noncontrolling interest related to the Company&#8217;s VIE includes </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent payments, which consist of milestone, royalty and option payments</font><font style="font-family:inherit;font-size:10pt;">, which are valued based on Level 3 inputs. Please refer to Note C, &#8220;Collaborative Arrangements and Acquisitions,&#8221; for further information.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, in-process research and development intangible assets of </font><font style="font-family:inherit;font-size:10pt;">$29.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$284.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, were recorded on the Company&#8217;s condensed consolidated balance sheet. In 2015, the Company recorded an in-process research development intangible asset of </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;"> related to Parion&#8217;s pulmonary ENaC platform, including the intellectual property related to VX-371 and VX-551, that are licensed by Parion to the Company. In 2014, the Company recorded an in-process research development intangible asset of </font><font style="font-family:inherit;font-size:10pt;">$29.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to VX-210 that is licensed by BioAxone to the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with its preparation of its financial statements for the three and nine months ended September 30, 2017, the Company determined that there were indicators that the value of the pulmonary ENaC platform intangible asset had become impaired. The Company determined that the fair value of the intangible asset had decreased significantly based on data received in September 2017 from a Phase 2 clinical trial of VX-371 that did not meet its primary efficacy endpoint. Based on this data, the Company evaluated the fair value of Parion&#8217;s pulmonary ENaC platform using the discounted cash flow approach from the perspective of a market participant and determined that the fair value of the intangible asset was zero as of September 30, 2017. The discounted cash flow model pertaining to the impairment of the pulmonary ENaC platform includes (i) assumptions regarding the probability of obtaining marketing approval for the drug candidate, (ii) estimates regarding the timing of and the expected costs to develop and commercialize the drug candidate, (iii) estimates of future cash flows from potential product sales with respect to the drug candidate and (iv) appropriate discount and tax rates. The Company recorded a </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;"> impairment charge and a benefit from income taxes of </font><font style="font-family:inherit;font-size:10pt;">$97.7 million</font><font style="font-family:inherit;font-size:10pt;"> in the three and nine months ended September 30, 2017 attributable to noncontrolling interest. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, goodwill of </font><font style="font-family:inherit;font-size:10pt;">$50.4 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded on the Company&#8217;s condensed consolidated balance sheet.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to United States federal, state, and foreign income taxes. For </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a </font><font style="font-family:inherit;font-size:10pt;">benefit from income taxes</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$125.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$117.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which included a benefit of </font><font style="font-family:inherit;font-size:10pt;">$120.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$111.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to the Company&#8217;s VIEs&#8217; income tax provision. The VIEs&#8217; benefit from income taxes during the </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> related primarily to the impairment of Parion&#8217;s pulmonary ENaC platform and decrease in the fair value of the contingent payments payable by the Company to Parion. The Company has </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> liability for taxes payable by the Company&#8217;s VIEs and the income tax provision and related liability have been allocated to noncontrolling interest. For </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a </font><font style="font-family:inherit;font-size:10pt;">provision for income taxes</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$24.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which included a benefit of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> and a provision of </font><font style="font-family:inherit;font-size:10pt;">$20.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to the Company&#8217;s VIEs&#8217; income tax provision. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company did not have unrecognized tax benefits. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. </font><font style="font-family:inherit;font-size:10pt;">As of September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> interest and penalties have been accrued. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continues to maintain a valuation allowance on the majority of its net operating losses and other deferred tax assets because it has a history of cumulative losses.&#160; Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards (NOLs) and income tax credit carryforwards that will be utilized in future periods in these jurisdictions. &#160;The Company&#8217;s U.S. federal net operating loss carryforwards totaled approximately </font><font style="font-family:inherit;font-size:10pt;">$4.1 billion</font><font style="font-family:inherit;font-size:10pt;"> as of December 31, 2016. On a quarterly basis, the Company reassesses the valuation allowance on its deferred income tax assets weighing positive and negative evidence to assess the recoverability of the deferred tax assets. Based on the Company&#8217;s recent financial performance and its future projections, it could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods.&#160; However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The Company&#8217;s total deferred tax asset balance subject to the valuation allowance was approximately </font><font style="font-family:inherit;font-size:10pt;">$1.7 billion</font><font style="font-family:inherit;font-size:10pt;"> at December&#160;31, 2016.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As described in Note A, &#8220;Basis of Presentation and Accounting Policies&#8221;, the Company adopted amended guidance, during the nine month period ended September 30, 2017. The amended guidance eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in additional paid-in capital and requires excess tax benefits and tax deficiencies to be recorded in the condensed consolidated statement of operations when the awards vest or are settled. Amendments related to accounting for excess tax benefits have been adopted prospectively, resulting in a tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$31.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$62.2 million</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. In connection with the adoption of this new standard, the Company recorded a cumulative-effect adjustment of </font><font style="font-family:inherit;font-size:10pt;">$410.8 million</font><font style="font-family:inherit;font-size:10pt;"> as of January 1, 2017 to accumulated deficit and deferred tax assets, with an equal offsetting adjustment to the Company&#8217;s valuation allowance. In addition, the Company has recorded </font><font style="font-family:inherit;font-size:10pt;">$9.4 million</font><font style="font-family:inherit;font-size:10pt;"> related to the impact from adoption of the provisions related to forfeiture rates to accumulated deficit. This change also increased the Company&#8217;s deferred tax assets by </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> that is offset by an increase to the valuation allowance in the same amount.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company files United States federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction for years before 2011, except where the Company has net operating losses or tax credit carryforwards that originate before 2011. The Company currently is under examination by the Canada Revenue Agency for the years ending December 31, 2011 through December 31, 2013. No adjustments have been reported. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to United States federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">67,826</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,688</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,584</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98,192</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77,604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on its evaluation of, among other factors, information regarding tezacaftor's safety and efficacy, the Company has capitalized </font><font style="font-family:inherit;font-size:10pt;">$9.6 million</font><font style="font-family:inherit;font-size:10pt;"> of inventory costs for tezacaftor manufactured in preparation for its potential product launch as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. In periods prior, the Company expensed costs associated with tezacaftor&#8217;s raw materials and work-in-process as a development expense. The Company submitted a New Drug Application to the United States Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for tezacaftor in combination with ivacaftor. The Company plans to continue to monitor the status of the tezacaftor regulatory process and the other factors used to determine whether or not to capitalize the tezacaftor inventory and, if there are significant negative developments regarding tezacaftor, the Company could be required to impair previously capitalized costs.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued new guidance applicable to revenue recognition that will be effective January 1, 2018. Early adoption was permitted for the year-ending December 31, 2017. The new guidance applies a more principles based approach to recognizing revenue. Under the new guidance, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new guidance must be adopted using either a modified retrospective approach or a full retrospective approach for all periods presented. Under the modified retrospective method, the cumulative effect of applying the standard would be recognized at the date of initial application within retained earnings. Under the full retrospective approach, the standard would be applied to each prior reporting period presented. Upon adoption, the Company will use the modified retrospective method. The Company continues to evaluate the new guidance and the effect the adoption will have on the condensed consolidated financial statements.&#160; The Company&#8217;s project team is finalizing its review of existing customer contracts and current accounting policies to identify and assess the potential differences that would result from applying the requirements of the new standard. Based on the Company&#8217;s assessment performed to date, the new revenue recognition guidance could impact the Company&#8217;s accounting for product shipments to certain countries through early access programs, including the French early access programs, whereby the associated product has received regulatory approval but the price is not fixed or determinable based on the status of ongoing pricing discussions, and could impact the Company&#8217;s accounting for certain reimbursement agreements that the Company plans to negotiate in the fourth quarter of 2017. As the Company completes its assessment, it is implementing appropriate changes to its controls to support revenue recognition and additional revenue-related disclosures under the new standard. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The amended guidance became effective for the Company during the first quarter of 2017. The amended guidance eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in additional paid-in capital. This created approximately </font><font style="font-family:inherit;font-size:10pt;">$410.8 million</font><font style="font-family:inherit;font-size:10pt;"> of deferred tax asset (&#8220;DTA&#8221;) relating to federal and state net operating losses (&#8220;NOLs&#8221;) that are fully reserved by an equal increase in valuation allowance. The Company recorded DTAs of approximately </font><font style="font-family:inherit;font-size:10pt;">$404.7 million</font><font style="font-family:inherit;font-size:10pt;"> relating to Federal NOLs and approximately </font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;"> relating to State NOLs, both of which are offset by a full valuation allowance. Upon adoption, the Company also elected to change its accounting policy to account for forfeitures of options and awards as they occur. The change was applied on a modified retrospective basis with a cumulative effect adjustment to the Company&#8217;s accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$9.4 million</font><font style="font-family:inherit;font-size:10pt;">, which increased the accumulated deficit as of January 1, 2017. This change also resulted in an increase to the DTA of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">, which is offset by a full valuation allowance. As a result, there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> cumulative-effect adjustment to accumulated deficit. The provisions related to the recognition of excess tax benefits in the income statement and classification in the statement of cash flows were adopted prospectively, and as such, the prior periods were not retrospectively adjusted.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued amended guidance related to the recording of financial assets and financial liabilities. Under the amended guidance, equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) are to be measured at fair value with changes in fair value recognized in net income. However, an entity has the option to either measure equity investments without readily determinable fair values at fair value or at cost adjusted for changes in observable prices minus impairment. Changes in measurement under either alternative will be recognized in net income. The amended guidance is effective for the year ending December 31, 2018. Early adoption is permitted. The Company expects the implementation of this standard to have an impact on its consolidated financial statements and related disclosures, as the Company held publicly traded equity investments as of September 30, 2017 as well as equity investments accounted for under the cost method. A cumulative-effect adjustment to the balance sheet will be recorded as of the beginning of the fiscal year of adoption. The implementation of&#160;this amended guidance&#160;is expected to increase volatility in net income as the volatility currently recorded in other comprehensive income related to changes in the fair market value of available-for-sale equity investments will be reflected in net income after adoption.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This guidance requires entities to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued amended guidance related to intra-entity transfers other than inventory. This guidance removes the current exception in GAAP prohibiting entities from recognizing current and deferred income tax expenses or benefits related to transfer of assets, other than inventory, within the consolidated entity. The current exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. The amended guidance is effective for the year ending December 31, 2018. Early adoption is permitted. The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the FASB issued amended guidance related to business combinations. The amended guidance clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new accounting guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company early adopted this new guidance as of January 1, 2017 and will apply this new guidance to future acquisitions.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the FASB issued amended guidance related to measurements of goodwill. The amended guidance eliminates a step from the goodwill impairment test. Under the amended guidance, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The amended guidance is effective for the year-ending December 31, 2020. Early adoption is permitted. The Company does not expect a significant effect on its condensed consolidated financial statements upon adoption of this new guidance.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the&#160;FASB&#160;issued amended guidance related to the scope of stock option modification accounting,&#160;to reduce diversity in practice and provide clarity regarding existing&#160;guidance. The new accounting guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company does not expect the adoption of this&#160;guidance&#160;to have a material effect on its condensed consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the FASB issued amended guidance applicable to hedge accounting. The new accounting guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those periods. Early adoption is permitted. The amended guidance helps simplify certain aspects of&#160;hedge&#160;accounting and enables entities to more accurately present their risk management activities in their financial statements.&#160; The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a discussion of other recent accounting pronouncements please refer to Note&#160;A, &#8220;Nature of Business and Accounting Policies&#8212;Recent Accounting Pronouncements,&#8221; in the </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (&#8220;Vertex&#8221; or the &#8220;Company&#8221;) in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, pharmaceuticals. As of September 30, 2017, the Company deconsolidated Parion Sciences, Inc. (&#8220;Parion&#8221;), a VIE the Company has consolidated since 2015. The Company's consolidated balance sheet as of September 30, 2017 excludes Parion. Please refer to Note C, &#8220;Collaborative Arrangements and Acquisitions&#8221; for further information regarding the deconsolidation of Parion. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, which are contained in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> that was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on </font><font style="font-family:inherit;font-size:10pt;">February&#160;23, 2017</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;</font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K&#8221;). </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation and deconsolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s significant accounting policies are described in Note&#160;A, &#8220;Nature of Business and Accounting Policies,&#8221; in the </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued new guidance applicable to revenue recognition that will be effective January 1, 2018. Early adoption was permitted for the year-ending December 31, 2017. The new guidance applies a more principles based approach to recognizing revenue. Under the new guidance, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new guidance must be adopted using either a modified retrospective approach or a full retrospective approach for all periods presented. Under the modified retrospective method, the cumulative effect of applying the standard would be recognized at the date of initial application within retained earnings. Under the full retrospective approach, the standard would be applied to each prior reporting period presented. Upon adoption, the Company will use the modified retrospective method. The Company continues to evaluate the new guidance and the effect the adoption will have on the condensed consolidated financial statements.&#160; The Company&#8217;s project team is finalizing its review of existing customer contracts and current accounting policies to identify and assess the potential differences that would result from applying the requirements of the new standard. Based on the Company&#8217;s assessment performed to date, the new revenue recognition guidance could impact the Company&#8217;s accounting for product shipments to certain countries through early access programs, including the French early access programs, whereby the associated product has received regulatory approval but the price is not fixed or determinable based on the status of ongoing pricing discussions, and could impact the Company&#8217;s accounting for certain reimbursement agreements that the Company plans to negotiate in the fourth quarter of 2017. As the Company completes its assessment, it is implementing appropriate changes to its controls to support revenue recognition and additional revenue-related disclosures under the new standard. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The amended guidance became effective for the Company during the first quarter of 2017. The amended guidance eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in additional paid-in capital. This created approximately </font><font style="font-family:inherit;font-size:10pt;">$410.8 million</font><font style="font-family:inherit;font-size:10pt;"> of deferred tax asset (&#8220;DTA&#8221;) relating to federal and state net operating losses (&#8220;NOLs&#8221;) that are fully reserved by an equal increase in valuation allowance. The Company recorded DTAs of approximately </font><font style="font-family:inherit;font-size:10pt;">$404.7 million</font><font style="font-family:inherit;font-size:10pt;"> relating to Federal NOLs and approximately </font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;"> relating to State NOLs, both of which are offset by a full valuation allowance. Upon adoption, the Company also elected to change its accounting policy to account for forfeitures of options and awards as they occur. The change was applied on a modified retrospective basis with a cumulative effect adjustment to the Company&#8217;s accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$9.4 million</font><font style="font-family:inherit;font-size:10pt;">, which increased the accumulated deficit as of January 1, 2017. This change also resulted in an increase to the DTA of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">, which is offset by a full valuation allowance. As a result, there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> cumulative-effect adjustment to accumulated deficit. The provisions related to the recognition of excess tax benefits in the income statement and classification in the statement of cash flows were adopted prospectively, and as such, the prior periods were not retrospectively adjusted.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued amended guidance related to the recording of financial assets and financial liabilities. Under the amended guidance, equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) are to be measured at fair value with changes in fair value recognized in net income. However, an entity has the option to either measure equity investments without readily determinable fair values at fair value or at cost adjusted for changes in observable prices minus impairment. Changes in measurement under either alternative will be recognized in net income. The amended guidance is effective for the year ending December 31, 2018. Early adoption is permitted. The Company expects the implementation of this standard to have an impact on its consolidated financial statements and related disclosures, as the Company held publicly traded equity investments as of September 30, 2017 as well as equity investments accounted for under the cost method. A cumulative-effect adjustment to the balance sheet will be recorded as of the beginning of the fiscal year of adoption. The implementation of&#160;this amended guidance&#160;is expected to increase volatility in net income as the volatility currently recorded in other comprehensive income related to changes in the fair market value of available-for-sale equity investments will be reflected in net income after adoption.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This guidance requires entities to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued amended guidance related to intra-entity transfers other than inventory. This guidance removes the current exception in GAAP prohibiting entities from recognizing current and deferred income tax expenses or benefits related to transfer of assets, other than inventory, within the consolidated entity. The current exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. The amended guidance is effective for the year ending December 31, 2018. Early adoption is permitted. The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the FASB issued amended guidance related to business combinations. The amended guidance clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new accounting guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company early adopted this new guidance as of January 1, 2017 and will apply this new guidance to future acquisitions.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the FASB issued amended guidance related to measurements of goodwill. The amended guidance eliminates a step from the goodwill impairment test. Under the amended guidance, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The amended guidance is effective for the year-ending December 31, 2020. Early adoption is permitted. The Company does not expect a significant effect on its condensed consolidated financial statements upon adoption of this new guidance.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the&#160;FASB&#160;issued amended guidance related to the scope of stock option modification accounting,&#160;to reduce diversity in practice and provide clarity regarding existing&#160;guidance. The new accounting guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company does not expect the adoption of this&#160;guidance&#160;to have a material effect on its condensed consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the FASB issued amended guidance applicable to hedge accounting. The new accounting guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those periods. Early adoption is permitted. The amended guidance helps simplify certain aspects of&#160;hedge&#160;accounting and enables entities to more accurately present their risk management activities in their financial statements.&#160; The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a discussion of other recent accounting pronouncements please refer to Note&#160;A, &#8220;Nature of Business and Accounting Policies&#8212;Recent Accounting Pronouncements,&#8221; in the </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sale of HIV Protease Inhibitor Royalty Stream</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline&#160;plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of </font><font style="font-family:inherit;font-size:10pt;">$160.0 million</font><font style="font-family:inherit;font-size:10pt;">. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline&#160;plc. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline&#160;plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Restructuring </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2017, the Company decided to consolidate its research activities into its Boston, Milton Park and San Diego locations and closed its research site in Canada affecting approximately </font><font style="font-family:inherit;font-size:10pt;">70</font><font style="font-family:inherit;font-size:10pt;"> positions. The Company has incurred aggregate restructuring charges of approximately </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;"> in the nine months ended September 30, 2017. As of September 30, 2017, the restructuring liability primarily relates to laboratory and office space for the research site in Canada that terminates in October 2018. The Company does not anticipate any significant additional charges related to this restructuring event in the future.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The restructuring charge and other activities recorded during the </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and the related liability balance as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.79365079365078%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring (credits) expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(125</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,315</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Asset impairments and other non-cash items</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,814</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,632</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,632</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2003 Kendall Restructuring</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15</font><font style="font-family:inherit;font-size:10pt;">-year lease that terminates in April 2018. The Company has not used more than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of this space since it adopted the plan to restructure its operations in 2003. This unused laboratory and office space currently is subleased to third parties. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">227</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,054</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">222</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,732</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,866</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,526</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,882</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fan Pier Move Restructuring</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the relocation of its Massachusetts operations to Fan Pier in Boston, Massachusetts, which commenced in 2013, the Company is incurring restructuring charges related to its remaining lease obligations at its facilities in Cambridge, Massachusetts. The majority of these restructuring charges were recorded in the third quarter of 2014 upon decommissioning </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> facilities in Cambridge. During 2015, the Company terminated </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of these lease agreements resulting in a credit to restructuring expense equal to the difference between the Company&#8217;s estimated future cash flows related to its lease obligations for these facilities and the termination payment paid to the Company&#8217;s landlord on the effective date of the termination. The third major facility included in this restructuring activity is </font><font style="font-family:inherit;font-size:10pt;">120,000</font><font style="font-family:inherit;font-size:10pt;"> square feet of the </font><font style="font-family:inherit;font-size:10pt;">Kendall Square Facility</font><font style="font-family:inherit;font-size:10pt;"> that the Company continued to use for its operations following its 2003 Kendall Restructuring. The rentable square footage in this portion of the </font><font style="font-family:inherit;font-size:10pt;">Kendall Square Facility</font><font style="font-family:inherit;font-size:10pt;"> was subleased to a third party in February 2015. The Company will continue to incur charges through April 2018 related to the difference between the Company&#8217;s estimated future cash flows related to this portion of the </font><font style="font-family:inherit;font-size:10pt;">Kendall Square Facility</font><font style="font-family:inherit;font-size:10pt;">, which include an estimate for sublease income to be received from the Company&#8217;s sublessee and its actual cash flows. The Company discounted the estimated cash flows related to this restructuring activity at a discount rate of </font><font style="font-family:inherit;font-size:10pt;">9%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">490</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">472</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,279</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">773</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,293</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">773</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,293</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Restructuring Activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has engaged in several other restructuring activities that are unrelated to its Research and Development Restructuring, </font><font style="font-family:inherit;font-size:10pt;font-style:normal;">2003 Kendall Restructuring</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:normal;">Fan Pier Move Restructuring</font><font style="font-family:inherit;font-size:10pt;">. The most significant activity commenced in October 2013 when the Company adopted a restructuring plan that included (i) a workforce reduction primarily related to the commercial support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection neared approval and (ii) the write-off of certain assets. This action resulted from the Company&#8217;s decision to focus its investment on future opportunities in CF and other research and development programs.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The remaining restructuring activities were completed in 2016. As such, there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> outstanding liability as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The activities related to the Company&#8217;s other restructuring liabilities for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.79365079365078%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(112</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">344</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s changes in accumulated other comprehensive income (loss) by component is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains (Losses) on Marketable Securities, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Foreign Currency Forward Contracts, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive loss before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,137</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,786</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25,981</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(44,904</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,398</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,398</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,137</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,786</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(27,379</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(46,302</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,735</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,865</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Foreign Currency Forward Contracts, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,709</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,715</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(890</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,779</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,779</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,709</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,936</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,669</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,789</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">230</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,714</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not include the securities in the following table in the computation of the dilutive net income (loss) per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unvested restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,241</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,624</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">281</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,624</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s cash, cash equivalents and marketable securities is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,350,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,350,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,979</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,979</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,384,968</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,384,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate equity securities </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (matures within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (matures within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">235,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">235,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (matures after 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,651</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">413,729</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(187</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">427,282</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,798,697</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,812,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,183,945</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,183,945</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,183,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,183,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (matures within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,506</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,213</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,347</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (matures within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (matures within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(85</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">229,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(85</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">250,612</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,413,220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(85</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,434,557</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income (loss) per share for the periods ended:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except per share amounts)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">Basic net income (loss) attributable to Vertex per common share calculation:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net income (loss) attributable to Vertex common shareholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(102,952</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38,841</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">162,800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144,997</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Undistributed earnings allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net income (loss) attributable to Vertex common shareholders&#8212;basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(102,952</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38,841</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">162,597</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144,997</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic weighted-average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">250,268</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">244,920</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">247,963</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">244,529</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic net income (loss) attributable to Vertex per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">Diluted net income (loss) attributable to Vertex per common share calculation:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net income (loss) attributable to Vertex common shareholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(102,952</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38,841</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">162,800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144,997</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Undistributed earnings allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net income (loss) attributable to Vertex common shareholders&#8212;diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(102,952</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38,841</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">162,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144,997</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted-average shares used to compute basic net income (loss) per common share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">250,268</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">244,920</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">247,963</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">244,529</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Effect of potentially dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">228</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted-average shares used to compute diluted net income (loss) per common share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">250,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">244,920</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">252,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">244,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Diluted net income (loss) attributable to Vertex per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized the following stock-based compensation expense:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,969</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,773</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,865</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">86,859</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">46,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,428</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,738</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,385</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less stock-based compensation expense capitalized to inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">73,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,209</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">215,334</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">178,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by line item:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">46,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">134,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sales, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,555</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">73,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,209</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">215,334</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">178,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s financial assets (excluding VIE cash and cash equivalents, which are recorded as Restricted cash and cash equivalents (VIE)) and liabilities subject to fair value measurements:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements as of September 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (asset position):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">466,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">466,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,979</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,979</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,608</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,608</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,944</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,944</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">295,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">295,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">928,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">538,625</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">389,484</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (liability position):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(977</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(977</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,874</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,874</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements as of December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (asset position):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">280,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">280,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">111,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,186</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,186</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">546,765</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">360,628</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186,137</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial instruments carried at fair value (liability position):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value of the Company&#8217;s outstanding foreign currency forward contracts not designated for hedge accounting included on the Company&#8217;s condensed consolidated balance sheets:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value of the Company&#8217;s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company&#8217;s condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2017</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,897</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(977</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,874</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,593</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">67,826</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,688</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,584</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98,192</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77,604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the notional amount of the Company&#8217;s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign Currency</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">234,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77,387</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">65,237</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,283</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">343,147</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">253,381</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The restructuring charge and other activities recorded during the </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and the related liability balance as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.79365079365078%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring (credits) expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(125</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,315</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Asset impairments and other non-cash items</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,814</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,632</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,632</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">490</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">472</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,279</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">773</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,293</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">773</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,293</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">227</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,054</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">222</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,732</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,866</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,526</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,882</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the Company&#8217;s other restructuring liabilities for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.79365079365078%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(112</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">344</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Remaining <br clear="none"/>Contractual Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$18.93&#8211;$20.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$20.01&#8211;$40.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">834</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">834</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$40.01&#8211;$60.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$60.01&#8211;$80.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.46</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.62</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$80.01&#8211;$100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,587</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">89.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">89.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$100.01&#8211;$120.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,137</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.36</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">586</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$120.01&#8211;$140.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">130.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$140.01&#8211;$160.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$160.01&#8211;$163.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">162.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">162.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">91.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77.92</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation and deconsolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the (increases) decreases in the fair value of the contingent payments related to the Company&#8217;s VIEs were as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Parion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(58,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">BioAxone</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(900</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(850</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company&#8217;s condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,874</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,874</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,824</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(144</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">144</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the contingent payments related to the Parion Agreement and the BioAxone Agreement as of the dates set forth in the table: </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Parion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">238,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">BioAxone</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Revenues, Net </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products principally to a limited number of specialty pharmacy providers in North America as well as government-owned and supported customers in international markets (collectively, its &#8220;Customers&#8221;). The Company&#8217;s Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery to the Customer as long as (i)&#160;there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii)&#160;collectibility is reasonably assured and (iii)&#160;the price is fixed or determinable. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to conclude that the price is fixed or determinable, the Company must be able to (i)&#160;calculate its gross product revenues from sales to Customers and (ii)&#160;reasonably estimate its net product revenues upon delivery to its Customers&#8217; locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a)&#160;trade allowances, such as invoice discounts for prompt payment and Customer fees, (b)&#160;estimated government and private payor rebates, chargebacks and discounts, (c)&#160;estimated reserves for expected product returns and (d)&#160;estimated costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company makes significant estimates and judgments that materially affect the Company&#8217;s recognition of net product revenues. In certain instances, the Company may be unable to reasonably conclude that the price is fixed or determinable at the time of delivery, in which case it defers the recognition of revenues. Once the Company is able to determine that the price is fixed or determinable, it recognizes the net product revenues associated with the units in which revenue recognition was deferred. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognition related to the Company&#8217;s French early access programs could be impacted by the new revenue recognition guidance that is effective January 1, 2018 and described in Note A, &#8220;Basis of Presentation and Accounting Policies&#8221;. The Company&#8217;s ORKAMBI net product revenues to date do not include any revenues from product sales in France because the price is not fixed or determinable. The Company began distributing ORKAMBI through early access programs in France during the fourth quarter of 2015. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s condensed consolidated balance sheet includes </font><font style="font-family:inherit;font-size:10pt;">$190.3 million</font><font style="font-family:inherit;font-size:10pt;"> collected in France related to shipments of ORKAMBI under the early access programs that is classified as Customer deposits. The Company expects that the difference between the amounts collected based on the invoiced price and the final price for ORKAMBI in France will be returned to the French government. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company concludes as of December 31, 2017 that the price of the ORKAMBI supplied under the early access programs is fixed or determinable based on, among other factors, the status of negotiations in France, it would record net product revenues for all sales since the inception of the early access programs for ORKAMBI based on the fixed or determinable price in the fourth quarter of 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company concludes that the price is not fixed or determinable as of December 31, 2017, these amounts would be subject to the new guidance applicable to revenue recognition effective January 1, 2018 using the modified retrospective adoption approach.&#160; Pursuant to the new guidance, the Company would record a cumulative effect adjustment to the Company&#8217;s accumulated deficit in the first quarter of 2018. The amount of the adjustment to accumulated deficit would be determined based upon (i)&#160;the status of pricing discussions in France upon adoption and (ii) the Company&#8217;s estimate of the amount of consideration the Company expects to retain related to the French ORKAMBI sales that occurred on or prior to December 31, 2017 that would not be subject to a significant reversal in amounts recognized. For French ORKAMBI sales after December 31, 2017 under the early access programs, the Company would recognize product revenues based on the Company&#8217;s estimate of consideration the Company expects to retain for which it is probable that a significant reversal in amounts recognized will not occur. In future periods, if the Company&#8217;s estimates regarding the amounts it will receive for ORKAMBI supplied pursuant to these programs change, the effect of the change in estimates would be reflected in net product revenues in the period in which the change in estimate occurred. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity in each of the product revenue allowance and reserve categories for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Trade <br clear="none"/>Allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Rebates, <br clear="none"/>Chargebacks <br clear="none"/>and Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Product <br clear="none"/>Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other <br clear="none"/>Incentives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">81,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">89,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision related to current period sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,776</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">118,592</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,603</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">153,209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjustments related to prior period sales</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Credits/payments made</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,409</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(97,393</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,809</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,021</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(127,632</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98,799</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,076</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An aggregate summary of net income attributable to noncontrolling interest related to the Company&#8217;s VIEs for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss attributable to noncontrolling interest before (benefit from) provision for income taxes and changes in fair value of contingent payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">238,946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">222,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Benefit from) provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(120,181</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(510</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(111,658</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,063</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Decrease (increase) in fair value of contingent payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">62,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(59,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss (income) attributable to noncontrolling interest</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">188,315</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">696</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">173,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(33,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below summarizes items related to the Company&#8217;s VIEs included in the Company&#8217;s condensed consolidated balance sheets as of the dates set forth in the table. Amounts as of September 30, 2017 related to BioAxone while amounts as of December 31, 2016 related to Parion and BioAxone.</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted cash and cash equivalents (VIE)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">47,762</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,812</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">280</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">399</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued expenses </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,021</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,338</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,446</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">181,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity in each of the product revenue allowance and reserve categories for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Trade <br clear="none"/>Allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Rebates, <br clear="none"/>Chargebacks <br clear="none"/>and Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Product <br clear="none"/>Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other <br clear="none"/>Incentives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">81,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">89,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision related to current period sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,776</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">118,592</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,603</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">153,209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjustments related to prior period sales</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Credits/payments made</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,409</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(97,393</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,809</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,021</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(127,632</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,747</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98,799</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,076</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s unrecognized stock-based compensation expense by type of award and the weighted-average period over which that expense is expected to be recognized:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September&#160;30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrecognized Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Recognition Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">175,298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.60</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">289,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.64</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.46</font></div></td></tr></table></div></div></div> EX-101.SCH 8 vrtx-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2108100 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation and Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Collaborative Arrangements and Acquisitions link:presentationLink link:calculationLink link:definitionLink 2404408 - Disclosure - Collaborative Arrangements and Acquisitions - Aggregate VIE Financial Information, Contingent Consideration Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2404409 - Disclosure - Collaborative Arrangements and Acquisitions - Aggregate VIE Financial Information, Items Related to the Company's VIEs (Details) link:presentationLink link:calculationLink link:definitionLink 2404407 - Disclosure - Collaborative Arrangements and Acquisitions - Aggregate VIE Financial Information, Summary of Net Income Attributable to Noncontrolling Interest (Details) link:presentationLink link:calculationLink link:definitionLink 2404406 - Disclosure - Collaborative Arrangements and Acquisitions - BioAxone Biosciences, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2404412 - Disclosure - Collaborative Arrangements and Acquisitions - Concert Pharmaceuticals (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Collaborative Arrangements and Acquisitions - CRISPR Therapeutics AG (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Collaborative Arrangements and Acquisitions - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) link:presentationLink link:calculationLink link:definitionLink 2404411 - Disclosure - Collaborative Arrangements and Acquisitions - Janssen Pharmaceuticals, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Collaborative Arrangements and Acquisitions - Merck KGaA (Details) link:presentationLink link:calculationLink link:definitionLink 2404410 - Disclosure - Collaborative Arrangements and Acquisitions - Moderna Therapeutics, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Collaborative Arrangements and Acquisitions - Parion Sciences, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Collaborative Arrangements and Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2422401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) link:presentationLink link:calculationLink link:definitionLink 1002001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest (unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share Computation Statement (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Hedging link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Hedging - Derivatives Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Hedging - Derivatives Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2419401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Long-term Obligations link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - Long-term Obligations - Fan Pier Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Long-term Obligations - Revolving Credit Facility (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Long-term Obligations - San Diego Lease (Details) link:presentationLink link:calculationLink link:definitionLink 2415404 - Disclosure - Long-term Obligations - Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Other Arrangements link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - Other Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Product Revenues, Net link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Product Revenues, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Product Revenues, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Restructuring Liabilities link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Restructuring Liabilities - Activity Related to Restructuring Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Restructuring Liabilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Restructuring Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Stock-based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Stock-based Compensation Expense - (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Stock-based Compensation Expense - Stock Options Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Stock-based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 vrtx-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 vrtx-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 vrtx-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Long-term Debt and Capital Lease Obligations [Abstract] Long-term Obligations Debt Disclosure [Text Block] Line of Credit Facility [Abstract] Line of Credit Facility [Table] Line of Credit Facility [Table] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Base Rate Base Rate [Member] Eurodollar Eurodollar [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Line of Credit Line of Credit [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Line of credit facility, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Proceeds from lines of credit Proceeds from Lines of Credit Repayments of lines of credit Repayments of Lines of Credit Line of credit facility additional borrowing capacity Line Of Credit Facility Additional Borrowing Capacity Amount of increased borrowing capacity available in the future. Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Debt covenant, consolidated leverage ratio Debt Covenant, Consolidated Leverage Ratio Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants. Debt covenant, minimum consolidated EBITDA Debt Covenant, Minimum Consolidated EBITDA Minimum consolidated EBITDA that must be maintained in order to be in compliance with debt covenants. Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Secured Term Loan Senior Loans [Member] LIBOR London Interbank Offered Rate (LIBOR) [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Face amount of term loan Debt Instrument, Face Amount Basis spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Unamortized discount on term loan Debt Instrument, Unamortized Discount Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Indefinite-Lived Intangible Assets by Major Class [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] In-process research development intangible asset Other Intangible Assets [Member] Variable Interest Entities [Axis] Variable Interest Entities [Axis] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Collaborative Arrangements by Agreement [Axis] Collaborative Arrangements by Agreement [Axis] Significant terms of collaboration arrangements, by individual agreement. Collaborative Arrangement Agreement [Domain] Collaborative Arrangement Agreement [Domain] Listing of significant collaboration agreements. Parion Sciences, Inc. Parion Sciences, Inc. [Member] Parion Sciences, Inc. BioAxone Biosciences Inc. BioAxone Biosciences Inc. [Member] BioAxone Biosciences Inc. Indefinite-Lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Intangible assets Other Indefinite-lived Intangible Assets Intangible asset impairment charge Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Income tax benefit Income Tax Expense (Benefit) Goodwill Goodwill Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Cystic Fibrosis Foundation Therapeutics Incorporated Cystic Fibrosis Foundation Therapeutics Incorporated [Member] Collaboration agreement entered into with Cystic Fibrosis Foundation Therapeutics Inc., for the development, manufacture and commercialization of a product of the entity. Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Milestone payments Milestone Payments This element represents the expenses recorded for milestone payments. Additional milestone payments Additional Milestone Payments This element represents the additional expenses recorded for milestone payments. Collaborative funding Collaborative Arrangement Research Development Funding This element represents the funding under collaborative agreement 2016 amendment for research and development. Additional collaborative funding Additional Collaborative Funding This element represents the additional annual funding under collaborative agreement 2016 amendment for research and development. Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock options Employee Stock Option [Member] Unvested restricted stock and restricted stock units Restricted Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-09, Forfeiture Rate Component Accounting Standards Update 2016-09, Forfeiture Rate Component [Member] Accounting Standards Update 2016-09, Forfeiture Rate Component Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Total Vertex Shareholders’ Equity Parent [Member] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Noncontrolling Interest Noncontrolling Interest [Member] Statement Statement [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance (shares) Shares, Outstanding Beginning Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Cumulative effect adjustment for adoption of new accounting guidance Cumulative Effect of New Accounting Principle in Period of Adoption Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax Net (loss) income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Issuance of common stock under benefit plans (shares) Stock Issued During Period, Shares, Employee Benefit Plan Issuance of common stock under benefit plans Stock Issued During Period, Value, Employee Benefit Plan Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition VIE noncontrolling interest upon deconsolidation Noncontrolling Interest, Increase From Deconsolidation, Variable Interest Entity Noncontrolling Interest, Increase From Deconsolidation, Variable Interest Entity Other Stockholders' Equity, Other Balance (shares) Ending Balance Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Net loss Changes in other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized holding gains (losses) on marketable securities, net of tax of zero, respectively Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized (losses) gains on foreign currency forward contracts, net of tax of $0.9 million, $0.2 million, $2.9 million and $(0.4) million, respectively Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total changes in other comprehensive loss Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss (income) attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive (loss) income attributable to Vertex Comprehensive Income (Loss), Net of Tax, Attributable to Parent Commitments and Contingencies Disclosure [Abstract] Indemnification claims Indemnification Claims Amount of indemnification claims currently outstanding Contingent liabilities Contingent Liabilities Amount of material contingent liabilities outstanding Earnings Per Share Earnings Per Share [Text Block] Decrease (increase) in fair value of contingent payments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Contingent consideration, liability Business Combination, Contingent Consideration, Liability Collaborative arrangement, up-front payment Collaborative Arrangement Up-front License Fee The amount of the up-front license fee paid by the entity pursuant to a collaborative arrangement. Maximum license fees and milestone payments Maximum license fees and milestone payments Maximum license fees and milestone payments In-process research and development intangible asset Variable Interest Entity, Consolidated, Carrying Amount, In-Process Research and Development Intangible Asset Variable Interest Entity, Consolidated, Carrying Amount, In-Process Research and Development Intangible Asset Deferred tax liability attributable to variable interest entity Variable Interest Entity, Consolidated, Carrying Amount, Deferred Tax Liability Variable Interest Entity, Consolidated, Carrying Amount, Deferred Tax Liability Purchase option, term of extension of expiration date (in years) Collaborative Arrangements, Purchase Option, Term of Extension of Expiration Date Collaborative Arrangements, Purchase Option, Term of Extension of Expiration Date Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net [Abstract] Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net [Abstract] Restricted cash and cash equivalents (VIE) Restricted Cash and Cash Equivalents, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Other assets Other Assets, Noncurrent Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Other liabilities, current portion Other Liabilities, Current Deferred tax liability Deferred Tax Liabilities, Net, Noncurrent Other liabilities, excluding current portion Other Liabilities, Noncurrent Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Restructuring and Related Activities [Abstract] Restructuring Liabilities Restructuring and Related Activities Disclosure [Text Block] Schedule of collaborative arrangement activity net loss attributable to noncontrolling interest Schedule of Collaborative Arrangement Activity Net Loss Attributable to Noncontrolling Interest [Table Text Block] Represents the summary of activity related to the Alios Collaboration. Changes in fair value of contingent payments Changes In Fair Value Of Contingent Consideration [Table Text Block] Changes In Fair Value Of Contingent Consideration Schedule of fair value of contingent payments Fair Value Of Consideration Transferred [Table Text Block] Fair Value Of Consideration Transferred [Table Text Block] Schedule of collaborative arrangement summary of items related to variable interest entities Schedule Of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities [Table Text Block] Represents details pertaining to Variable Interest Entities assets and liabilities included in the company's condensed consolidated balance sheets. Accounting Policies [Abstract] Number of operating segments Number of Operating Segments New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Domestic Tax Authority Domestic Tax Authority [Member] State and Local Jurisdiction State and Local Jurisdiction [Member] Accounting Standards Update 2016-09, Excess Tax Benefit Accounting Standards Update 2016-09, Excess Tax Benefit [Member] Accounting Standards Update 2016-09, Excess Tax Benefit Accounting Standards Update 2016-09 Accounting Standards Update 2016-09 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Operating loss carryforwards Operating Loss Carryforwards Cumulative effect of new accounting principle in period of adoption Deferred income tax assets, net Deferred Income Tax Assets, Net Schedule of earnings per share, basic and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Potential gross common equivalent shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Collaborative Arrangement Agreements [Table] Schedule of Collaborative Arrangement Agreements [Table] A schedule reflecting significant collaboration agreements in which the entity is a participant. Moderna Therapeutics, Inc. Moderna Therapeutics, Inc. [Member] Moderna Therapeutics, Inc. [Member] Schedule of Collaborative Arrangement Agreements [Line Items] Schedule of Collaborative Arrangement Agreements [Line Items] -- None. No documentation exists for this element. -- Collaborative arrangement, investment in collaborative partner, pursuant to convertible loan agreement Collaborative Arrangement, Investment in Collaborative Partner, Amount Collaborative Arrangement, Investment in Collaborative Partner, Amount Collaborative arrangement, development and regulatory potential milestone payments maximum Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized. Collaborative arrangement approval and reimbursement milestones Collaborative Arrangement Approval and Reimbursement Milestones Collaborative Arrangement Approval and Reimbursement Milestones Concert Pharmaceuticals Concert Pharmaceuticals [Member] Concert Pharmaceuticals Collaborative arrangement, development and commercialization rights potential maximum milestone payments Collaborative Arrangement, Development and Commercialization Rights Potential Maximum Milestone Payments Collaborative Arrangement, Development and Commercialization Rights Potential Maximum Milestone Payments Collaborative arrangement, additional maximum milestone payments based on regulatory approval Collaborative Arrangement, Additional Maximum Milestone Payments Based on Regulatory Approval Collaborative Arrangement, Additional Maximum Milestone Payments Based on Regulatory Approval Collaborative arrangement, purchase price Business Combination, Consideration VIE The fair value of the consideration from the Company to VIE that does not constitute consideration transferred pursuant to ASC 805, Business Combinations. Collaborative arrangement, transaction costs Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Number of milestones to be achieved in order for milestone payment to be recorded as an intangible asset Number Of Milestones To Be Achieved In Order For Milestone Payment To Be Recorded As An Intangible Asset Number Of Milestones To Be Achieved In Order For Milestone Payment To Be Recorded As An Intangible Asset Cash and Cash Equivalents [Abstract] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of the cash and cash equivalents and available-for-sale investments held by the entity. Schedule of Cash, Cash Equivalents and Available-for-sale Securities Types of Financial Instruments [Axis] Schedule of Cash, Cash Equivalents and Available-for-sale Securities Types of Financial Instruments [Axis] This element represents a number of concepts which capture the categories of financial instruments classified as cash and cash equivalents and available-for-sale investments. Types of Financial Instruments [Domain] Types of Financial Instruments [Domain] Provides general categories of financial instruments included as cash, cash equivalents and available-for-sale investments. Total cash and cash equivalents Cash and Cash Equivalents [Member] Cash and money market funds Cash and Money Market Funds [Member] Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time. Government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Commercial paper Commercial Paper [Member] Corporate debt securities Corporate Debt Securities [Member] Total marketable securities Available-for-sale Securities [Member] Government-sponsored enterprise securities (matures within 1 year) U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member] U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member] Corporate equity securities Equity Securities [Member] Commercial paper (matures within 1 year) Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Corporate debt securities (matures within 1 year) Corporate Debt Securities, Due Within One Year [Member] Corporate Debt Securities, Due Within One Year [Member] Corporate debt securities (matures after 1 year) Corporate Debt Securities, Due After One Year [Member] Corporate Debt Securities, Due After One Year Summary of cash, cash equivalents and marketable securities Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items] -- None. No documentation exists for this element. -- Amortized Cost Cash, Cash Equivalents, Available-for-sale Securities, Amortized Cost This item represents the cost of cash and cash equivalents and debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any. Gross Unrealized Gains Cash, Cash Equivalents, Available-for-sale Securities, Gross Unrealized Gain This item represents the gross unrealized gains for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized gains are the excess of the fair value over the carrying value as of the reporting date. Gross Unrealized Losses Cash, Cash Equivalents, Available-for-sale Securities, Unrealized Loss, Gross This item represents the gross unrealized losses for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized losses are the excess of the carrying value over the fair value as of the reporting date. Fair Value Cash, Cash Equivalents and Available-for-sale Securities, Fair Value This item represents the fair value of cash, cash equivalents and debt and equity securities, which are categorized neither as held-to-maturity nor trading. Other than temporary impairment losses, investments Other than Temporary Impairment Losses, Investments Gross realized gains (losses) Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative [Table] Derivative [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Other income (expense) Other Nonoperating Income (Expense) [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Prepaid and other current assets Prepaid Expenses and Other Current Assets [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Not designated as hedging instrument Not Designated as Hedging Instrument [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Foreign currency forward contracts Foreign Exchange Forward [Member] Derivative [Line Items] Derivative [Line Items] Derivative term Derivative, Term of Contract (Loss) gain recognized on forward contracts not designated as hedges Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Notional amount of foreign currency forward contract Derivative, Notional Amount Derivative asset, fair value Derivative Asset, Fair Value, Gross Asset Equity [Abstract] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Preferred Stock Preferred Stock [Member] CRISPR Therapeutics AG CRISPR Therapeutics AG [Member] CRISPR Therapeutics AG Right to license, number of targets (up to) Collaborative Arrangement, Right to License, Number of Targets Collaborative Arrangement, Right to License, Number of Targets Gross unrealized gains Prior to marketing approval, time period of notice required to terminate (in days) Collaborative Arrangement, Prior to Marketing Approval, Time Period of Notice Required to Terminate Collaborative Arrangement, Prior to Marketing Approval, Time Period of Notice Required to Terminate Subsequent to marketing approval, time period of notice required to terminate (in days) Collaborative Arrangement, Subsequent to Marketing Approval, Time Period of Notice Required to Terminate Collaborative Arrangement, Subsequent to Marketing Approval, Time Period of Notice Required to Terminate Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Name of Property [Axis] Name of Property [Axis] Name of Property [Domain] Name of Property [Domain] San Diego Lease San Diego Lease [Member] San Diego Lease [Member] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Construction in progress Construction in Progress [Member] Buildings Building [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Area of real estate property (in square feet) Area of Real Estate Property Length of lease Lessee Leasing Arrangements, Capital Leases, Term of Contract Lessee Leasing Arrangements, Capital Leases, Term of Contract Average yearly aggregate rent Average Yearly Aggregate Rent, Exclusive of Operating Expenses Average Yearly Aggregate Rent, Exclusive of Operating Expenses Amount of optional renewal terms Amount of Optional Renewal Terms Amount of Optional Renewal Terms Optional renewal term length Lessee Leasing Arrangements, Capital Leases, Renewal Term Lessee Leasing Arrangements, Capital Leases, Renewal Term Property and equipment, net Property, Plant and Equipment, Net Construction financing lease obligation, current and noncurrent Construction Financing Lease Obligation, Current and Noncurrent Represents the current noncurrent portion of a lease liability recorded as a result of capitalizing the landlord's costs of constructing facilities associated with building leases. Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-based compensation expense by line item Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Unrecognized stock-based compensation expense, net of estimated forfeitures Schedule of Unrecognized Share-based Compensation Expense [Table Text Block] Disclosure as of the latest balance-sheet date presented of the total compensation cost related to outstanding, nonvested share-based compensation awards not yet recognized, net of estimated forfeitures, and the weighted average period over which those unrecognized costs are expected to be reported. Stock options outstanding and exercisable Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Product Revenues [Abstract] Product Revenues [Abstract] Schedule of product revenue allowances and reserve categories Schedule of Valuation and Qualifying Accounts [Table Text Block] Tabular disclosure of product revenues allowances and reserve accounts (their beginning and ending balances, as well as reconciliation by type of activity during the period). Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] German Tax Authority German Tax Authority [Member] German Tax Authority Merck KGaA Merck KGaA [Member] Merck KGaA Right to license, number of development programs Collaborative Arrangement, Right To License, Number Of Development Programs Collaborative Arrangement, Right To License, Number Of Development Programs Right to license, number of clinical stage programs Collaborative Arrangement, Right to License, Number Of Clinical Stage Programs Collaborative Arrangement, Right To License, Number Of Clinical Stage Programs Number of pre-clinical stage programs Collaborative Arrangement, Right to License, Number Of Pre-Clinical Stage Programs Collaborative Arrangement, Right to License, Number Of Pre-Clinical Stage Programs Proceeds from collaborators Proceeds from Collaborators Collaborative revenues Collaborative Revenues The aggregate revenue from collaborative revenues. It includes the revenues earned by the entity from nonrefundable, up-front license fees; net reimbursements of research and/or development efforts, including manufacturing services; and milestone payments. Collaborative revenues, tax withholding Collaborative Revenues, Tax Withholding Collaborative Revenues, Tax Withholding Collaborative revenues, related to upfront payment upon delivery of license and to research and development transition activities Collaborative Revenues, Related to Upfront Payment Upon Delivery of License and to Research and Development Transition Activities Collaborative Revenues, Related to Upfront Payment Upon Delivery of License and to Research and Development Transition Activities Time period of notice required to terminate Collaborative Arrangement, Time Period of Notice Required to Terminate Collaborative Arrangement, Time Period of Notice Required to Terminate Time period of notice required to terminate after a product has received marketing approval Collaborative Arrangement, Time Period of Notice Required to Terminate After A Product Has Received Marketing Approval Collaborative Arrangement, Time Period of Notice Required to Terminate After A Product Has Received Marketing Approval Inventory Disclosure [Abstract] Schedule of Inventories by Type Schedule of Inventory, Current [Table Text Block] Drug Candidate [Axis] Drug Candidate [Axis] Potential drug candidate that milestone payments are based upon Drug Candidate [Domain] Drug Candidate [Domain] [Domain] for Potential drug candidate that milestone payments are based upon ENaC Inhibitors in CF Enac Inhibitors in Cf [Member] ENaC Inhibitors in CF Enac Inhibitors in Non Cf Enac Inhibitors in Non Cf [Member] ENaC Inhibitors in Non-CF Additional Enac Inhibitors Additional Enac Inhibitors [Member] Additional ENaC Inhibitors Collaborative arrangement regulatory potential milestone payments maximum, global filling and approval Collaborative Arrangement Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are commercialized. Change of control prior to clinical trial, time period of notice required to terminate (in days) Collaborative Arrangement, Change of Control Prior to Clinical Trial, Time Period of Notice Required to Terminate Collaborative Arrangement, Change of Control Prior to Clinical Trial, Time Period of Notice Required to Terminate Term of agreement following first commercial sale (in years) Collaborative Arrangement, Term of Agreement Following First Commercial Sale Collaborative Arrangement, Term of Agreement Following First Commercial Sale (Benefit from) provision for income taxes (Benefit from) provision for income taxes, attributable to intangible asset impairment Income Tax Expense (Benefit), Attributable To Intangible Asset Impairment Income Tax Expense (Benefit), Attributable To Intangible Asset Impairment (Benefit from) provision for income taxes, attributable to decrease in the fair value of contingent consideration liability Income Tax Expense (Benefit), Attributable To Decrease In The Fair Value Of Contingent Consideration Liability Income Tax Expense (Benefit), Attributable To Decrease In The Fair Value Of Contingent Consideration Liability Business Combination, Consideration Transferred [Abstract] Business Combination, Consideration Transferred [Abstract] Noncontrolling interest, fair value Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Deferred tax liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other liabilities / assets, net Other Liabilities / Assets, Net Other Liabilities / Assets, Net Deconsolidation of VIE Deconsolidation, Gain (Loss), Amount Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Restricted stock and restricted stock units Restricted Stock and Restricted Stock Units [Member] Restricted Stock and Restricted Stock Units Basic net income (loss) attributable to Vertex per common share calculation: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Net income (loss) attributable to Vertex common shareholders Net Income (Loss) Attributable to Parent Less: Undistributed earnings allocated to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Net income (loss) attributable to Vertex common shareholders—basic Net Income (Loss) Available to Common Stockholders, Basic Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Basic net income (loss) attributable to Vertex per common share (in dollars per share) Earnings Per Share, Basic Diluted net income (loss) attributable to Vertex per common share calculation: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Less: Undistributed earnings allocated to participating securities Undistributed Earnings, Diluted Net income (loss) attributable to Vertex common shareholders—diluted Net Income (Loss) Available to Common Stockholders, Diluted Effect of potentially dilutive securities: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Share-based payment arrangements (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Other (in shares) Incremental Common Shares Attributable to Dilutive Effect, Other Incremental Common Shares Attributable to Dilutive Effect, Other Weighted-average shares used to compute diluted net income (loss) per common share (in shares) Weighted Average Number of Shares Outstanding, Diluted Diluted net income (loss) attributable to Vertex per common share (in dollars per share) Earnings Per Share, Diluted Product Revenues, Net Product Revenues Disclosure [Text Block] Product Revenues Disclosure [Text Block] Basis of Presentation and Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Income Statement [Abstract] Revenues: Revenues [Abstract] Product revenues, net Sales Revenue, Goods, Net Royalty revenues Royalty Revenue Total revenues Revenues Costs and expenses: Costs and Expenses [Abstract] Cost of product revenues Cost of Goods Sold Royalty expenses Direct Operating Cost, Royalty Expense Research and development expenses Research and Development Expense Sales, general and administrative expenses Selling, General and Administrative Expense Restructuring expenses, net Restructuring Charges Total costs and expenses Costs and Expenses Loss from operations Operating Income (Loss) Interest expense, net Interest Income (Expense), Net Other (expenses) income, net Other Nonoperating Income (Expense) Loss before (benefit from) provision for income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Net loss Loss (income) attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Net (loss) income attributable to Vertex Net (loss) income: Basic (in dollars per share) Diluted (in dollars per share) Shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Diluted (in shares) Schedule of Cash Flow Hedging Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Derivatives Offsetting Derivatives Offsetting [Table Text Block] [Table Text Block] for Derivatives Offsetting [Table] Schedule of Foreign Exchange Contracts Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $18.93–$20.00 Exercise Price Range From Dollars 18.93 to Dollars 20.00 [Member] Represents the range of exercise prices from $18.93 to $20.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $20.01–$40.00 Exercise Price Range from Dollars 20.01 to Dollars 40.00 [Member] Represents the range of exercise prices from $20.01 to $40.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $40.01–$60.00 Exercise Price Range from Dollars 40.01 to Dollars 60.00 [Member] Represents the range of exercise prices from $40.01 to $60.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $60.01–$80.00 Exercise Price Range from Dollars 60.01 to Dollars 80.00 [Member] Represents the range of exercise prices from $60.01 to $80.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $80.01–$100.00 Exercise Price Range from Dollars 80.01 to Dollars 100.00 [Member] Represents the range of exercise prices from $80.01 to $100.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $100.01–$120.00 Exercise Price Range from Dollars 100.01 to Dollars 120.00 [Member] Represents the range of exercise prices from $100.01 to $120.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $120.01–$140.00 Exercise Price Range From Dollars 120.01 to Dollars 140.0 [Member] Exercise Price Range From Dollars 120.01 to Dollars 140.0 $140.01–$160.00 Exercise Price Range From Dollars 140.01 to Dollars 160.0 [Member] Exercise Price Range From Dollars 140.01 to Dollars 160.0 $160.01–$163.74 Exercise Price Range From Dollars 160.01 to Dollars 163.74 [Member] Exercise Price Range From Dollars 160.01 to Dollars 163.74 Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Exercise price, low end of range (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Exercise price, high end of range (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Exercise price range, options outstanding (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Exercise price range, options outstanding, weighted-average remaining contractual life (in years) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Exercise price range, options exercisable (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Statement of Financial Position [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] Kendall Restructuring Kendall Restructuring [Member] Kendall Restructuring [Member] Fan Pier Move Restructuring Fan Pier Move [Member] Fan Pier Move [Member] Research and Development Restructuring Research and Development Restructuring [Member] Research and Development Restructuring Other Restructuring Other Restructuring [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring activities Restructuring Reserve [Roll Forward] Liability, beginning of the period Restructuring Reserve Restructuring (credits) expense Cash payments Payments for Restructuring Asset impairments and other non-cash items Restructuring Reserve, Asset Impairment Charges Restructuring Reserve, Asset Impairment Charges Cash received from subleases Restructuring Reserve Settled with Cash Receipt from Sublease Amount of cash received in the period to fully or partially offset a specified, previously accrued type of restructuring cost. Liability, end of the period Inventories Inventory Disclosure [Text Block] Marketable Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Fair Value Disclosures [Abstract] Financial assets subject to fair value measurements (excluding VIE cash and cash equivalents, which are recorded as Restricted cash and cash equivalents (VIE)) Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Trade Allowances Allowance for Trade Receivables [Member] Rebates, Chargebacks and Discounts Rebates Chargebacks and Discounts [Member] A valuation allowance for amounts due to the entity for rebates, chargebacks and discounts in the normal course of business that are expected to be uncollectible. Product Returns Allowance for Sales Returns [Member] Other Incentives Copay Mitigation Rebates [Member] A valuation allowance for amounts due to the entity for copay mitigation rebates in the normal course of business that are expected to be uncollectible. Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Customer deposits Customer Deposits, Current Product Revenue Allowance and Reserve [Roll Forward] Movement in Valuation Allowances and Reserves [Roll Forward] Balance at December 31, 2016 Valuation Allowances and Reserves, Balance Provision related to current period sales Valuation Allowances and Reserves Provision Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to product revenues. Adjustments related to prior period sales Valuation Allowances and Reserves, Additions for Adjustments Credits/payments made Valuation Allowances and Reserves, Sales Credits or Payments, Current Represents the credits or payments to allowances and reserves. Balance at September 30, 2017 Summary of cash, cash equivalents and marketable securities Cash, Cash Equivalents and Investments [Table Text Block] Activity related to restructuring liability Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Fan Pier Leases Fan Pier Leases [Member] Represents the fan pier leases. Number of leases Lease Agreement, Number of Leases Represents the number of leases entered by the reporting entity. Number of buildings under lease agreement Lease Agreements Number of Buildings Represents number of buildings under lease agreements. Optional term of lease agreement (in years) Optional Term of Lease Agreement Represents additional period to extend term of lease agreement. Janssen Pharmaceuticals, Inc. Janssen Pharmaceuticals, Inc. [Member] Collaboration agreement entered into with Janssen Pharmaceutical, N.V. for the development, manufacture and commercialization of a product of the entity. Reimbursement for development and commercialization of compounds Reimbursement Revenue Collaborative Arrangements and Acquisitions Collaborative Arrangement Disclosure [Text Block] Unrealized holding gains (losses) on marketable securities, tax Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax Unrealized (losses) gains on foreign currency forward contracts, tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock-based compensation expense Share-based Compensation Depreciation and amortization expense Depreciation, Depletion and Amortization Write-downs of inventories to net realizable value Inventory Write-down Deferred income taxes Increase (Decrease) in Other Deferred Liability Impairment of property and equipment Asset Impairment Charges Intangible asset impairment charge Acquired in-process research & development Research and Development in Process Deconsolidation of VIE Gain (Loss) on Sale of Investments Other non-cash items, net Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued restructuring expense Restructuring Reserve, Period Increase (Decrease) Deferred revenues Increase (Decrease) in Deferred Revenue Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of marketable securities Payments to Acquire Available-for-sale Securities Maturities of marketable securities Proceeds from Sale and Maturity of Available-for-sale Securities Expenditures for property and equipment Payments to Acquire Property, Plant, and Equipment Purchase of in-process research & development Payments to Acquire in Process Research and Development (Decrease) increase in restricted cash and cash equivalents (VIE) Increase (Decrease) in Restricted Cash and Investments Investment in equity securities Payments to Acquire Investments Decrease (increase) in other assets Payments for (Proceeds from) Other Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Issuances of common stock under benefit plans Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Payments on revolving credit facility Advance from collaborator Proceeds From Collaborative Funding Proceeds From Collaborative Funding Payments on capital lease obligations Repayments of Long-term Capital Lease Obligations Proceeds from capital lease financing Proceeds from Long-term Capital Lease Obligations Payments on construction financing lease obligation Repayments of Construction Loans Payable Proceeds related to construction financing lease obligation Proceeds from Construction Loans Payable Repayments of advanced funding Repayments of Collaborative Funding Repayments of Collaborative Funding Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of changes in exchange rates on cash Effect of Exchange Rate on Cash and Cash Equivalents Net increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents—beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents—end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Cash paid for income taxes Income Taxes Paid, Net Capitalization of costs related to construction financing lease obligation Noncash or Part Noncash Acquisition, Fixed Assets Acquired Issuances of common stock from employee benefit plans receivable Employee Benefit Plan Payable (Receivable) Employee Benefit Plan Payable (Receivable) Products and Services Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Tezacaftor Tezacaftor [Member] Tezacaftor Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total Inventories Inventory, Net Capitalized inventory Other Inventory, Capitalized Costs, Gross Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Unrealized Holding Gains (Losses) on Marketable Securities, Net of Tax Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Unrealized Gains (Losses) on Foreign Currency Forward Contracts, Net of Tax Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] AOCI Attributable to Parent Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Other comprehensive loss before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Amounts reclassified from accumulated other comprehensive income (loss) Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates and Summary of Significant Accounting Policies Use of Estimates, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Stock-based Compensation Expense Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Money market funds Money Market Funds [Member] Government-sponsored enterprise securities Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Other assets Other Assets [Member] Other liabilities, current portion Other Current Liabilities [Member] Other liabilities, excluding current portion Other Noncurrent Liabilities [Member] Foreign currency forward contracts Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring basis Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair value of financial assets and liabilities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial instruments carried at fair value (asset position): Assets, Fair Value Disclosure [Abstract] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Marketable securities Marketable Securities Foreign currency forward contracts Foreign Currency Cash Flow Hedge Derivative at Fair Value, Net Total financial assets Assets, Fair Value Disclosure Financial instruments carried at fair value (liability position): Liabilities, Fair Value Disclosure [Abstract] Derivative liability current Derivative Liability, Current Derivative liability, noncurrent Derivative Liability, Noncurrent Total financial liabilities Financial Liabilities Fair Value Disclosure Cash and cash equivalents Variable Interest Entity, Consolidated, Carrying Amount, Cash and Cash Equivalents Variable Interest Entity, Consolidated, Carrying Amount, Cash and Cash Equivalents Other Income and Expenses [Abstract] Other Arrangements Other Nonoperating Income and Expense [Text Block] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Marketable securities, available for sale Available-for-sale Securities, Current Accounts receivable, net Accounts Receivable, Net, Current Inventories Total current assets Assets, Current Property and equipment, net Cost method investments Cost Method Investments Total assets Assets Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Deferred revenues, current portion Deferred Revenue, Current Accrued restructuring expenses, current portion Restructuring Reserve, Current Capital lease obligations, current portion Capital Lease Obligations, Current Customer deposits Credit facility Line of Credit, Current Other liabilities, current portion Total current liabilities Liabilities, Current Deferred revenues, excluding current portion Deferred Revenue, Noncurrent Accrued restructuring expenses, excluding current portion Restructuring Reserve, Noncurrent Capital lease obligations, excluding current portion Capital Lease Obligations, Noncurrent Deferred tax liability Construction financing lease obligation, excluding current portion Construction Financing Obligation, Noncurrent Represents the noncurrent portion of a lease liability recorded as a result of capitalizing the landlord's costs of constructing facilities associated with building leases. Advance from collaborator Due To Collaborative Arrangement Counterparty Due To Collaborative Arrangement Counterparty Other liabilities, excluding current portion Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Shareholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Common stock, $0.01 par value; 500,000,000 shares authorized; 252,683,346 and 248,300,517 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total Vertex shareholders’ equity Stockholders' Equity Attributable to Parent Total shareholders’ equity Total liabilities and shareholders’ equity Liabilities and Equity Other assets Designated as hedging instrument Designated as Hedging Instrument [Member] Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Euro Euro Member Countries, Euro British pound sterling United Kingdom, Pounds Australian dollar Australia, Dollars Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash flow hedging Cash Flow Hedging [Member] Amount of ineffectiveness on net investment hedges Amount of Ineffectiveness on Net Investment Hedges Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract] Foreign Currency Cash Flow Hedge Derivative at Fair Value, Net [Abstract] Fair Value - assets Foreign Currency Cash Flow Hedge Asset at Fair Value Fair Value - liabilities Foreign Currency Cash Flow Hedge Liability at Fair Value Offsetting Derivative Assets [Abstract] Offsetting Derivative Assets [Abstract] Gross Amounts Recognized Gross Amounts Offset Derivative Asset, Fair Value, Gross Liability Gross Amounts Presented Derivative Asset Gross Amounts Not Offset Derivative Asset, Not Offset, Policy Election Deduction Legal Offset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Offsetting Derivative Liabilities [Abstract] Offsetting Derivative Liabilities [Abstract] Gross Amounts Recognized Derivative Liability, Fair Value, Gross Liability Gross Amounts Offset Derivative Liability, Fair Value, Gross Asset Gross Amounts Presented Derivative Liability Gross Amounts Not Offset Derivative Liability, Not Offset, Policy Election Deduction Legal Offset Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Gross proceeds from sale of royalty rights receivable from GlaxoSmithKline Proceeds from Sale of Royalty Rights The cash inflow from the sale of the entity's right to receive future royalty payments. Deferred revenue royalty purchase agreement Deferred Revenue Royalty Purchase Agreement This element represents the carrying value of deferred revenue recorded with regard to agreement to sell rights to receive royalty payments, as on the balance sheet date. Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract] Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract] Loss attributable to noncontrolling interest before (benefit from) provision for income taxes and changes in fair value of contingent payments Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Net loss (income) attributable to noncontrolling interest Internal Revenue Service (IRS) Internal Revenue Service (IRS) [Member] Retained Earnings Income tax liability associated with variable interest entity Taxes Payable Unrecognized tax benefits Unrecognized Tax Benefits Income taxes, interest and penalties accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Increase in unrecognized tax benefits is reasonably possible Increase in Unrecognized Tax Benefits is Reasonably Possible Income taxes, material interest or penalties related to uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Effective income tax rate reconciliation, share-based compensation, excess tax benefit, amount Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount Deferred tax asset subject to valuation allowance Deferred Tax Assets, Gross Amount of unrecognized deferred tax liability, undistributed earnings of foreign subsidiaries Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock options Restricted stock and restricted stock units Employee Restricted Stock Option [Member] An arrangement whereby certain members of senior management are entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. ESPP share issuances Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Research and development expenses Research and Development Expense [Member] Sales, general and administrative expenses Selling General and Administrative Expense [Member] The allocation (or location) of expense to (in) selling, general and administrative expense. Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation expense: Share-based Compensation Allocation [Abstract] -- None. No documentation exists for this element. -- Share-based compensation expense by type of award Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost Less stock-based compensation expense capitalized to inventories Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount Total stock-based compensation included in costs and expenses Allocated Share-based Compensation Expense Type of award: Employee Service Share-based Compensation, Aggregate Disclosures [Abstract] Unrecognized Expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Weighted-average Recognition Period Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Restructuring and related cost, number of positions eliminated Restructuring and Related Cost, Number of Positions Eliminated Lease term (in years) Lease Term Total length of time of a real estate lease, stated in years. Restructuring and related activities, leased office space, maximum percentage used - not more than Restructuring and Related Activities, Leased Office Space, Maximum Percentage Used Maximum of percentage used of leased office space. Number of facilities decommissioned Restructuring and Related Activities, Number of Facilities Decommissioned Restructuring and Related Activities, Number of Facilities Decommissioned Number of leases terminated Number Of Lease Terminated Number Of Lease Terminated Discount rate related to leases (percent) Lease Restructuring Liability Accrual Discount Rate The credit-adjusted risk-free discount rate applied to the undiscounted amount of projected cash inflows and/or outflows to arrive at the present value of the lease restructuring liability recorded as of the balance sheet date. Restructuring reserve Fair Value Measurements Fair Value Disclosures [Text Block] EX-101.PRE 12 vrtx-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2017
Oct. 20, 2017
Document and Entity Information [Abstract]    
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA  
Entity Central Index Key 0000875320  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Sep. 30, 2017  
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Common Stock, Shares Outstanding (in shares)   252,902,848
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Revenues:        
Product revenues, net $ 549,642 $ 409,689 $ 1,544,252 $ 1,229,750
Royalty revenues 2,231 3,835 6,643 12,713
Collaborative revenues 26,292 259 286,123 1,008
Total revenues 578,165 413,783 1,837,018 1,243,471
Costs and expenses:        
Cost of product revenues 72,186 53,222 188,963 147,165
Royalty expenses 688 855 2,104 2,813
Research and development expenses 454,947 272,370 1,017,961 799,238
Sales, general and administrative expenses 120,710 106,055 361,285 322,921
Restructuring expenses, net 337 8 13,859 1,038
Intangible asset impairment charge 255,340 0 255,340 0
Total costs and expenses 904,208 432,510 1,839,512 1,273,175
Loss from operations (326,043) (18,727) (2,494) (29,704)
Interest expense, net (13,574) (20,140) (45,003) (60,993)
Other (expenses) income, net (77,553) (167) (80,634) 3,025
Loss before (benefit from) provision for income taxes (417,170) (39,034) (128,131) (87,672)
(Benefit from) provision for income taxes (125,903) 503 (117,581) 24,118
Net loss (291,267) (39,537) (10,550) (111,790)
Loss (income) attributable to noncontrolling interest 188,315 696 173,350 (33,207)
Net (loss) income attributable to Vertex $ (102,952) $ (38,841) $ 162,800 $ (144,997)
Net (loss) income:        
Basic (in dollars per share) $ (0.41) $ (0.16) $ 0.66 $ (0.59)
Diluted (in dollars per share) $ (0.41) $ (0.16) $ 0.64 $ (0.59)
Shares used in per share calculations:        
Basic (in shares) 250,268 244,920 247,963 244,529
Diluted (in shares) 250,268 244,920 252,095 244,529
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]        
Net loss $ (291,267) $ (39,537) $ (10,550) $ (111,790)
Changes in other comprehensive loss:        
Unrealized holding gains (losses) on marketable securities, net of tax of zero, respectively 5,961 (96) (7,786) 104
Unrealized (losses) gains on foreign currency forward contracts, net of tax of $0.9 million, $0.2 million, $2.9 million and $(0.4) million, respectively (5,453) 2,149 (27,379) 1,936
Foreign currency translation adjustment (3,884) (2,508) (11,137) (7,709)
Total changes in other comprehensive loss (3,376) (455) (46,302) (5,669)
Comprehensive loss (294,643) (39,992) (56,852) (117,459)
Comprehensive loss (income) attributable to noncontrolling interest 188,315 696 173,350 (33,207)
Comprehensive (loss) income attributable to Vertex $ (106,328) $ (39,296) $ 116,498 $ (150,666)
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) (Parenthetical) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]        
Unrealized holding gains (losses) on marketable securities, tax $ 0 $ 0 $ 0 $ 0
Unrealized (losses) gains on foreign currency forward contracts, tax $ 900,000 $ 200,000 $ 2,900,000 $ (400,000)
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 1,384,966 $ 1,183,945
Marketable securities, available for sale 427,282 250,612
Restricted cash and cash equivalents (VIE) 1,803 47,762
Accounts receivable, net 263,493 201,083
Inventories 98,192 77,604
Prepaid expenses and other current assets 152,238 70,534
Total current assets 2,327,974 1,831,540
Property and equipment, net 759,978 698,362
Intangible assets 29,000 284,340
Goodwill 50,384 50,384
Cost method investments 20,447 20,276
Other assets 10,542 11,885
Total assets 3,198,325 2,896,787
Current liabilities:    
Accounts payable 77,138 61,451
Accrued expenses 378,554 315,249
Deferred revenues, current portion 13,003 6,005
Accrued restructuring expenses, current portion 4,205 6,047
Capital lease obligations, current portion 19,881 19,426
Customer deposits 190,272 73,416
Credit facility 0 300,000
Other liabilities, current portion 27,686 10,943
Total current liabilities 710,739 792,537
Deferred revenues, excluding current portion 2,917 6,632
Accrued restructuring expenses, excluding current portion 146 1,907
Capital lease obligations, excluding current portion 20,259 34,976
Deferred tax liability 10,682 134,063
Construction financing lease obligation, excluding current portion 547,051 486,359
Advance from collaborator 77,258 73,423
Other liabilities, excluding current portion 26,029 28,699
Total liabilities 1,395,081 1,558,596
Commitments and contingencies
Shareholders’ equity:    
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding 0 0
Common stock, $0.01 par value; 500,000,000 shares authorized; 252,683,346 and 248,300,517 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively 2,500 2,450
Additional paid-in capital 7,034,113 6,506,795
Accumulated other comprehensive (loss) income (25,129) 21,173
Accumulated deficit (5,220,407) (5,373,836)
Total Vertex shareholders’ equity 1,791,077 1,156,582
Noncontrolling interest 12,167 181,609
Total shareholders’ equity 1,803,244 1,338,191
Total liabilities and shareholders’ equity $ 3,198,325 $ 2,896,787
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares
Sep. 30, 2017
Dec. 31, 2016
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 252,683,346 248,300,517
Common stock, shares outstanding 252,683,346 248,300,517
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest (unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Total Vertex Shareholders’ Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Noncontrolling Interest
Balance (shares) at Dec. 31, 2015     246,307        
Beginning Balance at Dec. 31, 2015 $ 1,093,628 $ 939,967 $ 2,427 $ 6,197,500 $ 1,824 $ (5,261,784) $ 153,661
Increase (Decrease) in Stockholders' Equity              
Other comprehensive loss, net of tax (5,669) (5,669)     (5,669)    
Net (loss) income (111,790) (144,997)       (144,997) 33,207
Issuance of common stock under benefit plans (shares)     1,722        
Issuance of common stock under benefit plans 50,894 50,894 $ 19 50,875     0
Stock-based compensation expense 181,278 181,351   181,351     (73)
Balance (shares) at Sep. 30, 2016     248,029        
Ending Balance at Sep. 30, 2016 1,208,341 1,021,546 $ 2,446 6,429,726 (3,845) (5,406,781) 186,795
Increase (Decrease) in Stockholders' Equity              
Cumulative effect adjustment for adoption of new accounting guidance | Accounting Standards Update 2016-09, Forfeiture Rate Component       9,371   (9,371)  
Balance (shares) at Dec. 31, 2016     248,301        
Beginning Balance at Dec. 31, 2016 1,338,191 1,156,582 $ 2,450 6,506,795 21,173 (5,373,836) 181,609
Increase (Decrease) in Stockholders' Equity              
Other comprehensive loss, net of tax (46,302) (46,302)     (46,302)    
Net (loss) income (10,550) 162,800       162,800 (173,350)
Issuance of common stock under benefit plans (shares)     4,382        
Issuance of common stock under benefit plans 299,039 299,006 $ 50 298,956     33
Stock-based compensation expense 218,991 218,991   218,991     0
VIE noncontrolling interest upon deconsolidation 3,910           3,910
Other (35)           (35)
Balance (shares) at Sep. 30, 2017     252,683        
Ending Balance at Sep. 30, 2017 $ 1,803,244 $ 1,791,077 $ 2,500 $ 7,034,113 $ (25,129) $ (5,220,407) $ 12,167
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash flows from operating activities:    
Net loss $ (10,550) $ (111,790)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Stock-based compensation expense 215,334 178,623
Depreciation and amortization expense 44,965 45,947
Write-downs of inventories to net realizable value 11,138 0
Deferred income taxes (113,969) 23,544
Impairment of property and equipment 1,946 0
Intangible asset impairment charge 255,340 0
Acquired in-process research & development 160,000 0
Deconsolidation of VIE 76,644 0
Other non-cash items, net (4,787) (904)
Changes in operating assets and liabilities:    
Accounts receivable, net (54,455) (9,760)
Inventories (28,570) (11,536)
Prepaid expenses and other assets (90,006) (8,979)
Accounts payable 6,925 (21,532)
Accrued expenses and other liabilities 148,102 26,121
Accrued restructuring expense (3,863) (8,151)
Deferred revenues 3,237 (10,204)
Net cash provided by operating activities 617,431 91,379
Cash flows from investing activities:    
Purchases of marketable securities (431,653) (616,625)
Maturities of marketable securities 247,149 535,379
Expenditures for property and equipment (56,817) (41,775)
Purchase of in-process research & development (160,000) 0
(Decrease) increase in restricted cash and cash equivalents (VIE) (15,643) 20,490
Investment in equity securities 0 (23,075)
Decrease (increase) in other assets 380 (93)
Net cash used in investing activities (416,584) (125,699)
Cash flows from financing activities:    
Issuances of common stock under benefit plans 298,205 51,165
Payments on revolving credit facility (300,000) 0
Advance from collaborator 10,000 0
Payments on capital lease obligations (14,188) (13,330)
Proceeds from capital lease financing 0 2,030
Payments on construction financing lease obligation (412) (356)
Proceeds related to construction financing lease obligation 4,700 0
Repayments of advanced funding (3,132) 0
Net cash (used in) provided by financing activities (4,827) 39,509
Effect of changes in exchange rates on cash 5,001 (265)
Net increase in cash and cash equivalents 201,021 4,924
Cash and cash equivalents—beginning of period 1,183,945 714,768
Cash and cash equivalents—end of period 1,384,966 719,692
Supplemental disclosure of cash flow information:    
Cash paid for interest 51,990 64,662
Cash paid for income taxes 4,154 1,617
Capitalization of costs related to construction financing lease obligation 33,827 824
Issuances of common stock from employee benefit plans receivable $ 868 $ 19
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Basis of Presentation and Accounting Policies
 9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Basis of Presentation and Accounting Policies
Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals. As of September 30, 2017, the Company deconsolidated Parion Sciences, Inc. (“Parion”), a VIE the Company has consolidated since 2015. The Company's consolidated balance sheet as of September 30, 2017 excludes Parion. Please refer to Note C, “Collaborative Arrangements and Acquisitions” for further information regarding the deconsolidation of Parion.

Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2017 and 2016.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2016, which are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 that was filed with the Securities and Exchange Commission (the “SEC”) on February 23, 2017 (the “2016 Annual Report on Form 10-K”).
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation and deconsolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
The Company’s significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in the 2016 Annual Report on Form 10-K.
Recent Accounting Pronouncements
In 2014, the Financial Accounting Standards Board (“FASB”) issued new guidance applicable to revenue recognition that will be effective January 1, 2018. Early adoption was permitted for the year-ending December 31, 2017. The new guidance applies a more principles based approach to recognizing revenue. Under the new guidance, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new guidance must be adopted using either a modified retrospective approach or a full retrospective approach for all periods presented. Under the modified retrospective method, the cumulative effect of applying the standard would be recognized at the date of initial application within retained earnings. Under the full retrospective approach, the standard would be applied to each prior reporting period presented. Upon adoption, the Company will use the modified retrospective method. The Company continues to evaluate the new guidance and the effect the adoption will have on the condensed consolidated financial statements.  The Company’s project team is finalizing its review of existing customer contracts and current accounting policies to identify and assess the potential differences that would result from applying the requirements of the new standard. Based on the Company’s assessment performed to date, the new revenue recognition guidance could impact the Company’s accounting for product shipments to certain countries through early access programs, including the French early access programs, whereby the associated product has received regulatory approval but the price is not fixed or determinable based on the status of ongoing pricing discussions, and could impact the Company’s accounting for certain reimbursement agreements that the Company plans to negotiate in the fourth quarter of 2017. As the Company completes its assessment, it is implementing appropriate changes to its controls to support revenue recognition and additional revenue-related disclosures under the new standard.
In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The amended guidance became effective for the Company during the first quarter of 2017. The amended guidance eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in additional paid-in capital. This created approximately $410.8 million of deferred tax asset (“DTA”) relating to federal and state net operating losses (“NOLs”) that are fully reserved by an equal increase in valuation allowance. The Company recorded DTAs of approximately $404.7 million relating to Federal NOLs and approximately $6.1 million relating to State NOLs, both of which are offset by a full valuation allowance. Upon adoption, the Company also elected to change its accounting policy to account for forfeitures of options and awards as they occur. The change was applied on a modified retrospective basis with a cumulative effect adjustment to the Company’s accumulated deficit of $9.4 million, which increased the accumulated deficit as of January 1, 2017. This change also resulted in an increase to the DTA of $3.4 million, which is offset by a full valuation allowance. As a result, there was no cumulative-effect adjustment to accumulated deficit. The provisions related to the recognition of excess tax benefits in the income statement and classification in the statement of cash flows were adopted prospectively, and as such, the prior periods were not retrospectively adjusted.
In 2016, the FASB issued amended guidance related to the recording of financial assets and financial liabilities. Under the amended guidance, equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) are to be measured at fair value with changes in fair value recognized in net income. However, an entity has the option to either measure equity investments without readily determinable fair values at fair value or at cost adjusted for changes in observable prices minus impairment. Changes in measurement under either alternative will be recognized in net income. The amended guidance is effective for the year ending December 31, 2018. Early adoption is permitted. The Company expects the implementation of this standard to have an impact on its consolidated financial statements and related disclosures, as the Company held publicly traded equity investments as of September 30, 2017 as well as equity investments accounted for under the cost method. A cumulative-effect adjustment to the balance sheet will be recorded as of the beginning of the fiscal year of adoption. The implementation of this amended guidance is expected to increase volatility in net income as the volatility currently recorded in other comprehensive income related to changes in the fair market value of available-for-sale equity investments will be reflected in net income after adoption.

In 2016, the FASB issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This guidance requires entities to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.

In 2016, the FASB issued amended guidance related to intra-entity transfers other than inventory. This guidance removes the current exception in GAAP prohibiting entities from recognizing current and deferred income tax expenses or benefits related to transfer of assets, other than inventory, within the consolidated entity. The current exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. The amended guidance is effective for the year ending December 31, 2018. Early adoption is permitted. The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.

In 2017, the FASB issued amended guidance related to business combinations. The amended guidance clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new accounting guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company early adopted this new guidance as of January 1, 2017 and will apply this new guidance to future acquisitions.

In 2017, the FASB issued amended guidance related to measurements of goodwill. The amended guidance eliminates a step from the goodwill impairment test. Under the amended guidance, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The amended guidance is effective for the year-ending December 31, 2020. Early adoption is permitted. The Company does not expect a significant effect on its condensed consolidated financial statements upon adoption of this new guidance.

In 2017, the FASB issued amended guidance related to the scope of stock option modification accounting, to reduce diversity in practice and provide clarity regarding existing guidance. The new accounting guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company does not expect the adoption of this guidance to have a material effect on its condensed consolidated financial statements and related disclosures.

In 2017, the FASB issued amended guidance applicable to hedge accounting. The new accounting guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those periods. Early adoption is permitted. The amended guidance helps simplify certain aspects of hedge accounting and enables entities to more accurately present their risk management activities in their financial statements.  The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.

For a discussion of other recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2016 Annual Report on Form 10-K.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Product Revenues, Net
 9 Months Ended
Sep. 30, 2017
Product Revenues [Abstract]  
Product Revenues, Net
Product Revenues, Net
The Company sells its products principally to a limited number of specialty pharmacy providers in North America as well as government-owned and supported customers in international markets (collectively, its “Customers”). The Company’s Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery to the Customer as long as (i) there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii) collectibility is reasonably assured and (iii) the price is fixed or determinable.
In order to conclude that the price is fixed or determinable, the Company must be able to (i) calculate its gross product revenues from sales to Customers and (ii) reasonably estimate its net product revenues upon delivery to its Customers’ locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a) trade allowances, such as invoice discounts for prompt payment and Customer fees, (b) estimated government and private payor rebates, chargebacks and discounts, (c) estimated reserves for expected product returns and (d) estimated costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers.
The Company makes significant estimates and judgments that materially affect the Company’s recognition of net product revenues. In certain instances, the Company may be unable to reasonably conclude that the price is fixed or determinable at the time of delivery, in which case it defers the recognition of revenues. Once the Company is able to determine that the price is fixed or determinable, it recognizes the net product revenues associated with the units in which revenue recognition was deferred.
Revenue recognition related to the Company’s French early access programs could be impacted by the new revenue recognition guidance that is effective January 1, 2018 and described in Note A, “Basis of Presentation and Accounting Policies”. The Company’s ORKAMBI net product revenues to date do not include any revenues from product sales in France because the price is not fixed or determinable. The Company began distributing ORKAMBI through early access programs in France during the fourth quarter of 2015. As of September 30, 2017, the Company’s condensed consolidated balance sheet includes $190.3 million collected in France related to shipments of ORKAMBI under the early access programs that is classified as Customer deposits. The Company expects that the difference between the amounts collected based on the invoiced price and the final price for ORKAMBI in France will be returned to the French government.
If the Company concludes as of December 31, 2017 that the price of the ORKAMBI supplied under the early access programs is fixed or determinable based on, among other factors, the status of negotiations in France, it would record net product revenues for all sales since the inception of the early access programs for ORKAMBI based on the fixed or determinable price in the fourth quarter of 2017.
If the Company concludes that the price is not fixed or determinable as of December 31, 2017, these amounts would be subject to the new guidance applicable to revenue recognition effective January 1, 2018 using the modified retrospective adoption approach.  Pursuant to the new guidance, the Company would record a cumulative effect adjustment to the Company’s accumulated deficit in the first quarter of 2018. The amount of the adjustment to accumulated deficit would be determined based upon (i) the status of pricing discussions in France upon adoption and (ii) the Company’s estimate of the amount of consideration the Company expects to retain related to the French ORKAMBI sales that occurred on or prior to December 31, 2017 that would not be subject to a significant reversal in amounts recognized. For French ORKAMBI sales after December 31, 2017 under the early access programs, the Company would recognize product revenues based on the Company’s estimate of consideration the Company expects to retain for which it is probable that a significant reversal in amounts recognized will not occur. In future periods, if the Company’s estimates regarding the amounts it will receive for ORKAMBI supplied pursuant to these programs change, the effect of the change in estimates would be reflected in net product revenues in the period in which the change in estimate occurred.
The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2017:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2016
$
2,568

 
$
81,927

 
$
3,492

 
$
1,214

 
$
89,201

Provision related to current period sales
18,776

 
118,592

 
3,603

 
12,238

 
153,209

Adjustments related to prior period sales
(188
)
 
(4,327
)
 
(13
)
 
(355
)
 
(4,883
)
Credits/payments made
(18,409
)
 
(97,393
)
 
(1,809
)
 
(10,021
)
 
(127,632
)
Balance at September 30, 2017
$
2,747

 
$
98,799

 
$
5,273

 
$
3,076

 
$
109,895
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Acquisitions
 9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaborative Arrangements and Acquisitions
Collaborative Arrangements and Acquisitions
Cystic Fibrosis Foundation Therapeutics Incorporated
The Company has a research, development and commercialization agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (“CFFT”) that was originally entered into in May 2004, and was most recently amended in October 2016 (the “2016 Amendment”). Pursuant to the agreement, as amended, the Company has agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016 and tiered royalties ranging from single digits to sub-teens on any approved drugs first synthesized and/or tested during a research term on or before February 28, 2014, including (i) KALYDECO (ivacaftor) and ORKAMBI (lumacaftor in combination with ivacaftor), which are the Company’s current products and (ii) tezacaftor in combination with ivacaftor. For combination products, such as ORKAMBI, sales will be allocated equally to each of the active pharmaceutical ingredients in the combination product.
In the first quarter of 2016, CFFT earned a commercial milestone payment of $13.9 million from the Company upon achievement of certain sales levels of lumacaftor. There are no additional commercial milestone payments payable by the Company to CFFT pursuant to the agreement. Pursuant to the 2016 Amendment, the CFFT provided the Company an upfront program award of $75.0 million and agreed to provide development funding to the Company of up to $6.0 million annually. The program award plus any future development funding represent a form of financing pursuant to Accounting Standards Codification (ASC) 730, Research and Development, and thus the amounts are recorded as a liability on the condensed consolidated balance sheet, primarily reflected in Advance from collaborator. The liability is reduced over the estimated royalty term of the agreement. Reductions in the liability are reflected as an offset to cost of product revenues and as interest expense.
The Company has royalty obligations to CFFT for ivacaftor, lumacaftor and tezacaftor until the expiration of patents covering those compounds. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent extensions. The Company has patents in the United States and European Union covering the composition-of-matter of lumacaftor that expire in 2030 and 2026, respectively, subject to potential extension. The Company has patents in the United States and European Union covering the composition-of-matter of tezacaftor that expire in 2027 and 2028, respectively, subject to potential extension.
CRISPR Therapeutics AG
In 2015, the Company entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. The Company has the exclusive right to license up to six CRISPR-Cas9-based targets, including targets for the potential treatment of sickle cell disease. In connection with the CRISPR Agreement, the Company made an upfront payment to CRISPR of $75.0 million and a $30.0 million investment in CRISPR pursuant to a convertible loan agreement that converted into preferred stock in January 2016. The Company expensed $75.0 million to research and development, and the $30.0 million investment was recorded at cost and was classified as a long-term asset on the Company’s condensed consolidated balance sheets. In the second quarter of 2016, the Company made an additional preferred stock investment in CRISPR of approximately $3.1 million. In connection with CRISPR’s initial public offering in October 2016, the Company purchased $10.0 million of common shares at the public offering price and the Company’s preferred stock investments in CRISPR converted into common shares. As of September 30, 2017, the Company recorded the fair value of its investment in CRISPR common shares of $56.9 million in marketable securities and a $13.7 million unrealized gain related to these common shares in accumulated other comprehensive income (loss) on the condensed consolidated balance sheet.
The Company will fund all of the discovery activities conducted pursuant to the CRISPR Agreement. For potential hemoglobinapathy treatments, including treatments for sickle cell disease, the Company and CRISPR will share equally all development costs and worldwide revenues. For other targets that the Company elects to license, the Company would lead all development and global commercialization activities. For each of up to six targets that the Company elects to license, other than hemoglobinapathy targets, CRISPR has the potential to receive up to $420.0 million in development, regulatory and commercial milestones and royalties on net product sales.
The Company may terminate the CRISPR Agreement upon 90 days’ notice to CRISPR prior to any product receiving marketing approval or upon 270 days’ notice after a product has received marketing approval. The CRISPR Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the CRISPR Agreement will continue in effect until the expiration of the Company’s payment obligations under the CRISPR Agreement.
Merck KGaA

On January 10, 2017, the Company entered into a strategic collaboration and license agreement (the “Merck KGaA Agreement”) with Merck KGaA, Darmstadt, Germany (“Merck KGaA”). Pursuant to the Merck KGaA Agreement, the Company granted Merck KGaA an exclusive worldwide license to research, develop and commercialize four oncology research and development programs. Under the Merck KGaA Agreement, the Company granted Merck KGaA exclusive, worldwide rights to two clinical-stage programs targeting DNA damage repair: its ataxia telangiectasia and Rad3-related protein inhibitor program, including VX-970 and VX-803, and its DNA-dependent protein kinase inhibitor program, including VX-984. In addition, the Company granted Merck KGaA exclusive, worldwide rights to two pre-clinical programs.

The Merck KGaA Agreement provided for an upfront payment from Merck KGaA to the Company of $230.0 million. During the first quarter of 2017, the Company received $193.6 million of the upfront payment and the remaining $36.4 million was remitted to the German tax authorities. Pursuant to a tax treaty between the United States and Germany, the Company filed a refund application for the tax withholding and expects to receive the refund in the fourth quarter of 2017. The income tax receivable is included in Prepaid expenses and other current assets at September 30, 2017. In addition to the upfront payment, the Company will receive tiered royalties on potential sales of licensed products, calculated as a percentage of net sales, that range from (i) mid-single digits to mid-twenties for clinical-stage programs and (ii) mid-single digits to high single digits for the pre-clinical research programs. Merck KGaA has assumed full responsibility for development and commercialization costs for all programs.

The Company evaluated the deliverables, primarily consisting of a license to the four programs and the obligation to complete certain fully-reimbursable research and development and transition activities as directed by Merck KGaA, pursuant to the Merck KGaA Agreement, under the multiple element arrangement accounting guidance. The Company concluded that the license has stand-alone value from the research and development and transition activities based on the resources and know-how possessed by Merck KGaA, and thus concluded that there are two units of accounting in the arrangement. The Company determined the relative selling price of the units of accounting based on the Company’s best estimate of selling price. The Company utilized key assumptions to determine the best estimate of selling price for the license, which included future potential net sales of licensed products, development timelines, reimbursement rates for personnel costs, discount rates, and estimated third-party development costs. The Company utilized a discounted cash flow model to determine its best estimate of selling price for the license and determined the best estimate of selling price for the research and development and transition activities based on what it would sell the services for separately. Based on this analysis, the Company recognized approximately $231.7 million in collaborative revenues related to the upfront payment upon delivery of the license and to the research and development and transition activities provided during the first quarter of 2017. During the three and nine months ended September 30, 2017, the Company recorded the reimbursement for the research and development and transition activities of $5.2 million and $12.8 million, respectively, as revenue in the Company’s consolidated statements of operations primarily due to the fact that the Company is the primary obligor in the arrangement. The Company is providing research and development and transition activities and will recognize the revenues and associated expenses as the services are provided.

Merck KGaA may terminate the Merck KGaA Agreement or any individual program by providing 90 days’ notice, or, in the case of termination of a program with a product that has received marketing approval, 180 days’ notice. The Merck KGaA Agreement also may be terminated by either party for a material breach by the other party, subject to notice and cure provisions. Unless earlier terminated, the Merck KGaA Agreement will continue in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.

Variable Interest Entities
The Company has entered into several agreements pursuant to which it has licensed rights to certain drug candidates from third-party collaborators, resulting in the consolidation of the third parties’ financial statements into the Company’s condensed consolidated financial statements as VIEs. In order to account for the fair value of the contingent payments, which consist of milestone, royalty and option payments, related to these collaborations under GAAP, the Company uses present-value models based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the timing of achieving the milestones, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent payments. The following collaborations are reflected in the Company’s financial statements as consolidated VIEs for portions or all of the periods presented:

Parion Sciences, Inc.

In June 2015, the Company entered into a strategic collaboration and license agreement (the “Parion Agreement”) with Parion.  Pursuant to the agreement, the Company is collaborating with Parion to develop investigational epithelial sodium channel (“ENaC”) inhibitors, including VX-371 (formerly P-1037) and VX-551 (formerly P-1055), for the potential treatment of CF and all other pulmonary diseases.  The Company is leading development activities for VX-371 and VX-551 and is responsible for all costs, subject to certain exceptions, related to development and commercialization of the compounds.

Pursuant to the Parion Agreement, the Company has worldwide development and commercial rights to Parion’s lead investigational ENaC inhibitors, VX-371 and VX-551, for the potential treatment of CF and all other pulmonary diseases and has the option to select additional compounds discovered in Parion’s research program.  Parion received an $80.0 million up-front payment and has the potential to receive up to an additional (i) $490.0 million in development and regulatory milestone payments for development of ENaC inhibitors in CF, including $360.0 million related to global filing and approval milestones, (ii) $370.0 million in development and regulatory milestones for VX-371 and VX-551 in non-CF pulmonary indications and (iii) $230.0 million in development and regulatory milestones should the Company elect to develop an additional ENaC inhibitor from Parion’s research program. The Company has agreed to pay Parion tiered royalties that range from the low double digits to mid-teens as a percentage of potential sales of licensed products.

The Company may terminate the Parion Agreement upon 90 days’ notice to Parion prior to any licensed product receiving marketing approval or upon 180 days’ notice after a licensed product has received marketing approval. If the Company experiences a change of control prior to the initiation of the first Phase 3 clinical trial for a licensed product, Parion may terminate the Parion Agreement upon 30 days’ notice, subject to the Company’s right to receive specified royalties on any subsequent commercialization of licensed products. The Parion Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Parion Agreement will continue in effect until the expiration of the Company’s royalty obligations, which expire on a country-by-country basis on the later of (i) the date the last-to-expire patent covering a licensed product expires or (ii) ten years after the first commercial sale in the country.

The Company determined that it had a variable interest in Parion via the Parion Agreement, and that the variable interest represented a variable interest in Parion as a whole because the fair value of the ENaC inhibitors represented more than half of the total fair value of Parion’s assets. The Company also concluded that it was the primary beneficiary as it had the power to direct the activities that most significantly affect the economic performance of Parion and it had the obligation to absorb losses and right to receive benefits that potentially could be significant to Parion.  Accordingly, the Company consolidated Parion's financial statements from June 4, 2015 through September 30, 2017. The Company deconsolidated Parion effective September 30, 2017. Notwithstanding the applicable accounting treatment, the Company's interests in Parion have been and continue to be limited to those accorded to the Company in the Parion Agreement.

As of June 4, 2015, the Company consolidated Parion’s financial statements, which included $255.3 million of intangible assets on the Company’s condensed consolidated balance sheet for Parion’s in-process research and development assets. These in-process research and development assets relate to Parion’s pulmonary ENaC platform, including the intellectual property related to VX-371 and VX-551, that are licensed by Parion to the Company. The Company also recorded the fair value of the net assets attributable to noncontrolling interest of $164.3 million, deferred tax liability of $91.0 million resulting primarily from a basis difference in the intangible assets and certain other net liabilities held by Parion of $10.5 million.  The difference between the fair values of the consideration and noncontrolling interest and the fair value of Parion’s net assets was recorded as goodwill. When determining the valuation of goodwill, the fair value of consideration for the license was zero since there was no consideration transferred outside the condensed consolidated financial statements. While there was a transfer of $80.0 million for the upfront payment to Parion, the cash remained within the Company’s condensed consolidated balance sheet since Parion was part of the consolidated entity. The cash received, net of any cash spent by Parion, was classified as restricted cash and cash equivalents (VIE) within the condensed consolidated balance sheet as it was attributed to the noncontrolling interest holders of Parion.

In the second quarter of 2017, Parion signed a license agreement with an affiliate of Shire plc related to the development of a drug candidate for the potential treatment of dry eye disease. The Company evaluated the license agreement entered into by Parion as a reconsideration event to determine whether it should continue to consolidate Parion as a variable interest entity into its condensed consolidated financial statements. The Company determined that there was no substantive change in the design of Parion subsequent to Parion’s agreement with Shire. Additionally, the Company concluded that it was appropriate to continue to consolidate the financial results of Parion because it continued to have (i) the power to direct the activities that most significantly affect the economic performance of Parion and (ii) the obligation to absorb losses and right to receive benefits that potentially could be significant to Parion. Based on the consolidation of Parion’s financial statements, during the three and nine months ended September 30, 2017, the Company has recognized (i) $20.0 million and $40.0 million, respectively, of collaborative revenues and (ii) a tax provision of $7.4 million and $14.8 million, respectively, both of which were attributable to noncontrolling interest related to payments that Parion received from Shire in the three and nine months ended September 30, 2017. The Company has no interest in Parion’s license agreement with Shire, including the economic benefits and/or obligations derived therefrom.
As of September 30, 2017, the Company determined that the fair value of Parion’s pulmonary ENaC platform had declined significantly based on data received in September 2017 from a Phase 2 clinical trial of VX-371 that did not meet its primary efficacy endpoint. The Company recorded an impairment charge of $255.3 million, which represented the entire value of the intangible asset in the third quarter of 2017. After evaluating the results of the clinical trial, the Company determined that it was no longer the primary beneficiary of Parion as it no longer had the power to direct the significant activities of Parion. The most important factor in this determination was the decrease in the fair value of Parion’s pulmonary ENaC platform relative to Parion’s other activities. Accordingly, the Company deconsolidated Parion as of September 30, 2017. The impairment charge of $255.3 million, decrease in the fair value of the contingent payments payable by the Company to Parion of $69.6 million and benefit from income taxes of $126.2 million resulting from these charges were recorded in the third quarter of 2017 attributable to noncontrolling interest. The benefit from income taxes consisted of benefits of $97.7 million and $28.5 million attributable to the impairment charge and decrease in the fair value of contingent payments, respectively. The net effect of these charges and impact of the deconsolidation was a loss of $7.1 million recorded in other income (expense), net attributable to Vertex in the consolidated statement of operations for the three and nine months ended September 30, 2017. The loss of $7.1 million was approximately the difference between (i) the aggregate of $85.0 million in upfront and milestone payments that the Company has made to Parion to date pursuant to the Parion Agreement and (ii) losses the Company recorded in 2015, 2016, and the first half of 2017 based on increases in the fair value of contingent payments payable by the Company to Parion.
Please refer to Note J, "Intangible Assets and Goodwill," for further information regarding the impairment of Parion’s pulmonary ENaC platform.
In connection with the deconsolidation of Parion, the Company evaluated whether the results of Parion should be presented as discontinued operations for the three and nine month period ending September 30, 2017. The Company concluded that the deconsolidation of Parion based on data from the Phase 2 clinical trial of VX-371 is not a development that significantly impacts the Company’s overall operations and financial results or plans to treat patients with CF. Research and development expenses incurred related to this program accounted for a minor portion of the Company’s overall annual research and development expenses and the Company remains focused on developing medicines to treat CF. Therefore, the Company has not presented the results related to Parion as discontinued operations in its condensed consolidated statements of operations for the three and nine month ending September 30, 2017.
BioAxone Biosciences, Inc.
In October 2014, the Company entered into a license and collaboration agreement (the “BioAxone Agreement”) with BioAxone Biosciences, Inc. (“BioAxone”), which resulted in the consolidation of BioAxone as a VIE beginning on October 1, 2014. The Company paid BioAxone initial payments of $10.0 million in the fourth quarter of 2014.
BioAxone has the potential to receive up to $90.0 million in milestones and fees, including development, regulatory and milestone payments and a license continuation fee. In addition, BioAxone would receive royalties and commercial milestones on future net product sales of VX-210, if any. The Company recorded an in-process research and development intangible asset of $29.0 million for VX-210 and a corresponding deferred tax liability of $11.3 million attributable to BioAxone. The Company holds an option to purchase BioAxone at a predetermined price. The option expires on the earliest of (a) the day the FDA accepts the Biologics License Application submission for VX-210, (b) the day the Company elects to continue the license instead of exercising the option to purchase BioAxone and (c) March 15, 2018, subject to the Company’s option to extend this date by one year.
Aggregate VIE Financial Information
An aggregate summary of net income attributable to noncontrolling interest related to the Company’s VIEs for the three and nine months ended September 30, 2017 and 2016 is as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Loss attributable to noncontrolling interest before (benefit from) provision for income taxes and changes in fair value of contingent payments
$
238,946

 
$
2,406

 
$
222,448

 
$
6,080

(Benefit from) provision for income taxes
(120,181
)
 
(510
)
 
(111,658
)
 
20,063

Decrease (increase) in fair value of contingent payments
69,550

 
(1,200
)
 
62,560

 
(59,350
)
Net loss (income) attributable to noncontrolling interest
$
188,315

 
$
696

 
$
173,350

 
$
(33,207
)


The decreases in the noncontrolling interest holders’ claim to net assets with respect to the fair value of the contingent payments in the three and nine months ended September 30, 2017 were primarily due to the decrease in the fair value of Parion’s pulmonary ENaC platform described above. The increases in the fair value of the contingent payments in the three and nine months ended September 30, 2016 were primarily due to a separate Phase 2 clinical trial of VX-371 achieving its primary safety endpoint in the second quarter of 2016. During the three and nine months ended September 30, 2017 and 2016, the (increases) decreases in the fair value of the contingent payments related to the Company’s VIEs were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Parion
$
69,550

 
$
(1,100
)
 
$
63,460

 
$
(58,500
)
BioAxone
—

 
(100
)
 
(900
)
 
(850
)


The fair value of the contingent payments related to the Parion Agreement and the BioAxone Agreement as of the dates set forth in the table:

 
September 30, 2017
 
December 31, 2016
 
(in thousands)
Parion
$
—

 
$
238,800

BioAxone
18,900

 
18,000



The table below summarizes items related to the Company’s VIEs included in the Company’s condensed consolidated balance sheets as of the dates set forth in the table. Amounts as of September 30, 2017 related to BioAxone while amounts as of December 31, 2016 related to Parion and BioAxone.
 
September 30, 2017
 
December 31, 2016
 
(in thousands)
Restricted cash and cash equivalents (VIE)
$
1,803

 
$
47,762

Prepaid expenses and other current assets
42

 
6,812

Intangible assets
29,000

 
284,340

Other assets
280

 
399

Accounts payable
455

 
415

Accrued expenses
1,021

 
1,330

Other liabilities, current portion
119

 
2,137

Deferred tax liability
8,338

 
131,446

Other liabilities, excluding current portion
—

 
300

Noncontrolling interest
12,167

 
181,609



The Company has recorded the VIEs’ cash and cash equivalents as restricted cash and cash equivalents (VIE) because (i) the Company does not have any interest in or control over the VIEs’ cash and cash equivalents and (ii) the Company’s agreements with each VIE do not provide for the VIEs’ cash and cash equivalents to be used for the development of the assets that the Company licensed from the applicable VIE. Assets recorded as a result of consolidating the Company’s VIEs’ financial condition into the Company’s balance sheets do not represent additional assets that could be used to satisfy claims against the Company’s general assets.
Other Collaborations
The Company has entered into various agreements pursuant to which it collaborates with third parties, including inlicensing and outlicensing arrangements. Although the Company does not consider any of these arrangements to be material, the most notable of these arrangements are described below.

Moderna Therapeutics, Inc.
In July 2016, the Company entered into a strategic collaboration and licensing agreement (the “Moderna Agreement”) with Moderna Therapeutics, Inc. (“Moderna”) pursuant to which the parties are seeking to identify and develop messenger Ribonucleic Acid (“mRNA”) Therapeutics for the treatment of CF. In connection with the Moderna Agreement, in the third quarter of 2016, the Company made an upfront payment to Moderna of $20.0 million and a $20.0 million cost-method investment in Moderna pursuant to a convertible promissory note that converted into preferred stock in August 2016. Moderna has the potential to receive future development and regulatory milestones of up to $275.0 million, including $220.0 million in approval and reimbursement milestones, as well as tiered royalty payments on future sales.
Under the terms of the Moderna Agreement, Moderna will lead discovery efforts and the Company will lead all preclinical, development and commercialization activities associated with the advancement of mRNA Therapeutics that result from this collaboration and will fund all expenses related to the collaboration.
The Company may terminate the Moderna Agreement by providing advance notice to Moderna, with the required length of notice dependent on whether any product developed under the Moderna Agreement has received marketing approval. The Moderna Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the Moderna Agreement will continue in effect until the expiration of the Company’s payment obligations under the Moderna Agreement.

The Company evaluates the carrying value of its $20.0 million cost-method investment in Moderna, which is not a publicly traded company, for impairment on a quarterly basis and has not recorded any adjustments to the carrying value of its investment to date.
Janssen Pharmaceuticals, Inc.
In June 2014, the Company entered into an agreement (the “Janssen Agreement”) with Janssen Pharmaceuticals, Inc. (“Janssen Inc.”), which was amended in October 2014 to clarify certain roles and responsibilities of the parties.

Pursuant to the Janssen Agreement, Janssen Inc. has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including JNJ-3872 (formerly VX-787). The Company received non-refundable payments of $35.0 million from Janssen Inc. in 2014, which were recorded as collaborative revenue. The Company has the potential to receive development, regulatory and commercial milestone payments as well as royalties on future product sales, if any. Janssen Inc. may terminate the Janssen Agreement, subject to certain exceptions, upon six months’ notice.
Janssen Inc. is responsible for costs related to the development and commercialization of the compounds. During the three and nine months ended September 30, 2017 the Company recorded reimbursement for these development activities of zero and $1.8 million, respectively. During the three and nine months ended September 30, 2016 the Company recorded reimbursement for these development activities of $2.8 million and $10.6 million, respectively. The reimbursements are recorded as a reduction to development expense in the Company’s condensed consolidated statements of operations primarily due to the fact that Janssen Inc. directs the activities and selects the suppliers associated with these activities.
Asset Acquisition
Concert Pharmaceuticals
In July 2017, the Company completed the acquisition of certain CF assets including VX-561 (formerly CTP-656) from Concert Pharmaceuticals Inc. (“Concert”) pursuant to an asset purchase agreement that was entered into in March 2017 (the “Concert Agreement”). VX-561 is an investigational CFTR potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of CF. As part of the Concert Agreement, Vertex paid Concert $160.0 million in cash for all worldwide development and commercialization rights to VX-561. If VX-561 is approved as part of a combination regimen to treat CF, Concert could receive up to an additional $90.0 million in milestones based on regulatory approval in the U.S. and reimbursement in the UK, Germany or France. The Company determined that substantially all of the fair value of the Concert Agreement was attributable to a single in-process research and development asset, VX-561, which did not constitute a business. The Company cannot conclude that there is any alternative future use for the acquired in-process research and development asset. Thus, the Company recorded the $160.0 million upfront payment as a research and development expense in the three and nine months ended September 30, 2017. The total purchase price for the transaction was $165.1 million including $5.1 million of transaction costs that were recorded as sales, general and administrative expenses. If the Company achieves one or more of the $90.0 million of regulatory approval and reimbursement milestones, the Company will record the value of the milestone as an intangible asset and will begin amortizing the asset in cost of product revenues in the period that the relevant milestone is achieved.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings Per Share
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Earnings Per Share
Earnings Per Share
Basic net income (loss) per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net income (loss) per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
The following table sets forth the computation of basic and diluted net income (loss) per share for the periods ended:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands, except per share amounts)
Basic net income (loss) attributable to Vertex per common share calculation:
 
 
 
 
 
 
 
Net income (loss) attributable to Vertex common shareholders
$
(102,952
)
 
$
(38,841
)
 
$
162,800

 
$
(144,997
)
Less: Undistributed earnings allocated to participating securities
—

 
—

 
(203
)
 
—

Net income (loss) attributable to Vertex common shareholders—basic
$
(102,952
)
 
$
(38,841
)
 
$
162,597

 
$
(144,997
)
 
 
 
 
 
 
 
 
Basic weighted-average common shares outstanding
250,268

 
244,920

 
247,963

 
244,529

Basic net income (loss) attributable to Vertex per common share
$
(0.41
)
 
$
(0.16
)
 
$
0.66

 
$
(0.59
)
 
 
 
 
 
 
 
 
Diluted net income (loss) attributable to Vertex per common share calculation:
 
 
 
 
 
 
 
Net income (loss) attributable to Vertex common shareholders
$
(102,952
)
 
$
(38,841
)
 
$
162,800

 
$
(144,997
)
Less: Undistributed earnings allocated to participating securities
—

 
—

 
(200
)
 
—

Net income (loss) attributable to Vertex common shareholders—diluted
$
(102,952
)
 
$
(38,841
)
 
$
162,600

 
$
(144,997
)
 
 
 
 
 
 
 
 
Weighted-average shares used to compute basic net income (loss) per common share
250,268

 
244,920

 
247,963

 
244,529

Effect of potentially dilutive securities:
 
 
 
 
 
 
 
Stock options
—

 
—

 
2,700

 
—

Restricted stock and restricted stock units
—

 
—

 
1,204

 
—

Other
—

 
—

 
228

 
—

Weighted-average shares used to compute diluted net income (loss) per common share
250,268

 
244,920

 
252,095

 
244,529

Diluted net income (loss) attributable to Vertex per common share
$
(0.41
)
 
$
(0.16
)
 
$
0.64

 
$
(0.59
)

The Company did not include the securities in the following table in the computation of the dilutive net income (loss) per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Stock options
10,278

 
12,947

 
3,904

 
12,947

Unvested restricted stock and restricted stock units
4,241

 
3,624

 
281

 
3,624
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements
 9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of September 30, 2017, the Company’s investments were primarily in money market funds, government-sponsored enterprise securities, corporate equity securities, corporate debt securities and commercial paper. Additionally, the Company utilizes foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on its condensed consolidated statement of operations.
As of September 30, 2017, all of the Company’s financial assets and liabilities that were subject to fair value measurements were valued using observable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, government-sponsored enterprise securities and corporate equity securities. The Company’s financial assets and liabilities valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consisted of investments in highly-rated investment-grade corporations and foreign currency forward contracts with highly reputable and creditworthy counterparties.
.
The following table sets forth the Company’s financial assets (excluding VIE cash and cash equivalents, which are recorded as Restricted cash and cash equivalents (VIE)) and liabilities subject to fair value measurements:
 
Fair Value Measurements as of September 30, 2017
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
466,702

 
$
466,702

 
$
—

 
$
—

Government-sponsored enterprise securities
14,979

 
14,979

 
—

 
—

Corporate debt securities
4,488

 
—

 
4,488

 
—

Commercial paper
14,608

 
—

 
14,608

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
56,944

 
56,944

 
—

 
—

Corporate debt securities
295,171

 
—

 
295,171

 
—

Commercial paper
75,167

 
—

 
75,167

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
42

 
—

 
42

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
8

 
—

 
8

 
—

Total financial assets
$
928,109


$
538,625

 
$
389,484

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(13,897
)
 
$
—

 
$
(13,897
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(977
)
 
—

 
(977
)
 
—

Total financial liabilities
$
(14,874
)
 
$
—

 
$
(14,874
)
 
$
—

 
Fair Value Measurements as of December 31, 2016
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
280,560

 
$
280,560

 
$
—

 
$
—

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
15,508

 
15,508

 
—

 
—

Corporate equity securities
64,560

 
64,560

 
—

 
—

Commercial paper
59,404

 
—

 
59,404

 
—

Corporate debt securities
111,140

 
—

 
111,140

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
14,407

 
—

 
14,407

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
1,186

 
$
—

 
1,186

 
$
—

Total financial assets
$
546,765

 
$
360,628

 
$
186,137

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(144
)
 
$
—

 
$
(144
)
 
$
—

Total financial liabilities
$
(144
)
 
$
—

 
$
(144
)
 
$
—


The Company’s VIE invested in cash equivalents consisting of money market funds of $1.5 million as of September 30, 2017, which are valued based on Level 1 inputs. These cash equivalents are not included in the table above. The Company’s noncontrolling interest related to the Company’s VIE includes the fair value of the contingent payments, which consist of milestone, royalty and option payments, which are valued based on Level 3 inputs. Please refer to Note C, “Collaborative Arrangements and Acquisitions,” for further information.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Marketable Securities
 9 Months Ended
Sep. 30, 2017
Cash and Cash Equivalents [Abstract]  
Marketable Securities
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of September 30, 2017
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
1,350,891

 
$
—

 
$
—

 
$
1,350,891

Government-sponsored enterprise securities
14,979

 
—

 
—

 
14,979

Commercial paper
14,610

 
—

 
(2
)
 
14,608

Corporate debt securities
4,488

 
—

 
—

 
4,488

Total cash and cash equivalents
$
1,384,968

 
$
—

 
$
(2
)
 
$
1,384,966

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
43,213

 
13,731

 
—

 
56,944

Commercial paper (matures within 1 year)
75,186

 
1

 
(20
)
 
75,167

Corporate debt securities (matures within 1 year)
235,679

 
8

 
(106
)
 
235,581

Corporate debt securities (matures after 1 year)
59,651

 
—

 
(61
)
 
59,590

Total marketable securities
$
413,729

 
$
13,740

 
$
(187
)
 
$
427,282

Total cash, cash equivalents and marketable securities
$
1,798,697

 
$
13,740

 
$
(189
)
 
$
1,812,248

 
 
 
 
 
 
 
 
As of December 31, 2016
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
1,183,945

 
$
—

 
$
—

 
$
1,183,945

Total cash and cash equivalents
$
1,183,945

 
$
—

 
$
—

 
$
1,183,945

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (matures within 1 year)
$
15,506

 
$
2

 
$
—

 
$
15,508

Corporate equity securities
43,213

 
21,347

 
—

 
64,560

Commercial paper (matures within 1 year)
59,331

 
73

 
—

 
59,404

Corporate debt securities (matures within 1 year)
111,225

 
—

 
(85
)
 
111,140

Total marketable securities
$
229,275

 
$
21,422

 
$
(85
)
 
$
250,612

Total cash, cash equivalents and marketable securities
$
1,413,220

 
$
21,422

 
$
(85
)
 
$
1,434,557


The Company has a limited number of marketable securities in insignificant loss positions as of September 30, 2017, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs of the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in the three and nine months ended September 30, 2017 and 2016.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accumulated Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss)
A summary of the Company’s changes in accumulated other comprehensive income (loss) by component is shown below:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains (Losses) on Marketable Securities, Net of Tax
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts, Net of Tax
 
Total
 
(in thousands)
Balance at December 31, 2016
$
(7,862
)
 
$
17,521

 
$
11,514

 
$
21,173

Other comprehensive loss before reclassifications
(11,137
)
 
(7,786
)
 
(25,981
)
 
(44,904
)
Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
(1,398
)
 
(1,398
)
Net current period other comprehensive (loss) income
$
(11,137
)
 
$
(7,786
)
 
$
(27,379
)
 
$
(46,302
)
Balance at September 30, 2017
$
(18,999
)
 
$
9,735

 
$
(15,865
)
 
$
(25,129
)

 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains on Marketable Securities
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts, Net of Tax
 
Total
 
(in thousands)
Balance at December 31, 2015
$
(2,080
)
 
$
126

 
$
3,778

 
$
1,824

Other comprehensive (loss) income before reclassifications
(7,709
)
 
104

 
6,715

 
(890
)
Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
(4,779
)
 
(4,779
)
Net current period other comprehensive (loss) income
$
(7,709
)
 
$
104

 
$
1,936

 
$
(5,669
)
Balance at September 30, 2016
$
(9,789
)
 
$
230

 
$
5,714

 
$
(3,845
)
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Hedging
 9 Months Ended
Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging
Hedging
The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from one to eighteen months.
The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company’s risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company determines that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of September 30, 2017, all hedges were determined to be highly effective and the Company had not recorded any ineffectiveness related to the hedging program.
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:
 
As of September 30, 2017
 
As of December 31, 2016
Foreign Currency
(in thousands)
Euro
$
234,477

 
$
164,368

British pound sterling
77,387

 
65,237

Australian dollar
31,283

 
23,776

Total foreign currency forward contracts
$
343,147

 
$
253,381


The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company’s condensed consolidated balance sheets:
As of September 30, 2017
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
42

 
Other liabilities, current portion
 
$
(13,897
)
Other assets
 
8

 
Other liabilities, excluding current portion
 
(977
)
Total assets
 
$
50

 
Total liabilities
 
$
(14,874
)
As of December 31, 2016
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
14,407

 
Other liabilities, current portion
 
$
(144
)
Other assets
 
1,186

 
Other liabilities, excluding current portion
 
—

Total assets
 
$
15,593

 
Total liabilities
 
$
(144
)
As of September 30, 2017, the Company expects amounts recorded in prepaid and other currents assets and other liabilities, current portion to be reclassed to earnings within twelve months.
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s condensed consolidated balance sheets:
 
As of September 30, 2017
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
50

 
$
—

 
$
50

 
$
(50
)
 
$
—

Total liabilities
$
(14,874
)
 
$
—

 
$
(14,874
)
 
$
50

 
$
(14,824
)
 
As of December 31, 2016
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
15,593

 
$
—

 
$
15,593

 
$
(144
)
 
$
15,449

Total liabilities
$
(144
)
 
$
—

 
$
(144
)
 
$
144

 
$
—


The Company also enters into foreign exchange forward contracts with contractual maturities of less than one month designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities including intercompany balances. The Company recognized losses of $4.1 million and $13.0 million, recorded in other income (expense), net, for the three and nine months ended September 30, 2017, respectively, related to foreign exchange contracts, which are not designated as hedging instruments under GAAP. The Company recognized a loss of  $1.2 million and a gain of $0.5 million, for the three and nine months ended September 30, 2016, respectively, related to foreign exchange contracts not designated as hedging instruments.

As of September 30, 2017, the notional amount of foreign exchange contracts where hedge accounting under GAAP is not applied was $113.8 million. The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts not designated for hedge accounting included on the Company’s condensed consolidated balance sheets:
 
As of September 30, 2017
 
As of December 31, 2016
 
(in thousands)
Prepaid expenses and other current assets
$
1,709

 
$
660
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories
 9 Months Ended
Sep. 30, 2017
Inventory Disclosure [Abstract]  
Inventories
Inventories
Inventories consisted of the following:
 
As of September 30, 2017
 
As of December 31, 2016
 
(in thousands)
Raw materials
$
12,678

 
$
6,348

Work-in-process
67,826

 
56,672

Finished goods
17,688

 
14,584

Total
$
98,192

 
$
77,604


Based on its evaluation of, among other factors, information regarding tezacaftor's safety and efficacy, the Company has capitalized $9.6 million of inventory costs for tezacaftor manufactured in preparation for its potential product launch as of September 30, 2017. In periods prior, the Company expensed costs associated with tezacaftor’s raw materials and work-in-process as a development expense. The Company submitted a New Drug Application to the United States Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for tezacaftor in combination with ivacaftor. The Company plans to continue to monitor the status of the tezacaftor regulatory process and the other factors used to determine whether or not to capitalize the tezacaftor inventory and, if there are significant negative developments regarding tezacaftor, the Company could be required to impair previously capitalized costs.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Goodwill
 9 Months Ended
Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill
Intangible Assets and Goodwill
Intangible Assets
As of September 30, 2017 and December 31, 2016, in-process research and development intangible assets of $29.0 million and $284.3 million, respectively, were recorded on the Company’s condensed consolidated balance sheet. In 2015, the Company recorded an in-process research development intangible asset of $255.3 million related to Parion’s pulmonary ENaC platform, including the intellectual property related to VX-371 and VX-551, that are licensed by Parion to the Company. In 2014, the Company recorded an in-process research development intangible asset of $29.0 million related to VX-210 that is licensed by BioAxone to the Company.
In connection with its preparation of its financial statements for the three and nine months ended September 30, 2017, the Company determined that there were indicators that the value of the pulmonary ENaC platform intangible asset had become impaired. The Company determined that the fair value of the intangible asset had decreased significantly based on data received in September 2017 from a Phase 2 clinical trial of VX-371 that did not meet its primary efficacy endpoint. Based on this data, the Company evaluated the fair value of Parion’s pulmonary ENaC platform using the discounted cash flow approach from the perspective of a market participant and determined that the fair value of the intangible asset was zero as of September 30, 2017. The discounted cash flow model pertaining to the impairment of the pulmonary ENaC platform includes (i) assumptions regarding the probability of obtaining marketing approval for the drug candidate, (ii) estimates regarding the timing of and the expected costs to develop and commercialize the drug candidate, (iii) estimates of future cash flows from potential product sales with respect to the drug candidate and (iv) appropriate discount and tax rates. The Company recorded a $255.3 million impairment charge and a benefit from income taxes of $97.7 million in the three and nine months ended September 30, 2017 attributable to noncontrolling interest.
Goodwill
As of September 30, 2017 and December 31, 2016, goodwill of $50.4 million was recorded on the Company’s condensed consolidated balance sheet.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Long-term Obligations
 9 Months Ended
Sep. 30, 2017
Long-term Debt and Capital Lease Obligations [Abstract]  
Long-term Obligations
Long-term Obligations
Fan Pier Leases
In 2011, the Company entered into two lease agreements, pursuant to which the Company leases approximately 1.1 million square feet of office and laboratory space in two buildings (the “Fan Pier Buildings”) at Fan Pier in Boston, Massachusetts (the “Fan Pier Leases”). The Company commenced lease payments in December 2013, and will make lease payments pursuant to the Fan Pier Leases through December 2028. The Company has an option to extend the term of the Fan Pier Leases for an additional ten years.
Because the Company was involved in the construction project, the Company was deemed for accounting purposes to be the owner of the Fan Pier Buildings during the construction period and recorded project construction costs incurred by the landlord. Upon completion of the Fan Pier Buildings, the Company evaluated the Fan Pier Leases and determined that the Fan Pier Leases did not meet the criteria for “sale-leaseback” treatment. Accordingly, the Company began depreciating the asset and incurring interest expense related to the financing obligation in 2013. The Company bifurcates its lease payments pursuant to the Fan Pier Leases into (i) a portion that is allocated to the Buildings and (ii) a portion that is allocated to the land on which the Fan Pier Buildings were constructed. The portion of the lease obligations allocated to the land is treated as an operating lease that commenced in 2011.
Property and equipment, net, included $479.0 million and $489.0 million as of September 30, 2017 and December 31, 2016, respectively, related to construction costs for the Fan Pier Buildings. The carrying value of the Company’s lease agreement liability for the Fan Pier Buildings was $472.2 million and $472.6 million as of September 30, 2017 and December 31, 2016, respectively.
San Diego Lease
On December 2, 2015, the Company entered into a lease agreement for 3215 Merryfield Row, San Diego, California with ARE-SD Region No. 23, LLC (the “San Diego Building”). Pursuant to this agreement, the Company agreed to lease approximately 170,000 square feet of office and laboratory space in a building to be built in San Diego, California. The lease will commence upon completion of the building, scheduled for the first half of 2018, and will extend for 16 years from the commencement date. Pursuant to the lease agreement, during the initial 16-year term, the Company will pay an average of approximately $10.2 million per year in aggregate rent, exclusive of operating expenses. The Company has the option to extend the lease term for up to two additional five-year terms.

Because the Company is involved in the construction project, the Company is deemed for accounting purposes to be the owner of the San Diego Building during the construction period and recorded project construction costs incurred by the landlord. The Company bifurcates its lease payments pursuant to the San Diego Lease into (i) a portion that is allocated to the San Diego Building and (ii) a portion that is allocated to the land on which the San Diego Building was constructed. Although the Company will not begin making lease payments pursuant to the San Diego Lease until the commencement date, the portion of the lease obligation allocated to the land is treated for accounting purposes as an operating lease that commenced in the fourth quarter of 2016. Upon completion of the San Diego Building, the Company will evaluate the San Diego Lease and determine if the San Diego Lease meets the criteria for “sale-leaseback” treatment. If the San Diego Lease meets the “sale-leaseback” criteria, the Company will remove the asset and the related liability from its consolidated balance sheet and treat the San Diego Lease as either an operating or a capital lease based on the Company’s assessment of the accounting guidance. The Company expects that upon completion of construction of the San Diego Building the San Diego Lease will not meet the “sale-leaseback” criteria. If the San Diego Lease does not meet “sale-leaseback” criteria, the Company will treat the San Diego Lease as a financing obligation and will depreciate the asset over its estimated useful life.

Property and equipment, net, included $73.9 million and $15.0 million as of September 30, 2017 and December 31, 2016, respectively, related to construction costs for the San Diego Building. The carrying value of the Company’s lease agreement liability for the San Diego Building was $71.8 million and $12.6 million as of September 30, 2017 and December 31, 2016, respectively.

Revolving Credit Facility
In October 2016, the Company entered into a Credit Agreement (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein. The Credit Agreement provides for a $500.0 million revolving facility, $300.0 million of which was drawn at closing (the “Loans”) and was repaid in February 2017. The Credit Agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the borrowing capacity under the Credit Agreement be increased by an additional $300.0 million. The Credit Agreement matures on October 13, 2021.
The proceeds of the borrowing under the Credit Agreement were used primarily to repay the Company’s then outstanding indebtedness under the Macquarie Loan (as defined below). The Loans will bear interest, at the Company’s option, at either a base rate or a Eurodollar rate, in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.75% to 1.50% and the applicable margins on Eurodollar loans range from 1.75% to 2.50%, in each case based on the Company’s consolidated leverage ratio (the ratio of the Company’s total consolidated debt to the Company’s trailing twelve-month EBITDA).
The Loans are guaranteed by certain of the Company’s domestic subsidiaries and secured by substantially all of the Company’s assets and the assets of the Company’s domestic subsidiaries (excluding intellectual property, owned and leased real property and certain other excluded property) and by the equity interests of the Company’s subsidiaries, subject to certain exceptions. Under the terms of the Credit Agreement, the Company must maintain, subject to certain limited exceptions, a consolidated leverage ratio of 3.00 to 1.00 and consolidated EBITDA of at least $200.0 million, in each case to be measured on a quarterly basis.
The Credit Agreement contains customary representations and warranties and usual and customary affirmative and negative covenants. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Term Loan
In July 2014, the Company entered into a credit agreement with the lenders party thereto, and Macquarie US Trading LLC (“Macquarie”), as administrative agent. The credit agreement provided for a $300.0 million senior secured term loan (the “Macquarie Loan”). On October 13, 2016, the Company terminated and repaid all outstanding obligations under the Macquarie Loan.
The Macquarie Loan initially bore interest at a rate of 7.2% per annum, which was reduced to 6.2% per annum based on the FDA’s approval of ORKAMBI. The Term Loan bore interest at a rate of LIBOR plus 5.0% per annum during the third year of the term.
The Company incurred $5.3 million in fees paid to Macquarie that were recorded as a discount on the Macquarie Loan and were recorded as interest expense using the effective interest method over the term of the loan in the Company’s condensed consolidated statements of operations.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stock-based Compensation Expense
 9 Months Ended
Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-based Compensation Expense
Stock-based Compensation Expense
During the three and nine months ended September 30, 2017 and 2016, the Company recognized the following stock-based compensation expense:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
 
 
Stock options
$
25,969

 
$
28,773

 
$
80,865

 
$
86,859

Restricted stock and restricted stock units
46,737

 
30,966

 
131,388

 
88,107

ESPP share issuances
2,428

 
2,425

 
6,738

 
6,385

Less stock-based compensation expense capitalized to inventories
(1,364
)
 
(955
)
 
(3,657
)
 
(2,728
)
Total stock-based compensation included in costs and expenses
$
73,770

 
$
61,209

 
$
215,334

 
$
178,623

 
 
 
 
 
 
 


Stock-based compensation expense by line item:
 
 
 
 
 
 
 
Research and development expenses
$
46,186

 
$
39,980

 
$
134,855

 
$
115,068

Sales, general and administrative expenses
27,584

 
21,229

 
80,479

 
63,555

Total stock-based compensation included in costs and expenses
$
73,770

 
$
61,209

 
$
215,334

 
$
178,623


The following table sets forth the Company’s unrecognized stock-based compensation expense by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of September 30, 2017
 
Unrecognized Expense
 
Weighted-average
Recognition Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
175,298

 
2.60
Restricted stock and restricted stock units
$
289,008

 
2.64
ESPP share issuances
$
2,636

 
0.46

The following table summarizes information about stock options outstanding and exercisable at September 30, 2017:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$18.93–$20.00
 
128

 
0.35
 
$
18.93

 
128

 
$
18.93

$20.01–$40.00
 
834

 
2.21
 
$
34.51

 
834

 
$
34.51

$40.01–$60.00
 
877

 
4.83
 
$
49.17

 
877

 
$
49.17

$60.01–$80.00
 
821

 
6.46
 
$
75.62

 
649

 
$
75.44

$80.01–$100.00
 
4,587

 
8.33
 
$
89.37

 
1,397

 
$
89.47

$100.01–$120.00
 
1,137

 
7.36
 
$
109.34

 
586

 
$
109.24

$120.01–$140.00
 
1,260

 
7.88
 
$
130.24

 
688

 
$
129.86

$140.01–$160.00
 
—

 
0.00
 
$
—

 
—

 
$
—

$160.01–$163.74
 
634

 
9.80
 
$
162.94

 
3

 
$
162.94

Total
 
10,278

 
7.22
 
$
91.28

 
5,162

 
$
77.92
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Other Arrangements
 9 Months Ended
Sep. 30, 2017
Other Income and Expenses [Abstract]  
Other Arrangements
Other Arrangements
Sale of HIV Protease Inhibitor Royalty Stream
In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of $160.0 million. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline plc. As of September 30, 2017, the Company had $8.0 million in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
 9 Months Ended
Sep. 30, 2017
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
The Company is subject to United States federal, state, and foreign income taxes. For the three and nine months ended September 30, 2017, the Company recorded a benefit from income taxes of $125.9 million and $117.6 million, respectively, which included a benefit of $120.2 million and $111.7 million, respectively, related to the Company’s VIEs’ income tax provision. The VIEs’ benefit from income taxes during the the three and nine months ended September 30, 2017 related primarily to the impairment of Parion’s pulmonary ENaC platform and decrease in the fair value of the contingent payments payable by the Company to Parion. The Company has no liability for taxes payable by the Company’s VIEs and the income tax provision and related liability have been allocated to noncontrolling interest. For the three and nine months ended September 30, 2016, the Company recorded a provision for income taxes of $0.5 million and $24.1 million, respectively, which included a benefit of $0.5 million and a provision of $20.1 million, respectively, related to the Company’s VIEs’ income tax provision.
As of September 30, 2017 and December 31, 2016, the Company did not have unrecognized tax benefits. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. As of September 30, 2017, no interest and penalties have been accrued. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of September 30, 2017 and December 31, 2016.
The Company continues to maintain a valuation allowance on the majority of its net operating losses and other deferred tax assets because it has a history of cumulative losses.  Accordingly, the Company has not reported any tax benefit relating to the remaining net operating loss carryforwards (NOLs) and income tax credit carryforwards that will be utilized in future periods in these jurisdictions.  The Company’s U.S. federal net operating loss carryforwards totaled approximately $4.1 billion as of December 31, 2016. On a quarterly basis, the Company reassesses the valuation allowance on its deferred income tax assets weighing positive and negative evidence to assess the recoverability of the deferred tax assets. Based on the Company’s recent financial performance and its future projections, it could record a reversal of all, or a portion of the valuation allowance associated with U.S. deferred tax assets in future periods.  However, any such change is subject to actual performance and other considerations that may present positive or negative evidence at the time of the assessment. The Company’s total deferred tax asset balance subject to the valuation allowance was approximately $1.7 billion at December 31, 2016.
As described in Note A, “Basis of Presentation and Accounting Policies”, the Company adopted amended guidance, during the nine month period ended September 30, 2017. The amended guidance eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in additional paid-in capital and requires excess tax benefits and tax deficiencies to be recorded in the condensed consolidated statement of operations when the awards vest or are settled. Amendments related to accounting for excess tax benefits have been adopted prospectively, resulting in a tax benefit of $31.4 million and $62.2 million for the three and nine months ended September 30, 2017, respectively. In connection with the adoption of this new standard, the Company recorded a cumulative-effect adjustment of $410.8 million as of January 1, 2017 to accumulated deficit and deferred tax assets, with an equal offsetting adjustment to the Company’s valuation allowance. In addition, the Company has recorded $9.4 million related to the impact from adoption of the provisions related to forfeiture rates to accumulated deficit. This change also increased the Company’s deferred tax assets by $3.4 million that is offset by an increase to the valuation allowance in the same amount.

The Company files United States federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction for years before 2011, except where the Company has net operating losses or tax credit carryforwards that originate before 2011. The Company currently is under examination by the Canada Revenue Agency for the years ending December 31, 2011 through December 31, 2013. No adjustments have been reported.
At September 30, 2017, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to United States federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring Liabilities
 9 Months Ended
Sep. 30, 2017
Restructuring and Related Activities [Abstract]  
Restructuring Liabilities
Restructuring Liabilities
Research and Development Restructuring
In February 2017, the Company decided to consolidate its research activities into its Boston, Milton Park and San Diego locations and closed its research site in Canada affecting approximately 70 positions. The Company has incurred aggregate restructuring charges of approximately $12.3 million in the nine months ended September 30, 2017. As of September 30, 2017, the restructuring liability primarily relates to laboratory and office space for the research site in Canada that terminates in October 2018. The Company does not anticipate any significant additional charges related to this restructuring event in the future.
The restructuring charge and other activities recorded during the the three and nine months ended September 30, 2017 and the related liability balance as of September 30, 2017 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2017
 
(in thousands)
Liability, beginning of the period
$
3,507

 
$
—

Restructuring (credits) expense
(125
)
 
12,315

Cash payments
(750
)
 
(7,869
)
Asset impairments and other non-cash items
—

 
(1,814
)
Liability, end of the period
$
2,632

 
$
2,632


2003 Kendall Restructuring
In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a 15-year lease that terminates in April 2018. The Company has not used more than 50% of this space since it adopted the plan to restructure its operations in 2003. This unused laboratory and office space currently is subleased to third parties.
The activities related to the restructuring liability for the three and nine months ended September 30, 2017 and 2016 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Liability, beginning of the period
$
1,990

 
$
6,388

 
$
4,328

 
$
7,944

Restructuring expense
227

 
30

 
1,054

 
222

Cash payments
(4,003
)
 
(5,340
)
 
(12,962
)
 
(13,104
)
Cash received from subleases
2,732

 
2,866

 
8,526

 
8,882

Liability, end of the period
$
946

 
$
3,944

 
$
946

 
$
3,944


Fan Pier Move Restructuring
In connection with the relocation of its Massachusetts operations to Fan Pier in Boston, Massachusetts, which commenced in 2013, the Company is incurring restructuring charges related to its remaining lease obligations at its facilities in Cambridge, Massachusetts. The majority of these restructuring charges were recorded in the third quarter of 2014 upon decommissioning three facilities in Cambridge. During 2015, the Company terminated two of these lease agreements resulting in a credit to restructuring expense equal to the difference between the Company’s estimated future cash flows related to its lease obligations for these facilities and the termination payment paid to the Company’s landlord on the effective date of the termination. The third major facility included in this restructuring activity is 120,000 square feet of the Kendall Square Facility that the Company continued to use for its operations following its 2003 Kendall Restructuring. The rentable square footage in this portion of the Kendall Square Facility was subleased to a third party in February 2015. The Company will continue to incur charges through April 2018 related to the difference between the Company’s estimated future cash flows related to this portion of the Kendall Square Facility, which include an estimate for sublease income to be received from the Company’s sublessee and its actual cash flows. The Company discounted the estimated cash flows related to this restructuring activity at a discount rate of 9%.
The activities related to the restructuring liability for the three and nine months ended September 30, 2017 and 2016 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Liability, beginning of the period
$
1,521

 
$
4,863

 
$
3,626

 
$
5,964

Restructuring expense
235

 
90

 
490

 
472

Cash payments
(3,262
)
 
(4,199
)
 
(10,578
)
 
(10,451
)
Cash received from subleases
2,279

 
2,539

 
7,235

 
7,308

Liability, end of the period
$
773

 
$
3,293

 
$
773

 
$
3,293


Other Restructuring Activities
The Company has engaged in several other restructuring activities that are unrelated to its Research and Development Restructuring, 2003 Kendall Restructuring and Fan Pier Move Restructuring. The most significant activity commenced in October 2013 when the Company adopted a restructuring plan that included (i) a workforce reduction primarily related to the commercial support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection neared approval and (ii) the write-off of certain assets. This action resulted from the Company’s decision to focus its investment on future opportunities in CF and other research and development programs.
The remaining restructuring activities were completed in 2016. As such, there was no outstanding liability as of September 30, 2017. The activities related to the Company’s other restructuring liabilities for the three and nine months ended September 30, 2016 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2016
 
(in thousands)
Liability, beginning of the period
$
1,233

 
$
1,450

Restructuring expense
(112
)
 
344

Cash payments
(1,121
)
 
(1,794
)
Liability, end of the period
$
—

 
$
—
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
Guaranties and Indemnifications
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of September 30, 2017 or December 31, 2016.
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Basis of Presentation and Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals. As of September 30, 2017, the Company deconsolidated Parion Sciences, Inc. (“Parion”), a VIE the Company has consolidated since 2015. The Company's consolidated balance sheet as of September 30, 2017 excludes Parion. Please refer to Note C, “Collaborative Arrangements and Acquisitions” for further information regarding the deconsolidation of Parion.

Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2017 and 2016.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2016, which are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 that was filed with the Securities and Exchange Commission (the “SEC”) on February 23, 2017 (the “2016 Annual Report on Form 10-K”).
Use of Estimates and Summary of Significant Accounting Policies
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation and deconsolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In 2014, the Financial Accounting Standards Board (“FASB”) issued new guidance applicable to revenue recognition that will be effective January 1, 2018. Early adoption was permitted for the year-ending December 31, 2017. The new guidance applies a more principles based approach to recognizing revenue. Under the new guidance, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new guidance must be adopted using either a modified retrospective approach or a full retrospective approach for all periods presented. Under the modified retrospective method, the cumulative effect of applying the standard would be recognized at the date of initial application within retained earnings. Under the full retrospective approach, the standard would be applied to each prior reporting period presented. Upon adoption, the Company will use the modified retrospective method. The Company continues to evaluate the new guidance and the effect the adoption will have on the condensed consolidated financial statements.  The Company’s project team is finalizing its review of existing customer contracts and current accounting policies to identify and assess the potential differences that would result from applying the requirements of the new standard. Based on the Company’s assessment performed to date, the new revenue recognition guidance could impact the Company’s accounting for product shipments to certain countries through early access programs, including the French early access programs, whereby the associated product has received regulatory approval but the price is not fixed or determinable based on the status of ongoing pricing discussions, and could impact the Company’s accounting for certain reimbursement agreements that the Company plans to negotiate in the fourth quarter of 2017. As the Company completes its assessment, it is implementing appropriate changes to its controls to support revenue recognition and additional revenue-related disclosures under the new standard.
In 2016, the FASB issued amended guidance applicable to share-based compensation to employees that simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The amended guidance became effective for the Company during the first quarter of 2017. The amended guidance eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in additional paid-in capital. This created approximately $410.8 million of deferred tax asset (“DTA”) relating to federal and state net operating losses (“NOLs”) that are fully reserved by an equal increase in valuation allowance. The Company recorded DTAs of approximately $404.7 million relating to Federal NOLs and approximately $6.1 million relating to State NOLs, both of which are offset by a full valuation allowance. Upon adoption, the Company also elected to change its accounting policy to account for forfeitures of options and awards as they occur. The change was applied on a modified retrospective basis with a cumulative effect adjustment to the Company’s accumulated deficit of $9.4 million, which increased the accumulated deficit as of January 1, 2017. This change also resulted in an increase to the DTA of $3.4 million, which is offset by a full valuation allowance. As a result, there was no cumulative-effect adjustment to accumulated deficit. The provisions related to the recognition of excess tax benefits in the income statement and classification in the statement of cash flows were adopted prospectively, and as such, the prior periods were not retrospectively adjusted.
In 2016, the FASB issued amended guidance related to the recording of financial assets and financial liabilities. Under the amended guidance, equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) are to be measured at fair value with changes in fair value recognized in net income. However, an entity has the option to either measure equity investments without readily determinable fair values at fair value or at cost adjusted for changes in observable prices minus impairment. Changes in measurement under either alternative will be recognized in net income. The amended guidance is effective for the year ending December 31, 2018. Early adoption is permitted. The Company expects the implementation of this standard to have an impact on its consolidated financial statements and related disclosures, as the Company held publicly traded equity investments as of September 30, 2017 as well as equity investments accounted for under the cost method. A cumulative-effect adjustment to the balance sheet will be recorded as of the beginning of the fiscal year of adoption. The implementation of this amended guidance is expected to increase volatility in net income as the volatility currently recorded in other comprehensive income related to changes in the fair market value of available-for-sale equity investments will be reflected in net income after adoption.

In 2016, the FASB issued amended guidance applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. This guidance requires entities to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.

In 2016, the FASB issued amended guidance related to intra-entity transfers other than inventory. This guidance removes the current exception in GAAP prohibiting entities from recognizing current and deferred income tax expenses or benefits related to transfer of assets, other than inventory, within the consolidated entity. The current exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. The amended guidance is effective for the year ending December 31, 2018. Early adoption is permitted. The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.

In 2017, the FASB issued amended guidance related to business combinations. The amended guidance clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new accounting guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company early adopted this new guidance as of January 1, 2017 and will apply this new guidance to future acquisitions.

In 2017, the FASB issued amended guidance related to measurements of goodwill. The amended guidance eliminates a step from the goodwill impairment test. Under the amended guidance, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The amended guidance is effective for the year-ending December 31, 2020. Early adoption is permitted. The Company does not expect a significant effect on its condensed consolidated financial statements upon adoption of this new guidance.

In 2017, the FASB issued amended guidance related to the scope of stock option modification accounting, to reduce diversity in practice and provide clarity regarding existing guidance. The new accounting guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company does not expect the adoption of this guidance to have a material effect on its condensed consolidated financial statements and related disclosures.

In 2017, the FASB issued amended guidance applicable to hedge accounting. The new accounting guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those periods. Early adoption is permitted. The amended guidance helps simplify certain aspects of hedge accounting and enables entities to more accurately present their risk management activities in their financial statements.  The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements.

For a discussion of other recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2016 Annual Report on Form 10-K.
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Product Revenues, Net (Tables)
 9 Months Ended
Sep. 30, 2017
Product Revenues [Abstract]  
Schedule of product revenue allowances and reserve categories
The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2017:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2016
$
2,568

 
$
81,927

 
$
3,492

 
$
1,214

 
$
89,201

Provision related to current period sales
18,776

 
118,592

 
3,603

 
12,238

 
153,209

Adjustments related to prior period sales
(188
)
 
(4,327
)
 
(13
)
 
(355
)
 
(4,883
)
Credits/payments made
(18,409
)
 
(97,393
)
 
(1,809
)
 
(10,021
)
 
(127,632
)
Balance at September 30, 2017
$
2,747

 
$
98,799

 
$
5,273

 
$
3,076

 
$
109,895
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Acquisitions (Tables)
 9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of collaborative arrangement activity net loss attributable to noncontrolling interest
An aggregate summary of net income attributable to noncontrolling interest related to the Company’s VIEs for the three and nine months ended September 30, 2017 and 2016 is as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Loss attributable to noncontrolling interest before (benefit from) provision for income taxes and changes in fair value of contingent payments
$
238,946

 
$
2,406

 
$
222,448

 
$
6,080

(Benefit from) provision for income taxes
(120,181
)
 
(510
)
 
(111,658
)
 
20,063

Decrease (increase) in fair value of contingent payments
69,550

 
(1,200
)
 
62,560

 
(59,350
)
Net loss (income) attributable to noncontrolling interest
$
188,315

 
$
696

 
$
173,350

 
$
(33,207
)
Changes in fair value of contingent payments
During the three and nine months ended September 30, 2017 and 2016, the (increases) decreases in the fair value of the contingent payments related to the Company’s VIEs were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Parion
$
69,550

 
$
(1,100
)
 
$
63,460

 
$
(58,500
)
BioAxone
—

 
(100
)
 
(900
)
 
(850
)
Schedule of fair value of contingent payments
The fair value of the contingent payments related to the Parion Agreement and the BioAxone Agreement as of the dates set forth in the table:

 
September 30, 2017
 
December 31, 2016
 
(in thousands)
Parion
$
—

 
$
238,800

BioAxone
18,900

 
18,000
Schedule of collaborative arrangement summary of items related to variable interest entities
The table below summarizes items related to the Company’s VIEs included in the Company’s condensed consolidated balance sheets as of the dates set forth in the table. Amounts as of September 30, 2017 related to BioAxone while amounts as of December 31, 2016 related to Parion and BioAxone.
 
September 30, 2017
 
December 31, 2016
 
(in thousands)
Restricted cash and cash equivalents (VIE)
$
1,803

 
$
47,762

Prepaid expenses and other current assets
42

 
6,812

Intangible assets
29,000

 
284,340

Other assets
280

 
399

Accounts payable
455

 
415

Accrued expenses
1,021

 
1,330

Other liabilities, current portion
119

 
2,137

Deferred tax liability
8,338

 
131,446

Other liabilities, excluding current portion
—

 
300

Noncontrolling interest
12,167

 
181,609
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings Per Share (Tables)
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Schedule of earnings per share, basic and diluted
The following table sets forth the computation of basic and diluted net income (loss) per share for the periods ended:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands, except per share amounts)
Basic net income (loss) attributable to Vertex per common share calculation:
 
 
 
 
 
 
 
Net income (loss) attributable to Vertex common shareholders
$
(102,952
)
 
$
(38,841
)
 
$
162,800

 
$
(144,997
)
Less: Undistributed earnings allocated to participating securities
—

 
—

 
(203
)
 
—

Net income (loss) attributable to Vertex common shareholders—basic
$
(102,952
)
 
$
(38,841
)
 
$
162,597

 
$
(144,997
)
 
 
 
 
 
 
 
 
Basic weighted-average common shares outstanding
250,268

 
244,920

 
247,963

 
244,529

Basic net income (loss) attributable to Vertex per common share
$
(0.41
)
 
$
(0.16
)
 
$
0.66

 
$
(0.59
)
 
 
 
 
 
 
 
 
Diluted net income (loss) attributable to Vertex per common share calculation:
 
 
 
 
 
 
 
Net income (loss) attributable to Vertex common shareholders
$
(102,952
)
 
$
(38,841
)
 
$
162,800

 
$
(144,997
)
Less: Undistributed earnings allocated to participating securities
—

 
—

 
(200
)
 
—

Net income (loss) attributable to Vertex common shareholders—diluted
$
(102,952
)
 
$
(38,841
)
 
$
162,600

 
$
(144,997
)
 
 
 
 
 
 
 
 
Weighted-average shares used to compute basic net income (loss) per common share
250,268

 
244,920

 
247,963

 
244,529

Effect of potentially dilutive securities:
 
 
 
 
 
 
 
Stock options
—

 
—

 
2,700

 
—

Restricted stock and restricted stock units
—

 
—

 
1,204

 
—

Other
—

 
—

 
228

 
—

Weighted-average shares used to compute diluted net income (loss) per common share
250,268

 
244,920

 
252,095

 
244,529

Diluted net income (loss) attributable to Vertex per common share
$
(0.41
)
 
$
(0.16
)
 
$
0.64

 
$
(0.59
)
Potential gross common equivalent shares
The Company did not include the securities in the following table in the computation of the dilutive net income (loss) per share attributable to Vertex common shareholders calculations because the effect would have been anti-dilutive during each period:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Stock options
10,278

 
12,947

 
3,904

 
12,947

Unvested restricted stock and restricted stock units
4,241

 
3,624

 
281

 
3,624
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Financial assets subject to fair value measurements (excluding VIE cash and cash equivalents, which are recorded as Restricted cash and cash equivalents (VIE))
The following table sets forth the Company’s financial assets (excluding VIE cash and cash equivalents, which are recorded as Restricted cash and cash equivalents (VIE)) and liabilities subject to fair value measurements:
 
Fair Value Measurements as of September 30, 2017
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
466,702

 
$
466,702

 
$
—

 
$
—

Government-sponsored enterprise securities
14,979

 
14,979

 
—

 
—

Corporate debt securities
4,488

 
—

 
4,488

 
—

Commercial paper
14,608

 
—

 
14,608

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
56,944

 
56,944

 
—

 
—

Corporate debt securities
295,171

 
—

 
295,171

 
—

Commercial paper
75,167

 
—

 
75,167

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
42

 
—

 
42

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
8

 
—

 
8

 
—

Total financial assets
$
928,109


$
538,625

 
$
389,484

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(13,897
)
 
$
—

 
$
(13,897
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(977
)
 
—

 
(977
)
 
—

Total financial liabilities
$
(14,874
)
 
$
—

 
$
(14,874
)
 
$
—

 
Fair Value Measurements as of December 31, 2016
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset position):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
280,560

 
$
280,560

 
$
—

 
$
—

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
15,508

 
15,508

 
—

 
—

Corporate equity securities
64,560

 
64,560

 
—

 
—

Commercial paper
59,404

 
—

 
59,404

 
—

Corporate debt securities
111,140

 
—

 
111,140

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
14,407

 
—

 
14,407

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
1,186

 
$
—

 
1,186

 
$
—

Total financial assets
$
546,765

 
$
360,628

 
$
186,137

 
$
—

Financial instruments carried at fair value (liability position):
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(144
)
 
$
—

 
$
(144
)
 
$
—

Total financial liabilities
$
(144
)
 
$
—

 
$
(144
)
 
$
—
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Marketable Securities (Tables)
 9 Months Ended
Sep. 30, 2017
Cash and Cash Equivalents [Abstract]  
Summary of cash, cash equivalents and marketable securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of September 30, 2017
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
1,350,891

 
$
—

 
$
—

 
$
1,350,891

Government-sponsored enterprise securities
14,979

 
—

 
—

 
14,979

Commercial paper
14,610

 
—

 
(2
)
 
14,608

Corporate debt securities
4,488

 
—

 
—

 
4,488

Total cash and cash equivalents
$
1,384,968

 
$
—

 
$
(2
)
 
$
1,384,966

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
43,213

 
13,731

 
—

 
56,944

Commercial paper (matures within 1 year)
75,186

 
1

 
(20
)
 
75,167

Corporate debt securities (matures within 1 year)
235,679

 
8

 
(106
)
 
235,581

Corporate debt securities (matures after 1 year)
59,651

 
—

 
(61
)
 
59,590

Total marketable securities
$
413,729

 
$
13,740

 
$
(187
)
 
$
427,282

Total cash, cash equivalents and marketable securities
$
1,798,697

 
$
13,740

 
$
(189
)
 
$
1,812,248

 
 
 
 
 
 
 
 
As of December 31, 2016
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
1,183,945

 
$
—

 
$
—

 
$
1,183,945

Total cash and cash equivalents
$
1,183,945

 
$
—

 
$
—

 
$
1,183,945

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (matures within 1 year)
$
15,506

 
$
2

 
$
—

 
$
15,508

Corporate equity securities
43,213

 
21,347

 
—

 
64,560

Commercial paper (matures within 1 year)
59,331

 
73

 
—

 
59,404

Corporate debt securities (matures within 1 year)
111,225

 
—

 
(85
)
 
111,140

Total marketable securities
$
229,275

 
$
21,422

 
$
(85
)
 
$
250,612

Total cash, cash equivalents and marketable securities
$
1,413,220

 
$
21,422

 
$
(85
)
 
$
1,434,557
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accumulated Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss)
A summary of the Company’s changes in accumulated other comprehensive income (loss) by component is shown below:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains (Losses) on Marketable Securities, Net of Tax
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts, Net of Tax
 
Total
 
(in thousands)
Balance at December 31, 2016
$
(7,862
)
 
$
17,521

 
$
11,514

 
$
21,173

Other comprehensive loss before reclassifications
(11,137
)
 
(7,786
)
 
(25,981
)
 
(44,904
)
Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
(1,398
)
 
(1,398
)
Net current period other comprehensive (loss) income
$
(11,137
)
 
$
(7,786
)
 
$
(27,379
)
 
$
(46,302
)
Balance at September 30, 2017
$
(18,999
)
 
$
9,735

 
$
(15,865
)
 
$
(25,129
)

 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains on Marketable Securities
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts, Net of Tax
 
Total
 
(in thousands)
Balance at December 31, 2015
$
(2,080
)
 
$
126

 
$
3,778

 
$
1,824

Other comprehensive (loss) income before reclassifications
(7,709
)
 
104

 
6,715

 
(890
)
Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
(4,779
)
 
(4,779
)
Net current period other comprehensive (loss) income
$
(7,709
)
 
$
104

 
$
1,936

 
$
(5,669
)
Balance at September 30, 2016
$
(9,789
)
 
$
230

 
$
5,714

 
$
(3,845
)
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Hedging (Tables)
 9 Months Ended
Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedging Instruments
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:
 
As of September 30, 2017
 
As of December 31, 2016
Foreign Currency
(in thousands)
Euro
$
234,477

 
$
164,368

British pound sterling
77,387

 
65,237

Australian dollar
31,283

 
23,776

Total foreign currency forward contracts
$
343,147

 
$
253,381
Derivatives Offsetting
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s condensed consolidated balance sheets:
 
As of September 30, 2017
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
50

 
$
—

 
$
50

 
$
(50
)
 
$
—

Total liabilities
$
(14,874
)
 
$
—

 
$
(14,874
)
 
$
50

 
$
(14,824
)
 
As of December 31, 2016
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
15,593

 
$
—

 
$
15,593

 
$
(144
)
 
$
15,449

Total liabilities
$
(144
)
 
$
—

 
$
(144
)
 
$
144

 
$
—
Schedule of Foreign Exchange Contracts
The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts not designated for hedge accounting included on the Company’s condensed consolidated balance sheets:
 
As of September 30, 2017
 
As of December 31, 2016
 
(in thousands)
Prepaid expenses and other current assets
$
1,709

 
$
660

The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company’s condensed consolidated balance sheets:
As of September 30, 2017
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
42

 
Other liabilities, current portion
 
$
(13,897
)
Other assets
 
8

 
Other liabilities, excluding current portion
 
(977
)
Total assets
 
$
50

 
Total liabilities
 
$
(14,874
)
As of December 31, 2016
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
14,407

 
Other liabilities, current portion
 
$
(144
)
Other assets
 
1,186

 
Other liabilities, excluding current portion
 
—

Total assets
 
$
15,593

 
Total liabilities
 
$
(144
)
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories (Tables)
 9 Months Ended
Sep. 30, 2017
Inventory Disclosure [Abstract]  
Schedule of Inventories by Type
Inventories consisted of the following:
 
As of September 30, 2017
 
As of December 31, 2016
 
(in thousands)
Raw materials
$
12,678

 
$
6,348

Work-in-process
67,826

 
56,672

Finished goods
17,688

 
14,584

Total
$
98,192

 
$
77,604
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stock-based Compensation Expense (Tables)
 9 Months Ended
Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-based compensation expense by line item
During the three and nine months ended September 30, 2017 and 2016, the Company recognized the following stock-based compensation expense:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
 
 
Stock options
$
25,969

 
$
28,773

 
$
80,865

 
$
86,859

Restricted stock and restricted stock units
46,737

 
30,966

 
131,388

 
88,107

ESPP share issuances
2,428

 
2,425

 
6,738

 
6,385

Less stock-based compensation expense capitalized to inventories
(1,364
)
 
(955
)
 
(3,657
)
 
(2,728
)
Total stock-based compensation included in costs and expenses
$
73,770

 
$
61,209

 
$
215,334

 
$
178,623

 
 
 
 
 
 
 


Stock-based compensation expense by line item:
 
 
 
 
 
 
 
Research and development expenses
$
46,186

 
$
39,980

 
$
134,855

 
$
115,068

Sales, general and administrative expenses
27,584

 
21,229

 
80,479

 
63,555

Total stock-based compensation included in costs and expenses
$
73,770

 
$
61,209

 
$
215,334

 
$
178,623
Unrecognized stock-based compensation expense, net of estimated forfeitures
The following table sets forth the Company’s unrecognized stock-based compensation expense by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of September 30, 2017
 
Unrecognized Expense
 
Weighted-average
Recognition Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
175,298

 
2.60
Restricted stock and restricted stock units
$
289,008

 
2.64
ESPP share issuances
$
2,636

 
0.46
Stock options outstanding and exercisable
The following table summarizes information about stock options outstanding and exercisable at September 30, 2017:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$18.93–$20.00
 
128

 
0.35
 
$
18.93

 
128

 
$
18.93

$20.01–$40.00
 
834

 
2.21
 
$
34.51

 
834

 
$
34.51

$40.01–$60.00
 
877

 
4.83
 
$
49.17

 
877

 
$
49.17

$60.01–$80.00
 
821

 
6.46
 
$
75.62

 
649

 
$
75.44

$80.01–$100.00
 
4,587

 
8.33
 
$
89.37

 
1,397

 
$
89.47

$100.01–$120.00
 
1,137

 
7.36
 
$
109.34

 
586

 
$
109.24

$120.01–$140.00
 
1,260

 
7.88
 
$
130.24

 
688

 
$
129.86

$140.01–$160.00
 
—

 
0.00
 
$
—

 
—

 
$
—

$160.01–$163.74
 
634

 
9.80
 
$
162.94

 
3

 
$
162.94

Total
 
10,278

 
7.22
 
$
91.28

 
5,162

 
$
77.92
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring Liabilities (Tables)
 9 Months Ended
Sep. 30, 2017
Research and Development Restructuring  
Restructuring Cost and Reserve [Line Items]  
Activity related to restructuring liability
The restructuring charge and other activities recorded during the the three and nine months ended September 30, 2017 and the related liability balance as of September 30, 2017 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2017
 
(in thousands)
Liability, beginning of the period
$
3,507

 
$
—

Restructuring (credits) expense
(125
)
 
12,315

Cash payments
(750
)
 
(7,869
)
Asset impairments and other non-cash items
—

 
(1,814
)
Liability, end of the period
$
2,632

 
$
2,632
Kendall Restructuring  
Restructuring Cost and Reserve [Line Items]  
Activity related to restructuring liability
The activities related to the restructuring liability for the three and nine months ended September 30, 2017 and 2016 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Liability, beginning of the period
$
1,990

 
$
6,388

 
$
4,328

 
$
7,944

Restructuring expense
227

 
30

 
1,054

 
222

Cash payments
(4,003
)
 
(5,340
)
 
(12,962
)
 
(13,104
)
Cash received from subleases
2,732

 
2,866

 
8,526

 
8,882

Liability, end of the period
$
946

 
$
3,944

 
$
946

 
$
3,944
Fan Pier Move Restructuring  
Restructuring Cost and Reserve [Line Items]  
Activity related to restructuring liability
The activities related to the restructuring liability for the three and nine months ended September 30, 2017 and 2016 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
Liability, beginning of the period
$
1,521

 
$
4,863

 
$
3,626

 
$
5,964

Restructuring expense
235

 
90

 
490

 
472

Cash payments
(3,262
)
 
(4,199
)
 
(10,578
)
 
(10,451
)
Cash received from subleases
2,279

 
2,539

 
7,235

 
7,308

Liability, end of the period
$
773

 
$
3,293

 
$
773

 
$
3,293
Other Restructuring  
Restructuring Cost and Reserve [Line Items]  
Activity related to restructuring liability
The activities related to the Company’s other restructuring liabilities for the three and nine months ended September 30, 2016 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2016
 
(in thousands)
Liability, beginning of the period
$
1,233

 
$
1,450

Restructuring expense
(112
)
 
344

Cash payments
(1,121
)
 
(1,794
)
Liability, end of the period
$
—

 
$
—
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Basis of Presentation and Accounting Policies (Details)
 9 Months Ended
Sep. 30, 2017
segment
Mar. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Accounting Policies [Abstract]      
Number of operating segments | segment 1    
Accounting Standards Update 2016-09, Excess Tax Benefit      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Operating loss carryforwards   $ 410,800,000 $ 410,800,000
Deferred income tax assets, net     3,400,000
Accounting Standards Update 2016-09, Forfeiture Rate Component | Accumulated Deficit      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Cumulative effect of new accounting principle in period of adoption     9,371,000
Accounting Standards Update 2016-09, Forfeiture Rate Component | Additional Paid-in Capital      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Cumulative effect of new accounting principle in period of adoption     (9,371,000)
Accounting Standards Update 2016-09 | Accumulated Deficit      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Cumulative effect of new accounting principle in period of adoption     $ 0
Domestic Tax Authority | Accounting Standards Update 2016-09, Excess Tax Benefit      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Operating loss carryforwards   404,700,000  
State and Local Jurisdiction | Accounting Standards Update 2016-09, Excess Tax Benefit      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Operating loss carryforwards   $ 6,100,000  
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Product Revenues, Net (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2017
Dec. 31, 2016
Valuation and Qualifying Accounts Disclosure [Line Items]    
Customer deposits $ 190,272 $ 73,416
Product Revenue Allowance and Reserve [Roll Forward]    
Balance at December 31, 2016 89,201  
Provision related to current period sales 153,209  
Adjustments related to prior period sales (4,883)  
Credits/payments made (127,632)  
Balance at September 30, 2017 109,895  
Trade Allowances    
Product Revenue Allowance and Reserve [Roll Forward]    
Balance at December 31, 2016 2,568  
Provision related to current period sales 18,776  
Adjustments related to prior period sales (188)  
Credits/payments made (18,409)  
Balance at September 30, 2017 2,747  
Rebates, Chargebacks and Discounts    
Product Revenue Allowance and Reserve [Roll Forward]    
Balance at December 31, 2016 81,927  
Provision related to current period sales 118,592  
Adjustments related to prior period sales (4,327)  
Credits/payments made (97,393)  
Balance at September 30, 2017 98,799  
Product Returns    
Product Revenue Allowance and Reserve [Roll Forward]    
Balance at December 31, 2016 3,492  
Provision related to current period sales 3,603  
Adjustments related to prior period sales (13)  
Credits/payments made (1,809)  
Balance at September 30, 2017 5,273  
Other Incentives    
Product Revenue Allowance and Reserve [Roll Forward]    
Balance at December 31, 2016 1,214  
Provision related to current period sales 12,238  
Adjustments related to prior period sales (355)  
Credits/payments made (10,021)  
Balance at September 30, 2017 3,076  
Cystic Fibrosis Foundation Therapeutics Incorporated    
Valuation and Qualifying Accounts Disclosure [Line Items]    
Customer deposits $ 190,300  
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Acquisitions - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) - Cystic Fibrosis Foundation Therapeutics Incorporated - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2016
Mar. 31, 2016
Sep. 30, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Milestone payments   $ 13,900,000  
Additional milestone payments     $ 0
Collaborative funding $ 75,000,000.0    
Additional collaborative funding $ 6,000,000.0    
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Acquisitions - CRISPR Therapeutics AG (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2016
USD ($)
Jun. 30, 2016
USD ($)
Dec. 31, 2015
USD ($)
target
Sep. 30, 2017
USD ($)
Dec. 31, 2016
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Fair Value       $ 1,812,248,000 $ 1,434,557,000
Gross unrealized gains       13,740,000 $ 21,422,000
CRISPR Therapeutics AG          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Right to license, number of targets (up to) | target     6    
Collaborative arrangement, up-front payment     $ 75,000,000    
Collaborative arrangement, investment in collaborative partner, pursuant to convertible loan agreement     30,000,000    
Collaborative funding     75,000,000    
Collaborative arrangement, development and regulatory potential milestone payments maximum     $ 420,000,000    
Prior to marketing approval, time period of notice required to terminate (in days)     90 days    
Subsequent to marketing approval, time period of notice required to terminate (in days)     270 days    
Preferred Stock | CRISPR Therapeutics AG          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Collaborative arrangement, investment in collaborative partner, pursuant to convertible loan agreement   $ 3,100,000      
Common Stock | CRISPR Therapeutics AG          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Collaborative arrangement, investment in collaborative partner, pursuant to convertible loan agreement $ 10,000,000        
Fair Value       56,900,000  
Gross unrealized gains       $ 13,700,000  
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Acquisitions - Merck KGaA (Details)
 3 Months Ended 9 Months Ended
Jan. 10, 2017
USD ($)
pre-clinical_stage_program
clinical-stage_program
development_program
Sep. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Collaborative revenues   $ 26,292,000   $ 259,000 $ 286,123,000 $ 1,008,000
Merck KGaA            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Right to license, number of development programs | development_program 4          
Right to license, number of clinical stage programs | clinical-stage_program 2          
Number of pre-clinical stage programs | pre-clinical_stage_program 2          
Collaborative arrangement, up-front payment $ 230,000,000.0          
Proceeds from collaborators     $ 193,600,000      
Collaborative revenues   $ 5,200,000     $ 12,800,000  
Collaborative revenues, related to upfront payment upon delivery of license and to research and development transition activities     231,700,000      
Time period of notice required to terminate 90 days          
Time period of notice required to terminate after a product has received marketing approval 180 days          
German Tax Authority | Merck KGaA            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Collaborative revenues, tax withholding     $ 36,400,000      
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Acquisitions - Parion Sciences, Inc. (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 28 Months Ended
Jun. 04, 2015
Jun. 30, 2015
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Dec. 31, 2016
Dec. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative revenues     $ 26,292,000 $ 259,000 $ 286,123,000 $ 1,008,000      
(Benefit from) provision for income taxes     (125,903,000) 503,000 (117,581,000) 24,118,000      
Business Combination, Consideration Transferred [Abstract]                  
Intangible assets     29,000,000   29,000,000   $ 29,000,000 $ 284,340,000  
Deconsolidation of VIE         7,100,000        
Intangible asset impairment charge     255,340,000 0 255,340,000 0      
Parion Sciences, Inc.                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative arrangement, up-front payment $ 80,000,000 $ 80,000,000         85,000,000    
Prior to marketing approval, time period of notice required to terminate (in days)   90 days              
Subsequent to marketing approval, time period of notice required to terminate (in days)   180 days              
Change of control prior to clinical trial, time period of notice required to terminate (in days)   30 days              
Term of agreement following first commercial sale (in years)   10 years              
(Benefit from) provision for income taxes     (126,200,000)            
(Benefit from) provision for income taxes, attributable to intangible asset impairment     (97,700,000)            
(Benefit from) provision for income taxes, attributable to decrease in the fair value of contingent consideration liability     (28,500,000)            
Business Combination, Consideration Transferred [Abstract]                  
Intangible assets 255,300,000                
Noncontrolling interest, fair value 164,300,000                
Deferred tax liabilities, net 91,000,000                
Other liabilities / assets, net $ 10,500,000                
Deconsolidation of VIE     7,100,000            
Intangible asset impairment charge     255,300,000            
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability     (69,600,000)            
ENaC Inhibitors in CF | Parion Sciences, Inc.                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative arrangement, development and regulatory potential milestone payments maximum   $ 490,000,000              
Collaborative arrangement regulatory potential milestone payments maximum, global filling and approval   360,000,000              
Enac Inhibitors in Non Cf | Parion Sciences, Inc.                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative arrangement, development and regulatory potential milestone payments maximum   370,000,000              
Additional Enac Inhibitors | Parion Sciences, Inc.                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative arrangement, development and regulatory potential milestone payments maximum   $ 230,000,000              
Variable Interest Entity, Primary Beneficiary                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
(Benefit from) provision for income taxes     (120,181,000) (510,000) (111,658,000) 20,063,000      
Business Combination, Consideration Transferred [Abstract]                  
Intangible assets     29,000,000   29,000,000   $ 29,000,000 $ 284,340,000  
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability     (69,550,000) 1,200,000 (62,560,000) 59,350,000      
Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc.                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Collaborative revenues     20,000,000   40,000,000        
(Benefit from) provision for income taxes     7,400,000   14,800,000        
Business Combination, Consideration Transferred [Abstract]                  
Intangible assets                 $ 255,300,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability     $ (69,550,000) $ 1,100,000 $ (63,460,000) $ 58,500,000      
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Acquisitions - BioAxone Biosciences, Inc. (Details) - BioAxone Biosciences Inc. - USD ($)
 1 Months Ended 3 Months Ended
Oct. 31, 2014
Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaborative arrangement, up-front payment   $ 10,000,000
Maximum license fees and milestone payments $ 90,000,000.0  
In-process research and development intangible asset 29,000,000  
Deferred tax liability attributable to variable interest entity $ 11,300,000  
Purchase option, term of extension of expiration date (in years) 1 year  
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Acquisitions - Aggregate VIE Financial Information, Summary of Net Income Attributable to Noncontrolling Interest (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]        
(Benefit from) provision for income taxes $ (125,903) $ 503 $ (117,581) $ 24,118
Net loss (income) attributable to noncontrolling interest (188,315) (696) (173,350) 33,207
Variable Interest Entity, Primary Beneficiary        
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]        
Loss attributable to noncontrolling interest before (benefit from) provision for income taxes and changes in fair value of contingent payments 238,946 2,406 222,448 6,080
(Benefit from) provision for income taxes (120,181) (510) (111,658) 20,063
Decrease (increase) in fair value of contingent payments 69,550 (1,200) 62,560 (59,350)
Net loss (income) attributable to noncontrolling interest (188,315) (696) (173,350) 33,207
Parion Sciences, Inc.        
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]        
(Benefit from) provision for income taxes (126,200)      
Decrease (increase) in fair value of contingent payments 69,600      
Parion Sciences, Inc. | Variable Interest Entity, Primary Beneficiary        
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]        
(Benefit from) provision for income taxes 7,400   14,800  
Decrease (increase) in fair value of contingent payments $ 69,550 $ (1,100) $ 63,460 $ (58,500)
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Acquisitions - Aggregate VIE Financial Information, Contingent Consideration Liability (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Variable Interest Entity, Primary Beneficiary          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Decrease (increase) in fair value of contingent payments $ 69,550 $ (1,200) $ 62,560 $ (59,350)  
Parion Sciences, Inc.          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Decrease (increase) in fair value of contingent payments 69,600        
Parion Sciences, Inc. | Variable Interest Entity, Primary Beneficiary          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Decrease (increase) in fair value of contingent payments 69,550 (1,100) 63,460 (58,500)  
Contingent consideration, liability 0   0   $ 238,800
BioAxone Biosciences Inc. | Variable Interest Entity, Primary Beneficiary          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Decrease (increase) in fair value of contingent payments 0 $ (100) (900) $ (850)  
Contingent consideration, liability $ 18,900   $ 18,900   $ 18,000
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Acquisitions - Aggregate VIE Financial Information, Items Related to the Company's VIEs (Details) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net [Abstract]    
Restricted cash and cash equivalents (VIE) $ 1,803 $ 47,762
Prepaid expenses and other current assets 152,238 70,534
Intangible assets 29,000 284,340
Other assets 10,542 11,885
Accounts payable 77,138 61,451
Accrued expenses 378,554 315,249
Other liabilities, current portion 27,686 10,943
Deferred tax liability 10,682 134,063
Other liabilities, excluding current portion 26,029 28,699
Noncontrolling interest 12,167 181,609
Variable Interest Entity, Primary Beneficiary    
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net [Abstract]    
Restricted cash and cash equivalents (VIE) 1,803 47,762
Prepaid expenses and other current assets 42 6,812
Intangible assets 29,000 284,340
Other assets 280 399
Accounts payable 455 415
Accrued expenses 1,021 1,330
Other liabilities, current portion 119 2,137
Deferred tax liability 8,338 131,446
Other liabilities, excluding current portion 0 300
Noncontrolling interest $ 12,167 $ 181,609
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Acquisitions - Moderna Therapeutics, Inc. (Details) - Moderna Therapeutics, Inc.
$ in Millions
 1 Months Ended
Jul. 31, 2016
USD ($)
Schedule of Collaborative Arrangement Agreements [Line Items]  
Collaborative arrangement, up-front payment $ 20.0
Collaborative arrangement, investment in collaborative partner, pursuant to convertible loan agreement 20.0
Collaborative arrangement, development and regulatory potential milestone payments maximum 275.0
Collaborative arrangement approval and reimbursement milestones $ 220.0
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Acquisitions - Janssen Pharmaceuticals, Inc. (Details) - Janssen Pharmaceuticals, Inc. - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2014
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Collaborative arrangement, up-front payment           $ 35,000,000
Time period of notice required to terminate 6 months          
Reimbursement for development and commercialization of compounds   $ 0 $ 2,800,000 $ 1,800,000 $ 10,600,000  
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Acquisitions - Concert Pharmaceuticals (Details) - Concert Pharmaceuticals
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2017
USD ($)
milestone
Jul. 30, 2017
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2017
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaborative arrangement, development and commercialization rights potential maximum milestone payments   $ 160.0    
Collaborative arrangement, additional maximum milestone payments based on regulatory approval   $ 90.0    
Collaborative funding     $ 160.0 $ 160.0
Collaborative arrangement, purchase price $ 165.1      
Collaborative arrangement, transaction costs $ 5.1      
Number of milestones to be achieved in order for milestone payment to be recorded as an intangible asset | milestone 1      
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings Per Share - Schedule of Earnings Per Share Computation Statement (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Basic net income (loss) attributable to Vertex per common share calculation:        
Net income (loss) attributable to Vertex common shareholders $ (102,952) $ (38,841) $ 162,800 $ (144,997)
Less: Undistributed earnings allocated to participating securities 0 0 (203) 0
Net income (loss) attributable to Vertex common shareholders—basic $ (102,952) $ (38,841) $ 162,597 $ (144,997)
Basic weighted-average common shares outstanding (in shares) 250,268 244,920 247,963 244,529
Basic net income (loss) attributable to Vertex per common share (in dollars per share) $ (0.41) $ (0.16) $ 0.66 $ (0.59)
Diluted net income (loss) attributable to Vertex per common share calculation:        
Less: Undistributed earnings allocated to participating securities $ 0 $ 0 $ (200) $ 0
Net income (loss) attributable to Vertex common shareholders—diluted $ (102,952) $ (38,841) $ 162,600 $ (144,997)
Effect of potentially dilutive securities:        
Other (in shares) 0 0 228 0
Weighted-average shares used to compute diluted net income (loss) per common share (in shares) 250,268 244,920 252,095 244,529
Diluted net income (loss) attributable to Vertex per common share (in dollars per share) $ (0.41) $ (0.16) $ 0.64 $ (0.59)
Stock options        
Effect of potentially dilutive securities:        
Share-based payment arrangements (in shares) 0 0 2,700 0
Restricted stock and restricted stock units        
Effect of potentially dilutive securities:        
Share-based payment arrangements (in shares) 0 0 1,204 0
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings Per Share (Details) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Antidilutive securities excluded from computation of earnings per share (in shares) 10,278 12,947 3,904 12,947
Unvested restricted stock and restricted stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Antidilutive securities excluded from computation of earnings per share (in shares) 4,241 3,624 281 3,624
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements (Details) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Recurring basis    
Financial instruments carried at fair value (asset position):    
Total financial assets $ 928,109 $ 546,765
Financial instruments carried at fair value (liability position):    
Total financial liabilities (14,874) (144)
Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Total financial assets 538,625 360,628
Financial instruments carried at fair value (liability position):    
Total financial liabilities 0 0
Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Total financial assets 389,484 186,137
Financial instruments carried at fair value (liability position):    
Total financial liabilities (14,874) (144)
Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Total financial assets 0 0
Financial instruments carried at fair value (liability position):    
Total financial liabilities 0 0
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts 42 14,407
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts 0 0
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts 42 14,407
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts 0 0
Other assets | Foreign currency forward contracts | Recurring basis    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts 8 1,186
Other assets | Foreign currency forward contracts | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts 0 0
Other assets | Foreign currency forward contracts | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts 8 1,186
Other assets | Foreign currency forward contracts | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Foreign currency forward contracts 0 0
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis    
Financial instruments carried at fair value (liability position):    
Derivative liability current (13,897) (144)
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis | Level 1    
Financial instruments carried at fair value (liability position):    
Derivative liability current 0 0
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis | Level 2    
Financial instruments carried at fair value (liability position):    
Derivative liability current (13,897) (144)
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis | Level 3    
Financial instruments carried at fair value (liability position):    
Derivative liability current 0 0
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis    
Financial instruments carried at fair value (liability position):    
Derivative liability, noncurrent (977)  
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis | Level 1    
Financial instruments carried at fair value (liability position):    
Derivative liability, noncurrent 0  
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis | Level 2    
Financial instruments carried at fair value (liability position):    
Derivative liability, noncurrent (977)  
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis | Level 3    
Financial instruments carried at fair value (liability position):    
Derivative liability, noncurrent 0  
Money market funds | Recurring basis    
Financial instruments carried at fair value (asset position):    
Cash equivalents 466,702 280,560
Money market funds | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Cash equivalents 466,702 280,560
Money market funds | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0 0
Money market funds | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0 0
Government-sponsored enterprise securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Cash equivalents 14,979  
Marketable securities   15,508
Government-sponsored enterprise securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Cash equivalents 14,979  
Marketable securities   15,508
Government-sponsored enterprise securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0  
Marketable securities   0
Government-sponsored enterprise securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0  
Marketable securities   0
Corporate debt securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Cash equivalents 4,488  
Marketable securities 295,171 111,140
Corporate debt securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0  
Marketable securities 0 0
Corporate debt securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Cash equivalents 4,488  
Marketable securities 295,171 111,140
Corporate debt securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0  
Marketable securities 0 0
Commercial paper | Recurring basis    
Financial instruments carried at fair value (asset position):    
Cash equivalents 14,608  
Marketable securities 75,167 59,404
Commercial paper | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0  
Marketable securities 0 0
Commercial paper | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Cash equivalents 14,608  
Marketable securities 75,167 59,404
Commercial paper | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Cash equivalents 0  
Marketable securities 0 0
Corporate equity securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Marketable securities 56,944 64,560
Corporate equity securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Marketable securities 56,944 64,560
Corporate equity securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Marketable securities 0 0
Corporate equity securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Marketable securities 0 $ 0
Variable Interest Entity, Primary Beneficiary | Level 1    
Financial instruments carried at fair value (liability position):    
Cash and cash equivalents $ 1,500  
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1
Marketable Securities (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Summary of cash, cash equivalents and marketable securities          
Amortized Cost $ 1,798,697,000   $ 1,798,697,000   $ 1,413,220,000
Gross Unrealized Gains 13,740,000   13,740,000   21,422,000
Gross Unrealized Losses (189,000)   (189,000)   (85,000)
Fair Value 1,812,248,000   1,812,248,000   1,434,557,000
Other than temporary impairment losses, investments 0 $ 0 0 $ 0  
Gross realized gains (losses) 0 $ 0 0 $ 0  
Total cash and cash equivalents          
Summary of cash, cash equivalents and marketable securities          
Amortized Cost 1,384,968,000   1,384,968,000   1,183,945,000
Gross Unrealized Gains 0   0   0
Gross Unrealized Losses (2,000)   (2,000)   0
Fair Value 1,384,966,000   1,384,966,000   1,183,945,000
Cash and money market funds          
Summary of cash, cash equivalents and marketable securities          
Amortized Cost 1,350,891,000   1,350,891,000   1,183,945,000
Gross Unrealized Gains 0   0   0
Gross Unrealized Losses 0   0   0
Fair Value 1,350,891,000   1,350,891,000   1,183,945,000
Government-sponsored enterprise securities          
Summary of cash, cash equivalents and marketable securities          
Amortized Cost 14,979,000   14,979,000    
Gross Unrealized Gains 0   0    
Gross Unrealized Losses 0   0    
Fair Value 14,979,000   14,979,000    
Commercial paper          
Summary of cash, cash equivalents and marketable securities          
Amortized Cost 14,610,000   14,610,000    
Gross Unrealized Gains 0   0    
Gross Unrealized Losses (2,000)   (2,000)    
Fair Value 14,608,000   14,608,000    
Corporate debt securities          
Summary of cash, cash equivalents and marketable securities          
Amortized Cost 4,488,000   4,488,000    
Gross Unrealized Gains 0   0    
Gross Unrealized Losses 0   0    
Fair Value 4,488,000   4,488,000    
Total marketable securities          
Summary of cash, cash equivalents and marketable securities          
Amortized Cost 413,729,000   413,729,000   229,275,000
Gross Unrealized Gains 13,740,000   13,740,000   21,422,000
Gross Unrealized Losses (187,000)   (187,000)   (85,000)
Fair Value 427,282,000   427,282,000   250,612,000
Government-sponsored enterprise securities (matures within 1 year)          
Summary of cash, cash equivalents and marketable securities          
Amortized Cost         15,506,000
Gross Unrealized Gains         2,000
Gross Unrealized Losses         0
Fair Value         15,508,000
Corporate equity securities          
Summary of cash, cash equivalents and marketable securities          
Amortized Cost 43,213,000   43,213,000   43,213,000
Gross Unrealized Gains 13,731,000   13,731,000   21,347,000
Gross Unrealized Losses 0   0   0
Fair Value 56,944,000   56,944,000   64,560,000
Commercial paper (matures within 1 year)          
Summary of cash, cash equivalents and marketable securities          
Amortized Cost 75,186,000   75,186,000   59,331,000
Gross Unrealized Gains 1,000   1,000   73,000
Gross Unrealized Losses (20,000)   (20,000)   0
Fair Value 75,167,000   75,167,000   59,404,000
Corporate debt securities (matures within 1 year)          
Summary of cash, cash equivalents and marketable securities          
Amortized Cost 235,679,000   235,679,000   111,225,000
Gross Unrealized Gains 8,000   8,000   0
Gross Unrealized Losses (106,000)   (106,000)   (85,000)
Fair Value 235,581,000   235,581,000   $ 111,140,000
Corporate debt securities (matures after 1 year)          
Summary of cash, cash equivalents and marketable securities          
Amortized Cost 59,651,000   59,651,000    
Gross Unrealized Gains 0   0    
Gross Unrealized Losses (61,000)   (61,000)    
Fair Value $ 59,590,000   $ 59,590,000    
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning Balance     $ 1,338,191 $ 1,093,628
Total changes in other comprehensive loss $ (3,376) $ (455) (46,302) (5,669)
Ending Balance 1,803,244 1,208,341 1,803,244 1,208,341
Foreign Currency Translation Adjustment        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning Balance     (7,862) (2,080)
Other comprehensive loss before reclassifications     (11,137) (7,709)
Amounts reclassified from accumulated other comprehensive income (loss)     0 0
Total changes in other comprehensive loss     (11,137) (7,709)
Ending Balance (18,999) (9,789) (18,999) (9,789)
Unrealized Holding Gains (Losses) on Marketable Securities, Net of Tax        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning Balance     17,521 126
Other comprehensive loss before reclassifications     (7,786) 104
Amounts reclassified from accumulated other comprehensive income (loss)     0 0
Total changes in other comprehensive loss     (7,786) 104
Ending Balance 9,735 230 9,735 230
Unrealized Gains (Losses) on Foreign Currency Forward Contracts, Net of Tax        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning Balance     11,514 3,778
Other comprehensive loss before reclassifications     (25,981) 6,715
Amounts reclassified from accumulated other comprehensive income (loss)     (1,398) (4,779)
Total changes in other comprehensive loss     (27,379) 1,936
Ending Balance (15,865) 5,714 (15,865) 5,714
AOCI Attributable to Parent        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning Balance     21,173 1,824
Other comprehensive loss before reclassifications     (44,904) (890)
Amounts reclassified from accumulated other comprehensive income (loss)     (1,398) (4,779)
Total changes in other comprehensive loss     (46,302) (5,669)
Ending Balance $ (25,129) $ (3,845) $ (25,129) $ (3,845)
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1
Hedging - Derivatives Designated as Hedging Instruments (Details) - USD ($)
 9 Months Ended
Sep. 30, 2017
Dec. 31, 2016
Derivative [Line Items]    
Amount of ineffectiveness on net investment hedges $ 0  
Foreign currency forward contracts    
Offsetting Derivative Assets [Abstract]    
Gross Amounts Recognized   $ 15,593,000
Offsetting Derivative Liabilities [Abstract]    
Gross Amounts Recognized   (144,000)
Foreign currency forward contracts | Designated as hedging instrument | Cash flow hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 343,147,000 253,381,000
Offsetting Derivative Assets [Abstract]    
Gross Amounts Recognized 50,000 15,593,000
Gross Amounts Offset 0 0
Gross Amounts Presented 50,000 15,593,000
Gross Amounts Not Offset (50,000) (144,000)
Legal Offset 0 15,449,000
Offsetting Derivative Liabilities [Abstract]    
Gross Amounts Recognized (14,874,000) (144,000)
Gross Amounts Offset 0 0
Gross Amounts Presented (14,874,000) (144,000)
Gross Amounts Not Offset 50,000 144,000
Legal Offset (14,824,000) 0
Foreign currency forward contracts | Designated as hedging instrument | Euro | Cash flow hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 234,477,000 164,368,000
Foreign currency forward contracts | Designated as hedging instrument | British pound sterling | Cash flow hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 77,387,000 65,237,000
Foreign currency forward contracts | Designated as hedging instrument | Australian dollar | Cash flow hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 31,283,000 23,776,000
Foreign currency forward contracts | Minimum | Cash flow hedging    
Derivative [Line Items]    
Derivative term 1 month  
Foreign currency forward contracts | Maximum | Cash flow hedging    
Derivative [Line Items]    
Derivative term 18 months  
Prepaid and other current assets    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - assets $ 42,000 14,407,000
Other assets    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - assets 8,000 1,186,000
Other liabilities, current portion    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - liabilities (13,897,000) (144,000)
Other liabilities, excluding current portion    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - liabilities $ (977,000) $ 0
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.8.0.1
Hedging - Derivatives Not Designated as Hedging Instruments (Details) - Foreign currency forward contracts - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Derivative [Line Items]          
Derivative asset, fair value         $ 15,593
Not designated as hedging instrument          
Derivative [Line Items]          
Derivative term     1 month    
Notional amount of foreign currency forward contract $ 113,800   $ 113,800    
Prepaid and other current assets | Not designated as hedging instrument          
Derivative [Line Items]          
Derivative asset, fair value 1,709   1,709   $ 660
Other income (expense) | Not designated as hedging instrument          
Derivative [Line Items]          
(Loss) gain recognized on forward contracts not designated as hedges $ (4,100) $ (1,200) $ (13,000) $ 500  
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories - Schedule of Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Raw materials $ 12,678 $ 6,348
Work-in-process 67,826 56,672
Finished goods 17,688 14,584
Total Inventories 98,192 $ 77,604
Tezacaftor    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Capitalized inventory $ 9,600  
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Goodwill (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Dec. 31, 2015
Jun. 04, 2015
Dec. 31, 2014
Indefinite-Lived Intangible Assets [Line Items]                
Intangible assets $ 29,000   $ 29,000   $ 284,340      
Intangible asset impairment charge 255,340 $ 0 255,340 $ 0        
Income tax benefit 125,903 (503) 117,581 (24,118)        
Goodwill 50,384   50,384   50,384      
Parion Sciences, Inc.                
Indefinite-Lived Intangible Assets [Line Items]                
Intangible assets             $ 255,300  
Intangible asset impairment charge 255,300              
Income tax benefit 126,200              
Variable Interest Entity, Primary Beneficiary                
Indefinite-Lived Intangible Assets [Line Items]                
Intangible assets 29,000   29,000   $ 284,340      
Income tax benefit 120,181 $ 510 111,658 $ (20,063)        
Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc.                
Indefinite-Lived Intangible Assets [Line Items]                
Intangible assets           $ 255,300    
Income tax benefit (7,400)   (14,800)          
Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences Inc.                
Indefinite-Lived Intangible Assets [Line Items]                
Intangible assets               $ 29,000
In-process research development intangible asset | Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc.                
Indefinite-Lived Intangible Assets [Line Items]                
Intangible asset impairment charge 255,300   255,300          
Income tax benefit $ 97,700   $ 97,700          
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.8.0.1
Long-term Obligations - Fan Pier Leases (Details)
$ in Thousands, ft² in Millions
 12 Months Ended
Dec. 31, 2011
ft²
lease
building
Sep. 30, 2017
USD ($)
Dec. 31, 2016
USD ($)
Property, Plant and Equipment [Line Items]      
Property and equipment, net   $ 759,978 $ 698,362
Fan Pier Leases      
Property, Plant and Equipment [Line Items]      
Number of leases | lease 2    
Area of real estate property (in square feet) | ft² 1.1    
Number of buildings under lease agreement | building 2    
Optional term of lease agreement (in years) 10 years    
Fan Pier Leases | Construction in progress      
Property, Plant and Equipment [Line Items]      
Property and equipment, net   479,000 489,000
Fan Pier Leases | Buildings      
Property, Plant and Equipment [Line Items]      
Construction financing lease obligation, current and noncurrent   $ 472,200 $ 472,600
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.8.0.1
Long-term Obligations - San Diego Lease (Details)
ft² in Thousands, $ in Thousands
Dec. 02, 2015
USD ($)
ft²
term_extension
Sep. 30, 2017
USD ($)
Dec. 31, 2016
USD ($)
Property, Plant and Equipment [Line Items]      
Property and equipment, net   $ 759,978 $ 698,362
San Diego Lease      
Property, Plant and Equipment [Line Items]      
Area of real estate property (in square feet) | ft² 170    
Length of lease 16 years    
Average yearly aggregate rent $ 10,200    
Amount of optional renewal terms | term_extension 2    
Optional renewal term length 5 years    
San Diego Lease | Construction in progress      
Property, Plant and Equipment [Line Items]      
Property and equipment, net   73,900 15,000
San Diego Lease | Buildings      
Property, Plant and Equipment [Line Items]      
Construction financing lease obligation, current and noncurrent   $ 71,800 $ 12,600
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.8.0.1
Long-term Obligations - Revolving Credit Facility (Details)
 1 Months Ended 9 Months Ended
Feb. 28, 2017
USD ($)
Oct. 31, 2016
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Line of Credit Facility [Line Items]        
Proceeds from lines of credit   $ 300,000,000    
Repayments of lines of credit $ 300,000,000   $ 300,000,000 $ 0
Line of credit facility additional borrowing capacity   300,000,000.0    
Line of Credit        
Line of Credit Facility [Line Items]        
Line of credit facility, current borrowing capacity   $ 500,000,000.0    
Debt covenant, consolidated leverage ratio   3.00    
Debt covenant, minimum consolidated EBITDA   $ 200,000,000.0    
Base Rate | Minimum | Line of Credit        
Line of Credit Facility [Line Items]        
Interest rate, stated percentage   0.75%    
Base Rate | Maximum | Line of Credit        
Line of Credit Facility [Line Items]        
Interest rate, stated percentage   1.50%    
Eurodollar | Minimum | Line of Credit        
Line of Credit Facility [Line Items]        
Interest rate, stated percentage   1.75%    
Eurodollar | Maximum | Line of Credit        
Line of Credit Facility [Line Items]        
Interest rate, stated percentage   2.50%    
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.8.0.1
Long-term Obligations - Term Loan (Details) - Senior Secured Term Loan - USD ($)
 1 Months Ended
Jul. 31, 2014
Dec. 31, 2015
Debt Instrument [Line Items]    
Face amount of term loan $ 300,000,000  
Interest rate, stated percentage 7.20% 6.20%
Unamortized discount on term loan $ 5,300,000  
LIBOR    
Debt Instrument [Line Items]    
Basis spread on variable rate (percent) 5.00%  
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stock-based Compensation Expense - (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Stock-based compensation expense:        
Less stock-based compensation expense capitalized to inventories $ (1,364) $ (955) $ (3,657) $ (2,728)
Total stock-based compensation included in costs and expenses 73,770 61,209 215,334 178,623
Research and development expenses        
Stock-based compensation expense:        
Total stock-based compensation included in costs and expenses 46,186 39,980 134,855 115,068
Sales, general and administrative expenses        
Stock-based compensation expense:        
Total stock-based compensation included in costs and expenses 27,584 21,229 80,479 63,555
Stock options        
Stock-based compensation expense:        
Share-based compensation expense by type of award 25,969 28,773 80,865 86,859
Type of award:        
Unrecognized Expense 175,298   $ 175,298  
Weighted-average Recognition Period     2 years 7 months 6 days  
Restricted stock and restricted stock units        
Stock-based compensation expense:        
Share-based compensation expense by type of award 46,737 30,966 $ 131,388 88,107
Type of award:        
Unrecognized Expense 289,008   $ 289,008  
Weighted-average Recognition Period     2 years 7 months 21 days  
ESPP share issuances        
Stock-based compensation expense:        
Share-based compensation expense by type of award 2,428 $ 2,425 $ 6,738 $ 6,385
Type of award:        
Unrecognized Expense $ 2,636   $ 2,636  
Weighted-average Recognition Period     5 months 16 days  
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stock-based Compensation Expense - Stock Options Outstanding and Exercisable (Details)
shares in Thousands
 9 Months Ended
Sep. 30, 2017
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price range, options outstanding (in shares) | shares 10,278
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 7 years 2 months 19 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 91.28
Exercise price range, options exercisable (in shares) | shares 5,162
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 77.92
$18.93–$20.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 18.93
Exercise price, high end of range (in dollars per share) $ 20.00
Exercise price range, options outstanding (in shares) | shares 128
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 4 months 6 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 18.93
Exercise price range, options exercisable (in shares) | shares 128
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 18.93
$20.01–$40.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 20.01
Exercise price, high end of range (in dollars per share) $ 40
Exercise price range, options outstanding (in shares) | shares 834
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 2 years 2 months 16 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 34.51
Exercise price range, options exercisable (in shares) | shares 834
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 34.51
$40.01–$60.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 40.01
Exercise price, high end of range (in dollars per share) $ 60
Exercise price range, options outstanding (in shares) | shares 877
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 4 years 9 months 29 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 49.17
Exercise price range, options exercisable (in shares) | shares 877
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 49.17
$60.01–$80.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 60.01
Exercise price, high end of range (in dollars per share) $ 80
Exercise price range, options outstanding (in shares) | shares 821
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 6 years 5 months 16 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 75.62
Exercise price range, options exercisable (in shares) | shares 649
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 75.44
$80.01–$100.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 80.01
Exercise price, high end of range (in dollars per share) $ 100
Exercise price range, options outstanding (in shares) | shares 4,587
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 8 years 3 months 29 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 89.37
Exercise price range, options exercisable (in shares) | shares 1,397
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 89.47
$100.01–$120.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 100.01
Exercise price, high end of range (in dollars per share) $ 120
Exercise price range, options outstanding (in shares) | shares 1,137
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 7 years 4 months 10 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 109.34
Exercise price range, options exercisable (in shares) | shares 586
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 109.24
$120.01–$140.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 120.01
Exercise price, high end of range (in dollars per share) $ 140.00
Exercise price range, options outstanding (in shares) | shares 1,260
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 7 years 10 months 17 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 130.24
Exercise price range, options exercisable (in shares) | shares 688
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 129.86
$140.01–$160.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 140.01
Exercise price, high end of range (in dollars per share) $ 160.00
Exercise price range, options outstanding (in shares) | shares 0
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 0 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 0.00
Exercise price range, options exercisable (in shares) | shares 0
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 0.00
$160.01–$163.74  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 160.01
Exercise price, high end of range (in dollars per share) $ 163.74
Exercise price range, options outstanding (in shares) | shares 634
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 9 years 9 months 18 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 162.94
Exercise price range, options exercisable (in shares) | shares 3
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 162.94
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.8.0.1
Other Arrangements (Details) - USD ($)
 12 Months Ended
Dec. 31, 2008
Sep. 30, 2017
Other Income and Expenses [Abstract]    
Gross proceeds from sale of royalty rights receivable from GlaxoSmithKline $ 160,000,000.0  
Deferred revenue royalty purchase agreement   $ 8,000,000
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Mar. 31, 2017
Schedule of Collaborative Arrangement Agreements [Line Items]            
(Benefit from) provision for income taxes $ (125,903,000) $ 503,000 $ (117,581,000) $ 24,118,000    
Unrecognized tax benefits 0   0   $ 0  
Income taxes, interest and penalties accrued 0   0      
Increase in unrecognized tax benefits is reasonably possible 0   0      
Income taxes, material interest or penalties related to uncertain tax positions     0   0  
Effective income tax rate reconciliation, share-based compensation, excess tax benefit, amount 31,400,000   62,200,000      
Deferred tax asset subject to valuation allowance         1,700,000,000  
Amount of unrecognized deferred tax liability, undistributed earnings of foreign subsidiaries 0   0      
Accounting Standards Update 2016-09, Excess Tax Benefit            
Schedule of Collaborative Arrangement Agreements [Line Items]            
Operating loss carryforwards         410,800,000 $ 410,800,000
Deferred income tax assets, net         3,400,000  
Retained Earnings | Accounting Standards Update 2016-09, Forfeiture Rate Component            
Schedule of Collaborative Arrangement Agreements [Line Items]            
Cumulative effect of new accounting principle in period of adoption         9,371,000  
Variable Interest Entity, Primary Beneficiary            
Schedule of Collaborative Arrangement Agreements [Line Items]            
(Benefit from) provision for income taxes (120,181,000) $ (510,000) (111,658,000) $ 20,063,000    
Income tax liability associated with variable interest entity $ 0   $ 0      
Internal Revenue Service (IRS)            
Schedule of Collaborative Arrangement Agreements [Line Items]            
Operating loss carryforwards         $ 4,100,000,000  
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring Liabilities - Narrative (Details)
ft² in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2017
position
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2014
facility
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Dec. 31, 2015
USD ($)
ft²
lease
Dec. 31, 2003
Jun. 30, 2017
USD ($)
Dec. 31, 2016
USD ($)
Jun. 30, 2016
USD ($)
Restructuring Cost and Reserve [Line Items]                      
Restructuring (credits) expense   $ 337,000 $ 8,000   $ 13,859,000 $ 1,038,000          
Research and Development Restructuring                      
Restructuring Cost and Reserve [Line Items]                      
Restructuring and related cost, number of positions eliminated | position 70                    
Restructuring (credits) expense   (125,000)     12,315,000            
Restructuring reserve   2,632,000     2,632,000       $ 3,507,000 $ 0  
Kendall Restructuring                      
Restructuring Cost and Reserve [Line Items]                      
Restructuring (credits) expense   227,000 30,000   1,054,000 222,000          
Lease term (in years)               15 years      
Restructuring and related activities, leased office space, maximum percentage used - not more than               50.00%      
Restructuring reserve   946,000 3,944,000   946,000 3,944,000 $ 7,944,000   1,990,000 4,328,000 $ 6,388,000
Fan Pier Move Restructuring                      
Restructuring Cost and Reserve [Line Items]                      
Restructuring (credits) expense   235,000 90,000   490,000 472,000          
Number of facilities decommissioned | facility       3              
Number of leases terminated | lease             2        
Area of real estate property (in square feet) | ft²             120        
Discount rate related to leases (percent)             9.00%        
Restructuring reserve   773,000 3,293,000   773,000 3,293,000 $ 5,964,000   $ 1,521,000 $ 3,626,000 4,863,000
Other Restructuring                      
Restructuring Cost and Reserve [Line Items]                      
Restructuring (credits) expense     (112,000)     344,000          
Restructuring reserve   $ 0 $ 0   $ 0 $ 0 $ 1,450,000       $ 1,233,000
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring Liabilities - Activity Related to Restructuring Liability (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Restructuring activities        
Restructuring (credits) expense $ 337,000 $ 8,000 $ 13,859,000 $ 1,038,000
Kendall Restructuring        
Restructuring activities        
Liability, beginning of the period 1,990,000 6,388,000 4,328,000 7,944,000
Restructuring (credits) expense 227,000 30,000 1,054,000 222,000
Cash payments (4,003,000) (5,340,000) (12,962,000) (13,104,000)
Cash received from subleases 2,732,000 2,866,000 8,526,000 8,882,000
Liability, end of the period 946,000 3,944,000 946,000 3,944,000
Fan Pier Move Restructuring        
Restructuring activities        
Liability, beginning of the period 1,521,000 4,863,000 3,626,000 5,964,000
Restructuring (credits) expense 235,000 90,000 490,000 472,000
Cash payments (3,262,000) (4,199,000) (10,578,000) (10,451,000)
Cash received from subleases 2,279,000 2,539,000 7,235,000 7,308,000
Liability, end of the period 773,000 3,293,000 773,000 3,293,000
Research and Development Restructuring        
Restructuring activities        
Liability, beginning of the period 3,507,000   0  
Restructuring (credits) expense (125,000)   12,315,000  
Cash payments (750,000)   (7,869,000)  
Asset impairments and other non-cash items 0   (1,814,000)  
Liability, end of the period 2,632,000   2,632,000  
Other Restructuring        
Restructuring activities        
Liability, beginning of the period   1,233,000   1,450,000
Restructuring (credits) expense   (112,000)   344,000
Cash payments   (1,121,000)   (1,794,000)
Liability, end of the period $ 0 $ 0 $ 0 $ 0
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Details) - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]    
Indemnification claims $ 0  
Contingent liabilities $ 0 $ 0
EXCEL 81 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 82 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 83 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 85 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 379 316 1 false 104 0 false 16 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.vrtx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Operations (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (unaudited) Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) Statements 3 false false R4.htm 1002001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedParenthetical Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) (Parenthetical) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Balance Sheets (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (unaudited) Statements 5 false false R6.htm 1003501 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterestUnaudited Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest (unaudited) Statements 7 false false R8.htm 1006000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 8 false false R9.htm 2101100 - Disclosure - Basis of Presentation and Accounting Policies Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPolicies Basis of Presentation and Accounting Policies Notes 9 false false R10.htm 2102100 - Disclosure - Product Revenues, Net Sheet http://www.vrtx.com/role/ProductRevenuesNet Product Revenues, Net Notes 10 false false R11.htm 2104100 - Disclosure - Collaborative Arrangements and Acquisitions Sheet http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitions Collaborative Arrangements and Acquisitions Notes 11 false false R12.htm 2105100 - Disclosure - Earnings Per Share Sheet http://www.vrtx.com/role/EarningsPerShare Earnings Per Share Notes 12 false false R13.htm 2106100 - Disclosure - Fair Value Measurements Sheet http://www.vrtx.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2107100 - Disclosure - Marketable Securities Sheet http://www.vrtx.com/role/MarketableSecurities Marketable Securities Notes 14 false false R15.htm 2108100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 15 false false R16.htm 2110100 - Disclosure - Hedging Sheet http://www.vrtx.com/role/Hedging Hedging Notes 16 false false R17.htm 2112100 - Disclosure - Inventories Sheet http://www.vrtx.com/role/Inventories Inventories Notes 17 false false R18.htm 2113100 - Disclosure - Intangible Assets and Goodwill Sheet http://www.vrtx.com/role/IntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 18 false false R19.htm 2115100 - Disclosure - Long-term Obligations Sheet http://www.vrtx.com/role/LongTermObligations Long-term Obligations Notes 19 false false R20.htm 2116100 - Disclosure - Stock-based Compensation Expense Sheet http://www.vrtx.com/role/StockBasedCompensationExpense Stock-based Compensation Expense Notes 20 false false R21.htm 2118100 - Disclosure - Other Arrangements Sheet http://www.vrtx.com/role/OtherArrangements Other Arrangements Notes 21 false false R22.htm 2119100 - Disclosure - Income Taxes Sheet http://www.vrtx.com/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 2120100 - Disclosure - Restructuring Liabilities Sheet http://www.vrtx.com/role/RestructuringLiabilities Restructuring Liabilities Notes 23 false false R24.htm 2122100 - Disclosure - Commitments and Contingencies Sheet http://www.vrtx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 24 false false R25.htm 2201201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies Basis of Presentation and Accounting Policies (Policies) Policies http://www.vrtx.com/role/BasisOfPresentationAndAccountingPolicies 25 false false R26.htm 2302301 - Disclosure - Product Revenues, Net (Tables) Sheet http://www.vrtx.com/role/ProductRevenuesNetTables Product Revenues, Net (Tables) Tables http://www.vrtx.com/role/ProductRevenuesNet 26 false false R27.htm 2304301 - Disclosure - Collaborative Arrangements and Acquisitions (Tables) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitionsTables Collaborative Arrangements and Acquisitions (Tables) Tables http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitions 27 false false R28.htm 2305301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.vrtx.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.vrtx.com/role/EarningsPerShare 28 false false R29.htm 2306301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vrtx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vrtx.com/role/FairValueMeasurements 29 false false R30.htm 2307301 - Disclosure - Marketable Securities (Tables) Sheet http://www.vrtx.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.vrtx.com/role/MarketableSecurities 30 false false R31.htm 2308301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss 31 false false R32.htm 2310301 - Disclosure - Hedging (Tables) Sheet http://www.vrtx.com/role/HedgingTables Hedging (Tables) Tables http://www.vrtx.com/role/Hedging 32 false false R33.htm 2312301 - Disclosure - Inventories (Tables) Sheet http://www.vrtx.com/role/InventoriesTables Inventories (Tables) Tables http://www.vrtx.com/role/Inventories 33 false false R34.htm 2316301 - Disclosure - Stock-based Compensation Expense (Tables) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseTables Stock-based Compensation Expense (Tables) Tables http://www.vrtx.com/role/StockBasedCompensationExpense 34 false false R35.htm 2320301 - Disclosure - Restructuring Liabilities (Tables) Sheet http://www.vrtx.com/role/RestructuringLiabilitiesTables Restructuring Liabilities (Tables) Tables http://www.vrtx.com/role/RestructuringLiabilities 35 false false R36.htm 2401402 - Disclosure - Basis of Presentation and Accounting Policies (Details) Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails Basis of Presentation and Accounting Policies (Details) Details http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies 36 false false R37.htm 2402402 - Disclosure - Product Revenues, Net (Details) Sheet http://www.vrtx.com/role/ProductRevenuesNetDetails Product Revenues, Net (Details) Details http://www.vrtx.com/role/ProductRevenuesNetTables 37 false false R38.htm 2404402 - Disclosure - Collaborative Arrangements and Acquisitions - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitionsCysticFibrosisFoundationTherapeuticsIncorporatedDetails Collaborative Arrangements and Acquisitions - Cystic Fibrosis Foundation Therapeutics Incorporated (Details) Details 38 false false R39.htm 2404403 - Disclosure - Collaborative Arrangements and Acquisitions - CRISPR Therapeutics AG (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitionsCrisprTherapeuticsAgDetails Collaborative Arrangements and Acquisitions - CRISPR Therapeutics AG (Details) Details 39 false false R40.htm 2404404 - Disclosure - Collaborative Arrangements and Acquisitions - Merck KGaA (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitionsMerckKgaaDetails Collaborative Arrangements and Acquisitions - Merck KGaA (Details) Details 40 false false R41.htm 2404405 - Disclosure - Collaborative Arrangements and Acquisitions - Parion Sciences, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitionsParionSciencesIncDetails Collaborative Arrangements and Acquisitions - Parion Sciences, Inc. (Details) Details 41 false false R42.htm 2404406 - Disclosure - Collaborative Arrangements and Acquisitions - BioAxone Biosciences, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitionsBioaxoneBiosciencesIncDetails Collaborative Arrangements and Acquisitions - BioAxone Biosciences, Inc. (Details) Details 42 false false R43.htm 2404407 - Disclosure - Collaborative Arrangements and Acquisitions - Aggregate VIE Financial Information, Summary of Net Income Attributable to Noncontrolling Interest (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitionsAggregateVieFinancialInformationSummaryOfNetIncomeAttributableToNoncontrollingInterestDetails Collaborative Arrangements and Acquisitions - Aggregate VIE Financial Information, Summary of Net Income Attributable to Noncontrolling Interest (Details) Details 43 false false R44.htm 2404408 - Disclosure - Collaborative Arrangements and Acquisitions - Aggregate VIE Financial Information, Contingent Consideration Liability (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitionsAggregateVieFinancialInformationContingentConsiderationLiabilityDetails Collaborative Arrangements and Acquisitions - Aggregate VIE Financial Information, Contingent Consideration Liability (Details) Details 44 false false R45.htm 2404409 - Disclosure - Collaborative Arrangements and Acquisitions - Aggregate VIE Financial Information, Items Related to the Company's VIEs (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitionsAggregateVieFinancialInformationItemsRelatedToCompanysViesDetails Collaborative Arrangements and Acquisitions - Aggregate VIE Financial Information, Items Related to the Company's VIEs (Details) Details 45 false false R46.htm 2404410 - Disclosure - Collaborative Arrangements and Acquisitions - Moderna Therapeutics, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitionsModernaTherapeuticsIncDetails Collaborative Arrangements and Acquisitions - Moderna Therapeutics, Inc. (Details) Details 46 false false R47.htm 2404411 - Disclosure - Collaborative Arrangements and Acquisitions - Janssen Pharmaceuticals, Inc. (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitionsJanssenPharmaceuticalsIncDetails Collaborative Arrangements and Acquisitions - Janssen Pharmaceuticals, Inc. (Details) Details 47 false false R48.htm 2404412 - Disclosure - Collaborative Arrangements and Acquisitions - Concert Pharmaceuticals (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsAndAcquisitionsConcertPharmaceuticalsDetails Collaborative Arrangements and Acquisitions - Concert Pharmaceuticals (Details) Details 48 false false R49.htm 2405402 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share Computation Statement (Details) Sheet http://www.vrtx.com/role/EarningsPerShareScheduleOfEarningsPerShareComputationStatementDetails Earnings Per Share - Schedule of Earnings Per Share Computation Statement (Details) Details 49 false false R50.htm 2405403 - Disclosure - Earnings Per Share (Details) Sheet http://www.vrtx.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.vrtx.com/role/EarningsPerShareTables 50 false false R51.htm 2406402 - Disclosure - Fair Value Measurements (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.vrtx.com/role/FairValueMeasurementsTables 51 false false R52.htm 2407402 - Disclosure - Marketable Securities (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesDetails Marketable Securities (Details) Details http://www.vrtx.com/role/MarketableSecuritiesTables 52 false false R53.htm 2408402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables 53 false false R54.htm 2410402 - Disclosure - Hedging - Derivatives Designated as Hedging Instruments (Details) Sheet http://www.vrtx.com/role/HedgingDerivativesDesignatedAsHedgingInstrumentsDetails Hedging - Derivatives Designated as Hedging Instruments (Details) Details 54 false false R55.htm 2410403 - Disclosure - Hedging - Derivatives Not Designated as Hedging Instruments (Details) Sheet http://www.vrtx.com/role/HedgingDerivativesNotDesignatedAsHedgingInstrumentsDetails Hedging - Derivatives Not Designated as Hedging Instruments (Details) Details 55 false false R56.htm 2412402 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.vrtx.com/role/InventoriesScheduleOfInventoriesDetails Inventories - Schedule of Inventories (Details) Details 56 false false R57.htm 2413401 - Disclosure - Intangible Assets and Goodwill (Details) Sheet http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails Intangible Assets and Goodwill (Details) Details http://www.vrtx.com/role/IntangibleAssetsAndGoodwill 57 false false R58.htm 2415401 - Disclosure - Long-term Obligations - Fan Pier Leases (Details) Sheet http://www.vrtx.com/role/LongTermObligationsFanPierLeasesDetails Long-term Obligations - Fan Pier Leases (Details) Details 58 false false R59.htm 2415402 - Disclosure - Long-term Obligations - San Diego Lease (Details) Sheet http://www.vrtx.com/role/LongTermObligationsSanDiegoLeaseDetails Long-term Obligations - San Diego Lease (Details) Details 59 false false R60.htm 2415403 - Disclosure - Long-term Obligations - Revolving Credit Facility (Details) Sheet http://www.vrtx.com/role/LongTermObligationsRevolvingCreditFacilityDetails Long-term Obligations - Revolving Credit Facility (Details) Details 60 false false R61.htm 2415404 - Disclosure - Long-term Obligations - Term Loan (Details) Sheet http://www.vrtx.com/role/LongTermObligationsTermLoanDetails Long-term Obligations - Term Loan (Details) Details 61 false false R62.htm 2416402 - Disclosure - Stock-based Compensation Expense - (Details) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseDetails Stock-based Compensation Expense - (Details) Details http://www.vrtx.com/role/StockBasedCompensationExpenseTables 62 false false R63.htm 2416403 - Disclosure - Stock-based Compensation Expense - Stock Options Outstanding and Exercisable (Details) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseStockOptionsOutstandingAndExercisableDetails Stock-based Compensation Expense - Stock Options Outstanding and Exercisable (Details) Details 63 false false R64.htm 2418401 - Disclosure - Other Arrangements (Details) Sheet http://www.vrtx.com/role/OtherArrangementsDetails Other Arrangements (Details) Details http://www.vrtx.com/role/OtherArrangements 64 false false R65.htm 2419401 - Disclosure - Income Taxes (Details) Sheet http://www.vrtx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.vrtx.com/role/IncomeTaxes 65 false false R66.htm 2420402 - Disclosure - Restructuring Liabilities - Narrative (Details) Sheet http://www.vrtx.com/role/RestructuringLiabilitiesNarrativeDetails Restructuring Liabilities - Narrative (Details) Details 66 false false R67.htm 2420403 - Disclosure - Restructuring Liabilities - Activity Related to Restructuring Liability (Details) Sheet http://www.vrtx.com/role/RestructuringLiabilitiesActivityRelatedToRestructuringLiabilityDetails Restructuring Liabilities - Activity Related to Restructuring Liability (Details) Details 67 false false R68.htm 2422401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.vrtx.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.vrtx.com/role/CommitmentsAndContingencies 68 false false All Reports Book All Reports vrtx-20170930.xml vrtx-20170930.xsd vrtx-20170930_cal.xml vrtx-20170930_def.xml vrtx-20170930_lab.xml vrtx-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://xbrl.sec.gov/currency/2017-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 87 0000875320-17-000060-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-17-000060-xbrl.zip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

-[MR0KI-_[/CS^_#3/!]%+!H%DW;YFLPXZIP#D!F#M%,""2!J5R_+&,#(&^&\%1!+CQAP<(VL4E2UO^S8<;#J>>BT M,XCU3/@/.M#UNBK']Z/%5;4N@W0@R&+;XQEQW'#CE;#2 M+4\"TC.C[!S75+;6>J@1FO5@YP?/LG>VR1!VEF/@+"60820UU4^^:COP8H6G MJ6T[!SH#Z6428E"'!0/C04>^X_?%O_)1?A-PW>\N?OY<%@]&O<&&04VDT8J% M);L>GU9D0 < '6)==H=(.B_*:F/S\#;_Z[=\4523?!IOUU[=O"WF 8:]MTL/ M-\ZH$A Y)A"3G >1J<>UU-&$2QKBW3!@9 B6:N?()N?3?Y75GZ]FX:.*F6B. M)M3NUIG6V%/CB<,XSJ0"0;Z1F\$3$E7UYND=%J,Z@S8YI7S0V3S8Z=$O=3RE M=K?.-#4,0.J]4=(R(:PRM:GNJ98IXYE[./[XOJ]NK#=/)Q M&<><\$T^GUU/BNIU3+UZ]L./8+;<%=7BX7J:+[.=Q[IB=Y&"38XT#C?.'+': M&^+#+MAB;*")1G8D%S$\; ;G0CV?5"Q4XSFQP_[NXB7!#$.&&CM.;(4X\*N@4JT$? +PM\JF;QRJ-04PU&JTRM\7L0W=5,5KE M&[7%?%1-[E9W*6IH#IP4G-1OAJ7"P@CHO2( (AQK^=4 >T=3>A!:'BETQ:!O MJB"F@S65*=9$IGA#^E&8@_[EMEUF 1Y-A808&4HE8$9!L$:(,6CQL,\C$K&C M!2<[!/L'+;]%:I"G(B^,C1V=KGQE6N\_8-GR: 8$8-09;B6DA M@ZPU6&*5S M)&7L1\/]9?\**3O%+.&YZ78+03_$2G2'(S$.MYR3I#JI4I-#WDVF\)W20!E\_F#D'L<< :J8! M1Y 08E'MDO-(M"\8W=L!?I^*/PFW-U^/:I>:][7) MPG I--X#I82RCG%%:Y>+,AZU-]][BW?I2\4=PG3VW=W^@*=]S3+!F2,"_[_V MKJVY<5M)O^^/2>%^>=DJ7%-3.\G,SB1[ZCRQ-#;M:(\LN239B??7+R"+\E42 M!0(DY9RJ9,KC(4#TUQ^!1G>C@91@7$/$PA*&&TD%@NF!N&+I+ 5G]HQ()7_R MS_<,?CJ?S"_BO7Z1GD_I&]N+X2?/+X;?-QVD]E<1+K7@BK-@PR@-$">PL6I4 M,(;3R\%DOSNV]%31$X1%LYK>R0'Z5M\O9O=!%+.L+Z=K/[G87$$T=#905-:7 MJY=C^MPB$>A@NPI:SQ0WC NK$;',*_FXVZ:$4^-:E1+I3]YC23][VU0><6R, MT Y*K"T,\Y1$6SDAL'(T63Z9M+4H@\NH,WJ:NJ3QWN"6-=.;1RMMJ4!$, BY MTZJ[)D+3E\WW?)A''?AO'ZXHM\HKAHB#"B"@ M@$?;0XHD_,Z <4=[TI5T0-N=D/DH>A]EG&9(=0_D;@]&9!SD<7?[BP&$H\D:::->.SS/;126OO>M=L.A+L^YNN;B,1ROV'[+>]VB0*'H, M*0-&DF !>:PD:21RRJ1ORHNY6S-JMR,:O64/QG,RQW*DFV<:630J%VMI"$R=?+;7:F8]*K7HY_LLZ$^CG; X7]V.THSJ5Z7#J/*7 .G-W0DIHIY1AU3#GGK&UDD(2,L$)Q% MGQTPZ"VY[(7)<,1.>OMPI9VEVE&CC%%4.2"5QHU4EJ#1WCZ3WV#J#,XP*C]^ M_]D[CU>..2R5E1HS:QC5TO!FTQ"^#0+';4MU4=5!K7="YR/I?Y3VUM!J'T;= MSV>ZH\OVVX0M"VET4LZ!4%42(D/HN9%] M&^W6B^5R\6>,($]NP[\EJ<8-]X3 M[W.1>&8FT'I,6KJHZ\N5#Y!%<5:-/((= Q V,@(& M1IBH6H8%N1!*3T5^1RQU>3E]3*ULLSRD=%,QP,.2J!U6 "!DK*3:;J4S '2H MP54LBS6O_GL K:^)P=8_UI\VZ761Q\U5NS&,]#WFUE]^#5OOF%=W?2@=JGTG M%2",*VB)!UAIB#Q$I)D>35@PT_T*Q?)=RTP=Q2!+GDOBB,SBOIY/YNN8<;F8 M32_C2#[7]_4RC.-;S%K<-X.T:EP1J@Q71GJL!/;0>6@;"\EX0V2R\HNEM!:8 M-TI E47I6S?U\S$Y_>DWJ]HH?6_C2G.!E,, &&P4=L(IT,1 C),RO: &/U.E MYX*J[WSE[Y.YG=;7BTWF]=!9RJ5K%B(D(*-:2P>5LL@K2QZK-@-**&P7J2HC M>:\U"SE50'LOG \[6V$]XFJ+0F F[O/FF:XU"ULK-+EFX4E8C3K#>9PU"RV! MDD */;96W$=Z D-?>C3LHUA,[;2R M'"J$8=B.*( PL RHW2@E=B/,1B^OD$56S 8_8IZM9J%F1NM@"4M/K3+":T5- M(S=P*MUW.YJ:A8E65'[P!B=-MJISQA JD;-22J"(D%0JL)4;6F1';@%EU6Q" M^;DT]/X^[!FEH3)VT@R48U:@9J%31,M@R$%!H>(,V"9)'E "/!?CLUZRZN^4 MFH6G0=7;(K*RJIB@=?QI9^5HDHO *:3Y69Q-U_' 3SF M1(5QU7\^5OS;3XD#;2I#+?7.:*,T8P R)ERS)BH$?;J?:\CJB6F*SP=3X27C MVA06Y-S)H/A M9!CR%#&M,7;-FNBH-.EIRD-64$PU,#,BE3QCC*:V)B!0B+#^41AV5I0!QSS; MR4MPND>J6$Y:J?FC)PC[SE6+?_V\F,R'3E-[F>;[N45NVIX6E03QB#E@D#-% MH./8ZL=I&V.+63LO61\R'LL]>^?I*FQ$4]Q5A"97D\0D.55 PT<'C0ZQ48 M)X4K.ZGV]2G$[L#T=ECUU5"/QH_>;U#%:SRLE0*KL'(IS(T1I)'.64+&'7#L MIK CVN^$T$?CP2A#AV-0_S!J_U[/IXME-+R.QP3?/%M!S1F72!KK#8?860=W M,F&O_/@" EV5\SK7O",D?:FY2P5L;("5 1/+>5@''>5*-XN@M82-]L[4G MZ M1U"&4'-*#60#*49< 2<$Y# FU1G?2!7D]>->Q-.5=+P8$VA-NTK3JW&&AFIK6-&A[%L M3R\'V15M=_''X)6R6ROPK?&6':)A*@/XR47]&'1J[=MY:E(YSZ""\:HV 9TW M $BPD]!I.4(2E'7U)$/S41FL5Q/_Z^^M-/5Q4FKS#MM*VJ AD09(ZFTB"FG@6MD)MBE MIP<4RQ,I2X_N&!6-W_TR6?ZK7D?*?J\O[I:A=;TO8K<=0]97I<<(]YWFVQU5 M,I/5'_'_&*V]G\QB7D8\[W8?WA?'X!?+[Y/G0_E\($"8J^M* XH5-B28EC1, M 40:OET^O/8*M/+ %$=B7Q@Q1[<5XLXQ3JB"0 N,?%@:\Y[@E&'^G69XHW] MJWHQ&+J%(ICY"1E&N_IRM9M?5'A=HV1>&/2E0'"HOA'/<::8A)0W, M&O@^C\VTP(I [RA@UEA+EN0+8-8!2P2T; MIX]V+&I=](#U.;)F5![>CTF68?9M$;B UBO\CI__/-"L"F()::ES#D,* =16 M["0%"/5Z//CP;BVWZEX?_VMVLFE.^KR> M:DA>Y "G/\4O;Q?+&%,];=XXV*XRB'')O+:Q5#)R052 &ED)XNF+2S%7;R$B MY .IMUH"C]E$)!A0PQ#B(%)<00HGA;D[E-KUH5K'* M%WVSH3-HG7RGKR,+>\,*JLG(,8O5_@('R3U6R%)M&$32A^VD$L:'X6YE-HZ, MJ;K:L-D.O4%%XM/0.AS"9[E!0K '0_1'L:XN@$\WMV&$T;WUY>K3_+Y>K3?>U@-;_#TM M*A2VG(:"8 $P!R0"PLG&R^$LM>G5*+-;Y(,Q*"^$O<9F\#;1BZ2.*Z601,(A([3#1"#(:(.^YZ9#/D7VLG:#$ZY7I'L_([%) MB2UU4N++^H]Z^;R@9%_O.7PGY7KYY5ERS^HJ%KT<7E M>%,=+WQT_WT7F'_U$&N&7FS. ZWBP:#98G6WK#^WJ%)W4.*L\=Y+I5L= 1X6EV.5[4[JIW(<< 4=,XA**X2EFH(M'I::#B5L,]>\ M*ZCI-X43RN'7[RD3LY@%?D3WY/2^?CZWZ0=UO:PW/Q\Z--*V?:4(?PNV\>2VO@O_N/HTOVAB7I=' HI)O55"&T>95AK&:S&!T 2"*&NL M.J>Y'M$]7&54N.@;PO[J>36K[6RV^',ROZCCOOM;O:J7]X_GFXX6\6O30:6$ M4$9PQ(/%IYQF1,MFG7:4FO208^'2?F6MD:(@CH-"+8K$'6]>*82-"K.WUQ9P M9XRGJ-DW.*NE&:?I4DJ])[&G$X)_)PZ-RLXY)^H,Y()O1NP7R]^6D\OZ6WU1 M3^\W?L_CAP2.-@ZV(V306NP!M1U^O/A7E+*I773D-&J;MA7W5&DL'7'2Q9LU 5:RD8/8#B5@ MBF5O%]%\*<"&F"!BZ&;UK5[?+5M4'S_'(*.R@:'R9"/-V4 M+9:4W=O$T!FM#KZ2V\G#+P'1QTM^MK0]EER[OTT59S'M81@R4LA ASWFS;@Q M]^E:+I9:76X2R A4;R_E2^+6:S,)G].5E>'N!+ M0F]5F/^,A%H(X3SWVL7_&IPAZ'#K8 ^616DNE<=S')M9/9G%7R7O9K?M*VR9 MC!=]"",==-2CS=W?SEH @+

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�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end